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ABSTRACT 
Background 
The Quality Outcomes Framework (QOF) was introduced in April 2004, and is the 
largest primary care pay for performance (P4P) scheme in the world1. To date 
research on the QOF to date has principally looked at its effects on process and 
surrogate outcomes rather than condition specific and clinically significant 
outcomes. Where research has looked at clinical outcomes, measures have not been 
condition specific, and were measured at a population or local level, not that of the 
individual patient. Large administrative databases like Clinical Practice Research 
Datalink (CPRD) and linked Hospital Episode Statistics (HES) allow researchers to 
track individuals across Primary and Secondary care to determine the impact of 
policies in either sphere. This study utilises the links between these two large 
datasets to determine the impact of evidence based targets in the QOF on clinical 
outcomes at the individual level 
Methods 
This thesis sets out to comprehensively examine the effect of physician incentives 
generally and the QOF specifically on individual level outcomes through a series of 
structured literature reviews and data analysis. The literature reviews, in conjunction 
with relevant clinical guidelines, triangulate the evidence around the effectiveness of 
incentives, their impact on CHD clinical outcomes, and the impact of QOF CHD 
targets. The selection of QOF targets for analysis is directed by clinical evidence. 
NICE and SIGN commissioned guidelines are consulted to select from the QOF 
those targets which had high level evidence of clinical benefit, which were 
extractable from large administrative datasets. This ensured in the data analysis that 
clinical benefits arising from treatment to QOF targets would be evident in the 
outcome measure.  
Individuals were selected into the dataset if they had a QOF qualifying Read code for 
CHD and linked into HES data. Since the QOF has been near universally adopted, 4 
years of pre-QOF data were used in addition to 7 years of QOF data, to measure 
compliance with evidence based targets in the QOF at the individual level. Outcomes 
were selected ICD 10 I20-25 codes, corresponding to the Ischaemic Heart Disease 
(IHD) category, and all relate to complications arising from poor condition 
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management. These had to represent the primary diagnosis for a hospitalisation and, 
depending on the severity, be either an emergency or non-emergency admission. 
Panel data econometric analysis was undertaken at the individual patient level. The 
outcome variable was specified in two ways, either as a hospitalisation count per 
year or a binary hospitalisation occurrence variable.  Adjustments were made to 
model specifications for over-dispersion and excess zeros in the outcome variable, 
correlation between the explanatory variables and the error term, and 
heteroskedasticity in the error term.  
Results 
Literature and clinical guideline reviews 
The high level evidence base on physician incentives in primary care showed no 
strong evidence for any particular form of incentivisation, let alone P4P. Incentives 
were followed up for short durations, and there was a focus on process and surrogate 
outcome measures. None linked incentives to individual level condition specific 
clinical outcomes.  
The majority of QOF targets do not measure or reward performance to a surrogate or 
clinical outcome measure. Rather they reward processes which often are not 
evidence based, and have no direct links to clinical outcomes, making it difficult to 
determine and attribute clinical benefits to them. In terms of data extractability using 
large administrative datasets, CHD QOF targets were judged to be most suitable. 
Evidence on the effects of physician incentive on clinical outcomes, hard and 
surrogate, in CHD patients was limited. Most examined their impact over a short 
time period. None of the studies monitored patient contact with primary and 
secondary care.  
The published literature on CHD and the QOF was very limited in that it largely 
relied on uncontrolled before and after cross sectional study designs, and one dataset 
from an inner London PCT.  
Econometric analysis 
Evidence based CHD QOF targets were found to significantly reduce outcomes in all 
whole population models and most sub group models S ZLWKLQ D RQH \HDr 
time period. The cholesterol QOF target was additionally found to reduce outcomes 
in the same period, in most analyses. Having a co-morbidity tended to increase 
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outcomes, however the results were not always statistically significant. Only Heart 
Failure (HF) was consistently found to significantly increase outcomes in all 
analyses 25	,55§, p<0.001)). Worsening levels of deprivation consistently led 
to a significantly greater number of outcomes with few exceptions. Being treated in a 
higher attaining practice on QOF CHD targets significantly reduced outcomes in all 
analyses (p<0.001). Having an outcome event prior to CHD coding significant 
increased outcomes throughout the analyses 25	,55§, p<0.001)). Increasing 
age and being male were generally causes of increased outcomes. Rheumatoid 
Arthritis, Strategic Health Authority (SHA) region, practice size and GP workload 
were found to have a minimal or no impact on outcomes. 
Conclusion 
This thesis has demonstrated at the individual patient level that evidence based CHD 
targets in the QOF are effective in reducing evidence linked hospital admissions 
allowing for a one year delay. It has done so using a large sample of patients from 
across England, over an 11 year period. These results have been tested in various 
model specifications to correct for heteroskedasticity in, and covariance with, the 
error term and an excess of zeros and over-dispersion in the outcome variable.  In all 
model specification this finding was found to hold true. This research has 
demonstrated the benefits of using large administrative datasets and the importance 
of linking outcomes to high level evidence.  
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Chapter 1 Introduction 
1.1 Introduction 
This thesis sets out to examine the effect of physician incentives generally, pay for 
performance (P4P) specifically, on health outcomes. It does so in the context of changes 
made to the UK primary healthcare sector in 2004 which saw the introduction of a P4P 
scheme referred to as the Quality Outcomes Framework (QOF). This is examined at an 
individual patient level using large administrative datasets, with evidence based CHD 
QOF indicators used in econometric analyses. 
1.2 Objective 
This chapter sets out the aims and objectives for this thesis and describes and appraises 
the key components that are covered within it. These are: 
1. The QOF, the physician incentive scheme which is the focus of this thesis. 
2. CHD, the condition that is used to examine the effectiveness of evidence based targets 
in the QOF. 
3. Large proprietary datasets, which were used to source data to model and analyse the 
QOF. 
1.3 Overview of the QOF 
1.3.1 Background 
The Quality Outcomes Framework (QOF) was introduced in April 2004 as part of the 
QHZ *HQHUDO 0HGLFDO 6HUYLFHV *06 FRQWUDFW µ'HOLYHULQJ ,QYHVtment in General 
3UDFWLFH¶SXEOLVKHGLQ'HFHPEHU2. It is considered to be one of the most ambitious 
pay for performance schemes ever undertaken anywhere in the world in primary care3. 
The GMS contract introduced new funding arrangements for primary care, and saw the 
abolition of the Red Book (Statement of Fees and Allowances), which had prior to this set 
out the payment tariffs for individual treatments. It contained six main funding streams, 
one of which was the QOF, which was expected to account for around 20% of practice 
income4. Although the scheme was voluntary, from the outset nearly 100% of GP 
practices chose to participate.  
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1.3.2 QOF domains 
The QOF was designed to incentivise improvements in practice organisation, the delivery 
of care and provision of additional services in certain designated clinical areas. It consists 
of four domains: clinical, organisational, patient experience and additional services. The 
organisational domain rewards practices for good organisational practice and Human 
Resource PDQDJHPHQWDQG LVEDVHGDURXQG WKH5R\DO&ROOHJHRI*HQHUDO3UDFWLWLRQHUV¶
Quality Practice Award. PDWLHQW H[SHULHQFH XVHV SDWLHQWV¶ HOLFLWHG IHHGEDFN FRQFHUQLQJ
the quality of access and care gathered through a quarterly national survey to determine 
practice payments. The additional services domain rewards those practices that provide 
extra functions such as cervical screening and maternity services. 
The biggest domain is the clinical domain, accounting for 550 points, just over 50% of 
the total points on offer in 2004/05. This domain is the focus of this chapter and thesis. 
Within the clinical domain there were 76 indicators in 11 clinical areas when the QOF 
was introduced: Coronary Heart Disease (CHD), Left Ventricular Disease (LVD), Stroke 
or Transient Ischaemic Attack (STIA), Hypertension, Diabetes, Chronic Obstructive 
Pulmonary Disease (COPD), Epilepsy, Hypothyroidism, Cancer, Mental Health (MH), 
and Asthma. Each target KDVµSD\PHQWVWDJHV¶ZKLFKVHW lower and upper thresholds for 
payments. Failure to meet the minimum threshold means payments are not triggered 
while the upper threshold sets a ceiling on the level of achievement for which the practice 
will receive QOF payments. For example, QOF target, BP4, payments thresholds were 
25% and 90% at its inception. This means that numbers of patients treated below the 25% 
threshold and above the 90% threshold would not generate QOF points and payments for 
their practices; and hence there was no financial incentive to treat patients if the lower 
threshold could not be reached, or to treat patients who fell outside the upper threshold. 
Payments are made proportionately within those thresholds. Practices are allowed to 
exempt patients provided certain criteria are met, which reduces the denominator and 
LQFUHDVHVDWWDLQPHQWWKLVLVFDOOHG³H[FHSWLRQUHSRUWLQJ´([FHSWLRQUHporting is designed 
to prevent general practices being financially disadvantaged for not treating certain 
patients:  Namely those who were non-compliant or had contraindications.  
1.3.3 How does the QOF work?  
What practices need to do to comply with QOF targets is detailed in the QOF business 
disease specific ruleset. These are updated as and when the QOF targets are updated. This 
thesis used version 17, produced 07/05/2010, as this was the most recent to the study 
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period. Practices receive payments based on the amount of their patients who meet the 
QOF target, which is determined by the size of each disease specific register, which, in 
turn, determines the numerator for the disease targets, and whose recording itself is a 
QOF target. Calculation of performance works as follows: the first target in each clinical 
LQGLFDWRU LV WHUPHG µ5HFRUGV¶ DQG LV D SD\PHQW PDGH WR WKH SUDFWLFH IRU LQLWLDOO\
establishing and then maintaining and updating a register consisting of patients, within 
the practice, who have the condition for that clinical indicator. For example, the first 
WDUJHWLQ+\SHUWHQVLRQ%3LVWKDWµ7KHSUDFWLFHFDQSURGXFHDUHJLVWHURISDWLHQWV with 
HVWDEOLVKHG K\SHUWHQVLRQ¶ 7KLV LV WKH RQO\ UXOH WR WKLV WDUJHW VR DWWDLQPHQW VKRXld be 
100%. This disease register then forms the disease register for the majority, but not all of 
the subsequent targets. Following on from the disease register there LV RIWHQ DQ µ,QLWLDO
'LDJQRVLV¶WDUJHW7KLVSD\VWKHSUDFWLFHEDVHGRQZKHWKHUDVSHFLILHGWHVWKDVEHHQXVHG
to verify the existence of the disease or to determine its specific form. This may be 
merged with, RU WKHUH PD\ EH D VHSDUDWH µ,QLWLDO PDQDJHPHQW¶ VHFWLRQ ZKLFK GRHs 
essentially the same thing. After achieving targets for initial diagnosis and investigation, 
WKHQH[WVHFWLRQGHDOVZLWKµ2QJRLQJPDQDJHPHQWWDUJHWVPrior to this point practices will 
have been paid for recording DSDWLHQW¶VFRQGLWLRQ and possibly performing a confirmatory 
test or assessment. It is in this section where practices start to have to hit specified clinical 
targets, in the form of surrogate and process outcome measures, to trigger payments. 
These tend to be for specific blood pressure readings HJPP+J; serum 
cholesterol levels HJPPROO and the prescription of certain pharmaceutical products 
such as ACE inhibitors, beta blockers, anti-platelets or anti-coagulants. Most of these 
apply to the whole disease register established in the first disease target minus exceptions; 
however some apply to sub groups of that population. For instance it could be CHD 
patients who have an MI coding, or Heart Failure patients with Left Ventricular 
Dysfunction (LVD). There still remains within this section however a significant number 
of targets that provide payment regardless of outcome. These are related to and precede 
the surrogate outcome targets, providing payment if the test or reading took place.   
1.3.4 Changes to the QOF 
The QOF, when first introduced in April 2004, contained eleven clinical conditions in the 
clinical domain, including LVD which formed a subgroup of the CHD target group. Since 
then the QOF has undergone a number of changes and the frequency of those changes has 
increased over its lifetime. The first and most substantive changes to the QOF occurred in 
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2006. This saw wholesale changes to lower QOF thresholds, the introduction of nine new 
clinical conditions and the retirement of LVD, with its targets being applied to the newly 
introduced Heart Failure (HF) condition group. Although there were minor changes to 
COPD in 2008, the next major change did not occur until 2009. This saw the introduction 
of a new clinical area, Cardiovascular Disease Primary Prevention (CVD-PP), and 
significant changes to the points offered to other clinical areas as well as greater 
weighting for the clinical domain within the QOF. As a result the clinical domain had 
come to dominate the QOF accounting for 70% of the points on offer, up from 52.4% at 
its inception. Changes made to the QOF from its introduction to the year 2010/11, the 
study period, are shown in Table 1-1 on the following page. LVD prior to the introduction 
of HF formed a subset of the CHD targets group and therefore its points, when present, 
DUHLQFOXGHGLQ&+'¶VWRWDOIRUWKDWSHULRG 
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Table 1-1 Changes to the QOF over the study period, 2004-2011 
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The net results of changes to the QOF during the study period have been to widen its 
scope and make initial steps in making the QOF more demanding. More recently as the 
rate of increase in NHS funding has slowed, monetary concerns have also played a 
significant role in changes to the QOF and in efforts to make it more exacting5. There 
have been two main factors driving and more recently accelerating these changes. Firstly 
successive governments have sought to claw-back some or all of the substantial gains 
witnessed in the early years of the QOF in GP pay and conditions6. Secondly the 
introduction of the NICE QOF committee in 2009 and initiatives emerging from that have 
led to a more active and evidence based approach in the formulation of new QOF targets, 
and in the retirement of existing targets7. The effect of this greater use of NICE evidence 
to formulate targets was seen in the decision in 2011 to replace 13 targets with 17 NICE 
recommended ones in eight clinical areas. 
1.3.5 QOF attainment 
QOF attainment has been high from the outset and followed an upward trajectory for 
most of the study period. This is shown for CHD and Overall performance at the English 
national level on all QOF clinical conditions in Figure 1-1 below. Details on the 
remaining QOF targets are shown in Table 1-2 on the following page. 
Figure 1-1 Performance on QOF targets, CHD and all targets 
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Table 1-2 QOF conditions performance over the study period, attainment at the English national level 
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Both Figure 1-1 and Table 1-2 are based on England national level attainment. 
LVD, which was present in the first two years of the QOF is not reported. This 
condition applied to a subset of CHD patients and was included in the CHD 
domain, though its results were reported separately. However it has been used in 
the calculation for average overall performance for all QOF targets. 
Figure 1-1 shows that average attainment over the study period on CHD QOF 
targets has been higher than the overall average for all QOF targets. Performance 
on both measures peaked in 2009, with 99.1% attainment on CHD and 97.3% 
overall. While CHD repeated that level of attainment in 2011, overall performance 
has slipped since, though it still remains high. 
Table 1-2 breaks down the overall figure by the composite conditions making up 
the QOF, CHD and LVD aside. This shows that for all conditions with the 
exception of depression and palliative care on average; since 2005/06, QOF 
practice attainment has been in the mid to high 90% region. In the case of obesity 
the average practice, allowing for rounding up, has achieved 100% on this target 
over its lifetime. All the figures point to universally high attainment with little 
exception, on all targets. 
1.3.6 Critique 
Too much of the QOF is devoted to rewarding activities such as recording disease 
status, the presence of disease specific complications, or whether surrogate 
outcome measures such as cholesterol levels are recorded. Beyond these examples 
the prescription targets are met simply by dispensing the specified drugs rather 
than for getting the patient to a desired outcome. Likewise a number of targets 
relate to reviews of conditions which are also activity based with no specified, 
discernible and consequently measurable clinical outcome. Where outcomes are 
specified they are surrogate or process measures rather than clinical outcomes. 
This is a general issue with any performance related pay scheme, particularly in an 
area such as primary care. Namely payments need to occur a reasonable time after 
the activity, in line with salary cycles or annual accounting periods. Consequently 
items that can be measured with reasonable immediacy, such as prescriptions, 
VXUURJDWHRXWFRPHVRUUHYLHZVRIDSDWLHQW¶VFRQGLWLRQDUHIDYRXUHGDVRSSRVHGWR
clinical outcomes which can occur in the years and decades following primary 
prevention and treatment. 
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Understandably a pay for performance scheme under which practices average over 
91% overall in the first year and then go on to improve on that performance raises 
questions as to how demanding the targets are. For those funding the scheme it also 
made it more costly than initially expected. At its introduction, expectations were 
WKDWWKH42)ZRXOGDFFRXQWIRURID*3¶VLQFRPHEDVHGXSRQ*3VDFKLHYLQJ
around 75% of the QOF points on offer on average. However average GP 
performance on the QOF turned out to be over 90%, accounting for 25% of 
practice income. This led to a total over spend on the QOF by the government of 
£1.76 billion in its first three years alone8. Despite committing substantial 
resources to the scheme - in excess of £1 billion a year - no pilot studies were 
undertaken prior to its implementation; no cost-effectiveness studies were done on 
any of the targets and, in some instances, neither were the targets based on strong 
clinical evidence. No baseline measures were taken prior to its implementation in 
order to determine subsequent performance, which turned out to be much better 
than predicted8. These costs could be absorbed by generous financial settlements 
IRUWKH1+6RYHUWKHVWXG\SHULRGEXWORRNLQJEDFNFULWLFDOO\IURPPRUHµDXVWHUH¶
times it may not have been a good use of scarce resources.  
Various reasons have been given for this high level of attainment. Some 
practitioners have claimed it shows that that they had been providing high quality 
care and investing in better care, prior to the QOF, but that went unrecognised until 
it was captured by the QOF9. In this sense the QOF was a period of catch up where 
pay and recognition caught up with previous effort and investment; as well as a 
continued commitment to quality. Others point out that the government of the day 
introduced the new contract to address recruitment and retention issues within 
general practice, and the QOF was part of a wider policy of intensive investment in 
the NHS and primary care to make general practice a more financially attractive 
proposition, rather than solely a quality-improvement mechanism9 10. In this regard 
WKHFRQFHUQZDVQRW WRFKDOOHQJH*3¶VWRdo more and improve patient outcomes 
EXWWRSD\*3¶VPRUHIRUZRUNWKH\ZHUHDOUHDG\XQGHUWDNLQJ,QGHHGWKH42)ZDV
VROG WR LWVPHPEHUVE\ WKH%0$DV µOHVVZRUNPRUHSD\DEHWWHUSHQVLRQ¶11 In 
terms of the evidence Campbell et al have found that care for CHD patients did not 
improve significantly beyond existing trend with the introduction of the QOF 
based on mean attainment on a range of QOF related measures; and while diabetes 
and asthma care did improve significantly beyond trend in WKH 42)¶V ILUVW \HDU
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they subsequently reverted back to trend12. Hence the QOF at best resulted in a 
small incremental improvement on existing trends and practitioners getting to a 
point on QOF measures a year or two earlier than they would otherwise have done.   
There is evidence that exception reporting has masked inequalities enabling 
practices to report uniformly high achievement13.  There is also evidence to show 
that it has also been used E\VRPHSUDFWLFHVWRµJDPH¶WKHV\VWHPE\DOWHULQJWKHLU
exception reporting rates in order to improve their QOF score14. There has been 
some suggestion that GP¶VµFKHUU\SLFNed¶SDWLHQWVZLWKWKHFRQGLWLRQZKRDUHWKH
easiest to manage and treat, though there is not strong evidence for this14.  There is 
mixed evidence on resource substitution, a process where physicians divert their 
efforts and attention to incentivised conditions at the expense of those not covered 
under the incentive scheme. Sutton et al found positive spill over effects into non 
incentivised areas of 10.9 percentage points for those patients targeted under the 
QOF15. Campbell et al on the other hand found that mean quality scores fell in 
most conditions on non-incentivised targets following the QOF, widening existing 
gulfs in attainment12. While Steel et al found no significant improvement in non-
incentivised compared to a significant improvement in those covered by incentives 
and linked to incentivised conditions 16   
Targets were set below 100% even after allowing for exception reporting, leading 
to what Fleetcroft et al termed a pay: performance gap17. This gap was the 
difference between the number of patients eligible for the target and those actually 
treated. Upper thresholds set below 100% counted for 52% of this gap, exception 
reporting the rest. Finally, critics have argued that the QOF has simply led to a 
QDWXUDO LQFHQWLYH UHVSRQVHE\*3V WR µIROORZ WKHPRQH\¶DQGEHWWHU UHFRUG WKRse 
areas of care that are incentivised and treat those conditions where points are 
available; which does not in itself necessarily equate to better quality of overall 
care18. 
1.4 Coronary Heart Disease 
This section discusses Coronary Heart Disease (CHD), the condition that was 
chosen to analyse the effects of evidence based targets in the QOF in this thesis. 
The process by which this condition was chosen will be covered in Chapter 3. 
11 
 
1.4.1 What causes Coronary Heart Disease? 
Coronary Heart Disease (CHD) is caused by a build-up of fatty deposits in the 
walls of the coronary arteries which supply blood to the heart. As these deposits 
build up this reduces the size of those arteries and limits their ability to pass blood 
and oxygen to the heart.  This causes the heart to work harder particularly during 
periods of physical exertion, leading to chest pains; an indication of the most 
common form and usually the first symptom of CHD, Angina. Pain and tightness 
can also occur in the shoulders, arms, throat or jaw. If this pain comes on 
gradually, improves with rest and lasts for a couple of minutes it is classed as 
stable angina. Unstable Angina is more serious where the pains are unpredictable 
and last longer, and can be a sign that a heart attack is imminent. A heart attack or 
myocardial infarction refers to the situation where one of the coronary arteries is 
completely blocked starving the heart of oxygen. Without treatment the patient will 
die or the heart will be permanently damaged. Due to its severe implications 
preventing patients from having an MI will be a primary objective of treatment for 
patients with existent CHD and secondary prevention measures. While CHD is a 
progressive disease, patients need not have suffered from Angina nor shown any 
symptoms of CHD or cardiovascular disease prior to having an MI. These patients 
would not come under the remit of the QOF or this thesis as patients cannot be 
treated under any of the secondary prevention of CHD QOF targets until CHD is 
diagnosed. 
1.4.2 Coronary Heart Disease: facts and figures 
CHD is the most prevalent of the cardiovascular diseases, the term given to the 
group of diseases that affect the heart and circulatory system. These are the most 
common cause of death in the UK accounting for nearly a third of all deaths, over 
179,000, in 2010. CHD alone accounted for over 80,000 of these making it the 
largest cause of death in the UK, responsible for 17% of all deaths in males and 
12% in females in 201019 20. It is also one of the most common causes of premature 
death in both sexes, in men the largest cause, accounting for 17% of all premature 
deaths; in females behind lung cancer and respiratory disease accounting for 8% of 
all premature deaths20. The estimated cost of CHD to the UK economy was over 
£6.7 billion in 200920. A little over half of this cost is due direct health care and 
informal care costs; with the remainder down to productivity losses20. 
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Based on QOF data for the year 2010/11 it is estimated there are around 2.3 
million people suffering with CHD in the UK20. Other estimates put the number of 
people living with CHD at approximately 2.7 million of which around 2 million 
have Angina, the most common symptom for CHD19.  It is least prevalent in 
England with 3.4% of the population on the QOF CHD register and most prevalent 
in Scotland with 4.4% registered as having CHD20. Rates of death from CHD are 
also highest in Scotland, though as with prevalence these figures hide significant 
regional variation. A breakdown of CHD prevalence for English SHA regions is 
shown in Figure 1-2 using 2010/11 data20. In relation to the English national 
prevalence rate of 3.4% clear regional divides are evident. CHD is most prevalent 
in the Northern SHAs, the North East, North West and Yorkshire and the Humber. 
The Midlands SHAs and East of England have near English average levels of 
prevalence, with the East Midlands SHA deviating the most from that average with 
a CHD prevalence rate of 3.6%. With the exception of the South West, all the 
southern SHAs have CHD prevalence figures below the English average, London 
SHA having the lowest CHD prevalence rate of 2.2%.  
Figure 1-2 CHD prevalence by English Strategic Health Authority, 2011 
 
Rates of deaths from CHD vary with deprivation, with rates increasing with each 
quintile increase in deprivation. Research by McCartney et al.21, reported by the 
English average 3.4%
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British Heart Foundation (BHF) shows a clear link between deprivation and death 
rates per 100,000 population from CHD, between the years of 1994 and 200820. 
Deprivation was measured using the Carstairs index at a local authority level, 
grouped by quintile, examined by gender and additionally for all ages and those 
under 75 years of age.   The results throughout the study period showed a clear 
progressive increase in rates of CHD deaths with each quintile increase in 
deprivation, for both genders, all ages and those under 75. These rates fell 
throughout the study period so that by 2008 rates were in all instances over half 
what they had been in 1994. Women in both age groups had the lowest rates 
throughout and enjoyed the biggest reductions in rates over the study period. 
However the differences in rates of deaths between the most and least deprived 
quintile, expressed as a ratio, was larger for females throughout, suggesting that the 
most deprived females performed less well compared to their least deprived peers 
than their male counterparts. Differences in rates between the least and most 
deprived were also greater for the under 75s in both genders. Furthermore over the 
study period, the differences in rates of death, expressed as a ratio, between the 
most and least deprived quintile increased from 1.3 to 1.5 for men of all ages; 1.4 
to 1.6 for women of all ages; 1.5 to 1.8 for men under 75; and 1.8 to 2.3 for women 
under 75.  
An alternative and arguably more comprehensive measure of deprivation is the 
Index of Multiple Deprivation (IMD), which considers seven aspects of 
deprivation as opposed to the Carstairs index four. This has been measured at the 
individual level using the 2007 algorithm in this study.  
1.3.3 Secondary prevention of Coronary Heart Disease 
This work is interested in patients who already have CHD and therefore in the 
prevention of secondary complications. This will involve the same lifestyle advice 
around increasing exercise, having a healthy diet and giving up smoking and other 
modifiable lifestyle factors that increase the risk of having CHD initially; and 
increase the risk of complications once diagnosed. However compared to primary 
prevention, following diagnosis individuals will require more intensive control and 
medical management through the use of drugs such as statins and ACE inhibitors, 
and these measures form the basis for CHD condition management in the QOF. At 
the same time reoccurrence and exacerbations in early and mid-stage 
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complications remain important negative outcomes that secondary prevention will 
seek to avoid. 
Office for national statistics figures reported by the BHF show a rapid increase in 
the use of anti-hypertensive and heart failure, anti-platelet, and lipid lowering drug 
classes for the primary and secondary prevention of CVD from 1981 to 2011, 
which covers the whole of the study period, January 2000 to April 201020. Starting 
from a low base, with prescriptions volumes below 1000 a year in 1981, 5000 for 
antihypertensives, volumes increased rapidly for all of these drug classes, most 
markedly after 2000, beginning in the early 1990s for anti-hypertensives and anti-
platelets, and the mid-1990s for lipid lowering drugs. By the end of the period it 
appears that prescriptions of anti-hypertensives and lipid lowering drugs were 
nearing a plateau at volumes of approximately 61,000 and 65,000 a year 
respectively; while those for anti-platelets appear to have peaked in 2009, at 
volumes of near 40,000 prescriptions per year. The impact of all of these drug 
classes will be assessed directly or indirectly on the study outcomes in the course 
of any analysis.  
The outcomes measured in this study relate to complications arising out of existent 
CHD, key among these are myocardial infarctions (MI). Work by Smolina et al.22, 
reported by the BHF show the incidence of hospitalisation per 100,000 with a 
primary diagnoses for Acute Myocardial Infarction (AMI) in England, between 
2002 and 2010, covering the majority of the study period20. These have been age 
standardised to the European standard population and are again reported by gender, 
for all ages, and those under 75. Incidence of AMI hospitalisation has fallen in 
both genders and age groups between 2002 and 2010, largely on a year by year 
basis. As expected the rates are highest in males though differences between the 
genders has narrowed over this period from a difference of 101 per 100,000 (169 
male compared to 68 per 100,000 female, 2002) to 71 per 100,000 for the all age 
group (122 male compared to 51 female, 2010); representing a fall of about a 
quarter in males and a fifth in females. For those under 75 there has also been a 
narrowing in the size of the absolute difference between males and females; 
although the rate of decline was similar at around one third in both genders (123 to 
86 per 100,000 male; 41to 29 per 100,000 female). 
 
15 
 
1.5 Large administrative datasets 
1.5.1 Introduction 
The QOF and other pay for performance schemes have been developed on the back 
of advances in information technology which have allowed the collation and 
analysis of large quantities of patient data. In the case of the QOF a national IT 
system referred to as the Quality Management Analysis System (QMAS), uses data 
provided by practices to calculate their QOF attainment. Within practices too there 
have been considerable investments in IT systems. The 2004 GMS contract 
formalised and standardised IT procurement arrangements by only agreeing to 
fund systems from an approved list of providers. Those same advances in IT, and 
greater demands for information and evidence based decision making, have led to 
WKHµFRPPHUFLDOLVDWLRQ¶RISDWLHQWGDWD WKURXJK WKHGHYHORSPHQWDQG growth of a 
number of administrative datasets that give researchers access to large quantities of 
patient data collected through GP computer systems. The biggest data warehouses 
for patient data within primary care are CPRD, THIN, and QResearch. CPRD and 
THIN use data provided by practices using the Vision system provided by 
InPractice, and QResearch from practices using systems provided by EMIS. In 
secondary care data is collected by HES. Provided below is a brief description of 
each of these data sources.  
1.5.2 Clinical Practice Research Datalink (CPRD) 
CPRD contains over 52 million patient records for Primary Care Practices in the 
UK with records going back to 1987. It contains over 650 practices that are 
considered to be up to research standard, meaning they have met data assurance 
standards such that the data they provide is considered to be research quality. 
Within these practices there are over 12 million patients, of whom near 6 million 
are active 23 24. 
1.5.3 The Health Improvement Network (THIN) 
THIN was developed as an alternative to CPRD in 2002 by EPIC (UK). Data 
collection commenced in 2003 however THIN does contain patient records going 
back as far as 1986, depending on the participating practices adoption of the 
relevant IT system.  THIN, as of July 2013, has electronic medical records on 11.1 
million patients, 3.7 million of whom are active, from 562 General Practices in the 
UK25. 
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1.5.4 QResearch 
QResearch is a not for profit organisation jointly funded by the University of 
Nottingham and EMIS. It dates back to the early 1990s and has records on over 13 
million patients from 660 General Practices26 
1.5.5 HES 
HES collects data on all admissions to NHS hospitals in England, including private 
patient, and non-residents; as well as admissions to private providers where the 
NHS is the purchaser of those services. Data is available from 1989 for admitted 
care and 2003 for outpatient attendance, with 12 million new episodes of admitted 
care and 40 million outpatient attendance records added each year27. 
1.5.6 Use of large administrative datasets in research 
Improvements in data storage capacities and GP IT systems have enabled the data 
warehouses to store greater volumes and variety of data increasing the scope of 
possible research. At the same time improvements in data processing and statistical 
packages have made it possible for the individual researcher to analyse complex 
data using relatively inexpensive personal computers. These developments have 
undoubtedly played a large part in driving the growth in research using data 
provided by these data warehouses. Now that these datasets are over 20 years old 
and in some instances nearer 30, they also offer the potential to examine the long 
term effects of policy and treatment. Examples of studies which have utilised the 
datasets in this manner include a study by Hayes, looking at 15 years prescribing 
trends in Bipolar disorder using THIN data28; and a study by Scowcrofe looking at 
thrombobrophylaxis rates in newly diagnosed AF patients over a 10 year period 
using CPRD data29. The advantages and disadvantages of using large pre collected 
datasets in research will be considered further in Chapter 8.  
1.5.7 Use of large administrative datasets in this research 
This study uses both CPRD and HES data. The recent introduction of linked 
patient data across these two datasets has enabled the researcher to track 
individuals from CPRD into certain HES linked files. This is the first study to our 
knowledge which has utilised these data linkages to look at individual patient level 
effects of QOF targets on clinical outcomes. Further details on how these two 
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datasets work in conjunction with each other and how the study used these linkages 
are provided in Chapter 6. 
1.6 Structure of the thesis 
The overall aim of this thesis is:  
To determine whether individual patient level performance against QOF target 
measures had an impact on evidence based clinical outcomes using CPRD and 
HES data. 
There are a number of pertinent points arising from this aim that will be addressed 
within the thesis. These are: 
1. What is the current evidence for the effectiveness of different forms of 
physician incentive on health outcomes?  
2. Which QOF targets had high level evidence and accessible data points to 
inform clinical outcome measures? 
3. What evidence exists for the effectiveness of physician incentives on hard 
and surrogate clinical outcomes in CHD patients? 
4. What research has been conducted on the effectiveness of QOF CHD 
targets? 
5. How can CPRD and HES be used to evaluate CHD QOF targets at an 
individual patient level? 
6. What do the analyses demonstrate about the association between QOF 
CHD targets and clinical outcomes? 
 
These questions and the overall aim will be addressed within the chapters of this 
thesis. The manner in which it will be done is outlined below where the aims and 
descriptions of each chapter are set out as well as their context within the thesis: 
 
Chapter 2 Evidence for the effectiveness of financial incentives in primary care 
Objective: To examine the evidence for the effectiveness of financial incentives in 
primary care, through a review of systematic reviews that report studies using high 
level study designs 
Description: This chapter introduces key economic concepts, and considers the 
effectiveness of physician incentives on the physician, patient, service implications 
and policy responses. The main focus is a review of reviews examining the high 
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level study design evidence, defined as well conducted randomised control trials 
(RCT), controlled before and after studies (CBA), meta-analyses or systematic 
reviews of those studies, level 1+ or 1++ studies or equivalent; looking at the 
impact of financial incentives in primary care30. The PICOD used in this review is 
as follows: 
x Population: Primary care physicians 
x Intervention: Any form of payment, incentive or reimbursement mechanism 
that affected the individual physician 
x Comparator: A suitable control who did not receive the intervention or a 
comparator group that received an alternative form of physician incentive. 
x Outcome: Any process, surrogate or clinical outcome measure  
x Design: RCTs, CBA studies 
Context: In examining the QOF it is important to be aware of the evidence for 
financial incentives in primary care, where P4P fits within it, and how 
effectiveness has been reported.  
 
Chapter 3 The evidence base for QOF clinical targets and feasibility of extracting 
linked hospital admissions 
Objective: To select from the QOF clinical domain, targets, which have high level 
evidence of improved clinical outcomes which can be readily extracted and 
modelled using CPRD and HES data. 
Description: This chapter looks at the clinical guideline evidence for QOF targets 
to determine which of them have high level evidence of clinical effectiveness. It 
then selects from the targets supported by high level evidence those which can be 
best measured and modelled using data extracted from CPRD and HES. 
Context: In order to demonstrate the effectiveness of the QOF it is important to 
select targets that have clinical benefits that are established, and can be measured 
using CPRD and HES data. 
 
Chapter 4 The effectiveness of physician incentives on CHD clinical outcomes 
Objective: To examine the effectiveness of financial incentives on hard and 
surrogate CHD clinical outcomes. 
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Description: This chapter looks at the evidence for the effects of physician 
financial incentives on hard and surrogate clinical outcomes in CHD patients. No 
requirements on study design were specified. The PICO used is as follows: 
x Population: Patients who had a known CHD diagnosis or were admitted with 
complications arising from CHD  
x Intervention:  Any form of physician financial incentive  
x Comparator: Within comparison (before and after) or between comparison 
against comparable populations in different settings (e.g. Countries, States) 
where different physician incentives operated. 
x Outcome:  Condition specific hard and surrogate clinical outcomes reported at 
the patient level. 
Context: The previous chapter identified CHD as the condition by which to assess 
the effectiveness of QOF targets. That effectiveness will be measured by clinical 
outcomes using large linked administrative datasets. This chapter therefore sets out 
to explore the existing study evidence for the effect of incentives on clinical 
outcomes in CHD patients. Since the review in Chapter 2 revealed a lack of high 
level research evidence on the effects of physician incentives and limited reporting 
of clinical outcomes: It was decided to relax the study design inclusion criteria to 
capture other relevant studies, and undertake a broader review of the literature. 
 
Chapter 5 CHD in the QOF 
Objective: To explore what research exists on CHD in the QOF, and what this 
research can contribute to the existing body of evidence. 
Description: This chapter reviews all the literature on CHD and the QOF without 
any restrictions on study design to determine what exists, how it is reported and 
what it shows. Studies are included if they met the following PICOD criteria: 
x Population: Patients diagnosed with CHD  
x Intervention: QOF P4P scheme 
x Outcomes: QOF CHD target measures, surrogate measures that mapped to 
those targets, or clinical outcomes, reported  at the patient level 
x Design: Had to include a minimum of two time points at least one of which had 
WREHSRVWWKH42)¶VLQWURGXFWLRQ 
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Context: Due to the absence of a comparator or control group, studies on the QOF 
have not been included in previous literature reviews. Given the focus of the thesis 
is on the QOF it was important to determine what research has already been 
undertaken on the QOF and CHD specifically. The absence of QOF studies in 
previous reviews reflected weaknesses in study design, largely a consequence of 
the way in which the scheme was implemented. This review therefore placed 
minimal restrictions on study design to ensure that as much of the existing 
literature was included as practically possible.  
 
Chapter 6 Methodology: Using CPRD and HES data to model the QOF 
Objective: To explain how data from CPRD and HES can be used to construct 
variables relevant to the analysis of the impact of the QOF 
Description: This chapter explains how the two databases are organised; data was 
extracted from their file structures, and used to create QOF and other variables 
relevant to this study.  
Context: As this study uses routinely available administrative data it is important to 
describe these sources and set out the methodological approaches that were used to 
create dependent and explanatory variables of interest. This is the first study on the 
QOF to link individuals across CPRD and HES, and therefore clarity on how data 
was sourced and variables constructed was important.  
 
Chapter 7 Data description and analysis 
Objective:  To explore the relationship between evidence based targets in the QOF 
and other relevant variables with the CHD clinical outcomes of interest. 
Description: This chapter introduces econometrics, panel data, and the alternative 
model specifications available. A descriptive analysis is undertaken on key study 
variables and their panel properties. Panel data econometric analysis is then 
conducted using those variables and its results interpreted 
Context: Previous chapters identified gaps in the literature with regards to an 
absence of clinical outcome measures and short follow up of patients and 
incentives. This chapter examines at the individual level whether there is a 
relationship between compliance with QOF CHD targets and condition specific 
clinical outcomes, over an 11 year period. It is the first study to do so using 
individual patient level linkages between CPRD and HES. 
21 
 
 
Chapter 8 Discussion and synthesis 
Objective: To summarise and synthesize the information gathered in the thesis 
Description: This chapter draws together the findings from all the chapters in the 
thesis to draw conclusions, policy implications, and recommendations for future 
research. 
Context: This is the culmination of all the previous chapters where the main points 
are brought together to comprehensively review the evidence gathered in the 
context of the overall research aim, and address its implications for clinical 
practice 
1.7 Summary  
The QOF represents a substantial and sustained investment in P4P in primary care 
in the UK NHS. It is one of the biggest investments in P4P in health care globally. 
As such it offers the researcher the opportunity to evaluate the effectiveness of this 
area of financial incentivisation. CHD is a chronic and life threatening condition 
affecting over 2.5 million in the UK; represents the biggest cause of premature 
death; and places a significant cost burden on the UK NHS and wider economy. 
Therefore reducing the complications arising from CHD through better 
management in primary care will not only directly benefit the individual patient 
but has the potential to be cost saving by reducing demands on other areas of the 
health service.  In addition to NHS cost savings, improved disease management in 
primary care has potentially wider societal and economic benefits. 
This thesis, over the following chapters, will attempt to determine whether meeting 
evidence based targets in the QOF for the secondary prevention of CHD has had a 
noticeable impact on clinical outcomes at the individual patient level. In doing so it 
should help to answer questions concerning the effectiveness of incentives in 
improving patient outcomes. This not only has policy implications for the QOF, 
and financial incentivisation in primary care generally, but ties in with the future 
direction of the NHS as set out in the White paper of 2010 and enacted by the 
Health and Social Care Act, 201231. The vision set out in the white paper puts 
patients at the heart of all decisions and places a relentless focus on clinical 
outcomes. This is the direction taken in the thesis which focuses research at the 
individual patient level and is concerned with clinically significant outcomes. It 
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will also demonstrate the challenges and benefits of modelling the QOF using large 
medical administrative datasets, and their potential in future research evaluating 
the effects of policy. 
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Chapter 2 Evidence for the effectiveness of 
financial incentives in primary care 
2.1 Objective 
To explore the economics of financial incentives and examine their effectiveness in 
primary care, through a review of systematic reviews that report primary studies 
using high level study designs (RCT or CBA studies) 
2.2 Introduction 
Pay for performance schemes, like the QOF, are a recent innovation within the UK 
and other health care systems. To place the QOF in a context this chapter will look 
at other forms of incentivisation that are also used, as well as different methods of 
funding and delivering health care. These will be considered in an economics 
context examining market imperfections in health care, their incentives effects on 
physicians and service delivery implications. Finally a review of reviews will look 
at the high level study design evidence on the effects of physician incentives. The 
research themes this chapter seeks to answer are: What high level study evidence 
exists for the performance of different forms of physician incentives in primary 
care? What does it show? How does it inform research on the QOF? 
2.3 Health care delivery and physician incentives 
2.3.1 Economic context 
Policy makers, providers and consumers of health care have faced a constant 
struggle to contain costs, meet increasing demands and keep up with increased 
expectations.  Different forms of incentivisation have been and still are used, Pay 
for Performance (P4P) being the most recently favoured; to maximise patient 
benefit at the lowest cost. These also reflect attempts to deal with market 
imperfections inherent in the health care system. Key among them is an 
information asymmetry between consumers and providers. Physicians, the 
providers of health care, are better informed than consumers of care, patients, 
meaning there is an incentive for them to create unnecessary demand for their 
services to boost their income. We refer to this excess demand created by the 
physician for their services as Supplier Induced Demand32. Any health 
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management system or payment mechanism will attempt to curb this incentive 
while maximising some notion of patient health and controlling costs. 
How health care is delivered reflects national priorities, politics and sensibilities. A 
free market in health care is not tolerated at a national level as the costs can be high 
and unpredictable, while some people, usually the most sick and infirm are the 
least likely to have the means to pay for it. Due to this uncertainty over costs and 
timing of demand, healthcare as a commodity is something which lends itself to 
insurance33. As those risks and costs are greatest in the sick and elderly and lowest 
in the younger  healthier working population, the latter given free choice would be 
more willing to forsake insurance or only take it up at a price commensurate to 
their risk. This would make costs unaffordable for the former, when their means 
are at their most limited, and therefore some form of compulsion is introduced into 
all modern health care systems, as it is in a number of other insurance markets.  In 
addition there are also positive externalities associated with healthcare, which are 
not reflected in its market cost. As a society we all benefit from aspects of public 
health provision as a healthier population means everyone is less likely to get 
infectious diseases34. Likewise we all benefit from mass immunisation 
programmes by the protection it confers on the whole of society. Left to the market 
there would be an under provision of these positive externalities, as individuals 
thinking only of their own benefits and not those conferred on the rest of society, 
would be willing to forego treatment imposing negative externalities on others35. 
2.3.2 Paying for and delivering health care 
For all the reasons discussed the UK and most other health systems use some form 
of pooled insurance where people actually or notionally pay into a centrally funded 
scheme. This fund can then be used to provide comprehensive universal health 
coverage such as the UK National Health Service (NHS). Alternatively it may be 
used to provide a universal minimum level which all citizens draw upon, or only 
those who risk being excluded entirely from health care for the financial reasons 
previously identified, such as the elderly and unemployed. In systems with a 
limited state provision additional individual health insurance will usually be 
purchased by the individual or provided by their employers, with statutory 
legislation compelling them to do so. 
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2.3.3 Paying physicians 
There are numerous forms of physician incentives common, but used in differing 
proportions, across the different healthcare delivery systems. There is the salaried 
system where the physician is paid an annual salary for their services. This may 
form the whole or part of their annual income. While this controls supplier induced 
demand, it neither contains costs, incentivises productivity, or rewards higher 
workload. Indeed it incentives the physician to minimise their workload either by 
denying care or passing on patients to other areas of the health care system where 
possible. To supplement payment in a salaried system and to incentivise the 
physician to contain costs we often find capitation payments. In its simplest form 
this is a fixed payment for each patient on a practice list, however in reality these 
will be adjusted for the age, deprivation and the disease prevalence profile of the 
population to reflect costs and workload. This forces the physician to contain costs 
within the capitation budget, while theoretically providing an incentive for 
physicians to recruit and retain patients so they receive that capitation element. Fee 
for service (FFS) is also used widely but most commonly in private health 
insurance schemes. This pays the physician a fee for each unit undertaken of the 
activity that attracts the fee. Under this system the physician is rewarded for their 
activity so it rewards efficiency and productivity in the fee attracting areas. 
However as the physician only gets paid if they undertake the activity, and for each 
unit they undertake, it is also the system where the incentive to induce demand is at 
its greatest, and where it is most difficult to contain costs. It can also lead to 
resource substitution away from areas not attracting the fee, or less generous fees, 
to those which do, to the detriment of care and outcomes in those areas. 
More recently we have seen a move towards pay for performance or target 
payments. These forms of payments are very similar, both rewarding physicians 
for reaching set targets. In the Cochrane review on target payments they are 
described DV D V\VWHPZKHUH ³D OXPS VXPSD\PHQW LVPDGH LI DQGRQO\ LI WKH
primary care physician (PCP) reaches a predetermined quantity or target level of 
care.36´ ,Q FRQWUDVW Say for performance (P4P) rewards physicians for meeting 
certain efficiency or quality measures. The differences are thus subtle as a target 
can be quality related and often activity targets are included with quality measures 
such as the event record targets in the QOF. Hence the divisions between the two 
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are often blurred and target payments and P4P are often seen as a single form of 
physician payments coming under the P4P banner. As these forms of physician 
payment are not activity based, unlike FFS, and triggered only, and once only, 
when the standard or target is met, there is no financial incentive for the physician 
to over treat or induce demand for their services. 
2.4 Review of reviews of primary care incentives 
A review of systematic reviews was undertaken to identify the current evidence in 
well-designed structured reviews, on the effectiveness of different forms of 
financial incentives in primary care. The Cochrane Library37; Embase and Medline 
databases on the Ovid SP search platform, and PubMed were searched for relevant 
systematic reviews. The reason behind the review was to gain an appreciation of 
the evidence for the effectiveness of P4P specifically, but also on physician 
incentives more generally to see if there were any lessons for primary care as a 
whole, and research on the QOF specifically. Only clinical or surrogate outcomes, 
or process measures, were of interest to this review. These relate to quantitative 
clinical interventions directed at, or measured at, a patient level. Process measures 
refer to clinical processes such as the prescription of drugs, surrogate outcomes to 
any measure that maps (correlates) to a clinical outcomes; such as blood pressure 
control, and clinical outcomes, to hospital based clinical activity. Qualitative 
performance measures such as patient satisfaction and compliance with guidelines 
were not of interest and not included. This review compares P4P schemes like the 
QOF to other forms of physician incentives. To best facilitate this only those 
reviews which focused on well-designed randomised controlled trials (RCT), and 
controlled before and after studies (CBA), or high quality meta-analyses of those 
study designs were included. These are referred to in this chapter, and throughout 
WKHWKHVLVDVµKLJKOHYHOVWXG\GHVLJQV¶In terms of national guideline development 
bodies such as the National Institute of Health and Care Excellence (NICE) and 
Scottish Intercollegiate Guidelines Network (SIGN), these would closely match 
level 1+ and 1++ levels of evidence 30. Since the focus was only on these, what are 
considered stronger, study designs, this necessarily meant that the large amount of 
UHVHDUFK LQ WKLV DUHDZKLFKXVHG OHVV µUREXVW¶ VWXG\GHVLJQVZDVQHJOHFWHG7KH
rationale for this approach is that the study designs chosen minimise bias and 
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confounding, and hence where there is evidence of an effect, there would be a 
significant degree of confidence that this was the result of the intervention. 
2.4.1 Inclusion criteria 
Systematic reviews were included if they met the following criteria: 
1. Population: Primary care physicians 
2. Intervention: Any form of payment, incentive or reimbursement 
mechanism that affected the individual physician 
3. Comparator: A suitable control who did not receive the intervention or a 
comparator group that received an alternative form of physician payment. 
4. Outcome: Any process, surrogate or clinical outcome measure 
5. Design: RCTs, CBA studies 
The main search terms are summarised in Figure 2-1 for the OvidSP search 
platform with full details on all database search terms provided in Appendix 1. 
Figure 2-1 Review of reviews literature search terms 
 
The PRISMA diagram in Figure 2-2 details the search for reviews of systematic 
reviews 
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Figure 2-2: Review of reviews PRISMA diagram 
 
Four separate databases were searched, with details on the number of articles found 
on each shown above.  All non-duplicate articles found underwent title and abstract 
review, with ten retrieved for full text review. Five of these were dropped at full 
review, with five included in the final review. 
2.4.2 Details of excluded and included studies 
2.4.2.1 Excluded reviews 
The reasons for excluding studies is given in the Table 2-1 with specific reference 
to the PICOD (Population, Intervention, Comparator, Outcome, Design) inclusion 
criteria the review failed where applicable. 
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Table 2-1 Excluded reviews, primary care incentives, details 
Study PICO Reason for exclusion 
Gosden, 
199938 
D The focus was not on high level study design research 
evidence: Majority of included studies were case control. 
Gosden, 
200139 
N/A This study repeats the findings of the Cochrane reviews 
previously undertaken by the authors, which are included in 
the review36 40. 
Peckham, 
201041 
N/A The article is a discussion paper which broadly discusses the 
literature rather than analysing it systematically 
Vahidi, 
201342 
D The focus was not on high level study design research 
evidence:  The majority of the primary literature were cohort 
and comparative studies 
Van 
Herck, 
201043 
D The focus was not on high level study design research 
evidence: Included any primary evaluation study published in 
a peer reviewed journal 
 
2.4.2.2 Included reviews 
Key points concerning the conduct of the included studies are summarised in Table 
2-2. 
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Table 2-2: Included reviews, primary care incentives, details 
Author Databases searched Search 
Period 
Interventions 
considered 
Selection criteria / Specific clinical focus Studies 
included 
Giuffrida, 
199936 
Medline, Embase, EconLit, 
Health Star, HMIS, Cochrane 
library 
1966-
1997 
Target 
payments 
-5&7¶V&%$,76 
-Had to meet EPOC criteria 
2 
Gosden, 
200040 
Embase, ISI Social Science 
Index, EconLit, Health Star, 
HMIS,  Cochrane library, 
Medline 
1966-
1997 
Capitation, 
salary, FFS 
-5&7¶V&%$,76 
-Had to meet EPOC criteria 
8 
Petersen, 
200644 
PubMed 1980-
2005 
Any financial 
incentive 
designed to 
improve care 
-5&7¶V&%$ 
-Studies had to assess the use of financial incentives as 
the independent variable and a measure of quality as 
the dependent variable 
17 
Scott, 
201145 
Medline, PsychInfo, Embase,  
Cumulative Index to Nursing 
and Allied Health, EconLit, 
PAIS, Cochrane library 
2000-
2009 
P4P, Salary, 
FFS, Mixed, 
Capitation 
-5&7¶V4XDVL5&7¶V&%$,76 
Had to meet EPOC criteria 
7 
Town, EconLit, Business Source 1966- Any financial -5&7¶V 6 
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200546 Premier, PsychInfo, Medline, 
Cochrane library 
2002 incentive Had to look at the incentive independently of any other 
service interventions 
-Could not be simply for participation in a study 
-Limited to preventative care 
Study design: CBA=Controlled Before and After, ITS=Interrupted Times Series, RCT= Randomised Control Trials 
Cochrane Library refers to a search of any of the Cochrane databases; HMIS=Health Management Information System 
EPOC criteria refers to Cochrane Effective Practice and Organisation of Care criteria 
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2.4.3 Included reviews discussion 
The systematic reviews search period includes years from 1966-2009; a large 
number of search platforms and literature databases. At the same time there is a 
concentration on certain databases and consequently there is duplication in the 
reviews returned and examined. 
Three of the included reviews are from the Cochrane collaboration. The earliest by 
Gosden, 2000, looks at capitation, FFS and salary40. The most recent by Scott, 
201145, looks at all forms of physician payment with the exception of target 
payments which are covered in the third Cochrane review by Giuffrida, 199936. 
Town focuses on a specific area, the effect of incentives on provider preventative 
care46. Petersen is one of the earlier studies and the only one to limit its search to one 
database, PubMed44.  
2.4.4 Quality of included reviews 
The methodological quality of included studies was assessed using a reduced form of 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) checklist47. Ten of the 27 checklist points specific to systematic review 
and pertinent to this review of reviews were selected. These are summarised in the 
text below and reported in Table 2-3 with full details of the checklist specification 
provided in Appendix 2. 
1. Provide a structured study summary in the abstract 
2. Describe the rationale for the review in the context of existing work 
3. Specify study inclusion criteria 
4. Describe all information sources 
5. Present the full search strategy for at least one database 
6. State the process of screening and selecting studies 
7. Specify any assessment of risk of bias that may have affected the cumulative 
evidence 
8. Summarise the main findings of the studies 
9. Discuss limitations at the study, outcome and review level 
10. Give a general interpretation of the findings in the context of other evidence 
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Table 2-3: PRISMA checklist, included systematic reviews 
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Giuffrida, 
199936 
¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ 10 
Gosden, 
200040 
¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ 10 
Scott, 
201145 
¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ 10 
Petersen, 
200644 
¥ ¥ ¥ ¥  ¥ ¥ ¥ ¥ ¥ 9 
Town, 
200546 
 ¥ ¥ ¥    ¥ ¥ ¥ 6 
 
Three of the five included reviews met all the criteria, with one study deficient in one 
of the criteria. The review in question was by Petersen and was deficient with regard 
to reporting fully replicable details of their search strategy for at least one database44. 
This may have been available from the authors, but was not made available within 
the paper itself or within supporting material referenced within the paper. The 
remaining review by Town was deficient in four of the criteria, meaning that it has  a 
number of methodological quality issues when judged against this checklist46. 
Common with the review by Petersen it does not provide fully replicable details for 
one of its searches. In addition there is not a structured summary in the abstract; the 
review does not assess the risk of bias within their included studies; and they fail to 
produce a PRISMA diagram or description of how documents were screened and 
filtered to final inclusion46. 
2.5 Primary study level reporting 
None of the systematic reviews conducted any form of meta-analysis using their 
included studies. This is unsurprising given that the outcome measures in the 
primary literature were heterogeneous, making it impossible to meta-analyse their 
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results. The reviews, the Cochrane reviews in particular, focus on reporting the 
findings of each included study. There is some attempt to draw together findings in 
terms of common themes but this is limited in its success as the study findings are so 
disparate. Therefore in this section the main findings of the individual studies 
covered in the systematic reviews that met the inclusion criteria are reported, and 
evaluated, in the context of this chapter objective. 
The findings of the studies are reported in two separate tables in the following pages. 
Table 2-4 relates to studies where the comparison is between alternative payment 
systems, this includes all the non P4P studies. Since P4P incentives are either 
compared against the absence of P4P in within study designs or a control who did 
not receive the incentives in a between study design, the comparator is always 
against non P4P and not an alternative form of incentive. Therefore the results for 
P4P, the largest body of work, are reported separately in Table 2-5. Studies looking 
at target payments are also included under the P4P classification since, as discussed 
earlier; these can also be viewed as performance based incentives. Target payments 
take various forms but all forms reward performance to a pre specified outcome.
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Table 2-4: Included studies, primary care incentives, non P4P 
Study Intervention Comparator Context Measure Outcome 
Davidson, 
199248 
Capitation  FFS / 
Capitation 
&KLOGUHQ¶V
Medicaid 
Programme, USA 
Physician patient 
visits during study 
Regression coefficients (effect on utilisation): 
&DSLWDWLRQS))6S 
Referrals to 
specialists and 
hospitals during study 
Regression coefficients (effect on utilisation): 
Capitation:-S))6S! 
Hospitalisations 
during study 
Regression coefficients (effect on utilisation): 
Capitation:-S))6S! 
Gosden, 
200349 
Fixed Salary Capitation UK NHS Cervical cytology Mean difference (PMS-GMS) after 1 year  
=0.38 (95% CI, -14.9 to 15.67) not significant 
Childhood 
immunisation 
Mean difference (PMS-GMS) after 1 year  
=-1.08 (95% CI, -17.95 to 15.80) not significant 
Pre-school booster Mean difference (PMS-GMS) after 1 year  
=-3.08 (95% CI, -9.63 to 3.47) not significant 
Hickson, 
198750 
Salary FFS USA: Resident 
paediatricians, 
Continuity clinics 
Emergency visits  Numbers per patient (9 months):0.22 v 0.12, p<0.01 
Scheduled visits  Numbers  per patient (9 months): 2.83 v 3.69, p<0.01 
Hutchison, Capitation FFS Ontario, Canada Hospital days per 3 years post intervention compared to 1 year before; 
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199651 1000 patients additional 3 hospital days/1000, p=0.774 
 Krasnik, 
199052 
 
 
Partial FFS  Capitation Copenhagen 
county, Denmark 
Face to face contacts +7.2% after 6 months, -0.5% after 12 months* 
Telephone contacts +10% after 6 months; +11% after 12 months* 
Prescription renewals -9% after 6 months; -27.4% after 12 months* 
Hospital referrals -9.7% after 6 months; -33.7% after 12 months* 
Specialist referrals  -9.3% after 6 months; -21.2% after 12 months* 
Diagnostic services +32.8% after 6 months; +52.2% after 12 months* 
Curative services +88.6% after 6 months; +79.8% after 12 months* 
*Change in absolute numbers  over a one week period per 1000 patients compared to 6 months prior to the intervention  
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Table 2-5: Included studies, primary care incentives, P4P  
Study Context Measure Outcome 
An,  
200853 
Fairview Physicians 
Associates, USA 
Mean % of smokers referred to a telephone 
counselling service 
11.4% in the intervention group; 4.2% control group, over 
10 months (p=0.001) 
Fairbrother, 
199954 
New York, USA Increase in up to date Immunisations in 
children under 3 years old over 8 months 
+25.3% Bonus & feedback (p<0.01), +4.3% Enhanced FFS 
& Feedback, +12.6% Feedback only, +6.1% Control 
Fairbrother,
200155 
New York, USA Increase in up to date Immunisations in 
children under 3 years old over 1 year 
+5.9% Bonus & feedback(p<0.05), +7.4% Enhanced FFS & 
Feedback (p<0.01), -2.5% Control 
Grady, 
199756 
Massachusetts, USA Annual mammography compliance in 
females over 50 
Absolute increase from baseline over a 1 year period: 
Intervention 17.9%  Control 13.7% (no significant dif.) 
Hillman, 
199857 
Philadelphia, USA Compliance with cancer screening 
guidelines: 
Absolute change from baseline over 18 month period 
Intervention: 26.3%   Control: 26.4% (no significant dif.) 
Hillman, 
199958 
Philadelphia, USA Preventative care in under 6 year olds Absolute change from baseline over 18 month period 
Intervention: 17.2%   Control: 11.3% (no significant dif.) 
Kouides, 
199859 
New York State, 
USA 
Influenza vaccination rate for eligible 
patients 
Median practice specific improvement over 1 year: 
+ 10.3% in intervention group; 
+3.5% in the control group, p=0.03  
Mullen, 
201060 
Independent Health 
Association, 
Cervical screening rate 
 
Mean difference in absolute change from baseline 
Int group 1 (QIP) = -0.043%  (p>0.1) 
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California USA Int group 2 (IHA1+QIP2) =3.5% (p<0.01) 
Int group 3 (IHA2+QIP2) =6.01% (p<0.01) 
Mammography screening rate 
 
Mean difference in absolute change from baseline 
Int group 1 (QIP) = -1.067% (p>0.1) 
Int group 2 (IHA1+QIP2) =0.12% (p>0.1) 
Int group 3 (IHA2+QIP2) = 1.29% (p>0.1) 
HbA1c testing 
 
Mean difference in absolute change from baseline 
Int group 1 (QIP) = 1.357% (p>0.1) 
Int group 2 (IHA1+QIP2) = -3.756% (p<0.1) 
Int group 3 (IHA2+QIP2) =1.916% (p>0.1) 
Childhood immunisation 
 
Mean difference in absolute change from baseline 
Int group 1 (QIP) = 3.155% (p<0.05) 
Int group 2 (IHA1+QIP2) =2.078% (p<0.1) 
Ritchie, 
199261 
Grampians, Scotland  Pre-school immunisation rates 3UDFWLFHVDFKLHYLQJFRYHUDJHŐ 
Primary school immunisation rates 3UDFWLFHVDFKLHYLQJFRYHUDJHŐ 
Rosenthal, 
200562 
PacifiCare Health 
Systems, USA 
Cervical cancer screening 
 
1 year difference in differences compared to control: 
3.6% (p=0.02) 
Mammography 1 year difference in differences compared to control: 
1.7% (p=0.13) 
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Haemoglobin A1c testing 1 year difference in differences compared to control: 
0% (p=0.5) 
Roski,  
200363 
Mid West USA 7-day sustained abstinence from 
smoking 
Int1 (incentive) = 22.4% Int2 (registry) = 21.7% 
Cont = 19.2% (between groups, p=0.2) 
Twardella, 
200764 
Germany Smoking abstinence at 12 months Int1 (Training + Incentive)= 3% (p=0.75)# 
Int2 (Training + Medication)= 12% (p=0.046)# 
Int3 (TI + TM)= 15% (p=0.02)# Control (usual care)= 3% 
Young, 
200765 
Rochester, NY, USA Haemoglobin A1c testing Difference in changes in adherence rate (Pre2 to Pre3 vs 
Pre3 to Post1) = 0.9% (Non-significant) 
Urinalysis Difference in changes in adherence rate (Pre2 to Pre3 vs 
Pre3 to Post1) = 1.7% (Non-significant) 
Lipoprotein density level (LDL) Difference in changes in adherence rate (Pre2 to Pre3 vs 
Pre3 to Post1) = 0.3% (Non-significant) 
Eye examination Difference in changes in adherence rate (Pre2 to Pre3 vs 
Pre3 to Post1) = 5.1% (p<0.001) 
Ő2YHUDPRQWKSHULRG5HVXOWVQRWVLJQLILFDQWZKHQDGMXVWHGIRUSUHYLRXVWLPHWUHQGFRPSDUHGWRWKHFRQWUROJroup 
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2.5.1 Primary study details 
2.5.1.1 Non P4P 
The individual studies cover the UK, USA, Canada and Denmark. Davidson 
compares primary care physicians (PCPs) paid by age adjusted capitation to two FFS 
groups, one paid the normal Medicaid fee and the other a new higher rate; double the 
H[LVWLQJUDWHDOORIZKRPSDUWLFLSDWHGLQWKH&KLOGUHQ¶V0HGLFDO3URJUDPPH48.  The 
capitation group had to set aside $25 a month to provide services they did not 
directly provide. If they spent below this budget they received a 40% bonus, if they 
exceeded it they were liable to a charge of up to $2000 per child and 25% of their 
budget. Gosden looked at the effect of changes introduced in the NHS (Primary 
&DUH $FW RI  ZKLFK SURYLGHG WKH RSSRUWXQLW\ IRU *3¶V WR PRYH IURP D
capitation General Medical Services (GMS) contract to locally arranged salaried 
employment to provide Personal Medical Services (PMS)49. Hickson compared 
resident paediatric PCPs allocated to FFS and fixed salary in Ontario, Canada50. 
Krasnik looked at the effect of introducing fees in a capitation system compared to a 
control group of PCPs already paid under a mixed capitation FFS system in 
Stockholm52.   
2.5.1.2 P4P 
Included studies looking specifically at P4P are drawn from the UK, USA and 
German health care systems. An et al, looked at the effect of financial incentives, 
$5000 for the first 50 patients, $25 for each patient thereafter; on referrals of 
smokers to a telephone counselling service by clinics in Minnesota, USA53. 
*UDG\¶V VWXG\ LV Foncerned with a bonus scheme that paid physicians $50 if their 
referral rate of women over 50 for mammography was over 50%.  
Kouides considered target payments made to 54 general practices based in Monroe 
County, New York state59. The intervention paid an additional 10% on top of the 
normal $8 fee for each influenza vaccination made over the target rate of 70%, and 
20% for each vaccination over an 85% target.  
Mullen examines the effects on 172 eligible medical groups of two schemes60. One 
implemented by PacifiCare Health Systems, known as the Quality Incentive 
Programme (QIP). The second a much larger scheme, which soon overshadowed the 
former, was a P4P scheme operated by the Independent Health Association (IHA), a 
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QRW IRUSURILWFRDOLWLRQRIVL[+02¶V LQ&DOLIRUQLD7KHDQDO\VLVZDVEURNHQGRZQ
further following an updated version of the QIP and different stages of adoption of 
the IHA (Year 1 or 2). The study uses difference in difference analysis, an 
econometric technique which compares the marginal effect difference within patients 
in the intervention and control group, assuming fixed time effects. In this instance 
the control group were comparable medical groups from the Pacific North West who 
were also in contracts with PacifiCare. Rosenthal also considered the HMO, 
PacifiCare Health Systems, to look at the effect of quarterly bonus payments, 
administered through the QIP programme in 134 medical groups on rates of cervical 
cancer and mammography screening, and HbA1c testing62. The control group were 
33 medical groups from the Pacific North West, whose results were reported 
contemporaneously. Difference in differences analysis was again used to compare 
differences in marginal attainment between the intervention and control group.  
Ritchie looked at the Grampian region of Scotland covering 95 General Practices and 
 *3¶V LPPHGLDWHO\ EHIRUH DQG DIWHU WKH  *3 FRQWUDFW FKDQJHV61. These 
changes led to practices being given a lump sum payment if they immunised 70% of 
their eligible population and a higher lump sum if that figure was 90% or more. 
Roski examines the effects of incentives paid to 25 clinics in the Mid-West of the 
USA for meeting pre-set targets for recording smoking status and offering smoking 
cessation advice (intervention 1)63. Ten of these were also provided with access to a 
centralised patient registry and intervention system (intervention 2).  
TwardelODFRQVLGHUV WKHHIIHFWRIDQ LQFHQWLYHRIIHUHG WR*HUPDQ*3¶VRIIRU
every patient they recruited who smoked more than 10 cigarettes a day and who were 
smoke free at 12 months follow up64. The study was split into four arms with a 
control group of 20 practices offering usual care; 21 in the incentive scheme (Int1); 
21 whom could spend up to the amount of the incentive on offering free 
prescriptions for drugs proven effective in smoking cessation (Int2); and a fourth arm 
who had the flexibility to spend the money on offering free prescriptions or keep it, 
in whatever proportion they wished (Int3). All three intervention groups were offered 
training on methods of delivering smoking cessation. 
There are two studies by Fairbrother, both looking at the effectiveness of incentives 
in the area of infant immunisation in New York, USA54 55. The earlier of the two 
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included studies looks at the effect of a cash bonus and enhanced FFS, both 
combined with feedback, compared to a group that received feedback only and a 
control group. Physicians were randomly allocated to one of the four groups. Those 
in the cash bonus group were paid $1000 for practice wide increases from baseline of 
20%, $2500 for 40% improvement, and $5000 for an 80% up to date coverage rate54. 
The enhanced FFS intervention group received quarterly payments of $5 for each 
vaccination given within 30 days of it coming due, and $15 for each visit at which 
more than 1 vaccine was due and all were administered. The effectiveness of the 
interventions was measured 4 and 8 months from baseline. The later study was 
intended to follow the first, but was delayed by 12 months55. In this study the 
effectiveness of the intervention was measured at 4, 8 and 12 months from baseline, 
and there was a number of other changes: In the bonus group the threshold for the 
$1000 payment increased to 30% and for the $2500 payment to 45%; while a new 
payment of $7500 was introduced for a 90% up to date coverage rate. In addition the 
feedback only group was removed; details for the enhanced FFS group however did 
remain the same. Of the 60 physicians who took part in the first study 8 were lost to 
the second study, and 12 physicians were newly recruited to take their place. 
Two studies are also included by Hillman, concerning different clinical areas57 58. 
The earliest looks at incentives paid for compliance with cancer screening guidelines 
which paid half yearly bonuses for good performers57. Based on aggregate scores 
and improvement in scores the best performing 3 sites received a bonus equal to 20% 
of capitation for all females over 50 on their list, with the 3 next best performers 
receiving a 10% of capitation bonus for females over 50 on their list. The more 
recent study was concerned with preventative care in children under 6 years of age58. 
Based upon a minimum attainment of 20% on all quality indicators relating to 
immunisations and visits; the three highest performing practices received an extra 
20% on top of their capitation rate for the under 6 population; and the three next best 
an extra 10%.  
Young et al, use an interrupted times series analysis, to look at the effect of an 
LQFHQWLYH VFKHPH SDLG WR  3&3¶V LQ WKH 5RFKHVWHU ,QGLYLGXDO 3UDFWLFH
$VVRFLDWLRQEDVHGRQWKHLUSHUIRUPDQFHRQGLDEHWHVWDUJHWV UHODWLYHWRRWKHU3&3¶V
in the study group65. To fund the incentive scheme each member had 5% of their fees 
with-held but would have 50-150% of that returned based on their relative 
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performance. The targets were for HbA1c test, Urinalysis, Lipoprotein density levels 
and eye examinations.   
2.5.2 Discussion of findings 
There is a large heterogeneity of interventions considered and outcome measures 
used, which makes meta-analyses impractical. No strong evidence was found for a 
specific form of physician incentive. Incentives which reward activity or outcomes 
were generally found to lead to desired improvements on those measures. However 
these improvements were measured using process measures principally so it is 
uncertain if they had any clinical benefits.  
Overall none of the primary studies looked at the effectiveness of incentives in 
primary care to evidence linked clinical outcomes. Instead the focus was largely on 
process measures in primary care and where secondary care outcomes were reported 
they were general measures of hospitalisation. None of the P4P studies looked at 
clinical outcomes, and very few used surrogate outcome measures. 
As with the reporting in the tables the discussion is split down into P4P studies and 
non P4P studies with an additional overall section which draws findings from all the 
studies for shared clinical areas. 
2.5.2.1 Non P4P studies 
Three of the five non P4P studies compare FFS and capitation. These largely found 
more activity on the part of FFS physicians in routine and preventative primary care. 
Davidson found a statistically significant higher rate of physician visits in the higher 
))6 LQWHUYHQWLRQ FRPSDUHG WR WKH XVXDO ))6 UDWH FRQWURO JURXS S
Differences in referrals to specialists and hospital, and hospitalisations during the 
intervention period, were however insignificant. In comparison those paid by 
capitation registered a smaller increase in visits relative to higher rate FFS 
physicians, but one tKDWZDVVWLOOVWDWLVWLFDOO\VLJQLILFDQWSDQGDVWDWLVWLFDOO\
significant decrease in referrals and hospitalisations. Hence the authors concluded 
that there was no disadvantage to patients from the switch to capitation48. 
Hutchison finds no statistically significant difference in hospital days per 1000 
patients between the two payment methods51. Krasnik, a lower rate of prescribing by 
FFS physicians but a higher rate of face to face consultations, after 6 months only; 
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and in referrals, diagnostic, and curative services, after both 6 and 12 months52. 
These results were not tested for statistical significance. 
The remaining two non P4P studies included salaried physicians, comparing them 
against capitation and FFS remunerated physicians. Gosden finds no significant 
difference in cervical cytology, childhood immunisation and preschool booster rates 
between capitation and fixed salary. Hickson  that paediatric physicians paid by FFS 
carried out more scheduled visits per patient (p<0.01) and fewer emergency visits 
(p<0.01) than their capitation remunerated counterparts; the latter the authors 
attribute to a better continuity of care by FFS physicians50. The comparison between 
the results of these two studies would seem to confirm the hypothesis that activity 
based incentive payments do generate greater physician activity. This may have 
some clinical benefits but with no clinical outcomes reported it is not possible to 
confirm this from these studies.  
2.5.2.2 P4P studies 
The evidence generally showed an improvement in outcomes but these were 
insignificant in the majority of studies, and so overall not conclusive. An, finds a 
PXFK KLJKHU UDWH RI UHIHUUDOV WR D VPRNLQJ FRXQVHOOLQJ VHUYLFH IRU WKRVH 3&3¶V
offered incentives, a result which is statistically significant (p=0.001)53. Mullen 
shows significant positive increases in mean absolute screening percentages for those 
physicians paid by the two P4P incentive schemes as opposed to those paid by a 
single P4P scheme the Quality Incentive Programme (QIP), and from later variants 
of the same schemes (p<0.01). However the results on the other measures are less 
encouraging with those paid by the QIP alone having higher mean absolute changes 
in childhood immunisation (p<0.05) than those paid by combinations of the QIP and 
Independent Health Association (IHA) (p<0.1), and QIP alone outperforming IHA1 
and QIP2 on HbA1c60. Looking at similar outcomes to Mullen, Rosenthal finds 
significant improvements on cervical cancer screening in the intervention group 
compared to the control (p=0.02), but not in mammography screening (p=0.13), and 
HbA1c testing (p=0.5)62.  
Roski looks at the effect of incentives on smoking recording and cessation, with and 
without a patient registry, compared to a control63. Rates of abstinence, intention to 
quit and use of a counselling programme were higher in the intervention groups but 
lower for the use of pharmaceutical aids and cessation assistance. On the main 
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outcome measure 7 day sustained smoking abstinence Roski found no significant 
difference between the intervention and control groups (p=0.02). The only 
significant difference found was with regard to a higher percentage of the registry 
population reporting having used any counselling service for smoking cessation 
(p=0.001). Twardella also examines the effects of incentives on smoking cessation64. 
This showed no impact of the incentives relative to a control group, but noticeable 
difference in rates when the GP had the option to spend some (p=0.02) or all 
(p=0.05) of the incentive on offering free prescriptions for proven pharmaceuticals in 
that area.  
Grady looks at the annual change in mammography compliance and finds no 
significant difference in this figure in the intervention group relative to the control56. 
In the study by Ritchie the number of practices achieving at least a 95% coverage 
figure for primary school immunisation increased by 50% over a 21 month period 
following the intervention, and by 20% for the at least a 90% coverage61. For pre-
school immunisation the numbers meeting at least a 95% and 90% coverage, both 
increased by 41%. However after fitting a logistic regression model the authors 
found no significant difference to trend following the introduction of targets 
payments.  
There are two studies by Fairbrother, both looking at the same target payment 
scheme on childhood immunisation rates.54 55. In the earlier study the bonus group 
increased coverage significantly more than the control group (p<0.05). However this 
was from a much lower baseline than the enhanced FFS group, 29.1% compared to 
46.2%. From a much higher baseline in the second study period the increase in up to 
date coverage for the bonus group was more modest but still significant  (p<0.05),  
albeit less than that experienced in the enhanced FFS group (p<0.01). When the 
incentive was withdrawn for the 12 months between the two studies, coverage did 
not fall back and remained similar to the rates seen at the end of the first incentive 
period. While this was only a short period it suggests that targets may change 
behaviour even after they are withdrawn.  
Finally Young finds no significant difference in adherence rates, allowing for time 
trends, of a P4P scheme based on relative performance and paid for by withholding 
existing monies, on all measures, with the exception of eye examinations65. 
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2.5.2.3 Overall findings 
A number of studies have a shared focus on the same clinical measures which 
presents the opportunity to find agreement and disagreement in their results and 
attempt to weigh up the wider effect of physician incentives. One of these is 
childhood immunisation, which five studies consider49 54 55 60 61. Three of these 
considered target payments, with two coming from the same author, examining 
broadly the same scheme in New York State54 55, the remaining study considered a 
scheme in the UK49. All showed an increase from baseline, the studies by Fairbrother 
showed this to be significant compared to the control group54 55, the study by Ritchie 
found it to be insignificant when existing trends were taken into consideration49. In 
the study by Ritchie the majority of physicians met the required levels to trigger 
payments, while in the Fairbrother studies, based on overall attainment figures one 
target was met in the first period, and none in the second period. Despite this the 
effect was significant in both periods compared to the control group. It is worth 
noting that the Fairbrother studies did not adjust for baseline attainment, or trend as 
in the study by Ritchie, so it possible that these effects may not have been significant 
had they done so.  
The study by Mullen also considers the impact on childhood immunisation in a pay 
for performance setting60. This showed, counter intuitively and in contrast to the 
other clinical areas considered, that greater incentives available through participating 
in multiple schemes had a less significant impact than participating in the single QIP 
scheme (p<0.05). This may be a service that physicians are minded to do regardless 
of specific incentives which would explain this result. Finally the study by Gosden 
looks at the impact of moving from capitation to fixed salary payments on childhood 
immunisation rates49. Unsurprisingly, since neither payment method incentives 
productivity nor improved outcomes, the results were not significantly different.  
Three studies looked at cervical cancer screening49 60 62. In the study by Gosden the 
change from capitation to fixed salary again had no impact on screening rates at the 
95% significance level49. Mullen found a significant increase in the marginal mean 
difference for those participating in multiple incentive schemes compared to the 
control group (p<0.01), but an insignificant difference between the single incentive 
and control groups (p<0.1)60. This results suggest that the financial size of incentives 
do play a role contrary to their findings for childhood immunisation60. Equally 
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Rosenthal finds a significant increase in cervical cancer screening rate in those 
receiving P4P incentives compared to a control group (p=0.02)62. 
Three studies, all P4P, consider HbA1c testing as one of their outcomes60 62 65. 
Mullen finds a fall in the marginal rate of testing in those who adopted the IHA in its 
first year (IHA1) and the second version of QIP (QIP2) but an increase in those 
joining in the second year of the IHA incentive scheme, IHA2+QIP2. However, none 
of these changes were significantly different to baseline rates (p>0.1).  Rosenthal 
finds the same increase from baseline in the intervention and control group (2.1%), 
though only in the intervention group is this increase significant (p=0.02)62. Finally 
Young who uses an interrupted time series to attempt to adjust for trend finds no 
significant increase in HbA1c testing following the introduction of P4P, when the 
existing trend is taken into consideration (p>0.05). 
Two P4P studies look at smoking cessation services63 64. Both the study by Roski 
and Twardella suggest that incentives alone had no impact on smoking cessation. 
+RZHYHU7ZDUGHOODIRXQGWKDWJLYLQJLQGLYLGXDOSK\VLFLDQ¶VGLVFUHWLRQRQKRw some 
or all of that financial incentive was spent did have a significant impact on smoking 
abstinence in patients.  
Overall comparing across the different interventions these results suggest that 
payment methods that do not distinguish by performance such as capitation and 
fixed salary had no impact on levels of activity. P4P does have a positive impact on 
the whole, but one that is not consistently statistically significant.  
2.6 Implications for practice 
The primary studies have identified a number of implications for practice.  These are 
listed below: 
x The studies did not find conclusively in favour of any particular form of financial 
LQFHQWLYH 7KH\ JHQHUDOO\ VKRZHG WKDW 3&3¶V UHVSRQGHG WR JUHDWHU ILQDQFLDO
incentives with better performance or more activity in those areas which attracted 
incentives. It is uncertain from the studies included whether this was at the 
expense of non-incentivised areas, however giYHQ WKDW D SK\VLFLDQ¶V WLPH LV
limited it is plausible to assume that there was may have been some level of 
resource substitution. 
48 
 
x Using existing money to pay for the incentive may have a negative impact on its 
effectiveness64 ZKLOH JLYLQJ LQGLYLGXDO SK\VLFLDQ¶V JUHDWHU DXWRQRP\ LQ KRZ
financial incentives can be spent to meet targets appeared to improve attainment 
on those targets64 65.  
x All studies that have looked at the impact of changes in physician payment have 
done so over a relatively short time period. Incentives where they have been put 
in place have been limited in their duration. Possibly due to this the focus has 
been on process measures with no consideration of hard clinical outcomes or 
endpoints.  
x There is evidence that physician response to incentives may be short lived, with 
normal activity levels resumed after an initial spurt in activity when the incentive 
is first introduced. In the study by Krasnik, FFS generated more activity 
compared to a capitation system in areas that attracted the fee, but differences 
dissipated over time52. This was consistent with the target income hypothesis 
explored in the Krasnik paper.  This hypothesis suggests that a physician¶V
supply of labour and behaviour is determined by their motivation to maintain a 
target level of income. Hence in the short term changes to incentives can lead to 
significant changes in behaviour and activity by the physician, while they learn 
to adapt to the new circumstances.  In the longer term however, once that 
learning process is complete, activity and behaviour settles around that level 
needed to maintain their target income. On the opposite side evidence was found 
which showed that performance did not drop to levels seen before the 
introduction of the incentive, in this case target payments, when they were 
temporarily withdrawn54 55  
x Mixed incentives schemes by mitigating the perceived weakness or perverse 
incentives in a specific form of incentivisation, may lead to more desirable 
outcomes. In the study by Hickson IL[HGVDODU\3&3¶VXQGHUWRRN IHZHU URXWLQH
visits and had higher emergency admissions in secondary care50. This could be 
indicative of the incentive in such a system to pass workload onto other parts of 
the system. However in the study by Davidson looking at capitation which has a 
similar incentive to pass costs onto other parts or the system; when this was 
combined with an incentive to limit referral to outside services, those referrals 
were lower48. 
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2.7 Implications for future research 
This review identified a lack of high level study evidence on the effects of incentives 
in primary care, with 5 reviews returned and 18 separate studies meeting the review 
study design criteria. This reflects the difficulties of doing such research in the area 
of physician payment, where randomisation is difficult and concealment impossible. 
In such circumstances future research should consider quasi randomised, and other 
lower level study designs in any review of the evidence.  
In terms of the future research on physician incentives there is a need for research 
which looks at the impact of primary care incentives on condition specific outcomes 
or endpoints, and considers the effects of incentives over an extended duration. This 
need is most significant for P4P given the absence of clinical outcomes and lack of 
surrogate outcomes identified by this research. 
2.8 Conclusion 
This chapter has identified gaps in the research evidence on the effects of physician 
payment in primary care. Among these is an absence of studies looking at clinical 
endpoints and the impact of incentives over an extended duration. Another issue is 
that outcomes have tended to be general process measures, specifically in the P4P 
literature, with no link to evidence.  
It is important that the relationship between the intervention and outcome measure is 
supported by high level research evidence, to ensure that clinical benefits are 
demonstrable. The next chapter aims to ensure this process is followed in the thesis 
by examining the clinical evidence for QOF targets to select those which have a high 
level evidence base through to condition specific hospital admissions, and have been 
in place for a sufficient duration to ensure any effect is measurable. This ensures that 
if the financial incentive is effective in improving clinical outcomes that impact will 
be evident in the outcome variable.  
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Chapter 3 The evidence base for QOF clinical 
targets and feasibility of extracting linked 
hospital admissions 
 
3.1 Objective 
To select from the QOF clinical domain, exemplar targets whose clinical benefits 
have been evidenced in high level study design research, and can be modelled using 
CPRD and HES data. This will involve: 
1. Using NICE and SIGN clinical guidelines to find which targets from the 
QOF guidance 2009/10 had the highest level of clinical evidence 
2. From those targets which have the highest clinical evidence selecting those 
for whom clinical benefits can best be measured and extracted using CPRD 
and HES data. 
3.2 Background 
When the New General Medical Services contract was drawn up in 2003 the 
µ4XDOLW\6WDQGDUGV¶ZKLFK LQFOXGHG WKH42)FOLQLFDl targets were drawn up by an 
independent panel of experts based on evidence and current professional practice66. 
7KH FRQWUDFW ZDV WKH UHVXOW RI FRQVXOWDWLRQV EHWZHHQ *3¶V UHSUHVHQWHG E\ the 
General Practitioners Committee of the BMA and the government of the day.  They 
WRRN SODFH DJDLQVW D EDFNGURS RI GLIILFXOWLHV LQ UHFUXLWLQJ DQG UHWDLQLQJ *3¶V D
determination to address it and the money to do so. Under such circumstances it is 
perhaps not surprising that the details on how the expert panel agreed on the initial 
targets is lacking, although rationale has been provided in QOF guidance. The over-
riding aim may have been to make the profession more attractive financially, rather 
than a focXVRQ µTXDOLW\RXWFRPHV¶  There has been criticism of the design of the 
QOF incentive scheme by among others, Ashworth et al, who raised concerns around 
the usefulness of using QOF targets to determine improvements in patient care, and 
questioned whether the QOF was more concerned with paying for recording than 
paying for performance18. In 2005 and 2007 the QOF was reviewed by an expert 
panel of appointed primary care academics supported by a group of clinicians, using 
feedback  from calls for evidence sent out to a cohort of  Primary Care Trusts7. Not 
until the introduction of QOF NICE committee in 2009 did the policy of evaluating 
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existing QOF targets and piloting new targets become rigorous, independent, and 
transparent.  
Hence it is often unclear as to why specific targets were chosen and how their 
wording and the specific payment thresholds were decided upon. For this reason the 
decision was made to go through the QOF guidance 2009/10, to discover which, of 
all the targets in the clinical domain, had high level clinical evidence. Then based on 
that evidence determine which of those could be effectively measured and examined 
using CPRD and HES data. This was to ensure that targets chosen for analysis would 
produce substantive and measurable benefits that would be picked up in any 
analysis. The previous chapter highlighted a number of deficiencies in existing 
research on incentives in primary care. Specifically the absence of clinical outcome 
measures, a short intervention or follow up period, and heterogeneity in outcome 
measures. The approach taken in this chapter seeks to ensure that those deficiencies 
are addressed in this research. By ensuring that targets have been stable or in place 
for a significant portion of the QOF intervention period, it will be possible to 
examine their longer term effects. In linking their effect into clinical outcomes 
supported by high level evidence their effectiveness will be clearly demonstrable. By 
basing outcome measurement on clinical evidence only, this removes the scope to 
self select those measures, and reduces the potential for bias in their selection.  
3.3 Methodology 
In order to ensure that any targets selected had high level clinical evidence and that 
those benefits could be clearly measured in the primary and secondary care datasets 
a three stage selection process was undertaken: 
Stage 1; an appraisal of the QOF 2009/10 guidance to remove those targets which 
had no measurable clinical outcomes, or possible link to clinical outcomes  
Stage 2; a review of the NICE and SIGN clinical guideline evidence to find which 
targets, of those remaining, had the highest level of clinical evidence. 
Stage 3; an examination of the suitability of the remaining targets with regards to 
their longevity, stability, and whether their benefits could be measured and linked 
across CPRD and HES data.  
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3.3.1 Stage 1: Review of the QOF clinical guidance 
The 2009/10 guidance was chosen as there were no changes made in 2010/11 so it 
represented the most up to date for the study period. Within the QOF for that year 
there were 19 clinical conditions, a smoking domain, and 86 targets in total. Each 
condition follows a similar flow of targets, starting with an initial condition register, 
which is used as the denominator for a number of subsequent targets. The following 
VHFWLRQQRWSUHVHQWLQDOOFRQGLWLRQVLVWHUPHGµGLDJQRVLV¶RUµLQLWLDOPDQDJHPHQW¶
which relate to confirmatory tests for the disease or tests to determine its specific 
IRUP)LQDOO\WKHUHLVDQµRQJRLQJPDQDJHPHQW¶VHFWLon which contains the bulk of 
the QOF targets. Details of the targets and conditions removed at this stage are given 
in Figures 3-1 and 3-2. 
Figure 3-1 QOF targets removed by guidance section 
 
This process is further broken down in Figure 3-2.  
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Figure 3-2 QOF target types removed by section, more detail 
 
7KH ILUVW WDUJHWV UHPRYHG ZHUH WKRVH ZLWKLQ WKH µ5HFRUGV¶ VHFWLRQ RI WKH GLVHDVH
indicators that referred to the practice producing a register for each respective 
condition. These numbered twenty in total and for two domains were the only 
targets, resulting in their complete removal. They incentive practices to maintain 
condition registers for their patients enabling them to be treated promptly, however 
any benefits will be dependent on subsequent management and treatment. The next 
targets removed were those subsequent to the disease registers, within the diagnosis 
and initial management section where present, which referred to a diagnostic test to 
confirm the presence of the disease or tighten its definition. One example of this is 
HF2 which rewarded the practice if heart failure had been confirmed by 
echocardiogram or specialist assessment. Again the benefits of these targets are 
determined by how the information is utilised; and since this is not stipulated in 
these targets it would be extremely difficult to measure their impact. Six targets were 
removed at this point in the process 
The next area e[DPLQHG ZHUH WKRVH WKDW FDPH LQWR WKH µ2QJRLQJ PDQDJHPHQW¶
section of the disease domain, which contains the bulk of the targets and relates to 
KRZWKHSDWLHQW¶s condition is managed. Within this section three groups of targets 
have been removed. The first RIWKHVHDUHUHIHUUHGWRDVµURXWLQHUHFRUGV¶7KHVHDUH
targets for recording that an event has taken place without specifying the outcome, 
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for surrogate measures like blood pressure or cholesterol measurement. These 
precede targets which stipulate what level those measures need to meet, and it may 
be possible to combine them in a single target. While clinical benefits may result 
IURP WKHVH µURXWLQH UHFRUGV¶ IRU LQVWDQFH WKH\ LQFHQWLYH *3¶V WR PRQLWRU EORRG
pressure in all patients and not just those likely to meet the target level which may 
improve outcomes in those patients; those benefits are difficult to quantify and 
attribute. For this reason they were therefore removed. 
Following on from these there are what have been termed investigative records. 
These are again targets which refer to a record of a test but are for investigative and 
preventative reasons and disease specific. As before while there may be some 
benefits from these targets, they are difficult to quantify or are picked up in 
subsequent targets. So for instance, in diabetes there is a target for the percentage of 
patients with a record of micro-albuminuria testing in the previous 15 months, 
DM13. In some instances these will lead into a subsequent target to treat those 
patients based on its results; such as DM15 which rewards prescriptions of ACE 
inhibitors to diabetic patients with micro-albuminuria. There were ten targets fitting 
this classification all of whom were removed. 
)LQDOO\WKHUHZHUHWDUJHWVWKDWKDYHEHHQFDWHJRULVHGDVµSDWLHQWUHYLHZV¶7KHVHUHIHU
WRWDUJHWVZKLFKLQYROYHDUHYLHZRIWKHSDWLHQW¶VFRQGLWLRQRUDQDJUHHGFDUHSODQ$
third of these are in mental health and they are present in dementia also, both 
conditions where the individual may be dependent or reliant on others or outside 
services to administer aspects of their care. Therefore the consent and opinion of 
those additional interested individuals or bodies is sought, as well as that of the 
individual, to review present care and agree future care. An example in Mental 
Health is MH6 which refers to the percentage of patients with a documented 
comprehensive care plan agreed between the individual, their family and, or their 
FDUHU7KHRWKHUDVSHFWWRWKLVµSDWLHQWUHYLHZV¶FDWHJRU\DUHUHYLHZVRIWKHFRQGLWLRQ
for diseases where care will need to be amended, scaled up or back depending upon 
responses to previous treatments and changes in the severity of it. As targets in this 
category only refer to a process and make no stipulation on an expected outcome it is 
difficult to attribute any subsequent improvements to them. Hence nine targets fitting 
this description were removed. At the end of this review of the QOF guidance 58 
targets had been removed, leaving 28 targets remaining. 
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3.3.2 Stage 2: Best practice guidelines 
The next stage was to consult national clinical guidelines to review the level of 
clinical evidence for the remaining targets.  NICE and SIGN commissioned 
guidelines were the first areas consulted to find clinical evidence for QOF targets. If 
guidance for targets were missing from these areas, individual or joint guidance from 
disease specific organisations was consulted. Both NICE and SIGN use the same 
ranking methodology to score the research evidence and generate recommendations. 
NICE classifications and their corresponding level of evidence is shown in Figure 3-
3, taken from the Atrial Fibrillation NICE guideline.67 The same guidance is 
produced in a slightly adapted format within the SIGN guidelines and replicated in 
the guidance produced by the British Hypertension Society (BHS)68. In this chapter 
DQGWKURXJKRXWWKHWKHVLVWKHWHUPµKLJKOHYHOHYLGHQFH¶LVXVHGWRUHIHUWROHvel 1+ 
and 1++ study designs 
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Figure 3-3: NICE, Evidence to recommendations, AF guidelines 
 
This study was primarily interested in Grade A recommendations, level 1+ and 1++ 
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evidence, or their equivalent, though lower levels are reported.  In the past few years 
NICE guideline evidence has adopted the Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) toolbox to rank the quality of 
HYLGHQFH 7KH\ WKHQ SURGXFH µUHFRPPHQGDWLRQV¶ RU µNHy priorities for 
LPSOHPHQWDWLRQ¶ IRU WKRVH DUHDV ZKLFK KDYH WKH KLJKHVW UDQNLQJ HYLGHQFH ,Q WKH
GRADE ranking system this equates to a strong recommendation which describes 
circumstances where they are very certain that the benefits of the treatment do or do 
not outweigh its risks and burden69 70. Where the GRADE criteria have been applied 
LQPDNLQJ WKH UHFRPPHQGDWLRQDQ µ5¶ LV SODFHGEHIRUH WKH UHIHUHQFHG VRXUFH ,W LV
not possible to make direct comparisons between the two ranking tools. GRADE 
limits itself to just two levels of recommendation, strong and weak, which are 
GHWHUPLQHG E\ WKH VFDOH RI WKH WUHDWPHQW¶V EHQHILW UHODWLYH WR LWV ULVN DQG ILQDQFLDO
costs. This is a very different approach to the A-D class of recommendation used in 
earlier guideline evidence, most notably with regards to cost, where there was no 
explicit requirement to consider the costs implications of any recommendation. 
However in terms of the level of clinical evidence, a GRADE recommendation 
would reasonably equate to no lower than level 2++/Class B evidence. On other 
occasions no evidence could be found for the target. In these cases only the guideline 
source is given, with the reason for the lack of a level of recommendation provided 
in the summary column. 
Outlined in Table 3-1 is a summary of the documents examined and information 
gathered on the clinical effectiveness of the remaining 28 targets. Where targets were 
common across conditions and guidance was shared or reasoning similar, the 
evidence is presented for the group of conditions and targets collectively, rather than 
separately. 
Table 3-1  QOF targets, source and level of evidence 
QOF Indicator(s) 
2009 summary 
Clinical guideline(s) summary Level/ 
source of 
evidence 
CHD; Stroke; 
Hypertension:  
Patients in whom 
Individuals with established cardiovascular disease 
with sustained systolic blood pressure greater than 
140mmHg and/or diastolic greater than 90mmHg 
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the last blood 
pressure reading, 
measured in the 
previous 15 
months (9 
months for 
Hypertension) is 
150/90 or less. 
For CKD a blood 
pressure of 
140/85 or less. 
For diabetes a 
blood pressure of 
145/85 or less. 
CHD6; 
STROKE6; BP5; 
DM12; CKD3. 
should be considered for blood pressure lowering 
drug therapy.                        
 In patients aged over 80 with treated hypertension, 
a blood pressure target of 150/90 or below should 
be aimed for.   
140/90 in those aged under 80.   
The same levels were referenced and 
recommended in the most recent Angina guideline.                                                                         
In non-diabetics with hypertension, the optimal BP 
treatment goals are <140/85 and the minimum 
acceptable level <150/90.                              
 In diabetic patients the optimal BP target should 
be <135/80 with a minimum acceptable (audit 
standard) of <140/80                                 
 Patients with CKD and proteinuria should have a 
target maximum systolic blood pressure of 
130mmHg                                                           
In patients with CKD aim for a systolic BP target 
range of 120-139, diastolic BP<90.     
Diabetic patients with cardiovascular disease 
should have a diastolic BP target<=80 mmHg; and 
a systolic BP<130mmHg.                        
 In Stroke the target should be less than 140/85, 
130/80 and below if they have diabetes. 
 
A71 SIGN 
 
 
1+72 NICE 
R72NICE 
 
R73NICE
 
 
B68 BHS 
 
 
B68 BHS 
 
 
A74SIGN 
                                            
A?75NICE 
 
A76 SIGN   
D76SIGN                     
            
D77NICE 
Smoking 
cessation advice 
to patients with 
any or any 
combination of 
CHD, Stroke, 
Hypertension, 
Diabetes, COPD, 
CKD, Asthma, 
There is limited high quality evidence for the 
effectiveness of offering advice and behavioural 
support from NHS Stop Smoking Services.                                               
Pharmacy led interventions have been shown to 
have a significant validated impact on quit rates.                                              
Nicotine replacement therapies or bupropion 
should be used as part of a smoking cessation 
programme to augment professional advice and 
increase long term abstinence rates.                 
1 x 1++ 
study78  
NICE
 
A78 NICE 
 
              
 
A71 NICE 
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Schizophrenia, 
Bipolar disorder 
or other 
pyschoses.    
SMOKING4 
No guideline evidence was found specifically 
related to the effectiveness of smoking cessation 
advice in patients with schizophrenia, bipolar 
disorders or other psychoses.  
 
 
 
NICE79 80 
CHD9. Patients 
with CHD 
prescribed an 
aspirin, 
alternative anti-
platelet therapy, 
or an anti-
coagulant (unless 
a 
contraindication 
of side-effects 
are recorded)  
Aspirin should be offered to all patients after an 
MI and be continued indefinitely.       
Clopidogrel should be offered as a first line 
monotherapy after an MI.                   
Clopidogrel, in combination with low dose aspirin, 
is recommended for use in the management of non 
ST segment elevation acute coronary syndrome in 
people who are at moderate to high risk of MI or 
death.        
Aspirin (75mg) a day should be routinely given 
and continued long term in patients with diabetes 
and CHD.                                 
Consider 75mg daily dosage of aspirin in people 
with stable angina, taking into account the risk of 
bleeding and co-morbidities.  
 A81 NICE 
 
 
A81 NICE 
 
 
                             
 
A81 NICE 
 
 
A71 NICE 
 
 
R73 NICE 
CHD10. Patients 
with CHD who 
are currently 
treated with a 
beta blocker  
Patients with clinical MI should be maintained on 
long term beta blocker therapy.                  
Beta blockers should be used as the first line 
therapy for the relief of symptoms of stable angina.  
              
A71 NICE 
 
A82 SIGN 
CHD11. Patients 
with a history of 
MI (diagnosed 
after 1 April 
2003) treated 
with an ACE 
inhibitor or 
Angiotensin II 
After an MI all patients with preserved left 
ventricular function or left ventricular dysfunction 
(LVD) should continue with an ACE inhibitor 
indefinitely, whether or not they have symptoms of 
heart failure.  
In post MI patients who have to discontinue an 
ACE inhibitor because of intolerance or allergy, an 
ARB should be substituted. 
 
 
                            
 
A81 NICE 
 
 
A81 NICE 
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antagonist. 
HF3. Patients 
with a current 
diagnosis of 
heart failure due 
to LVD treated 
with an ACE 
inhibitor or 
ARB, who can 
tolerate therapy 
and for whom 
there is no 
contra-indication 
ACE inhibitors should be considered in patients 
with all NYHA classes of heart failure due to 
LVD. 
Patients with chronic heart failure due to LVD 
alone, or heart failure, LVD or both following MI, 
who are intolerant of ACE inhibitors should be 
considered for an ARB 
 
 
A83 SIGN 
 
 
 
A83 SIGN 
HF4. Patients 
with a current 
diagnosis of HF 
due to LVD 
treated with an 
ACEI or ARB, 
who are 
currently treated 
with a beta 
blocker licensed 
for heart failure 
All patients with heart failure due to LVD of all 
NYHA functional classes should be started on beta 
blocker therapy as soon as their condition is stable. 
Offer both ACE inhibitors and beta-blockers 
licensed for heart failure to all patients with heart 
failure due to LVD. Use clinical judgement when 
deciding which drug to start first 
 
 
A83 SIGN 
 
 
1++84 
NICE 
STROKE12. 
Patients with a 
stroke shown to 
be non-
haemorrhagic, or 
a history of TIA, 
who receive an 
anti-platelet 
agent, or an anti-
Low dose aspirin (75mg daily) and dipyridamole 
(200mg modified release daily) should be 
prescribed after ischaemic stroke or TIA.  
Clopidogrel (75mg daily) monotherapy should be 
considered as an alternative to combination aspirin 
and dipyridamole after ischaemic stroke or TIA.  
 
 
A77 NICE 
 
 
A77 NICE 
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coagulant 
DM23, 24 and 
25. Patients with 
diabetes in 
whom the last 
HbA1c is 7, 8 or 
9 or less 
respectively. 
HbA1c should be controlled, ideally around 7%, in 
all diabetic patients to prevent the onset and 
progression of diabetic eye disease.                 
An HbA1c target of 7.5% is reasonable to reduce 
the risk of microvascular disease, with a target of 
6.5% at diagnosis. Targets should be based on 
individual circumstances in order to balance 
benefits and harms, in particular hypoglycaemia 
and weight gain.  
                                                    
 
A76 SIGN 
 
 
                  
 
 
A76 SIGN 
DM15. Diabetes 
patients with a 
diagnosis of 
proteinuria or 
micro-
albuminuria who 
are treated with 
ACE inhibitors 
or A2 
antagonists. 
Both type 1 and 2 diabetic patients with micro-
albuminuria should be treated with ACE inhibitors 
RU$5%¶VLQW\SHSDWLHQWVRQO\LUUHVSHFWLYHRI
blood pressure.  
$&( LQKLELWRUV DQGRU $5%¶V VKRXOG EH XVHG DV
agents of choice in diabetic patients with Chronic 
Kidney Disease and proteinuria.  
 
 
 
A76 SIGN 
 
 
A76 SIGN 
EPILEPSY8. 
Patients aged 
over 18 and on 
drug treatment 
for epilepsy who 
have been 
seizure free for 
the last 12 
months 
It is difficult to draw specific recommendations 
from the clinical guidelines for this target. Firstly 
there is evidence that if someone has been seizure 
free for 2 or more years, the odds of a seizure are 
sufficiently low that treatment can be withdrawn. 
Treatment whether using mono or combination 
drug therapy has to be patient specific, and at the 
patients consent. Side effects can outweigh any 
treatment effects in terms of seizures avoided. Risk 
RI VHL]XUH DUH KLJKHVW LQ WKH XQGHU ¶V DQG WKH
over 59. Future seizure risk depends on seizure 
type, neurological deficit and epilepsy syndrome85.   
85
 NICE 
MH5. Patients No evidence found within the schizophrenia 79 80 NICE 
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on lithium 
therapy with a 
record of lithium 
levels in the 
therapeutic range 
guideline80. Lithium is a key priority 
recommendation in bipolar patients dependent on 
co-morbidities, response to previous treatment, 
patient preference and history of adherence. It 
should only be used if symptoms are not severe 
because of its slow onset. There is a lack of 
evidence around what is a therapeutic range.  The 
WKUHH SODFHER FRQWUROOHG 5&7¶V UHSRUWHG LQ WKH
guideline adopted a minimum plasma level of 
6mmol/l or more. UK laboratories use a lower 
limit of 4-6mmol/l or less79 
CK5. CKD 
patients with 
hypertension and 
proteinuria who 
are treated with 
an ACEI or ARB 
$&( LQKLELWRUV DQGRU $5%¶V VKRXOG EH XVHG DV
agents of choice in CKD patients with proteinuria 
regardless of diabetes status.  
Offer ACEI or ARB to  non-diabetic CKD patients 
with hypertension   
 
 
A74 SIGN 
 
R75 NICE 
AF3. Patients 
with atrial 
fibrillation who 
are treated with 
anti-coagulants 
or platelets 
In patients with permanent AF where 
antithrombotic therapy is given to prevent strokes 
and/or thromboembolism, adjusted warfarin should 
be given.  
Where warfarin is not appropriate aspirin should 
be given.                 
 In AF patients who are either post stroke or have a 
TIA, warfarin is the most effective 
thromboprophylactic agent.  
 
 
 
A67 NICE         
 
B67 NICE 
              
 
A67 NICE 
PP2. People with 
hypertension 
diagnosed after 1 
April 2009 who 
are given 
lifestyle advice 
on increasing 
Diets low in total and saturated fats should be 
recommended to reduce CV risk.                           
People with hypertension should be advised to 
reduce their salt intake as much as possible to 
reduce BP.                                                 
Physical activity of at least moderate intensity is 
recommended for the whole population. 
                                                                                                          
A71NICE 
 
 
A71 NICE                         
 
B71 NICE             
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physical activity; 
smoking; alcohol 
and diet 
All people who smoke should be advised to quit 
and offered support to do so.                     
 Patients may be advised that light to moderate 
alcohol consumption may be protective against the 
development of CHD 
                    
B71 NICE 
 
 
B71 NICE      
3.3.2.1 Evidence discussion 
3.3.2.1.1 Blood pressure  
It is clear that blood pressure control has high level clinical evidence in all the 
conditions where it constitutes a target. What is usually less certain is the evidence 
behind the specified level in the QOF, with the QOF target tending to be less 
stringent than those recommended by the guidelines. In the case of Hypertension, 
Stroke and CHD the QOF sets a target of 150/90mmHg or less.  However the 
guideline evidence argues that the QOF level should be considered the minimum 
DFFHSWDEOH DQ µDXGLW¶ OHYel, which is suitable only for hypertensive patients over 
80727KHHYLGHQFHDYDLODEOHIRUDOHYHOEHORZWKDWµDXGLWOHYHO¶KRZHYHURI
for  patients under 80 years of age in the NICE guidance72; and of 140/85 from the 
BHS is sub Grade A standard68.  
For diabetes the QOF target for blood pressures is 145/85. Grade A level evidence, 
was found for a diastolic blood pressure of 80mmHg or below in diabetic patients 
with CVD76. Weak, Grade D level evidence was found for a systolic blood pressure 
of 130mmHg or below in the same patient group76. The BHS meanwhile 
recommends a target level of 140/80 or less citing Grade B level evidence. None of 
which is in exact agreement with the QOF target. 
Like diabetes, CKD has a more stringent target than the other conditions, in this 
instance it is140/85.  There is some contradiction within the guidelines regarding a 
target level, with NICE recommending a 140/90 or below level which appears to be  
based on high level evidence75, and  SIGN, 130mmHg and below for systolic blood 
pressure with high level evidence74.  Indeed the NICE guidelines for CKD recognise 
the difficulties in setting a diastolic and systolic blood pressure target in this 
condition in tandem, as treatments given to maintain systolic blood pressure in an 
optimal range, result in diastolic blood pressure falling below its optimal range. For 
this reason they recommend a systolic range of 120-139 mmHg and a diastolic target 
64 
 
of 90mmHg or less. This recommendation appeared to be based on the highest level 
FOLQLFDOHYLGHQFHDOWKRXJKLWFRXOGQ¶WEHGHWHUPLQHGZLWKFHUWDLQW\75.  
Overall it would have to be concluded that while there is high level evidence for 
controlling blood pressure, there is uncertainty around specific levels that it should 
be controlled to. That while the QOF targets are probably not stringent enough they 
represent a good compromise based on uncertainty over what the exact level should 
be.  
3.3.2.1.2 Cholesterol control 
In all the conditions where cholesterol control is a target, the level is set at 5mmol/l 
or less. Once again there is high level evidence for the policy of control, but in this 
case greater certainty, and high level evidence as to what level should be aimed for. 
That is for a level of 4mmol/l or less, one that is more ambitious than that set by the 
42)ZKLFKWKHJXLGHOLQHVUHFRPPHQGDVDQµDXGLW OHYHO¶D WDUJHW WKDWDOOSDWLHQWV
should reach and we can measure progress to86 87. While the clinical evidence argues 
that 4mmol/l is the optimal level, and doctors should consider increasing statin 
dosage to meet it; it also acknowledges that less than half of patients will meet it86. 
Given this fact, and despite questions over the level at which it is set; the level set by 
the QOF can be seen as a target which incentives provision for all patients. One 
which practices should aim to ensure all its patients meet and a significant number 
progress beyond. 
3.3.2.1.3 Glycaemic control in diabetes patients 
Within the QOF there were 3 targets for HbA1c levels; for levels at 9 or less, 8 or 
less and 7 or less. There is grade A level evidence concerning the control of 
glycaemic levels in diabetic patients ideally to 7%, though with some flexibility to 
reflect individual patient circumstances76. This range suggests lowering HbA1c to 
6.5 in those patients who can tolerate treatment to that level, and 7.5 as a reasonable 
level to reduce the risk of microvascular disease76. The logic behind having three 
WDUJHWVIRUWKLVRQHPHDVXUHLQWKH42)LVFOHDUO\WRUHZDUG*3¶VIRUSURgressively 
ORZHULQJ D SDWLHQW¶V JO\FDHPLF OHYHO ZKLOH DW WKH VDPH WLPH SURYLGLQJ VXIILFLHQW
incentive to treat patients who are unlikely to reach lower target thresholds. However 
it was felt that based on the strongest clinical evidence there was certainly no 
evidence for the higher level target, particularly given that the 8 or less target 
provided some room to progressively lower glycaemia down to its optimal range. In 
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which case it may be better to allocate the points from the 9 or less target to the 
rePDLQLQJ WZR WR SURYLGH D JUHDWHU LQFHQWLYH IRU *3¶V WR EULQJ SDWLHQWV GRZQ
towards the optimal range. For this reason DM25, HbA1c of 9 or less was dropped.  
3.3.2.1.4 Prescription and immunisation targets 
In all targets which refer to prescribing ACE inhiELWRUV RU $5%¶V DVSLULQ
anticoagulants or platelets there is high level supportive clinical evidence. In the case 
of Heart Failure there is an additional target, HF4, relating to the prescription of 
ACE or ARB and beta blockers. The evidence statements in the Heart Failure 
clinical guidance showed high level evidence for the prescription of both ACEI and 
beta blockers using an RCT study design comparing the drug class against placebo84. 
Within the NICE HF guideline there was also RCT studies which sought to 
determine which of the two drugs when used in combination, should be initiated 
first84. The evidence was inconclusive and that judgement was left to the individual 
clinician in the guideline recommendation. What was not shown in the NICE 
guideline however was the evidence for ACE inhibitor or ARB plus beta blockers 
over ACE or ARB alone; or for that matter beta blockers compared to ACE 
inhibitors or ARB.  So in this instance the evidence for this target, as worded, was 
unable to be determined from the clinical guidance. For this reason this target was 
dropped and only HF3 was taken into the next stage. There was strong evidence for 
prescribing beta blockers to CHD patients, and for the QOF target as worded, 
CHD1071 82. 
3.3.2.1.5 Mental health, epilepsy and influenza immunisation 
For mental health and epilepsy the evidence was conditional on so many patient 
factors and based on a number of provisions that it is near impossible to frame a 
target which covers all these eventualities. Given this the guidance on what 
constitutes a lithium therapeutic range, in the mental health target is possibly 
deliberately vague, as it needs to reflect individual patient characteristics. The 
therapeutic range currently used by UK laboratories and referenced in the guidance, 
LVORZHUWKDQWKDWDGRSWHGLQWKHIHZ5&7¶VWRKDYHWDNHQSODFHLQWKLVDUHD79. Due to 
the lack of robust evidence for this target it had to be dropped. With epilepsy there 
was also great uncertainty around the target. Linking drug therapy and seizure free 
period is dependent on a range of patient factors including type of seizures, side 
effects and drug tolerance and therefore will not be appropriate to all85. For this 
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reason this target was also removed. Finally no clinical evidence to support the 
inclusion of influenza immunisation targets in the QOF was found except a reference 
to it being a current recommendation of the Department of Health and Joint 
Committee on Vaccination and Immunisation, contained within the QOF guidance 
itself. These targets as a result were also dropped. 
3.3.2.1.6 Primary prevention 
In cardiovascular disease primary prevention, PP2, there is high level evidence that 
reducing salt and fat intake reduces cardiovascular complications. However this 
evidence relates to controlled environments where individuals are compelled to do 
so71. There is lower level evidence around the protective qualities of alcohol within 
moderated limits and smoking cessation advice both applied to the whole 
population71. What could not be found was evidence for the effectiveness of offering 
lifestyle advice alone outside of controlled environments where there was some form 
of compulsion on participants to follow it. It is difficult to map lifestyle guidance to 
clinical outcomes. This target also replicates the smoking cessation target for 
hypertensive patients. Given these reasons the evidence for this target was 
considered to be uncertain and it was removed. 
3.3.2.1.7 Smoking cessation 
The health benefits of ceasing smoking are well established, even in those patients 
who been heavy smokers for long periods88. There is high level evidence for 
smoking cessations services delivered through NHS stop smoking services and 
pharmacy led interventions, but weaker evidence for the policy generally71 78. 
Additionally there is high level evidence for the effectiveness of nicotine 
replacement therapies in patients with cardiovascular and respiratory disease, 
particularly when used in conjunction with cessation services78. However the target 
is not explicit in its wording as to what form advice should take, or which therapies 
should be applied, so its validity is very open to interpretation. Nonetheless as the 
target refers to specialist services, which have an evidence base, and as it gives the 
GP the opportunity to recommend nicotine replacement therapies as part of a 
smoking cessation programme; it was considered to be in keeping with the high level 
evidence cited.  
The targets starting this process and remaining at its conclusion are shown in Figure 
3-4 below. 
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Figure 3-4: Stage 2 summary 
 
3.3.3 Stage 3: Targets with high level clinical evidence 
3.3.3.1 Objective 
To select from the 19 targets found to have high level clinical evidence, those which 
could be effectively analysed using CPRD and HES data. The following factors were 
considered when making the decision: 
1. The targets longevity 
2. The stability of the target 
3. The size of the patient population treated by the target 
4. The ability to extract data on clinical outcomes in HES 
3.3.3.2 Description 
Nineteen targets had a high level of clinical evidence; covering seven disease 
conditions, as well as a smoking cessation target which included multiple disease 
conditions. Faced with a range of possible QOF targets the decision was whether to 
focus on a number of individual targets across a range of conditionsRQH¶VWKDWZHUH
common across a range of conditions such as the Blood Pressure and Serum 
Cholesterol monitoring, or focus on one or more disease condition. To reach a final 
decision in a logical manner a number of points important to the analysis were 
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checked against each target. These were to do with longevity of the target, namely 
the number of QOF years in the VWXG\ LQ ZKLFK WKH WDUJHW IHDWXUHG 7KH WDUJHW¶V
stability, in terms of the number of changes to the points awarded and payment 
thresholds during the QOF study period.  Patient numbers affected by the target and 
the ability to measure the expected clinical benefits of the target, and attribute it to 
the target, using HES data. 
Since their introduction QOF targets have undergone a number of changes with 
targets being dropped, new ones introduced; payment thresholds, wording and points 
amended. Within the QOF every time a target has changed its wording the initial 
target has been dropped and a new one created with a new target number. In this 
thesis the 2009/10 wording and numbering is used as this is the most up to date in 
the study period. Earlier versions of the QOF have been visited to see if the target 
exists in those and if not whether its wording is comparable.  If the target number 
occurred in previous QOF guidelines or its 2009/10 wording was directly 
comparable to earlier versions, this would count towards the longevity of the target, 
which is a maximum of 7 years for the study period. However each change in 
wording, points and payment threshold would be reflected in the stability criteria. To 
measure the impact and benefits of a target with confidence the target should 
preferably be in the QOF for a long period but not have changed over that period, 
reflected in a high longevity and low stability figure. 
This study draws from a very large dataset where small sample sizes are unlikely to 
be an issue. Nonetheless it is still important to consider the size of the potential 
population, as while it may not be a factor that excludes targets it is one which could 
make analysis potentially more difficult and therefore be a deciding factor when 
choosing which targets to analyse. For this purpose the prevalence of the condition is 
shown for whole condition targets, or where it refers to a subset of that population, 
the approximate population prevalence for that subset. Details on how these figures 
were calculated are covered in detail in Appendix 3. 
The fourth consideration was whether the outcome could be measured in HES, and 
clearly attributed to the target. This was of prime importance since as shown in the 
previous chapter there is an absence of studies looking at the effect of incentives in 
primary care on clinical outcomes and the overall aim of the thesis is to find 
evidence for the effectiveness of QOF targets. To address this deficiency and meet 
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the thesis aim it was necessary to establish that the clinical outcome for the target, 
that had been shown to supported by high level evidence in the previous stages; 
could be clearly linked to the QOF target in the datasets.  
The results of applying these criteria are shown in Tables 3-2 to 3-8, along with the 
expected health improvements. The smoking cessation target is not included in the 
tables below as using these criteria would give misleading results regarding its 
suitability. This is a target that applies to multiple conditions and was initially listed, 
when the QOF was first introduced, as a separate target in each of the core chronic 
conditions to which it applies today. In 2006 smoking as a condition in its own right 
was introduced into the QOF and those separate targets merged in to one. In 2008, 
smokers from the mental health condition group were added. So despite being 
around since the beginning of the QOF for certain conditions, it would have a low 
figure for longevity due to the high number of changes the target has incurred. Even 
applying the target in the context of a specific QOF condition, despite essentially 
remaining the same, a misleadingly high stability figure would result given all the 
changes mentioned. The expected improvement in clinical outcomes are also 
common across all respiratory and cardiovascular diseases from successfully quitting 
smoking and relate to reduced mortality, hospitalisations, morbidity, cardiovascular 
and respiratory complications. 
3.3.3.3 Analysis 
Table 3-2 CHD Secondary prevention high level evidenced targets 
Target Longevity Stability Population  
 %       
Clinical outcomes 
CHD6 
BP 150/90 
or less 
7 2 3.4% Reduced risk of major and non-
fatal cardiovascular 
complications; all cause and 
cardiovascular mortality72 
CHD8 
Cholesterol 
5mmol/l or 
less 
7 2 3.4% Reduced risk of all-cause 
mortality, cardiovascular 
mortality, CHD mortality and 
fatal MI. Also for rates of non-
fatal stroke, TIA, MI and 
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unstable angina86 
CHD9 
Anti-
platelets or 
coagulants 
7 1 3.4% Reduced risk of death and 
cardiovascular events, non-fatal 
MI or stroke71 81. 
CHD10 
Beta 
blockers 
7 1 3.4% Reduced risk of death, all-cause 
mortality, cardiovascular-cause 
mortality, non-fatal MI73 81. 
CHD11 
MI: ACEI 
or AII 
7 1 0.54% Reduction in all-cause mortality, 
and recurrent MI81 73 
All of the CHD targets have been in place since the beginning of the QOF period 
and have also been very stable. The whole population targets have a large 
prospective population, but for the MI subgroup it is substantially smaller. There is 
a clear link between the targets and expected benefits which are extractable using 
CPRD and linked HES data 
 
Table 3-3 Heart Failure high level evidenced targets 
Target Longevity Stability Population  
 %       
Clinical outcomes 
HF3 
ACEI or 
ARB 
5 0 0.4% Reduced risk of hospital admissions 
due to heart failure or related 
complications and in mean level all-
cause mortality84 
This target was present for 5 years of the QOF study period and underwent no 
changes during that period. The potential patient population is low but the expected 
benefits are clearly related to the condition. 
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Table 3-4 Atrial Fibrillation high level evidenced targets 
Target Longevity Stability Population  
 %       
Clinical outcomes 
AF3 
Anti-
platelets or 
coagulants 
5 1 1.4% Reduced risk of thromboembolic 
complications, ischaemic stroke 
and vascular events (MI, stroke, 
haemorrhage, vascular death)67 
The target was present for 5 years of the study period and had a single change. The 
potential patient population is low in relation to other conditions. In terms of 
expected benefits there are potential problems in being able to attribute the outcome 
to the target using the datasets since the outcomes manifest themselves in other 
conditions such as Stroke and CHD. 
 
Table 3-5 Chronic Kidney Disease high level evidenced targets 
Target Longevity Stability Population  
 %       
Clinical outcomes 
CKD3 
BP 140/85 or 
less 
5 0 4.2% Slows the deterioration of 
glomerular filtration rate and 
reduce proteinuria; reducing 
cardiovascular risk74 
CKD5 
Hypertension 
& 
proteinuria: 
ACEI or 
ARB 
3 1 0.21% Reduced risk of all-cause 
mortality, proteinuria, and 
end stage renal disease. 
Reductions in the rate of 
disease progression74. 
CKD5 is present for only 3 years of the QOF study period and underwent a change 
during it. The prospective patient population is small; though the expected benefits 
can be related to the target. CKD3 is present for 5 years and has been stable. The 
population prevalence appears to be adequate though the outcomes that manifest 
themselves in reduced cardiovascular risk may be hard to link in the HES data. 
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Table 3-6 Diabetes high level evidenced targets 
Target Longevity Stability Population  
 %       
Clinical outcomes 
DM23 
HbA1c, 7 
or less 
2 0 5.3% Reduced risk of micro-
albuminuria and retinopathy76. 
DM24 
HbA1c, 8 
or less 
2 0 5.3% Reduced risk of micro-
albuminuria and retinopathy76. 
DM12 
BP, 145/85 
or less 
7 2 5.3% Reduced risk of macro-
vascular and microvascular 
disease. Reduction in major 
cardiovascular events71 76  
DM15 
Proteinuria 
or micro- 
albuminuria
: ACE or 
AII 
7 1 0.59% Reduced risk of arterial events 
(mortality or stroke) and MI76 
DM17 
Cholesterol, 
5mmol/l or 
less 
7 1 5.3% Reduced risk of all-cause 
mortality, cardiovascular 
mortality, CHD mortality and 
fatal MI. Also for rates of non-
fatal stroke, TIA, MI and 
unstable angina76 86 
DM23 and DM24 have a low longevity figure which would make analysis very 
problematic. All the targets have been stable, DM12 the least with 2 changes but 
over a 7 year period. There is no issue with the percentages for the relevant 
population for all of the targets with the potential exception of DM15. In terms of 
outcomes for the remaining targets outside of DM23 & 24, it may be difficult to 
attribute these to a diabetes QOF target as they are cardiovascular events and not 
metabolic complications 
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Table 3-7 Hypertension high level evidenced targets 
Target Longevity Stability Population  
 %       
Clinical outcomes 
BP5 
BP, 150/90 
or less 
 
7 2 13.4% Reduced risk of major and non-
fatal cardiovascular 
complications; all cause and 
cardiovascular mortality71 72 
This target covers the whole of the QOF study period, and was largely stable. The 
prospective study population is large. The clinical outcomes are broad, and would 
apply to a host of clinical treatments. This is further complicated by the fact that the 
target itself is shared across a number of cardiovascular and metabolic conditions 
which would make it difficult to isolate the effects of this specific target.  
Table 3-8 Stroke and Transient Ischaemic Attack high level evidenced targets 
Target Longevity Stability Population  
 %       
Clinical outcomes 
STROKE6 
BP, 150/90 
or less 
7 1 1.7% Reduced risk of major and non-
fatal cardiovascular 
complications and all-cause 
mortality71 77 
STROKE8 
Cholesterol, 
5mmol/l or 
less 
7 1 1.7% Reduced risk of all-cause 
mortality, cardiovascular 
mortality, CHD mortality and 
fatal MI. Also for rates of non-
fatal stroke, TIA, MI and 
unstable angina77 86 
STROKE12 
Anti-
platelets or 
coags 
7 2 1.7% Significant reduction in 
symptomatic pulmonary 
embolism or recurrent stroke.77 
All the targets have longevity, stability and are sufficiently prevalent. There may be 
issues with attributing the outcomes of the first two STIA to those targets as they 
are common cardiovascular outcomes shared with a number of QOF targets. 
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3.3.3.4 Results 
The results of this section are summarised in the figure 3-5 below with details of 
targets dropped and those where concerns were raised against each criteria. Years 
and changes are merged as years proved to be a much bigger factor in decisions; 
with changes in one instance adding weight to the decision to drop a target and 
making an additional target questionable. 
Figure 3-5 Stage 3 Summary 
 
3.3.3.4.1 Longevity and stability 
A number of CHD, Stroke, Hypertension and certain Diabetes targets have been 
present throughout the QOF study period. As had glycaemic control for diabetic 
patients; however this target had seen repeated changes such that the present targets 
could not be directly compared against previous versions. With only 2 years of data 
these targets had to be dropped as this would not be sufficiently long to pick up an 
effect. Even applying earlier versions it would be difficult to apportion an effect of 
treatment on outcomes as the treatment target has constantly moved. Focusing on 
\HDUV VWLOO&.'¶V \HDUVRI IROORZXS LVSUREDEO\ LQVXIILFLHQW IRUEHQHILWV WREH
reflected. In that short period it also had a change to its points awarded, and the 
target applied to a small proportion of the population. Due to all these concerns this 
target was also dropped.  
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For the remaining targets there are no concerns as in most cases these targets have 
been present throughout the QOF study period. None of these therefore escaped the 
changes made to the QOF in 2006, which saw reform of payment thresholds, among 
other changes. However the substance of the targets has remained essentially the 
same.  They have also been no more than two changes to the stability terms of the 
target. The remainder were introduced in 2006 so have 5 years of data but no 
changes over that period, AF3 aside.  
3.3.3.4.2 Prospective population size 
In the case of prevalence this obviously favours the common chronic conditions, 
hypertension in particular, raises potential issues for Heart Failure and certain targets 
which consider a subset of the condition population; namely CHD11 and DM15. 
However this is being used for information only at this stage, not to specifically 
exclude targets, but as an additional source of information and potential deciding 
factor in any final decision.  
3.3.3.4.3 Access to clinical outcomes in HES 
The final column looks at the expected benefits of the target, taken from the best 
practice guidelines. Within HES data the study is interested in the primary diagnosis 
coding given to the patient upon hospitalisation. For all the remaining targets an 
expected common benefit was a reduction in cardiovascular complications. 
Repeatedly mentioned among these were both fatal and non fatal MI, CHD and 
Stroke. It is important when using pre-collected data like CPRD and HES where 
patients are not being observed that events in either can be linked. Extraction of 
relevant data is facilitated when outcomes are condition specific and where there is a 
clear progression from the care and condition to any outcomes. In this area CHD 
secondary prevention stood out. Following diagnosis, if the condition is well 
managed in primary care, we expect to see fewer ischaemic heart disease admissions. 
There is a clear causal pathway with poor care leading to more complications, and 
more severe forms of the condition, with each progressive form having a separate 
outcome code. 
With the diabetes targets, STROKE6 and 8, AF3 and CKD3 the link is not so clear. 
Complications manifest themselves in other conditions and then coding and 
extractability within HES becomes an issue. Firstly because there is not the certainty 
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concerns about the data, as there could be doubts that the underlying cause or the 
presenting condition formed the primary diagnosis. For BP5 while the outcomes are 
clearly linked to hypertension management, the issues are with the fact that the 
outcomes are broad and related to a number of other clinical treatments and that the 
target is replicated across a number of QOF conditions. Hence there would be real 
difficulties in finding and thereby linking outcomes specifically related to this target 
in HES.  
3.3.3.5 Summary 
Going through all the criteria the targets remaining are the CHD targets, HF3, and 
STROKE12. For HF3 the percentage of the study population that would be covered 
under this target is low enough to question the practicality of analysing it, and its 
absence for two years of the study period is also a negative. STOKE12 is strong on 
longevity and stability with outcomes that are clearly linked to the target. However 
again this is a target which is common in a number of other targets, involves a drug 
that is given widely, and most likely in addition to a host of other drugs with similar 
benefits, which could make direct linkages to secondary outcome measures 
problematic. CHD was a strong performer on all the criteria set. In particular it was 
very strong with regard to the ability to measure and relate clinical outcomes in HES. 
An additional benefit, given the number of CHD targets going into this final stage 
and performing well on the criteria used, is that it offers the opportunity to select a 
large part of the QOF targets for a single disease domain. This offers the opportunity 
to consider the effects of a package of care for a single disease group, which is how 
the QOF works in practice; rather than considering separate aspects of care across 
multiple conditions. 
3.3.3.5.1 Smoking 
Smoking is a predictor of poor health generally, and a significant risk factor for all 
cardiovascular diseases, CHD and Stoke in particular88-90. The benefits of ceasing to 
smoke are therefore significant and smoking cessation services have proven effective 
in helping patients to quit78. It was however omitted from this section as the criteria 
used would give a misleading result on the stability and longevity of the targets and 
prejudice its selection. Following the appraisal of the other targets a decision now 
had to be made on this target. The options available were to apply it to CHD only, in 
effect applying the pre 2006 version of the target. Or alternatively apply it to all 
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conditions that were included in Stage 3 or apply the target as worded, which would 
include additional conditions. Given these options the natural solution was to apply it 
to CHD, keeping with the focus of the other targets.  
3.4 Conclusion 
The objective of this chapter was to find which targets had the highest level of 
clinical evidence through a two stage process; and then in the third and final stage 
determine which of those it would be possible to analyse using CPRD and HES 
linked data. In this third stage, the CHD targets performed consistently well on all 
the criteria set.  They possessed stability, longevity and clear linkage to Secondary 
care outcomes.  The breadth of the targets presents the opportunity to consider a 
whole package of care, and to consider a QOF disease domain almost in its entirety. 
With a number of these targets shared by other conditions and common outcomes 
there is also the opportunity to draw lessons for other conditions. No other condition 
or combination of targets offered this opportunity. On the basis of this, the 
Secondary prevention of CHD, QOF targets, were chosen as the area of research in 
this PhD.  
The next chapter will undertake a literature review to uncover what research has 
been undertaken to date on the effect of physician incentives on hard clinical 
outcomes and endpoints.  Since CHD is now the exemplar condition, this will 
provide the reviews focus. 
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Chapter 4 The effectiveness of physician 
incentives on CHD clinical outcomes 
 
4.1 Objective 
To examine the effectiveness of financial incentives on hard, and surrogate, CHD 
clinical outcomes. 
4.2 Introduction 
In the previous chapter CHD QOF targets were selected as the exemplar targets 
following a review of the clinical guideline evidence. The focus now narrows to 
CHD and this chapter looks at the literature regarding the effectiveness of physician 
incentives on CHD clinical outcomes.  
The review in Chapter 2 revealed a lack of high level study design evidence on 
incentives. It was felt that if this review limited itself to high level study design 
evidence, given its focus on CHD, few if any studies would be returned. The study 
design criteria were therefore relaxed to include any study design. Chapter 2 also 
identified a lack of clinical outcomes which this review sought to address. 
This review set out to find evidence principally for the effectiveness of P4P 
incentives on clinical outcomes. This was to find out if research, similar to that 
which this thesis would undertake on the QOF, had previously been undertaken. 
Given that the distinction between primary and secondary care is not as clearly made 
in other health systems as it is in the UK, and these studies could provide useful 
information for this research, incentives in secondary care were also included. It was 
also felt that limiting the search to P4P would find few studies, and that evidence on 
other forms of incentives could provide useful information on the effectiveness of 
incentives more generally. Most importantly in the context of this research it would 
provide some means of comparison for any final results on the QOF, which lacks a 
control group or comparator.  
This chapter is interested in surrogate, and more specifically, hard CHD clinical 
outcomes. Hard clinical outcomes are defined as a significant clinical event where 
the individual has a serious or end stage form of disease. An example for CHD 
patients would be a myocardial infarction (MI). Surrogate clinical outcomes relate to 
measures, generally measured in primary care, that have an evidenced relationship 
79 
 
with a clinical outcome, and hence form a mapped measure. An example would be 
cholesterol control and CVD risk. Surgery to resolve CHD complications in this 
context was considered to be a hard clinical outcome, as it was assumed that this 
would predominantly be undertaken in patients who had more serious forms of 
CHD, and could therefore be considered to be a significant clinical event. However 
since surgical rates are also related to access to services and the physicians ability to 
induce demand, to ensure these had clinical benefits and hence were clinically 
necessary, hard clinical endpoints such as mortality had to be reported in those 
studies91. To ensure that outcomes were the result of incentives and not caused by 
differences in patient groups covered by different forms of incentives, some attempt 
had to be made to match patients on key socio-demographic variables. This could 
take place within patients, such as before and after study designs on the same 
patients, or between comparable patients from different settings, e.g. states or 
countries.  
This chapter is looking at the impact of physician financial incentives on clinical 
outcomes measured at the patient level. As with Chapter 2, it is not interested in 
physician level outcome measures in judging the effectiveness of those incentives, 
even though the incentives impact on the physician and not the patient. The reason 
for this is that while physicians may benefit financially from these incentives, be 
directed to act in a certain manner, or provide certain treatments as a result of their 
introduction; they also have an impact on the patient. Due to the manner in which 
healthcare is organised it is often via the physician that policy makers seek to 
influence patient outcomes. It is this direction of effect that this thesis seeks to 
explore, and hence patient level outcomes are its focus. 
4.3 Background 
Given that this review is looking at incentives in primary and secondary care the 
search terms have been broadened to reflect this. It also means that this review will 
cover different forms of service delivery, and new terminology, that it is important to 
understand. These are broken down into three categories, national and local 
government backed insurance schemes; private insurance backed; and managed care 
organisations.  The predominant form of incentivisation operating in each is also 
discussed. 
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4.3.1 National and local government backed insurance schemes 
 Examples of centrally funded and administered schemes are the NHS in the UK and 
Medicare and Veteran Affairs (VA) in the USA. Medicare provides care to everyone 
aged 65 and over, as well as those under that age with certain disabilities. Physicians 
treating Medicare patients are principally paid on a fee for service (FFS) basis. The 
VA provides a range of benefits, one of which is healthcare to former members of 
the Armed Forces. Physicians are directly employed by the Department for Veterans 
Affairs and are therefore paid on a salaried basis 
In countries like the USA there is also state and national government involvement in 
health care. An example of which is Medicaid in the USA. This is a means tested 
limited provision for low income families, funded at the federal and state level. 
Dependent on state of residence patients may be expected to make co-payments. 
Around 70% of physicians who treat Medicaid patients are paid on a capitation basis, 
the remainder are paid on a FFS basis. 
4.3.2 Private insurance backed schemes 
Private health insurance schemes are most common in the USA but are also used in 
Western Europe and Australia. These operate on the same basis as any insurance 
scheme where individuals pay a premium based on their level of coverage, risk and 
the size of deductible or co-payment. Physicians who work in the private insurance 
sector are generally paid on a FFS basis 
4.3.3 Managed care organisations  
The best known of these are Health Maintenance Organisations (HMOs), in the 
USA. These liaise with health care providers to provide care for their members on a 
prepaid basis. Physicians agree to provide a set level of care as laid out in the HMO 
guidelines in return for a guaranteed stream of income. Individuals take out 
insurance with HMOs through their workplace or on the open market. They are 
similar to the NHS in that they employ physicians in primary care to act as 
gatekeepers to secondary care services in order to control costs.  Physicians are paid 
through various forms of incentivisation depending upon their contractual 
relationship with the managed care organisation. The most common in HMOs is 
capitation. 
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4.4 Inclusion criteria 
The article had to be written in English, or translated into English. An attempt had to 
be made in the study to match individuals in the intervention and control arms on 
key socio-demographic variables with adjustments made either at baseline or in final 
results. In addition to these stipulations patients were included if they met the 
following PICO criteria: 
1. Population: Patients who had a known CHD diagnosis or were admitted with 
complications arising from CHD  
2. Population: Where the patients had co-existing conditions, the results of the 
intervention on CHD were reported separately or could be disaggregated from 
any final results 
3. Intervention:  Any form of physician financial incentive  
4. Comparator: Within comparison (before and after) or between comparison 
against comparable populations in different settings (e.g. Countries, States) 
where different physician incentives operated. 
5. Outcome:  Condition specific hard and surrogate clinical outcomes reported at 
the patient level. 
4.5 Search Terms 
The main search terms are summarised below and specified in full for each search 
engine in Appendix 4. Just looking at the QOF or P4P would severely limit this 
search hence search terms covered all forms of incentive. To capture CHD clinical 
outcomes, Mesh heading for CHD were included and matched to incentive search 
terms using the AND command. 
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Figure 4-1 CHD Physician Incentives Search Terms 
 
4.6 Search Methodology  
The search used the OvidSP search platform, from which the following databases 
were searched: Embase, Medline, HMIC and PyscINFO.  Further to this a grey 
literature search was undertaken of the websites belonging to the following 
institutions: The Commonwealth Fund; Nuffield Trust; and The Kings Fund.  
The PRISMA diagram in figure 4-2 explains how the search was conducted. In order 
to capture primary and secondary care studies, generic terms for physicians were 
used when included. As a result over 700 articles were sourced by this search, as 
these terms picked up all articles where payments or incentives and CHD were 
mentioned in the abstract. 118 of the articles were duplicates leaving 643 articles 
whose abstracts were screened to see if they met the inclusion criteria, of which 18 
full articles were reviewed. The main reasons for dropping articles at the abstract 
review stage were that the intervention was directed at the patient; there was no 
control or comparator; the intervention was not financial; the study did not look at 
clinical outcomes; and the patient did not have CHD. After reading these documents, 
a further 10 were dropped, leaving 8 journal articles which fully met the inclusion 
criteria. 
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Figure 4-2 CHD Physician Incentives PRISMA diagram 
 
4.6.1 Articles excluded after full text screen  
Reasons for excluding 10 of 18 articles at the full text screen stage are given in table 
4-1 along with the specific PICO inclusion criteria they failed to meet. Author refers 
to the cited primary author. 
Table 4-1 CHD Physician Payment Articles, Reasons for study exclusion 
Author PICOD Explanation for exclusion 
Assaf, 
199392 
O Does not measure clinical outcomes ....Looks at the effect 
of a change in a payment regime from FFS to a 
prospective payment scheme on use of diagnostic codes. 
It is unclear however whether changes to coding indicates 
changes in activity or choice of codes in response to 
financial incentives. 
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Brown, 
200493 
O Does not report clinical endpoints....Looks at differences 
in rates of surgical procedures between HMO and FFS 
patients. These are reported in isolation so there is no 
means of determining if they are a result of poor 
condition management and/or had clinical benefits.  
Choudhry, 
201194 
I The intervention was not directed at the 
physician.....Looks at patient co-payments 
Heidenreich, 
200295 
I The intervention was not financial....Looks at the effects 
of concentration of HMOs on patient care.  This measure 
is applied to the intervention and control, and acts as a 
proxy for competition.  
Hilleman, 
200496 
I The intervention was not financial....The intervention 
examined was a physician prompt system  
Jackevicius, 
200897 
I The intervention was not financial...The intervention 
examined was changes to administrative rules. 
Jha, 
201298 
P CHD population could not be disaggregated...CHD was 
one of a number of conditions incentivised under the P4P 
scheme examined.  
Nelson, 
199899 
P O CHD population could not be disaggregated and outcome 
not CHD specific.... Looks at the effects of patient 
demographics, chronic conditions and physician 
incentives on resource utilization, measured as numbers 
of all hospitalisations 
Ryan, 
2009100 
C There was no comparator or control arm...Looked at 
Hospital Care, a pay for reporting scheme for hospitals 
who wish to treat patients under the Medicare payment 
scheme.  However no control or comparator was used to 
assess the effectiveness of the scheme. 
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Shen, 
2003101 
I The intervention was not financial....Refers to the effects 
of financial pressures measured by HMO penetration and 
prospective payment levels, rather than a comparison of 
payment methods 
 
4.7 Included studies  
Details of the included studies are summarised in Table 4-2. Composite measures 
refer to any qualitative outcome or outcomes composed from other outcome 
measures.  
Table 4-2 CHD Physician Payment Included Studies Details 
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INTERVENTION INCENTIVE 
FFS   ¥   ¥   
Salaried    ¥ ¥  ¥  
P4P  ¥       
Mixed ¥        
Capitation        ¥ 
COMPARISON INCENTIVE 
FFS ¥   ¥ ¥  ¥ ¥ 
Mixed   ¥   ¥   
Non P4P   ¥       
Capitation      ¥   
Uninsured      ¥   
OUTCOME MEASURES 
In hospital mortality  ¥  ¥  ¥ ¥ ¥ 
30 day mortality 
measures  
¥  ¥     ¥ 
1 year and above 
mortality measures 
¥    ¥    
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Composite measures ¥ ¥       
Length of stay 
measures 
   ¥     
Angiography rates      ¥  ¥ 
 
Four, half of the included studies are direct comparisons between HMOs (mixed and 
salaried) and FFS. Of the remaining half, one looks at P4P, one compares FFS to 
Salaried, one capitation to FFS, and the remaining study compares a number of 
physician incentives. Further details on specific studies are set out in the tables 
below. All of the studies used routinely or pre collected data to analyse the effects of 
financial interventions, none collected data specifically for their study: 
Carlisle et al, 1992102 
Population Patients over 65 admitted with a principal diagnosis of Acute 
Myocardial Infarction (AMI)  
Intervention Mixed- salaried and capitation  
Comparator FFS  
Outcome 1. 30 day mortality rate following admission  
2. 180 day mortality rate following admission  
3. Quality of process score (mean) 
Setting Secondary Care 
Context USA, 1 July 1985-1 July 1986 
Data source Hospital medical records ± pre collected data 
Notes 1. Three HMOs operating in separate states, were selected from a 
national consortium of twelve. A final sample fully meeting the 
selection criteria involving 369 admissions to 27 hospitals were used 
2. The FFS sample was taken from a previous study and included 
1119 patients drawn from 297 hospitals in five states. 
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3. Outcomes were adjusted for sickness at admission. This 
incorporated items from the Killip and Norris measures of the 
severity of AMI, the APACHE II severity of illness scale and 
measures of co-morbidity. 
4. The quality of process score is an algorithm incorporating 93 
specific process of care measures, reviewed by an expert panel to see 
if they were clinically acceptable and could be reliably recorded. It 
includes measures on physician and nurse performance and 
appropriate use of tests, procedures and pharmaceuticals, as well as 
intensive care or telemetry. 
Glickman et al, 2007103 
Population Patients with acute non-ST segment elevation myocardial infarction 
admitted to  500 CRUSADE reporting hospitals  
Intervention P4P 
Comparator Absence of P4P 
Outcome 1. Incentivised composite measure   
2. Non incentivised composite  
3. In hospital mortality  
Setting Secondary Care 
Context USA, 1 July 2003 and 30 June 2006 
Data source Patients enrolled in the ACC/AHA CRUSADE national quality 
improvement initiative ± pre collected data 
Notes 1. 105,383 patients included in the study 
2. Can rapid risk stratification of unstable angina patients with early 
implementation of the American College of Cardiology/American 
Heart Association (ACC/AHA) guidelines (CRUSADE) 
3. Hospital Quality Incentive Demonstration (HQID) is a P4P 
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scheme which provided a bonus to hospitals that met Centers for 
Medicare and Medicaid (CMS) measures across a range of clinical 
conditions including AMI. Hospitals in the top 20% on these 
measures received a reimbursement bonus, while poorly performing 
hospitals risked being excluded from future contracts with Medicare 
and Medicaid. 
4. Incentivised composite based on CMS measures (Aspirin at 
arrival; aspirin at discharge; ACEI or ARB for LVD; smoking 
cessation counselling for active or recent smokers; beta blocker at 
arrival and beta blocker at discharge). Non incentivised 
(Glycoprotein IIb/IIa inhibitor use; Clopidogrel at discharge; any 
heparin use; lipid lowering medication; dietary modificiation 
counselling; referral for cardiac rehabilitation; ECG within 10 
minutes; cardiac catheterization within 48 hours) 
Luft, 2003104 
Population All Medicare beneficiaries (aged over 65) admitted with AMI  
Intervention FFS  
Comparator Mixed-salaried and capitation 
Outcome 1. 30 day standardised mortality ratio  (SMR)-Model A 
2. 30 day standardised mortality ratio (SMR)-Model B 
Setting Secondary Care 
Context California, USA, 1994-96 
Data source California Hospital Outcome Project ± pre collected data 
Notes 1.  Data is taken from hospital submitted discharge abstracts 
2.  The two models were produced by the UCLA with 30 day 
mortality as the dependent variable. Model A potentially under 
compensates for true case mix differences as it only includes 
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variables (co-morbidities etc.) known prior to admission. Model B 
additionally includes variables revealed during admission (e.g. shock, 
other co-morbidities); potentially over-compensating for risk 
differences by including variables that may be complications of care. 
Paone et al, 1995105 
Population Patients who received a Coronary Artery Bypass Graft (CABG)  
Intervention Salaried 
Comparator FFS 
Outcome 1. In hospital mortality rate 
2. Mean ICU length of stay  
3. Total hospital length of stay 
Setting Secondary Care  
Context Henry Ford Hospital, USA, 1 Jan 1990 to 31 Jan 94 
Data source Computerized cardiac surgical database,  routinely collected 
Notes 1.  The Henry Ford hospital is the sole provider of cardiac services to 
patients in the HAP and provides services to the community at large 
using alternative health insurance arrangements 
2. 569 HAP (all Medicare beneficiaries excluded) compared to 225 
FFS patients 
Petersen et al, 2003106 
Population Men, 65 and over, who had had an AMI within the preceding 8 
weeks 
Intervention Salaried 
Comparator FFS 
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Outcome 1. Angiography (Model 1) 
2. Angiography (Model 2) 
3. 1 year mortality (Model 1) 
4. 1 year mortality (Model 2) 
Setting Secondary Care 
Context USA, Jan 1994 to September 1995 
Data source Various routinely/ pre-collected data sources 
Notes 1.  To ensure diagnostic and not therapeutic emergency primary 
angioplasty were compared; only patients who became eligible for 
angiography more than 12 hours after the onset of symptoms but 
before discharge were included. 
2.  Patients considered to have a clinical need for angiography if they 
were in class I of the ACC-AHA guidelines 
3.  Model 1 adjusted for age, race, BMI, presence of morbidities and 
other risk factors. Model 2 adjusted additionally for the availability 
of angiography and cardiac surgery on site 
4.  Medicare records collected from 7 US states for male patients 
discharged between 1 Feb 1994 and 30 July 1995. 
5. Veterans Affairs (VA) male patients discharge from non-
psychiatric VA hospitals between 1 Jan 1994 and 30 Sept 1995 
6. 1665 males from 81 facilities (VA population). 19, 305 males 
patients from 1530 non-federal acute care hospitals (Medicare) 
Sada et al, 1998107 
Population Patients under 65 enrolled in the National Registry of Myocardial 
Infarction (NRMI)   
Intervention FFS 
91 
 
Comparator Mixed 
Outcome 1. Non-discretionary angiography rates in high risk patients 
2. In hospital mortality 
Setting Secondary Care 
Context USA, June 1994 to October 1995 
Data source NMRI: Pre- collected data from 1482 hospitals (26% of all 
medical/surgical hospitals)  
Notes 1. The study population totalled 17,600 patients; 10,498 FFS 
(59.6%), 3,273 HMO (18.6%), 1,354 Medicaid (7.7%) and 2,475 
uninsured patients (14%). 
2. Uninsured were those without identifiable insurance 
3. Whether treatment was deemed discretionary/non-discretionary 
and patients were at a high/low risk was  based on ACC/AHA 
guidelines 
Starr et al, 1996108 
Population Patients admitted for CABG surgery at St Vincent Hospital and 
Medical Centre 
Intervention FFS 
Comparator Salaried 
Outcome 1. Operative mortality 
Setting  Secondary Care 
Context Oregon, USA, January 1985 to March 1994 
Data source St Vincent hospital database and Keiser Permanente ± routinely 
collected 
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Notes 1.  The final regression model included 3686 (43%) of the 8483 
qualifying patients. No significant differences were observed 
between those excluded (based on one or more missing risk factors) 
and those included 
Young and Cohen, 1992109 
Population  Patients who had an emergency admission, with a principal 
diagnosis of AMI. 
Intervention Capitation 
Comparator FFS 
Outcome 1. Inpatient mortality 
2. 30 day post admission mortality 
3. 30 day post discharge mortality 
4. Arteriography 
5. CABG 
6. Angioplasty 
Setting Secondary Care 
Context Massachusetts, USA, 1987 
Data source Various routinely/ pre- collected data sources 
Notes 1. Diagnosis based on ICD 9 codes 410-410.9 
2. The study population contained 4,033 patients; 3755 privately 
insured; 278 Medicaid 
3. Results adjusted for differences in clinical and demographic 
characteristics and type of hospital where treatment occurred 
 
4.7.1 Quality assessment of included studies 
A reduced form of the Downs and Black ranking scale was used to assess the quality 
of the included studies110.  This particular ranking scale was chosen because it is 
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widely used, seen as a gold standard and was comparable to or better than equivalent 
ranking scales111. The Downs and Black rating scale contains 27 questions in 3 
categories; Reporting; External validity; and Internal validity. Questions were chosen 
that reflected the nature of the studies being evaluated, to ensure any deficiencies 
evident would be due to poor relative study design. Consequently questions relating 
to blinding were omitted as the studies were interested in how physicians responded 
to incentives therefore blinding was impractical. Likewise questions relating to 
compliance with the intervention were also not relevant as compliance with a 
financial incentive is assumed. The checklists which were retained and deemed 
suitable were in the areas of study design, reporting, controlling for confounders and 
potential for bias. While the intervention was directed at the physician the concern 
was with how this impacted on patient outcomes. Hence when assessing outcomes 
and judging study quality, the concern was to ensure patients were comparable 
between the intervention and control or comparator arms. The assumption in this 
review and the published literature is that physicians as a group are broadly similar 
in both arms and hence any difference in outcomes is due to responses to incentives 
and payment mechanisms by the physician, and not difference in their clinical 
knowledge, training or practices. Details regarding the ten criteria are summarised 
below as interpreted in relation to the studies evaluated; with further details on the 
Down and Black checklist provided in Appendix 5. Table 4-3 details how each of the 
included studies performed in relation to these. The author column refers to the 
principal author.  
1. Are the main outcomes to be measured clearly described in the Introduction 
or Methods section? 
2. Are the characteristics of the patients included in the study clearly described? 
3. Are the main findings of the study clearly described? 
4. Have actual probability values been reported (e.g. 0.035 rather than <0.05) 
for the main outcomes except where the probability value is less than 0.001? 
5. Is the intervention and control group followed up for the same length of 
time? 
6. Were the statistical tests used to assess the main outcomes appropriate? 
7. Were the main outcome measures used accurate (valid and reliable)? 
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8. Were patients in the intervention and control arm selected from the same 
hospital, comparable care settings, joint registry or reporting schemes? 
9. Were the study periods in the intervention and control group matched? 
10. Was there adequate adjustment for confounding in the analyses from which 
the main findings were drawn? 
Table 4-3 Down and Black Checklist 
Author 1 2 3 4 5 6 7 8 9 10 
Carlisle  ¥ ¥ ¥  ¥ ¥ ¥ ¥ ¥  
Glickman  ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ 
Luft     ¥ ¥ ¥ ¥ ¥ ¥ 
Paone  ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ 
Petersen  ¥ ¥ ¥  ¥ ¥ ¥   ¥ 
Sada  ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ 
Starr  ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ ¥ 
Young  ¥ ¥ ¥  ¥ ¥ ¥ ¥ ¥ ¥ 
4.7.2 Quality assessment discussion 
Ticks show that the checklist criteria were met, a score of 1 on the ranking criteria; 
while shading shows it was missed, a zero score. Generally the studies performed 
well on these measures and were well conducted observational studies, with a clear 
description of data sources, patient selection criteria, analyses and results, with 
appropriate adjustments for confounders. Nonetheless there were significant 
concerns about two studies, namely Luft and Petersen104 106. Both of these failed to 
give a full breakdown of the p values for their main outcome measures. In the study 
by Petersen they are not reported at all; in Luft they are reported for certain 
significance levels. The Luft article performs poorly on all reporting measures104. 
The main outcomes are not described until the results section. There are no output 
tables, results are presented within text and are difficult to extract and relate at times. 
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Nor is there a breakdown of the key patient characteristics in the intervention and 
control bar general details in the text, though reference is made to earlier work where 
this information may be available. Petersen performs poorly on internal validity as 
the study periods in the intervention and control group differ, albeit by only 3 
months. It is also not certain if the intervention and control group are matched 
sufficiently, as  the VA study sample used national data after the number of VA 
hospitals in the 7 states from which the Medicare population was selected, was found 
to be too small to provide adequate analytic power.  
Outside of these studies both Young and Carlisle fail to give a full breakdown of p 
values for their results, though do report them at the 1% and 5% significance 
levels109. More seriously in the case of Carlisle it is unclear whether the results are 
adjusted for the significantly higher number of females in the FFS study arm102. It is 
possible that differences in risks between the genders could be captured in the 
adjustments for sickness at admission but it is not possible to be certain on this.  
4.8 Results 
All eight studies are from the USA and secondary, hospital care. None linked 
primary care incentives to clinical outcomes, and all used administrative databases. 
Results from the studies are shown in Table 4-4, and are broken down by clinical 
measures and forms of reimbursement. 
96 
 
Table 4-4: Included studies, physician incentives CHD, results 
SURGERY 
Study Outcome Intervention Comparator Results 
Petersen Clinically needed Angiography Salaried FFS Adjusted Odds Ratio 
Model 1: 0.75 (0.57-0.96) Model 2: 1.02 (0.82-1.26) 
Sada Angiography: High risk patients, 
non-discretionary 
FFS Capitation OR  3.13 (95% CI, 2.80-3.85)# 
Sada Angiography: High risk patients, 
non-discretionary 
FFS Mixed OR 1.45 (95% CI, 1.19-1.75)# 
 
Sada Angiography: High risk patients, 
non-discretionary 
FFS Uninsured OR 2.08 (95% CI, 1.69-2.52)# 
Young Arteriography utilisation Capitation FFS OR 0.38 (95% CI, 0.23-0.78) 
Young CABG utilisation Capitation FFS OR 0.27 (95% CI, 0.21-0.65) 
Young Angioplasty utilisation Capitation FFS OR 0.28 (95% CI, 0.24-0.63) 
MORTALITY 
Carlisle Mortality: 30 day post admission Mixed FFS Mixed: 23.8%;  FFS: 24.2% ; p>0.05 
Carlisle Mortality: 180 day following 
admission 
Mixed FFS Mixed: 35.3%; FFS: 35.4%; p>0.05 
Glickman Mortality: In hospital P4P Non P4P P4P: 4.87% (2003); 3.93% (2006);  OR 0.91 (95% CI 
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0.84-0.99) 
Control: 5.03% (2003); 4.06% (2006); OR 0.97 (95% 
CI 0.94-0.99)  P (comparison) = 0.21 
Luft Standardised Mortality Rate FFS Mixed Model A: 1.047 (p<0.01) 
Model B: 1.018 (p, non-significant) 
Paone Mortality: In hospital Salaried FFS Salaried 1.9%;  FFS 2.2%;  p=0.794 
Petersen Mortality: 1 year Salaried FFS Adjusted Odds Ratio 
Model 1: 1.10 (0.92-1.33) Model 2: 1.08 (0.89-1.28) 
Sada Mortality: In hospital Capitation FFS OR 1.55 (95% CI, 1.19-2.01)*  
OR 1.40 (95% CI, 1.04-1.87)± 
Starr Operative Mortality FFS Salaried p=0.059#? 
Young Mortality: In hospital Capitation FFS OR 1.91 ( 1.28-2.95) 
Young Mortality: 30 day post admission Capitation FFS OR 1.92 (95% CI, 1.33-2.95) 
Young Mortality: 30 day post discharge Capitation FFS OR 1.90 (95% CI, 1.31-2.89) 
OTHER MEASURES 
Carlisle Quality of process score Mixed FFS Mixed:  0.54; FFS: 0.23; P<0.01 
Glickman Incentivised composite P4P Non P4P P4P: 87% (2003); 94.2% (2006);  OR (95% CI) 1.23 
(1.15-1.30) 
Control: 88% (2003); 93.6% (2006);  OR (95% CI) 
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1.17 (1.14-1.20)  P (comparison) = 0.16 
Glickman Non incentivised composite P4P Non P4P P4P: 59.5% (2003); 73.1% (2006); OR (95% CI) 1.09 
(1.05-1.14) 
Control: 60.5% (2003); 68.6% (2006); OR (95% CI) 
1.08 (1.06-1.09) P (comparison) = 0.49 
Paone Mean ICU stay Salaried FFS Salaried: 2.6 +/-0.3 days FFS: 2.3 +/- 0.3 days 
p=0.734 
Paone Total length of hospital stay Salaried FFS Salaried: 9.8 +/- 0.8 days FFS: 8.6 +/- 0.6 days 
p=0.911 
*After adjustment of model for variables present on admission 
± After adjustment of the model for differences in treatments 
#? FFS as a risk factor # Adjusting for different hospital and demographic characteristics between groups 
OR= Odds Ratio 
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As the focus was on the effect of incentives on clinical outcomes, measures non 
clinical such as length of stay are only reported where these were additionally 
included. Likewise studies which look at surgical procedures were only included if 
clinical endpoints were also included, and vice versa. For all of these measures there 
is a potential for bias, as reporting is selective and hence results may not be 
generalisable. It is worth noting that issues such as this are not limited to this review 
and reflect issues with research in this area, some of which were identified in 
Chapter 2. 
4.8.1 Surgical procedures  
Petersen et al find significantly lower odds of clinically needed angiography, based 
on the patients being in class 1 of the ACC-AHA guideline in VA patient treated 
under a salaried system compared to FFS, OR 0.75, 95% CI 0.57-0.96, when 
adjusting for patient risk factors only106. However when this figure is adjusted for the 
on-site availability of cardiac procedures (Model 2) there is no significant difference, 
OR 1.02, 95% CI 0.82-1.26.                                                                               
Sada looks at non-discretionary use of angiography in patients at high risk of future 
cardiac events patients, specified as those in whom it would be most likely to confer 
a survival benefit, which was lower in all other forms of health payments relative to 
FFS107. High risk FFS patients were found to have over 3 times higher odds of 
receiving non-discretionary angiography than high risk Medicaid patients where 
physicians were paid by capitation (OR 3.13, 95% CI, 2.80-3.85). Sada also finds 
that high risk FFS patients have 45% higher odds than their HMO counterparts 
(mixed incentives) and more than twice the odds of equivalent uninsured patients to 
receive non-discretionary angiography: HMO (OR 1.45. 95% CI, 1.19-1.75); 
Uninsured OR (2.08. 95% CI, 1.69-2.52). 
Young and Cohen consider the number of arteriography, CABG and angioplasty 
procedures109. No distinction is made between clinically necessary and unnecessary 
interventions, although all patients were emergency admissions suggesting their 
needs would be high. They found much lower odds of utilisation for all three 
procedures in patients covered by capitation compared to FFS; Arteriography, OR 
0.38, 95% CI, 0.23-0.78; CABG, OR 0.27, 95% CI, 0.21-0.65; Angioplasty, OR 
0.28, 95% CI, 0.24-0.63. 
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4.8.2 Mortality 
While HMOs comprising a mix of salaried and capitation generally had lower rates 
of mortality than FFS the differences were largely insignificant102 104 105 108. Only in 
the study by Luft and then in his under specified model did mixed incentive HMO 
patients have significantly lower rates of mortality (p0.05)104. There are two studies 
that compare capitation in the Medicaid system against FFS107 109.  In both studies 
the odds of death is significantly higher for patients in the capitation system, by 40% 
or 55%, depending on what adjustments are made, in the study by Sada107, and 
around 90% on the 3 measures used by Young109. Petersen compares the salaried 
Veterans Affairs health care system against FFS Medicare patients106. The odds 
ratios adjusted for risk factors show a higher rate of death within 1 year of an AMI in 
VA patients, Model 1, 1.10 (0.92-1.33); which falls slightly when adjusted for access 
to onsite cardiac surgery and angiography, Model 2, 1.08 (0.89-1.28). However in 
both instances confidence intervals are wide and cross 1, meaning that the results are 
not statistically significant.  
Glickman looks at the before and after effects of the introduction of P4P in an 
incentivised and non-incentivised group. This showed that mortality fell in both 
groups over the study period, OR P4P 0.91 (0.84-0.99), OR Control 0.97 (0.94-0.99), 
a level of change that was not significantly different between the two groups, 
p=0.21103. 
4.8.3 Other measures 
The studies by Glickman and Carlisle looked at measures of quality of patient care 
which related to following correct care protocols. In the paper by Carlisle a mixed 
salaried and capitation HMO group performed significantly better than FFS on a 
quality of process score (0.54 vs 0.23, p<0.01) which included 93 separate measures 
of care based on clinician performance, and the appropriate use of tests, facilities, 
procedures and drugs102. Glickman considers non incentivised and incentivised 
targets in the presence and absence of P4P103. For the incentivised targets, 
performance over the study period improved in the control group, from 88% to 
93.6%, but by a greater amount in hospitals participating in P4P, from 87% to 
94.2%. There was however no statistically significant change in the rate of change 
between the intervention and control (p=0.16). In terms of non-incentivised targets 
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the results were the same with the P4P group enjoying a bigger increase relative to 
the control but again the difference between the two was non-significant (p=0.49).                                                                 
Paone finds a slightly higher mean ICU stay (2.6 days vs 2.3 days) and total length 
of hospital stay (9.8 days vs 8.6 days) in patients from a salaried HMO compared to 
FFS, though neither result was significant, p=0.794 and 0.734 respectively105. 
4.9 Discussion 
Overall the literature reveals the complexities of disaggregating effects and drawing 
lessons in this area of health care research. Not only is the researcher faced with the 
challenge of dealing with patient differences which are inherent in the different 
forms of service delivery but there are different incentives operating at the 
organisational and the individual physician level. Nonetheless there are still a 
number of significant findings and general results than can be drawn. These are 
broken down into findings, limitations, lessons for practice, and future research 
recommendations 
4.9.1 Findings 
The literature on the effects of incentives on CHD clinical outcomes was all USA 
based and looked at Secondary care. No studies were found that linked primary care 
incentives into CHD clinical outcomes as proposed by this thesis. Only one study 
was found that looked at P4P. This looked at similar targets to those selected for this 
study but as a composite measure and in patients admitted to hospital with acute non 
ST MI. This found no statistically significant impact of P4P on incentivised 
measures, non-incentivised measures, or in hospital mortality. Hence while P4P was 
ineffective in this context, it did not lead to resource substitution. In addition to these 
principal findings a number of incidental findings were made, which did not relate to 
the research question but are of wider interest. 
In line with economic theory FFS tended to lead to greater resource utilisation, or 
conversely alternative payment methods which do not pay by activity lead to lower, 
or under, resource utilisation. However there is evidence that access to services, and 
greater physician and patient choice may be partly responsible for this result rather 
than it being wholly a physician response to FFS to induce demand. Individual 
studies themselves factored this into their outcome measures by only looking at 
clinically necessary angiography, so largely discounting any unnecessary surgery 
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from their results. Additionally the study by Petersen showed that once the results 
were adjusted for the availability of onsite cardiac facilities, VA patients had slightly 
higher odds of receiving clinically needed angiography than FFS, though the result 
was not significant106. The VA healthcare system concentrates care in large 
regionalised hospitals similar to teaching hospitals in the UK.  In comparison FFS 
offers both the physician and patient greater choice and access to services.  
Big discrepancies in the utilisation of clinically necessary surgery in the Medicaid 
capitation system and among the uninsured, compared to FFS, were associated with 
significantly higher mortality rates.  However despite lower surgical utilisation in all 
forms of HMOs, there were no significant differences in mortality rates between FFS 
and HMOs. This suggests that there is some level of surgical intervention that while 
clinical necessary had no impact on mortality. It is possible that these patients had 
some quality of life benefit, and surgery therefore conferred some benefit which was 
QRWSLFNHGXSLQPRUWDOLW\2UFRQYHUVHO\WKDW+02¶VE\SUHVHQWLQJWKHSK\VLFLDQ
with greater resource constraints, made them more judicious in their use of surgery. 
Hence it may have avoided over investigation and the use of invasive surgery in 
patients where surgery was harmful or the benefits were marginal. Medicaid appears 
WR SODFH WRR PDQ\ UHVRXUFH FRQVWUDLQWV RQ SK\VLFLDQ¶V DQG DFFHVV UHVWULFWLons on 
patients leading to significantly worse outcomes, with FFS perhaps placing too little, 
leading to unnecessary investigation and intervention. HMOs may represent a 
compromise between the two which does not excessively constrain physician 
discretion, but still restricts the incentive to intervene and induce demand. 
A final finding leading on from this is that overall HMOs performed much better 
than their resource constrained counterparts and at worst performed as good as but 
generally better than FFS. These have an element of limited choice and cost controls 
found in the Medicaid capitation funded systems but provision of care is far less 
UHVWULFWHG7KH\DUHVLPLODU WRDQ1+6PRGHORIFDUHZLWKSK\VLFLDQ¶VSURYLGLQJD
primary and secondary care interface and managing access to Secondary care. 
However there is far greater competition in this system than in the NHS and not the 
clear separation of primary and secondary care. With care in both sectors provided 
under these plans there is the incentive for both to work together to ensure 
efficiencies and be more innovative.  
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4.9.2 Limitations 
There are a number of limitations in the included literature. Firstly all the studies 
examine routinely or pre collected data, none use data specifically generated for the 
purposes of their study. This presents possible data quality issues and also increases 
the potential that findings show correlation and not causality and that data was used 
to fit rather than determine results. With the exception of Starr who examines the 
effects of the intervention over a nine year period, all of the studies examine the 
effects of the intervention over a relatively short study period. Clinically significant 
endpoints such as mortality are also measured over short time spans, of no more than 
1 year, usually less, when surgery in particular may provide benefits that extend to 
periods way beyond that. All the studies look at Secondary care only; none looked at 
the effect of physician incentives in primary care on clinical outcomes. With the 
exception of Glickman none considered the impact of P4P, or looked at surrogate or 
prescribing measures which have relevance to the QOF. However this was done so in 
WKHFRQWH[WRIKRVSLWDOFDUHLQSDWLHQW¶VDGPLWWHGZLWK$0,.  
4.10 Implications for practice 
In both this Chapter and in Chapter 2, no evidence has been uncovered for the 
clinical benefits of P4P. Hence despite the increasing preference for it, and 
significant invest in it in UK primary care, there appears to be little evidence 
supporting it, whether we look at process measures or clinically significant 
outcomes. 
Resource constraints which place excessive restrictions on access to services do have 
significant impacts on clinical endpoints. After adjusting for socio-demographic 
factors Medicaid patients were significantly more likely to die and significantly less 
likely to receive clinically necessary cardiac surgery. This could be due to the 
managed care programmes which these programmes use placing excessive gate 
keeping demands on physicians undermining their ability to treat; and co-payments 
deterring this economically deprived group from seeking primary preventative care, 
leading to poor secondary care outcomes.  
Some form of physician gate keeping role, resource limitations and competition to 
contain costs while maintaining quality would appear to be necessary to limit over 
investigation and treatment. These are characteristics of the HMO managed care 
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system that may account for the fact that it secured at worst as good clinical 
endpoints for patients despite fewer surgical interventions.  
4.11 Implications for future research 
This review has focused on clinical outcomes. FFS not only place lower resource 
constraints on physicians but also offer patients the greatest access to services. An 
effect of this may be greater demands by patients for services including surgery. This 
works suggests this does not always impact on longevity, but there may be quality of 
life benefits not considered, which patients who have the means are willing to pay 
for. 
With only one study identified on P4P there is a clear need for research to assess its 
effectiveness on clinical outcomes, certainly in the area of CHD care. With 
Glickman only following up the intervention for 3 years, future research would 
benefit from using a longer period of follow up to determine if effects are related to 
duration of the intervention.  
Research is needed which spans primary and secondary care to look at the benefits of 
integrated working between the two. This should seek to determine if improved or 
more intensive condition management in primary care impacts on secondary care 
activity and clinical outcomes.  
4.12 Summary 
The focus of Chapter 2 was on the effect of physician payment in Primary care. This 
review relaxed the study design criteria in that review, extended the search for 
literature into Secondary care, while limiting the focus to CHD. As a result this 
thesis has considered the impact of physician payment through primary and into 
secondary care and clinical outcomes, the latter albeit for CHD only. This is 
important for this research as it is what it intends to do for the QOF. The logic being 
that a focus on process measures and arguably surrogate outcomes misses the real 
concern of whether targets and changes in physician incentives impact on important 
clinical outcomes. While no single piece of research has been found which does this 
in the area of CHD care, this is important, as it shows a clear need for the work being 
undertaken in this thesis. The QOF represent a significant investment in primary 
care. Most significantly in a global budgeted service it consumes resources that 
could otherwise be used in other areas of the health service. Hence it is important 
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that there is evidence that investment in the QOF have led to improved clinical 
outcomes and consequently fewer demands being placed on secondary care. 
Following the Health and Social Care Act (2012) primary care physicians now find 
themselves in control of even greater shares of health expenditure and responsible 
for purchasing services. Consequently it is more important than ever to demonstrate 
that allocating greater resources to primary care leads to positive clinical outcomes to 
justify this change. 
4.13 Conclusion 
This review has revealed a paucity of work on the effect of incentives on clinical 
outcomes, and consequently the need for further research. There was no evidence 
found for the clinical benefits of P4P, and hence justification for the choice of this 
means in delivering the QOF over alternatives.  
In terms of this thesis it has highlighted the need for further research which considers 
the effect of incentives in primary care on evidence linked hospital admissions. The 
next chapter will examine P4P from a UK perspective, and examine one of the 
biggest financial investments in P4P in the world, the QOF. This will seek to find 
research on the QOF and CHD to determine how its effectiveness has been 
demonstrated and reported.  
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Chapter 5 CHD in the QOF 
 
5.1 Objective 
To determine what research exists on CHD in the QOF, what it shows, and what this 
research contributes to it. This will involve: 
1. A structured literature search to identify the literature looking at the impact of 
QOF CHD targets. 
2. Evaluating the research methods and outcome measures used. 
3. Appraising the research in terms of what has been found and where it is deficient 
5.2 Background 
Chapter 2 examined the systematic review evidence for the effectiveness of different 
forms of physician payment in primary care. In Chapter 4 the focus moved to CHD 
and the effect of different forms of physician incentive on clinical outcomes.  To 
date due to the inclusion criteria imposed, this thesis has not looked at the effects of 
the QOF on CHD outcomes. This chapter sets out to address this and explore what 
evidence has been found for the effectiveness of the QOF on CHD care. This will 
complete the review of the effects of incentives on patient care. The specific question 
for this review is how has the QOF impacted on CHD care? Answering this question 
will UHYHDOZKDW W\SHRI UHVHDUFKKDVEHHQXQGHUWDNHQKRZ WKH42)¶V LPSDFWKDV
been measured and what this research will contribute to existing knowledge in this 
field.    
5.3 Introduction 
No pilot studies were published prior to the QOF so there is no body of evidence 
supporting its introduction. With near universal adoption there is no control group to 
evaluate its effectiveness. All of this makes research on the QOF challenging, and 
one where the choice over study design will be limited.  While the QOF has been in 
place for nearly a decade, increasing the scope for research into its effects, it is still 
an area of research which is relatively young and evolving. In order to inform and 
place this research it was important to uncover what research had been published on 
QOF CHD care to date. Given the nature of the intervention, and in order to capture 
the literature fully, no stipulations were placed on study design 
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5.4 Inclusion criteria 
1. Population: Patients diagnosed with CHD  
2. Population: Where patients were treated under other QOF conditions, the results 
for CHD were reported separately. 
3. Intervention: QOF P4P scheme. 
4. Comparators: Had to involve a minimum of two time points at least one of which 
KDGWREHSRVWWKH42)¶VLQWURGXFWLRQ 
5. Outcomes: Had to measure performance on QOF targets, measures that mapped 
to QOF targets, or clinical outcomes. 
6. Outcomes:  Had to consider the impact of the QOF at the patient level. 
7. Outcomes: Where composite measures are used they need to be composed in 
their entirety of QOF targets 
The search used the OvidSP and ISI Web of Knowledge search platforms. Within 
OvidSP the following databases were searched: Embase, Medline, HMIC and 
PyscINFO. Details of the full search terms used for each database are detailed in 
Appendix 6, and summarised in the Venn diagram below. 
Figure 5-1: CHD QOF Search terms 
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The review was interested in articles which looked at the QOF in relation to CHD, so 
primarily with articles which contained these two search terms. Pay for performance 
(P4P) is the main descriptive term used to describe physician incentive schemes 
which pay by result or outcome, of which the QOF is an example. Hence this was 
also included as a search term in order to ensure any study on the QOF, which 
included pay for performance in preference, and in the absence of QOF, in its search 
fields, was also included. Whether or not such a study had a QOF focus was 
determined at the screening stage. Hence while all studies falling within the overlaps 
shown with shading were returned by the search, only those in the cross hatched area 
in Figure 5-1, were included.  
Figure 5-2: CHD QOF PRISMA diagram 
 
 
The search yielded 174 published articles, of which 35 were duplicates. Title and 
abstract screening of the non-duplicate articles using the exclusion and inclusion 
criteria led to the removal of 125 of those articles. Fourteen full journal articles were 
retrieved and reviewed. A further ten were removed at the full article review phase, 
with four considered to meet the inclusion criteria in full.  
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5.5 Articles excluded after full review 
Table 5-1 outlines the reasons behind the exclusion of studies at the full text review 
stage, as well as which PICO criteria the study failed to meet. 
Table 5-1: CHD QOF, studies excluded at full text review 
Author(s) PICO Description of study and reasons for exclusion 
Bottle, 
2008112 
P 3DWLHQWV¶ &+' VWDWXV XQFHUWDLQ 5HJUHVVLRQ DQDO\VLV LV
used to look at the relationship between QOF CHD targets 
and secondary care outcomes measured in HES. However it 
is not linking those events directly to CHD patients rather to 
all patients in the PCT adjusting for QOF CHD scores and 
other variables.  
Campbell, 
2007113 
O The outcome measure used is a composite measure that 
included non QOF CHD targets.......This composite mean 
score measure is calculated in 1998 and 2003 and the trend 
growth rate between those two points is used to predict 
attainment in 2005. Actual attainment in 2005 then 
determines how the QOF affected attainment relative to a 
predicted trend. However the majority of the indicators 
included in the composite score are not present in the QOF; 
and in instances where the indicator matches the QOF target, 
very often the measurement qualifying period differs from 
that in the QOF 
Campbell, 
200912 
O The outcome measure used is a composite measure that 
included non QOF targets......This study builds upon the 
study reported above following access to new data for 2007. 
This is used to compare trend growth rates between 2005 and 
2007 with that between 1998 and 2000.  
Crawley, 
2009114 
P 3DWLHQWV¶ &+' VWDWXV QRW FOLQLFDOO\ YHULILHG8VHV +HDOWK
Survey for England data to look at the effect of occupational 
class on QOF attainment. Patients were selected if they 
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declared a doctor confirmed diagnosis of CHD, however this 
was not medically verified. 
Kiran, 
2010115 
P 3DWLHQWV¶ &+' VWDWXV XQFHUWDLQ5HODWHV &+' KRVSLWDO
admissions and deaths to a CHD quality measure which 
includes Stroke, Hypertension, Diabetes and Smoking 
domain QOF targets in addition to CHD at a practice level. It 
was not possible to be certain that the patients admitted had 
CHD or were QOF CHD qualifying 
Levene, 
2010116 
P 3DWLHQWV¶ &+' VWDWXV XQFHUWDLQThe article is concerned 
with CHD mortality for each year of a three year period but 
does not make QOF CHD care its main focus. Rather it 
examines those rates in relation to the proportion of 
maximum points achieved in CHD, diabetes, hypertension, 
blood pressure, and serum cholesterol control; as well as a 
host of other practice characteristics. In final models CHD is 
dropped entirely as a predictor for CHD admissions.  
McLean, 
2007117 
O Outcomes are not measured at the patient level.....Looks at 
the effect of practice location in terms of distance to urban 
settlement on attainment on QOF targets. Potential wider 
patient level factors behind the relationship are not explored, 
nor any adjustments made, meaning the relationship is merely 
a practice level one. 
Purdy, 
201013 
P I Uncertainty over whether patient had CHD and was treated 
under the QOF incentive scheme.....The study uses HES data 
to look at emergency hospital admissions for MI or Angina, 
over a 12 month QOF period, 2004/05. It then runs a model 
with these as the dependent variable, with a number of 
explanatory variables including national CHD prevalence and 
QOF targets score. The study is not looking at the QOF or 
CHD specifically as it is possible that the patients in HES 
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neither had CHD, nor were treated by the QOF. 
Ryan, 
2011 
O Outcomes were not measured at the patient level...Aggregates 
QOF CHD targets into two composite measures; surrogate 
outcomes and process measures. The relationship between 
improvements in attainment on the composite process and 
surrogate outcome measures is then explored. This is 
however conducted at an English national level and not the 
patient level. 
Strong, 
2006118 
P O Outcomes were analysed at a whole practice level and the 
study does not focus on CHD patients..... The study looks at 
the correlation between CHD QOF target scores and 
deprivation. As deprivation is measured at the practice level, 
there is no direct link being made between deprivation within 
CHD patients and their QOF scores. Nor can this be 
disaggregated from the final results.  
 
5.6 Articles included after full review 
Two of the studies focus purely on blood pressure and look at systolic and diastolic 
blood pressure levels rather than attainment to the QOF threshold119 120. Both of 
these use data from the same source, namely family practices in Wandsworth PCT, 
London, as does the study by Millet121. The remaining study collects its data from 
Scottish practices who participated in SPICE, a clinical effectiveness programme 
developed by the Royal College of General Practitioners (Scotland), and whom used 
the General Practice Administrative Software System (GPASS)122. All of the studies 
which used data provided by Wandsworth PCT, conducted sub group analysis by 
ethnicity, with Murray performing additional subgroup analysis by gender120. In the 
study by Millet only sub group results are reported and whole population figures are 
not121. Furthermore, Millett uses a 140/80 threshold for BP control, which is more 
exacting than the threshold used in the QOF. Three of the four included studies 
compare just two time points in their results120-122, though one of these had data to 
enable them to compare substantially more120. The remaining study compares trend 
rates in a QOF period against those in a pre QOF period119. None of the studies used 
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data specifically generated for the purposes of their study. Further details on each of 
the four included studies are provided below: 
 
Lee et al, 2011119 
Population Patients over 18, diagnosed with CHD, Stroke or 
Hypertension registered with 29 family practices in 
Wandsworth in 2007 
Study design Retrospective cohort 
Method of Analysis Segmented regression analysis of interrupted time series 
Study period 2000-2007 
Subgroup(s) Ethnicity: White, Black and Asian  
Outcome(s) 1. Mean Systolic BP change  
2. Mean Diastolic BP change  
3. Mean Cholesterol level change  
Limitations x A small sample size of 1,753 CHD patients, meant that 
some of the results did not achieve statistical due to a lack 
of power 
Notes x Unbalanced panel data, collected retrospectively from 
patients registered in 2007 
 
McGovern et al, 2008122 
Population Patients with a CHD Read code selected from 310 practices in 
Scotland who used the GPASS administrative system and 
participated in SPICE 
Study design Serial cross section 
Method of Analysis Binary logistic regression model 
Study period March 2004 & March 2005 
Sub group(s) Female, Age 75+, Most deprived quintile: compared to Males, 
Aged 65 and below, least deprived quintile, respectively 
Outcome(s) 1. Angina patient exercise test/specialist assessment 
2. Smoking status recorded 
3. Smokers cessation advice 
4. Blood pressure recorded 
113 
 
5. Blood pressure 150/90 or less 
6. Cholesterol recorded 
7. &KROHVWHURO5mmol/l 
8. Anti-platelet or anti-coagulant therapy recorded 
9. Blocker therapy recorded 
10. ACE inhibitor recorded 
11. Influenza vaccination recorded 
Limitations x There is a near 50% rise in the CHD population in March 
2005 compared to 2004 despite a slight fall in the database 
population, which cannot be explained entirely as a QOF 
incentive effect to better record and diagnose. 
Notes x Scottish Programme for Improving Clinical Effectiveness 
is part of a clinical effectiveness programme developed by 
the Royal College of General Practitioners (Scotland) 
x General Practice Administrative Software System is used 
by approximately 36% of all practices in Scotland 
 
Millett et al, 2009121 
Population Patients with CHD registered with 32 general practices in 
Wandsworth, London. 
Study design Cross sectional survey 
Method of Analysis Multivariate logistic regression 
Study period June 2003-Oct 2003 and Nov 2005-Jan 2006 
Sub group(s) Ethnicity: White, Black and South Asian 
Outcome(s) 1. Angina patient exercise test/specialist assessment 
2. Smoking status recorded 
3. Smokers cessation advice 
4. Blood pressure recorded 
5. Blood pressure 140/80mmHg or less 
6. Cholesterol recorded 
7. &KROHVWHURO5mmol/l 
8. Aspirin prescribed 
9. Blocker therapy prescribed 
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10. ACE inhibitor prescribed 
Limitations x None 
Notes x Odds ratios were adjusted for age, gender, deprivation and 
practice level clustering 
 
Murray et al, 2010120 
Population Patients with CHD selected from 29 General Practices in 
Wandsworth, London 
Study design Longitudinal 
Method of Analysis Unpaired two tailed t tests of mean values  
Study period 1998 and 2007 
Sub group(s) Ethnicity: White; Black and South Asian 
Gender: Male or Female 
Outcome(s) 1. Systolic BP mean difference 
2. Diastolic BP mean difference 
3. Cholesterol level mean difference 
Limitations x Although the study collects 10 years of data the results 
only report differences between 1998 and 2007 
Notes x Patient records were retrospectively collected for all 
patients aged 18 years and above registered on 31st 
December 2007, for each of the previous 10 years from 
January 1998 to December 2007. 
 
5.7 Table of results 
The results from the included studies are reported in Table 5-2, broken down by 
group, and target or clinical area. Whole population figures are shown in bold and 
italics. Significance levels where reported in the studies are included in the table.  
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Table 5-2: CHD QOF Included study results 
Study Comparators, Metrics used Group Target Result 
Lee Trend Change 
2005-07 vs 2000-03 
mmHg 
Whole population Systolic BP -0.53 (-1.09,  0.02) 
Black  0.63 (-1.28,  2.53) 
White  -0.36 (-1.02, 0.29) 
South Asian  -1.77 (-3.05, -0.50)** 
Trend Change 
2005-07 vs 2000-03 
mmHg 
Whole population Diastolic BP 0.32 (0,  0.64) 
Black  0.83 (-0.24,  1.90) 
White  0.13 (-0.25, 0.51) 
South Asian  0.91 (0.2, 1.63)* 
Trend Change 
2005-07 vs 2000-03 
mmol/l 
Whole population Cholesterol 0.02 (-0.01,  0.05) 
Black  0.14 (0.04,  0.25)** 
White  0.01 (-0.03, 0.05) 
South Asian  0.01 (-0.06, 0.08) 
McGovern 
 
March 2004 v March 2005 
Percentage of patients meeting 
the target 
Whole population 
 
([HUFLVHWHVWLQJ ? 63.9% v 66.2%* 
Smoking status recorded 69.5% v 95.7%* 
Smoking cessation advice 81% v 96.2%* 
BP recorded 75.7% v 97.2%* 
%3PP+J 79.3% v 80%* 
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Cholesterol recorded 44.1% v 85.8%* 
&KROHVWHURO5mmol/l 86.3% v 75.5%* 
Anti-platelet or coagulant 65.8% v 90.3%* 
Beta blocker 42.6% v 70%* 
ACE inhibitor ± 66.4% v 77.9%* 
Influenza vaccination 57.4% v 85.5% 
March 2004 & March 2005 
Odds Ratio 
Female¹ ([HUFLVHWHVWLQJ#? 0.93 (0.84-1.04) 0.87 (0.81-0.93) 
Smoking status recorded 1.15 (1.09-1.21) 1.06 (0.98-1.15) 
Smoking cessation advice 1.10 (0.99-1.21) 1.19 (1.05-1.34) 
McGovern March 2004 & March 2005 
Odds Ratio 
Female¹ BP recorded 0.92 (0.87-0.97) 0.89 (0.82-0.97) 
%3150/90mmHg 0.84 (0.79-0.89) 0.84 (0.80-0.87) 
Cholesterol recorded 0.87 (0.83-0.92) 0.82 (0.78-0.87) 
&KROHVWHUROPPROO 0.57 (0.53-0.62) 0.54 (0.51-0.56) 
Anti-platelet or coagulant 0.89 (0.85-0.93) 0.73 (0.70-0.77) 
Beta blocker 0.85 (0.81-0.88) 0.81 (0.79-0.84) 
ACE inhibitor ± 0.67 (0.56-0.81) 0.88 (0.79-0.98) 
Influenza vaccination 1 (0.96-1.04) 0.91 (0.88-0.94) 
March 2004 & March 2005 
Odds Ratio 
Age 75+² ([HUFLVHWHVWLQJ#? 0.41 (0.35-0.49) 0.37 (0.34-0.40) 
Smoking status recorded 0.54 (0.48-0.60) 0.99 (0.89-1.15) 
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Smoking cessation advice 0.56 (0.48-0.66) 0.44 (0.36-0.53) 
BP recorded 0.37 (0.32-0.42) 0.73 (0.65-0.81) 
%3PP+J 0.90 (0.84-0.97) 0.86 (0.81-0.90) 
Cholesterol recorded 0.45 (0.41-0.49) 0.73 (0.68-0.78) 
&KROHVWHUROPPROO 1.39 (1.22-1.58) 1.19 (1.12-1.26) 
Anti-platelet or coagulant 0.60 (0.55-0.67) 0.97 (0.91-1.03) 
Beta blocker 0.39 (0.36-0.42) 0.53 (0.51-0.56) 
ACE inhibitor ± 0.56 (0.45-0.69) 0.50 (0.43-0.57) 
Influenza vaccination 1.44(1.28-1.61) 2.85(2.67-3.04) 
March 2004 & March 2005 
Odds Ratio 
Most deprived 20% ³ ([HUFLVHWHVWLQJ#? 0.76 (0.57-1.02) 0.84 (0.61-1.14) 
Smoking status recorded 1.04 (0.86-1.26) 0.78 (0.62-0.99) 
Smoking cessation advice 1.35 (0.92-1.97) 0.83 (0.60-1.14) 
BP recorded 0.95 (0.74-1.20) 0.59 (0.45-0.78) 
%3PP+J 1.05 (0.89-1.24) 1.06 (0.93-1.21) 
Cholesterol recorded 1 (0.77-1.31) 0.79 (0.57-1.08) 
&KROHVWHUROPPROO 1.31 (0.83-2.06) 1.31 (0.98-1.76) 
Anti-platelet or coagulant 1.11 (0.95-1.28) 1.14 (1-1.22) 
McGovern March 2004 & March 2005 
Odds Ratio 
Most deprived 20% ³ Beta blocker 0.87 (0.77-0.97) 0.84 (0.76-0.92) 
ACE inhibitor ± 1.64 (1.18-2.28) 1.67 (1.34-2.10) 
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Influenza vaccination 0.92 (0.78-1.09) 0.83 (0.74-0.94) 
Millett Adjusted Odds Ratio 
2003:2005 
White Smoking status recorded 3.6 (2.5-5.4) 
Black  3.5 (2.2-5.7) 
South Asian  5.3 (3-9.5) 
White Cholesterol measured 1.6 (1.2-2.1) 
Black  2.1 (0.9-4.9) 
South Asian  2.6 (0.9-7.7) 
White BP measured 2.9 (2-4.2) 
Black  3.0 (1.1-8.6) 
South Asian  6.3 (2.2-18.3) 
White Aspirin prescribed 1.6 (1.3-1.9) 
Black  2.1 (1.4-3.3) 
South Asian  1.8 (0.9-3.6) 
White Beta blocker prescribed 1.3 (1.1-1.5) 
Black  1.3 (1-1.7) 
South Asian  1.2 (0.9-1.7) 
White ACE inhibitor ± 1.4 (1.1-1.7) 
Black  2.1 (1-4.6) 
South Asian  1.4 (0.7-2.7) 
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White &KROHVWHUROPPROO 1.5 (1.3-1.8) 
Black  1.7 (1.1-2.5) 
South Asian  1.2 (0.9-1.7) 
White %3PP+J 1.3 (1-1.6) 
Black  1.7 (1-2.7) 
South Asian  1.5 (1-2.2) 
Murray Difference in mean: 1998-2007 
mmHg 
All Male patients Systolic BP -6.25    P<0.001 
All Female patients  -9.43    P<0.001 
White Male  -5.69    P<0.001 
White Female  -10.11  P<0.001 
Black Male  -8.00   P=0.120 
Black Female  -9.45    P=0.134 
South Asian Male  -7.11    P=0.049 
South Asian Female  -4.27    P=0.376 
All Male patients Diastolic BP -6.73    P<0.001 
All Female patients  -6.31    P<0.001 
White Male  -5.59    P<0.001 
White Female  -6.55    P<0.001 
Black Male  -15.62  P<0.001 
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Black Female  -4.77    P=0.196 
South Asian Male  -7.47    P<0.001 
South Asian Female  -7.19    P=0.008 
All Male patients Cholesterol -0.87    P<0.001 
All Female patients  -0.90    P<0.001 
White Male  -0.94    P<0.001 
White Female  -0.81    P<0.001 
Black Male  -0.20    P=0.656 
Black Female  -1.08    P=0.007 
South Asian Male  -0.70    P=0.006 
South Asian Female  -1.08    P=0.036 
33ï&RPSDUHGWRPDOHVð&RPSDUHGWRXQGHUVñ&RPSDUHGWROHDVWGHSULYHG 
#? Patients with angina    ± Patients with a history of myocardial infarction    95% confidence intervals shown in parentheses ( ) 
Whole population results shown in bold and italics    Subgroup results shown in normal font 
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5.8 Included studies discussion 
None of the studies reported hard clinical outcomes or endpoints. Studies examined 
the impact of incentives over a short period, often using as little as two time points. 
Only one study adjusted results for existing trends and only one used data that was 
not from an administrative dataset collected by Wandsworth PCT, an inner London 
borough. In terms of informing this thesis, and answering the research question, it 
has identified a clear need for the research being undertaken by this thesis. No 
previous research has examined the effectiveness of QOF targets on evidence linked 
hospital admissions at the individual patient level, or tentatively researched this area.  
Results are discussed in detail by target area below: 
5.8.1 Blood Pressure 
Lee does not examine the QOF target but looks at the underlying measures, systolic 
and diastolic blood pressure, examining changes between 2005 and 2007 relative to 
trend between 2000 and 2003119. For the whole population systolic blood pressure 
was lower than trend by 0.53 mmHg, though this result was not significant at a 95% 
significance level. For all subgroups with the exception of black ethnicities the 
decrease was below trend, though only in South Asians was it significantly so, 
S )RU GLDVWROLF EORRG SUHVVXUH DW WKH ZKROH SRSXODWLRQ OHYHO DQG IRU HDFK
subgroup, levels were higher than they would have been had they followed the pre 
42)WUHQGWKRXJKRQO\LQ6RXWK$VLDQVZDVLWVLJQLILFDQWO\VRS 
Murray also looks at the underlying blood pressure measures rather than attainment 
to QOF thresholds120. Though in this instance the comparison is between 2007 and 
1998 and the figures are reported for males and females at the population level with 
subgroup analysis by ethnicity and gender. Systolic blood pressure fell between 1998 
DQG  E\ PP+J LQ PDOHV DQG E\ PP+J LQ IHPDOHV S LQ ERWK
instances. Within the different ethnic groups systolic blood pressure was lower in 
2007 compared to 1998, though these results were not significant at a 95% 
confidence level for both male and female black ethnicities and South Asian females. 
Diastolic blood pressure fell by 6.73mmHg in all male patients and by 6.31mmHg in 
DOO IHPDOHSDWLHQWVEHWZHHQDQGS ,W IHOO LQDOOPDOHDQGIHPDOH
ethnic groups with a 99% significance level, with the exception of black females, -
4.77%, p=0.196. 
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At the population level McGovern finds a large increase in BP recording 
immediately following the QOF, from 75.7% in March 2004 to 97.2% in March 
2005, which was statisticDOO\VLJQLILFDQWS122. In terms of patients meeting the 
BP150/90 target the effect is less dramatic but still significant, rising to 80% from 
S:KHQH[DPLQLQJVXEJURXSSRSXODWLRQVWKHRGGVRIDIHPDOH&+'
patient having their blood pressure recorded was around 10% lower than males; and 
controlled around 15% lower, in both the pre and post QOF study period. Patients 
aged 75 and above had lower odds of having their blood pressure recorded and 
controlled in both periods though this improved noticeably in the first year of the 
QOF for recording but was marginally lower for control, relative to those 65 and 
under. The most deprived had a 5% lower odds of having their blood pressure 
recorded prior to the QOF but a 5% higher odds of having it controlled at or below 
150/90 relative to the least deprived. While the odds of blood pressure being 
controlled remained similar in the first year of the QOF the odds for having blood 
pressure recorded declined noticeably to 41% lower than that in the least deprived. 
Millett compares odds ratios for 2003 and 2005 adjusted for age, gender, deprivation 
and practice level clustering121. No whole population level results were provided. 
The adjusted odds ratio was higher in all ethnic groups for blood pressure recording 
in 2005 relative to 2003. In all these results the 95% confidence interval did not cross 
one. For blood pressure control Millett uses a more demanding target than that 
DGRSWHG E\ WKH 42) %3 )RU DOO HWKQLF JURXSV WKH DGMXVWHG RGGV UDWLR LV
greater than 1; 1.3 White, 1.7 Black and 1.5 South Asian. However for all groups the 
95% confidence includes 1, suggesting no significant difference at a 95% 
significance level  
5.8.3 Cholesterol 
At the population level Lee finds that cholesterol levels were higher between 2005 
and 2007 then they would have been expected to be if they had followed the trend 
rate experienced between 2000 and 2003, by 0.02mmol/l119. However this result was 
not significant. In terms of ethnicity subgroups cholesterol levels were higher in 
2005 than they would have been had they followed the 2000-2003 trend, though only 
LQWKH%ODFNHWKQLFJURXSZHUHWKH\VLJQLILFDQWO\VRPPROOS 
Murray also looks at cholesterol levels rather than the QOF thresholds, comparing 
mean differences between 1998 and 2007120. Mean levels are lower in 2007 for both 
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PDOHV DQG IHPDOHV E\ PPROO DQG PPROO UHVSHFWLYHO\ S :KHQ
these are further broken down into ethnicity subgroups the results are all significant 
at a 95% significance level with the exception of Black males, -0.2mmol/l, p=0.656. 
McGovern finds a large and statistically significant increase in the number of 
patients with a cholesterol record after the first year of the QOF, 85.8% (March 
FRPSDUHGWR0DUFKS122. However he also finds a drop in 
the percentage having their cholesterol controlled to 5mmol/l or less, from 86.3% in 
0DUFK  WR  LQ 0DUFK  S ,Q WHUPV RI VXbgroups females had 
13% lower odds of having cholesterol recorded and 43% lower odds of meeting the 
QOF target in March 2004, relative to males. Both of these figures worsened slightly 
LQ WKH 42)¶V ILUVW \HDU 2YHU ¶V KDG  ORZHU RGGV RI KDYLQJ FKROHVWerol 
recorded but 39% higher odds of meeting the QOF threshold in March 2004, relative 
to those aged 65 and below. In the first year of the QOF these figures had risen to 
27% lower odds and fallen to 19% higher odds, respectively. For the most deprived 
the odds of meeting the QOF target were 31% higher in both periods relative to the 
least deprived. In terms of having a cholesterol level record, there were equal odds in 
0DUFKEXWE\WKHHQGRIWKH42)¶VILUVW\HDUWKHPRVWGHSULYHGZHUHOHVV
likely to have their cholesterol recorded. 
Millett  measures cholesterol recording and control to the QOF threshold, comparing 
adjusted odds of meeting the target in 2003 against 2005121. In all ethnic groups the 
adjusted odds of meeting both targets increased over that period. The 95% 
confidence intervals around the adjusted odds ratio remained above 1, for the white 
and black ethnic groups, but for the South Asian ethnic group the 95% confidence 
interval fell below 1 on both measures, recorded (0.9-7.7), 5mmol/l or less (0.9-1.7). 
5.8.4 Smoking 
The adjusted odds ratio for having smoking status recorded was over 3 times higher 
in the white and black ethnic groups and over 7 times higher in South Asians in 2005 
compared to 2003, in the study by Millett121.   
McGovern finds that the percentage of patients with a record of smoking status and 
given smoking cessation advice both climbed above 95% in the year immediately 
IROORZLQJWKH42)¶VLQWURGXFWLRQIURPIRUUHFRUGLQJDQGIRUFHVVDWLRQ
advice in March 2004122. Females had higher odds of smoking status recording and 
smoking cessation advice in both study years. However whereas those odds fell 
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relative to males for smoking recording from 1.15 to 1.06, they increased for 
cessation advice from 1.19 to 1.28. Those aged 75 and above saw a large increase in 
the odds of having smoking status recorded from nearly half that in those aged 65 
and below to near equal odds. The odds of being offered smoking cessation advice 
however fell back from 44% lower to 56% lower. The least deprived went from 
having 4% higher odds of having smoking status record, though with 95% 
confidence intervals crossing 1, to haYLQJORZHURGGVLQ WKH42)¶VILUVW\HDU
Smoking cessation also fell back from 35% higher odds, though again with 95% 
confidence intervals crossing 1, to 22% lower odds 
5.8.5 Prescriptions 
Both McGovern and Millett look at CHD QOF prescription targets. In the study by 
McGovern the percentage of the population meeting the QOF prescription targets 
increased in the first year of the QOF, by over 25%  for anti-platelets to 90.3%, near 
28% for beta blockers to 70%, and 11.5% to 77.9% for ACE inhibitors122. Those 
aged 75 and above had lower odds of meeting all QOF prescription targets relative to 
those aged 65 and below, though odds improved to near equal for anti-platelets, to 
47% lower for beta blockers but fell further behind for ACE inhibitors to 50% lower 
odds.  Females also had lower odds of receiving QOF prescribed drugs than males in 
both periods, though this time with odds for anti-platelets and beta-blockers falling, 
EXW RGGV IRU $&( LQKLELWRUV LQFUHDVLQJ LQ WKH \HDU IROORZLQJ WKH 42)¶V
introduction. The most deprived had higher odds of receiving anti-platelets and ACE 
inhibitors prior to the QOF, 11% and 64% higher respectively, with both odds 
increasing marginally in the first year.   
Millet finds that patients of all ethnicities had higher adjusted odds of receiving all 
incentivised drugs in 2005 compared to 2003121. However for beta blockers and ACE 
inhibitors in the non-white population, and aspirin in South Asians, the 95% 
confidence interval included 1 
5.9 Limitations 
There are a number of limitations in the included studies which are split down into 
two broad headings; generalisability and strength of evidence. 
Three quarters of the included studies used data from Wandsworth PCT119-121. This is 
an inner city area of South West London, affluent by London standards, urban with 
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no rurality, with a relatively young and very ethnically diverse population. As such 
its population is not representative of the UK as a whole. Furthermore the qualifying 
patient numbers in each study from this region were small, ranging from 913 to just 
over 3,100.  Based on a relatively small sample from a small geographical area of 
London, and on one PCT, it is difficult to draw service wide lessons from the results. 
McGovern uses a larger sample, one covering around 36% of practices in 
Scotland122.  However it is not clear if these are representative of Scotland practices 
in general. Nor whether given the size of Scotland relative to the UK as whole and 
differences in service organisation across the different nations, that these results 
would be applicable across the whole of the UK. Two of the studies use the measures 
underlying the QOF rather than the specific QOF targets thresholds119 120. While they 
show what is happening in the measures that map to the QOF targets which one 
would expect to broadly predict attainment on the targets, they can nonetheless hide 
significant between patient variation.  
In terms of strength of evidence, small sample sizes in most of the studies raises 
concerns around the statistical power of reported outcomes. This issue is indeed 
recognised by Lee, who reports that a number of results did not reach statistical 
significance due to a lack of statistical power. Most of the studies have very limited 
data points in their analysis. In the case of McGovern, Millett and Murray they are 
simply comparing two points in time which make it impossible to account for any 
underlying trends which may be influencing the results additional to a QOF 
intervention effect. This is particularly noticeable in the study by Murray that looks 
at absolute differences in mean figures for readings taken in 1998 and 2007. While 
this includes a period in the QOF the significant time difference between the two 
dates and the earliest date and the introduction of the QOF in 2004, means that it is 
difficult to attribute differences to the QOF. It is unclear in the study by Murray why, 
when they apparently had ten years of longitudinal data, they used these two time 
points only. Nor why they did not make greater use of their data to examine trends 
and report further on pre QOF and QOF trends that they refer briefly to.  
5.10 Implications for practice 
The evidence base on the clinical effects of CHD QOF targets is extremely limited 
and extends simply to analysis of attainment on the QOF targets, with a reliance on a 
small number of routinely collected datasets. Analysis rarely extends beyond a 
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comparison between two points in time measures with little consideration of time 
trends. As such there is no strong evidence of clinical benefits of either the targets or 
using P4P to deliver improvements in patient outcome. 
5.11 Implications for future research 
This research area is significantly underdeveloped and has a number of deficiencies 
which future research should attempt to address. Specifically there is a need for more 
ambitious research which extends beyond simply looking at attainment on QOF 
targets or their mapped measures. This should look at the effectiveness of QOF 
targets on relevant clinical outcomes, ideally over longer periods which can account 
for trends.  Studies need to be sufficiently powered to pick up any effects, and extend 
beyond the data sources used by the studies in this review. 
5.12 Summary 
The objective of this literature review was to determine the impact of the QOF on 
CHD care and the scope and depth of research undertaken to date. On the whole it 
has shown an improvement in performance to CHD QOF targets and on their 
mapped measures. What has not been established is to what extent, if any, the QOF 
has been responsible for these improvements; in part due to the lack of a control 
group but also due to a lack of follow up in the included studies. Nor has any 
evidence been found for the impact of QOF targets on relevant clinical outcomes. 
5.13 Conclusion 
This literature review has identified a clear need for further research in this area. 
This research should address the limitations of the research identified in this review. 
Having focused purely on QOF targets or their mapped measures the question of 
whether the QOF has impacted on relevant clinical outcomes is still one that future 
research needs to address. To account for underlying trends as well as any 
cumulative benefits from repeated compliance; the research should involve repeated 
patient observations where possible and a sufficient period of follow up to pick up 
any intervention effects. These are items that this research will seek to address in the 
remaining chapters. The next chapter will describe the databases used in this study 
and how study variables were created using the information extracted from them.  
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Chapter 6 Methodology: Using CPRD and HES 
data to model the QOF 
6.1 Objective 
To explain how CPRD and HES data can be used to construct variables relevant in 
the modelling of the QOF. This will involve: 
1. Briefly describing how the CHD patient cohort was defined in CPRD and linked 
into HES data 
2. Describing the CPRD file structure and how it can be used to define and extract 
data to construct CHD QOF targets and other explanatory variables  
3. Defining secondary care outcome measures and describing how they can be 
identified using the HES data file structure 
4. Describing how data was quality assured and how missing or unreliable data 
were dealt with 
6.2 Defining the CHD study population 
The starting point for the study was to define the study population. This took place in 
the CPRD dataset before the patients were linked into HES.  Patients were selected 
on the basis that they had a CHD Secondary prevention Read code recognised for 
reimbursement purposes by QOF Business rules version 17. Qualifying Read codes 
are detailed in Appendix 7. Those Read codes needed to be recorded at any time 
during the study period, 01/01/2000 to 01/04/2011. In order to have a starting 
population a second define was undertaken, this time allowing Read codes prior to 
the study start date to qualify, but only for those patients who had a Read code 
during the study. This process did not change the patients in the population nor the 
study start date, it simply ensured that on the first day of the study there were 
SDWLHQWVDOUHDG\µUHFUXLWHG¶LQWRWKHVWXG\ 
6.2.1 Defining the study population: CPRD and HES linkages 
As the study was concerned with the impact of QOF care on secondary care 
outcomes, the patient cohort defined in CPRD had to be linked into HES. This 
reduced the CPRD cohort since not all CPRD practices have consented to HES 
linkages and HES collects data on the English NHS only, limiting the study 
population to patients in English practices. The CPRD population was linked into 
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HES in two stages. The first tranche of HES linked data which was made available to 
the study in August 2012 defined the HES linked population. This HES upload 
included data up to the end of December 2010, contained 304 consenting practices 
and over 4.5 million patient events.  In March 2013 a new upload was received 
which included HES linked data up to the end of March 2012 and contained 374 
consenting practices. Had this data been used in the study it would have increased 
the existing study population over the course of the study by just under 12,000 
before any data cleansing, and added an additional QOF year to the study. In the 
absence of time to make changes, the new HES upload was used to take the HES 
data up to the end of March 2011 to fit in with the end of the QOF year, for the 
previously defined patient population. Hence, in effect, the new HES upload was 
used to find the secondary care events of interest; but only for existing patients who 
had been linked using the previous upload.  
The way the two databases interact and where the patient population fits in is 
illustrated in the Venn diagram, Figure 6-1. The figures represent approximations of 
the active population, i.e. both up to standard and contributing data in any given year 
of the study rather than total number of patient records on each. 
Figure 6-1CPRD and HES linkages 
 
CPRD and HES are stand alone databases, illustrated by the two circles above. So 
long as a practice on CPRD consents to linkages its patients at that point become 
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HES linked. Of the over 5 million active and up to standard patients within CPRD 
this applied to approximately 2.5 million of its population, roughly 2.2 million of 
whom had been matched in HES; across 304 separate practices (figures based on the 
December 2010 uplift). HES only covers the English NHS, and contains inpatient 
data only. A patient in a HES linked practice has their data captured in HES by 
matching a combination of their date of birth, gender, NHS number and postcode. 
For the HES link upload used in this study to determine the qualifying patients, 
nearly 5 million patients qualified for linkages and 3.9 million had an inpatient 
admission matched to them. In the study that population is restricted further to 
patients who have a CHD Read coding in CPRD and are HES linked, illustrated by 
the shaded oval in the overlap between the HES and CPRD circles.  
6.2.2 Defining and extracting the study population using CPRD 
The CPRD file structure that was used to define, extract and then create variables is 
illustrated in diagrammatic form in Figure 6-2 on the following page. Explanation of 
the process and diagram are given in subsequent pages. 
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Figure 6-2 CPRD file structure: Diagramatic representation 
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Within the QOF, Read codes are used to classify conditions and treatments. In 
CPRD the comparable information is recorded using medical codes (medcode). The 
first task in ascertaining the patient population was to translate CHD Read codes into 
medcodes using the Medical browser provided by CPRD. Version 1.3.2, November 
2011, was used in this study.  
With GPRD medical codes it is then possible to perform a search for patients on the 
database who have an entry for one or more of those medcodes, by feeding them into 
the Define tool. Up to 2 inclusion criteria and 4 exclusion criteria can be specified in 
the define tool, by inputting the medcodes of interest in each. A time period for the 
search is specified, which was the study period in this instance and a minimum and 
maximum age range for qualifying patients can be entered, though none was for this 
study. The CPRD database is updated monthly using information submitted by 
practices. These updates not only add to information on patients based on activity 
since the last database build but can include updates and additions to information 
submitted for previous periods. The January 2012 database build was used for all 
data defines. Only events in the registration period were selected meaning they had 
WR WDNH SODFH LQ WKH SDWLHQW¶s current registration period. The period within which 
codes are acceptable are also selected at this point from one of three options: any in 
the study period; any before the study end; and first ever in study period. In this 
study first ever in the study period were first selected, as this was the point from 
which patients became eligible to participate, namely from the point of their first 
CHD code in the study period. Subsequent to this however, to ensure a non-zero 
study start population, the any before the study end option was selected, which 
produces a list of patients with the codes of interest at any point prior to the study 
end date. If the previously defined patients had a CHD coding prior to the study start 
date, they entered the study at its start, 01/01/2000, providing it met quality control 
markers. 
Within the define browser there are 5 fields (tick box options) which generate files 
on different aspects of care. The first four: Referral, Test, Clinical and Immunisation 
look at patient activity with respect to consultation episodes, referrals for outside 
services, clinical tests and immunisations delivered in surgery. The last one, 
Therapy, cannot be selected at the same time as Referral, Test and Clinical, and vice 
versa; as they search on product codes, namely for medical prescriptions issued to 
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the patient. When the define process is completed, text files are produced from each 
of the four files listing the date when that medical code was recorded, and the 
identifier for the patient it was recorded against (patid). In addition separate log files 
give details of the search, numbers satisfying each inclusion and exclusion criteria, 
and a list of patients meeting the inclusion criteria. 
The define tool simply produces a list of patients with an index date denoting the 
date when the one of the specified medcodes of interest was first recorded. To gather 
further information on those patients the Extract browser is then used. This uses the 
patient lists from one of the inclusion or exclusion files generated in the define 
process to extract further details on those patients. At this stage it is also possible to 
get therapy details on patients who were selected on the basis of medical codes. 
Likewise it is possible to find clinical details on patients selected on the basis that 
they had been given a certain therapy, for instance a prescription for anti-coagulants. 
If choosing this route the product browser is used to search for relevant codes as 
opposed to the medical browser.  
The extract tool has ten tick box fields which generate separate files for each of those 
fields, shown on the horizontal line in Figure 6-1, and the additional clinical file 
which is shown beneath. While additional clinical is a separate file it has to be linked 
to the clinical file using the additional identifier variable, adid. These ten tick box 
fields are further separated into a number of further tick box fields specific to that 
file, making it possible to specify the content of the file. In conducting this research 
all files and fields were extracted, meaning that all CPRD database details on the 
study population were extracted. In addition to the Define and Extract browser there 
are two additional browsers, Refine and Transform. These were not used in the 
course of this work and are therefore not elaborated on further. 
6.2.3 What form CPRD data takes and how files are linked 
The extract tool generates ten files: Clinical, Additional Clinical Details, 
Consultation, Immunisation, Patient, Practice, Referral, Staff, Test and Therapy. 
Different aspects of patient care, staff and practice details are held on these files. 
Depending on the nature and scope of the research being undertaken it may be 
necessary to link across the various files to build up a bigger picture on the unit of 
analysis. In CPRD there are 3 possible units of analysis, the patient through the 
unique patient identifier, patid, the practice through their unique identifier, pracid, or 
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alternatively an individual member of staff through staffid. In the case of this study 
the data was aggregated and analysed at the patient level. Although the QOF rewards 
practice attainment, the incentivised treatments are delivered, and their impact felt, at 
the individual patient level. Hence for this study which was concerned with the 
clinical impact of physician incentives, the patient represented the logical unit of 
measurement. In addition to these unit identifiers there are also a number of shared 
identifying variables that enable entries to be linked across files. A summary of the 
nature of the information contained on the separate files is specified below: 
x The patient file contains patient specific information such as sex, date of birth, 
and registration date.  
x The Practice file provides information about the practice where the patient was 
treated such as its geographical location, and time since it has been up to 
standard for CPRD data collection purposes. 
x The Staff file records the gender and role of practice staff.  
x The Clinical file details all medical events including symptoms, signs and 
diagnoses. When further details regarding these events were recorded in the 
VWUXFWXUHGDUHDVRIWKH*3¶VVRIWZDUHWKHVHDUHVKRZQLQWKH$GGLWLRQDO&OLQLFDO
Details file. These details are linked by an additional identifier (adid) unique to 
the clinical event and recorded in up to seven data fields whose details are 
determined by consulting the entity data file. 
x The Consultation file contains details on the type of consultation as entered by 
the practice staff according to a pre-determined list. This primarily details the 
type and duration of the consultation. It is linked to the staff file by means of the 
staffid and where further clinical events occur as a result of the consultation, to 
the clinical file, by a unique consultation identifier consid.  
x The Immunisation file contains details on all immunisations recorded on the GP 
vision system including product details, where it was administered, the reasons 
and method.   
x The Referral file details any patient referrals to outside care agencies, normally 
to secondary care centres, generated by the different staff members and recorded 
on their systems.  
x The Test file details all tests requested on behalf of the patient by the practice 
staff. This information is given in numbered fields, 4, 7 or 8 data fields in length; 
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whose values are determined by its numbered enttype, which in consultation with 
the entity file and various look up variables gives details on the tests undertaken.  
x The Therapy file gives details on all prescriptions issued to individual patients by 
individual practice staff. 
6.2.4 Using CPRD data to create QOF variables: An example 
The QOF target in question determined which file needed to be consulted. Naturally 
the first task was to build a CHD patient population that would act as the 
denominator in the majority of targets. Patients entered the study population at their 
first recorded CHD Read code date, in the case of this study it was specified that it 
needed to be during the study period. So long DVWKDWGDWHZDVLQWKHSDWLHQW¶VFXUUHQW
registration period and when the practice was classed as up to standard, meaning of 
research quality, this date was acceptable. Otherwise the first coding following 
practice up to standard was used. The patient remained in the CHD study population 
up until the study end or the earliest of their transfer out date or death date. If the 
transfer out or death date occurred at any point in a QOF year, 1st April to 31st  
March the following year, the patients were classed as QOF qualifying for that QOF 
year so attainment on QOF targets was measured. Likewise the patient immediately 
entered the CHD denominator and QOF population at first CHD coding, so formed 
part of the CHD population from the first QOF year they entered. This is in keeping 
with QOF business rules, though exceptions can be made for patients who became 
QOF qualifying in the last three months of a QOF year and did not meet a QOF 
target. It should be noted that the same targets and rules applied to the whole study 
period, including years prior to the QOF, so in the context of this study QOF years 
refers to an accounting period when QOF targets were applied, and not necessarily 
that the QOF P4P scheme was in existence.  
Having established the denominator the next task was to determine the numerator for 
each target. This differed for each target, and brief outlines of how each was 
determined are given later on in this chapter. For purposes of illustration the QOF 
target, CHD8, last measured total cholesterol, measured in the previous 15 months, 
of 5mmol/l or less, is used. The first point of reference to determine where this is 
recorded in CPRD is the entity spreadsheet. Searching on the medical term of interest 
in the description field determines which CPRD file the information is contained in, 
and what coding, enttype, is used to record it. There is further information on this 
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spreadsheet which, in conjunction with CPRD lookup files, details what is recorded 
in the file data fields for that enttype. Among these is the actual reading or result and 
the unit of measurement used.  
The entity spreadsheet reveals that serum cholesterol can be found in the test file by 
searching for the value 163 in the entity variable. It also specifies what look up file 
needs to be consulted to determine units of measure and which field in the test file 
this information is recorded in. In this instance the SUM look up file needs to be 
consulted to determine the unit of measure recorded in the data3 field. In near 100% 
of instances where a unit of measure was recorded, mmol/l was used, which related 
directly to the QOF wording. Where data is entered an eventdate, the date the event 
happened, should be recorded. In its rare absence the sysdate, system date, was used 
in its place which is the date the event was entered on the surgery IT systems from 
which CPRD collects its data. This usually, though not always, matches the former. 
These dates were then placed into QOF years using the same criteria as that applied 
to the denominator. The wording of the QOF target specifies three components that 
must be met for the serum cholesterol test result to be QOF qualifying. Firstly that 
the reading should be 5mmol/l or less; secondly that the last recorded measure in that 
QOF year should meet that criteria; and thirdly that the last reading can be at any 
point in the preceding 15 months. In order to determine these were met all readings 
over the past 15 months prior to the end of the QOF year were selected. These were 
then ranked in date order, and if the last recorded reading over that period was 
5mmol/l or less the patient met the QOF criteria, and formed part of the practice 
numerator to determine QOF achievement. Both patient and practice level 
performance was recorded, though the  analysis took place at the patient level, so the 
study was more concerned with whether or not the patient met the target rather than 
WKHSUDFWLFH¶VRYHUDOOSHUIRUPDQFH 
6.3 How is HES linked data organised? 
The lowest level of activity in HES is an episode. An episode in this sense refers to 
each time a patient receives a medical intervention. A patient may receive a number 
of episodes of care with the same consultant in the course of a routine examination 
or surgery, and once the last episode in the process is administered by the consultant 
this constitutes a finished consultant episode. The patient may then be seen by 
different consultants or health professionals including the initial consultant in 
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between, generating a number of finished consultant episodes, before finally being 
discharged from that hospital. This process of care constitutes a spell. Should the 
patient then be discharged from their first hospital immediately to a different NHS 
hospital or other NHS funded provider for continued care, the recording process 
continues in the order discussed. The whole process of care from the time when the 
patient enters the health system to the time that they are discharged back into the 
community is referred to as a continuous inpatient spell. This consists of one or more 
VSHOO¶V, which refers to the care received in one hospital or health setting, which in 
turn consists of one or more finished consultant episodes, which are a record of care 
with each consultant.  
As with CPRD, HES data is split into files. In HES files are primarily broken down 
into episodes and hospitalisations, the latter referring to spells of care. Episodes are 
uniquely identified by an epikey variable and spells by a spell number, spno variable. 
As well as ICD 10 codes, OPCS 4 procedure codes are recorded by episode in a 
procedure file, and further files are provided on periods of augmented care, time 
spent in critical care and maternity care, where applicable. All of these files can be 
related to one another through the patient identifier and one or a combination of 
episode key or spell number whichever is most applicable to the care recorded 
6.4 QOF targets examined in this study 
A description of how CPRD was used to model the QOF target CHD8 has already 
been described in detail. Table 6-1 goes through the wording of the remaining targets 
and the rule set followed to model these in CPRD. For guidance in drawing up these 
rule sets and determining compliance with QOF targets, QOF Business Rules were 
used. Although the QOF was not introduced until April 2004, the same rules were 
applied for periods prior to that for means of comparison. Full details of the medical 
and Read codes used are given in Appendix 7. In all instances the denominator was 
the whole study population unless specified otherwise. Exclusions were not 
applicable; and in all cases it was assumed that missing data meant the event had not 
taken place and the target was therefore unmet, except where specified. Table 6-1 
details the rules followed for QOF targets only, with details on the remaining 
variables provided in Appendix 8, along with the expected relationship of all the 
variables with the study outcome measures. 
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Table 6-1 QOF study variables ruleset 
CHD6 The percentage of patients with CHD in whom the last blood 
pressure reading (measured in the last 15 months) is 150/90mmHg 
or less 
Variable name BP 
CPRD ruleset A last recorded blood pressure at or below 150/90 measured at any 
point in the QOF year or 3 months prior to it, recorded in the 
additional file against an enttype of 1. 
CHD9 The percentage of patients with CHD with a record in the last 15 
months that aspirin, an alternative anti-platelet therapy, or an 
anticoagulant is being taken 
Variable name Anti 
CPRD ruleset At least one prescription for aspirin, an anti-platelet or anti-
coagulant (recorded in the therapy file using bnfcodes 15, 196, 912, 
918 and 919); during a QOF year and the 3 months prior. 
CHD10 The percentage of patients with CHD who are currently treated 
with a beta blocker (unless a contraindication or side effects are 
recorded) 
Variable name BB 
CPRD ruleset At least one prescription for a beta-blocker in the last six months of 
the QOF year recorded in the therapy file using bnfcode 18. 
CHD11 The percentage of patients with a history of  myocardial infarction 
(diagnosed after 1 April 2003) who are currently treated with an 
ACE inhibitor or Angiotensin II antagonist 
Variable name Acea2q 
CPRD ruleset Pre QOF period: A Myocardial Infarction Read code entered within 
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CPRD after 1 April 1999, and at least one prescription for an ACE 
inhibitor or Angiotension II antagonist (recorded using bnfcodes 5 
and 142), in the last six months of a QOF year  
QOF period: A Myocardial infarction Read code, entered within 
CPRD after 1 April 2003 and at least one prescription for an ACE 
inhibitor or Angiotension II antagonist (recorded using bnfcodes 5 
and 142), in the last six months of a QOF year  
Denominator All patients with an MI code entered on or after 01/04/1999 prior to 
01/04/2004. After this date all patients with an MI code on or after 
01/04/2003. 
Exclusions Patients with a MI Read code prior to 01/04/1999 in the pre QOF 
period 
Patients with a MI Read code prior to 01/04/2004 in QOF period 
Related to 
Smoking3 
The percentage of patients with CHD whose  notes contain a record 
of smoking status in the previous 15 months 
Variable name Smokstat 
CPRD ruleset A smoking medcode recorded in the clinical file in the QOF year 
and the three months prior. These are broken down into the 
categories set out in that QOF ruleset: never, ex and current. Some 
patients had multiple records over a QOF year, and could move 
between smoking states. Where multiple records existed, the codes 
were selected in the following preference order, a current smoking 
record in the first instance, then ex and finally never. 
Related to 
Smoking4 
The percentage of patients with CHD who smoke, whose  notes 
contain a record that smoking cessation advice or referral to a 
specialist service, where available, has been offered within the 
previous 15 months 
Variable name Smcess 
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CPRD ruleset A smoking cessation medcode recorded in the clinical or referral 
file during a QOF financial year, and the three months prior, 
matched against a current smoker code recorded at any point in the 
same 15 month period, in the smokstat variable. 
Denominator All patients with a current smoker code 
Exclusions All patients with no record or a non-current smoker code 
 
6.5 HES outcomes of interest 
The study was concerned with secondary care admissions for complications arising 
out of existent CHD, which could be indicative of poor condition management in 
primary care. These outcomes were ICD10 codes for Ischaemic Heart Disease, I20 to 
I25. Codes within this grouping for myocardial infarction (I21 and I23) had to form 
the primary diagnosis during a hospitalisation. The remaining codes within this 
grouping (I20, I22, I24 and I25), are for first or early stage forms of CHD, and for 
that reason not all codes were selected, and for those that were, the hospitalisations 
had to be emergency admissions. The reason being that non-emergency admissions 
for these codes may not be indicative of poor management in primary care, as they 
could be pre planned and therefore represent the contrary. The details of all the 
ICD10 codes used are detailed in Appendix 7, pages 279 and 280, and the rule set 
used to create the outcome variables detailed below. Again the denominator is the 
CHD patient population, and missing data signifies that a hospital admission of 
interest did not take place in all instances with additional points listed where 
appropriaWH7KHKRVSLWDOLVDWLRQKDGWRRFFXUDIWHU&+'FRGLQJZKHQWKHSDWLHQW¶V
SUDFWLFH ZDV XS WR VWDQGDUG DQG EHIRUH WKH HDUOLHVW RI WKH SDWLHQW¶V WUDQVIHU RXW RU
death date. Not meeting these criteria meant the event was excluded from analysis. 
Other exclusions are reported where applicable 
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Table 6-2 HES study variables ruleset 
Variable HES Ruleset 
miadmis Refers to a hospitalisation where an MI code formed the primary 
diagnosis. These were recorded in the primary diagnosis across a 
hospitalisation HES file in the ICD_Primary variable. Any codes in 
the I21, I22 or I23 groupings recorded in that field qualified. 
emang Relates to an emergency hospitalisation where specific ICD10 I20, 
I24 and I25 codes formed the primary diagnosis. These were recorded 
in the primary diagnosis across a hospitalisation HES file in the 
ICD_Primary variable. To select only emergency admissions this file 
had to be merged by patient id (patid) and spell number (spno) to the 
same event record in the HES Episodes file. In this file the method of 
admission variable (admimeth) gives details on how the patient was 
admitted. The following codes constituted an emergency admission: 
21, Emergency via A&E; 22, Emergency via GP; 23, Emergency via 
bed bureau; 24, Emergency via consultant outpatient clinic; and 28, 
Emergency other means. If the hospital admission had one of these 
codes the record was retained. 
Exclusions x Primary diagnoses by hospitalisation which were not an 
emergency admission 
alladmis This was created by adding the emang variable to the miadmis 
variable. It represents a count of all admissions for all secondary care 
outcomes of interest 
alladmisx This has been created from the alladmis variable, adding additional 
MI events. For a full explanation of this variable see 6.7.1 
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6.5.1 Measuring outcomes, definitions and impact on numbers  
Work by Herrett et al looks at the differences in numbers of acute myocardial 
infarctions (AMI) in patients when measured in CPRD, HES, and the Myocardial 
Ischaemia National Audit Project (MINAP)123. Office for National Statistics (ONS) 
cause specific mortality data was additionally used as a confirmatory and cross 
referencing source where applicable. All of these sources with the exception of 
MINAP were available to this study. While this meant that this study could not adopt 
the approach taken by Herrett et al, this was the smallest of the three databases, and 
therefore its impact was relatively minor in comparison. It also did not prevent 
analysis of the impact of broadening the search and definition of MI.  
The process used by +HUUHWW HW DO ZDV DV IROORZV ,Q &35' DFXWH 0,¶V ZHUH
identified by searching on condition specific Read codes, in HES by the primary 
diagnosis in the first episode of a hospital admission using ICD10 codes, and 
MINAP using internationally agreed definition markers. While there was significant 
shared coverage between the three datasets, the different databases and definitions 
QRQHWKHOHVV UHYHDOHG GLIIHULQJ QXPEHUV RI DFXWH 0,¶V 0,1$3 XVHV WKH PRVW
stringent criteria of the three and had the fewest cases. CPRD where the criteria for 
recording an event was the least stringent had the most, with HES falling between 
the two. This poses potential problems when relying on just one of these datasets as 
events may be missed or overestimated. Over the course of the Herret study, 01 Jan 
 WR  0DUFK  IRU LQVWDQFH  SRWHQWLDO DFXWH 0,¶V ZHUH UHFRUGHG LQ
CPRD but neither of the other two databases, 2352 in HES alone, and 1634 in 
MINAP alone. 
/HVVRQVIURPWKLVSDSHUZHUHDSSOLHGWRWKLVVWXG\WRDGGSRWHQWLDODGGLWLRQDO0,¶VWR
the alladmis variable. A new variable, alladmisx, was created and the following 
process undertaken to find these additional events: 
x First MI codes at or following first CHD Read coding were extracted from the 
CPRD clinical file 
x If these codes fell within 30 days of discharge following a hospital admission 
recorded in the HES primary diagnosis by hospitalisation file they were retained. 
x Providing there was no other admission in that 30 day period and that this 
admission was not given one of the study ICD 10 codes of interest and therefore 
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already recorded in the alladmis outcome variable: This was considered to be a 
potentially missed MI hospitalisation  
This process was a more cautious approach than that applied by Herrett, but reduced 
the possibility of over estimation brought about by potentially counting routine and 
repeat entries. Only the first recorded MI code was used as only in these 
circumstances could it be proposed with reasonable confidence that a hospital 
admission prior had been the result of an MI, even if it did not form the primary 
diagnosis. Subsequent codes recorded in CPRD could simply represent routine 
entries following consultation, and where they followed a hospital admission where 
MI was not the primary diagnosis would more likely represent secondary and tertiary 
diagnoses. Over the study period this added a further 2942 events (9.3%) to those 
picked up in the study outcome specification, alladmis variable. 
6.6 Missing data and data issues 
If data was missing on the patient population during their study qualifying period, it 
was assumed that the activity did not take place. There is the possibility that no 
record rather than indicating the absence of an event; reflected it simply not being 
recorded. This is of course impossible to ascertain or control for. However there are 
a number of factors which mitigate this and certainly make it unlikely. Firstly all of 
the patients were in practices that were up to standard, meaning that their data 
collection and entry practices were considered to be at a research standard. The data 
related to prescriptions and important test measures that practices would need to 
KDYHD UHFRUGRI WR HQVXUH WKHSDWLHQW¶V FRQGLWLRQZas being effectively monitored 
and treated. In a chronically ill patient population this would be even more of an 
imperative. Finally, certainly since the QOF, but also partially in schemes prior, 
there was a financial incentive to ensure that such events were recorded when they 
took place. Hence it is reasonable to assume that the absence of data meant that the 
patient was not receiving the care examined. 
Inaccurate or incorrectly entered data appeared to be a rarity, and as there were 
usually multiple records for each QOF target event in each year, it did not 
necessarily prejudice any final results. However human error is impossible to 
eliminate and for the purposes of the study, cut offs were generated outside of which 
the data was considered medically unreliable or extremely unlikely. These were a 
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serum cholesterol of greater than 30mmol/l; systolic blood pressure below 70mmHg 
and at 250mmHg and above; diastolic blood pressure below 40mmHg and at 
250mmHg and above. Such incidences were very rare and accounted for less than 
1% of observations. Where they did occur the reading was classed as invalid and the 
next available valid reading which fell within the plausible range was used. 
In rare instances, 0.0015% of total clinical records, the date an event occurred was 
missing in CPRD, however in all instances a system date was present. The system 
date refers to the date the event was recorded on the GP practice I.T system. In 
general where both were recorded the two were in agreement, however it is possible 
for one to deviate from the other, usually by a couple days but very rarely 
significantly so. For instance in situations where events are entered retrospectively 
E\DSUDFWLFHDGPLQLVWUDWRUXVLQJD*3¶VQRWHVRUWKHUHLVDORQJGHOD\LQJHWWLQJD
test result.  However such occurrences are rare and where the date of event was 
missing the system date was used in its place. 
There were 83 patients within the population who were first diagnosed with CHD at 
less than 30 years of age. These were a tiny percentage (0.1%) and were most likely 
patients who suffered from congenital heart disease that had been wrongly entered as 
a CHD Read code. There was also the possibility that date of birth had been entered 
incorrectly for these patients meaning their age was incorrect. Due to the small 
probability of actual CHD in the under 30 population the following cautious 
approach was taken: All patients who had a first CHD diagnosis under 18 years of 
age were dropped from the study; and of the remaining aged 18 to 30 population,  
patients were dropped if they were present on the database for 1 year only. It was felt 
that if no data had been entered for that patient following CHD coding, indicating it 
was not being treated, it was very likely that the patient did not have CHD and 
therefore the code had been entered incorrectly. This led to a loss of 25 patients and 
one of the myocardial infarction outcomes. As a minimum of two patient 
observations are required for panel data analysis these patients would have dropped 
out of data analysis regardless, so this had no impact on final results. 
Over 11% of individuals had a record in HES for one of the study outcomes prior to 
a QOF recognisable diagnosis of CHD in CPRD. A much smaller percentage had 
multiple outcomes prior to study entry. These were on occasions prior to the 
registration period specified above, in which case they may have occurred 
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subsequent to a CHD code outside the qualifying period in this study. However in 
the majority of instances they were the first time CHD became recognisable in those 
patients and thus recorded in CPRD. In all instances these were retained and placed 
in the pre-study outcome variable, Hospre (See Appendix 8). 
$QLQGLYLGXDO¶VSDUWLFLSDWLRQLQWKHVWXG\GXULQJWKHLUTXDOLI\LQJSHULRGZDVHQGHGDW
the earlier of their transfer out or death date. It was noted that these dates differed in 
around 40% of instances where both occurred. On average the difference was 18 
days, and in 98% of cases the difference was less than 60 days, meaning there will 
have been minimal if any impact on the panel. However in 0.7% of cases (0.2% of 
total data) the difference was over 6 months and up to 16 years. In these instances 
qualifying years of data may have been lost to the study.  
6.7 Summary 
The quality and accuracy of data was assured throughout the study using controls put 
in place by CPRD as well as by conditions placed by this study. Hence at the define 
VWDJHRQO\GDWDLQWKHLQGLYLGXDO¶VFXUUHQWUHJLVWUDWLRQSHULRGZDVDGPLVVLEOHQDPHO\
during their current registration period and when their practice was considered to be 
up to a research standard. This was confirmed and assured by this study when the 
data was placed into a panel data structure for analysis.  These two processes ensured 
WKHGDWDFRPSOLHGZLWK&35'¶VUHVHDUFKVWDQGDUGPDUNHUV7KHVDPHPDUNHUVZHUH
applied to the HES data using the same conventions, both by using variables placed 
in HES to act as quality markers (hes_start and hes_end) and by confirmatory checks 
using the base CPRD variables that were used to create those quality markers.  
Aside from these there was little in the way of amendments to the data or need to 
question it, and the data was seen to be of a very high standard. A number of 
minimal adjustments were made, which did not affect data integrity as their 
frequency was very small, and as they often applied to data with multiple records, 
did not change the data used. These are detailed below: 
1. Controls were placed on permissible blood pressure readings and cholesterol but 
these only applied to a small percentage of the total records, less than 1%.  
2. A number of patients were given a CHD Read code from birth to the age of 30, 
which were most likely incorrect codes for congenital heart failure. These 
accounted for less than 0.1% of the CHD study population however.   
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3. A very small percentage of clinical entries (0.0015%) had no date of event 
recorded. In these instances the system date was always present, and used in its 
place, though it should be noted that these are not always in agreement. 
In addition to these there were some general issues with how the QOF targets were 
applied in this study. Specifically 
1. Exception reporting codes were not applied as the data was concerned with the 
effect of treatment and outcomes at the individual patient level, and these have 
greater significance for practice attainment  
2. Equally the practice attainment variable, pracatt, did not adjust for exception 
reporting 
3. In this study an individual became immediately QOF qualifying upon entry and 
hence was included in that QOF. In contrast patients entering in the last 3 months 
of a QOF year can be exempted from targets. 
The chapter noted work undertaken by Herrett et al, which showed differences in 
QXPEHUV RI $0,¶V UHFRUGHG LQ &35' +(6 DQG 0,1$3123. The latter was not 
available to this study, so this was explored for HES and CPRD only, with ONS data 
also acting as a further reference point, as it did in the work by Herrett. An approach 
ZDVWDNHQZKLFKXWLOLVHG+(6DQG&35'WRSLFNRXWSRWHQWLDOPLVVHG$0,¶V7KLV
was a more formal approach than that undertaken by Herrett et al, which was 
deemed more suitable to this study and reduced the risk of over-estimation of events. 
Over the duration of the study this increased the number of outcomes by 9.3%, 
which are recorded along with existing outcome events in a new outcome variable, 
alladmisx. 
6.8 Conclusion 
This chapter has described how CPRD and HES were used to define the study 
population and create the variables for use in subsequent analyses. The following 
chapter will describe and analyse those variables, and construct an econometric 
model to examine the relationship between the quality of CHD care given to patients 
in primary care and its impact on relevant clinical outcomes.   
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Chapter 7 Data Description and Analysis 
 
7.1 Objective 
The objective of this chapter is to describe the data, introduce econometrics, specify 
an econometric model and undertake analysis of it. This will be conducted in the 
following steps: 
1. An overview of econometrics 
2. Model specification  
3. Descriptive analysis of the data 
4. Model estimation and discussion of results 
7.2 Background 
The data extracted by this thesis has been placed into a panel data format. The unit of 
analysis is the individual CHD patient. Panel data combines two dimensions, in this 
thesis cross sectional and time series.  
Table 7-1 Panel data structure, a two patient example over 4 time periods 
patid Year alladmis BP pracatt 
1096 1 0 0 0.8 
1096 2 0 1 0.82 
1096 3 2 1 0.85 
1096 4 0 0 0.87 
35769 1   0.68 
35769 2 0 1 0.7 
35769 3 1 1 0.77 
35769 4 1 1 0.73 
 
An example of the panel data format used in this study is presented for hypothetical 
patients in Table 7-1. The outcome (also referred to as dependent) variable, alladmis, 
in this thesis is the number of primary diagnosis hospital admissions or emergency 
admissions for selected ICD10 I20-I25 codes. BP and pracatt are explanatory 
variables (covariates) which are believed to have some causal relationship with the 
outcome variable; the extent of which is captured by their coefficients, denoted and 
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referred to DVWKHLUEHWDȕBP shows whether the individual met the QOF BP target 
and pracatt, relates to practice attainment on QOF targets. Since the study includes a 
number of explanatory variables, key among which are the QOF target variables, it is 
a form of multivariate analysis. A final point with regard to this illustration is to do 
with the type of panel used in the study. As individual 35769 does not contribute 
observations in year 1 the dataset is called an unbalanced panel. These points will be 
developed further below. 
7.2.1 What is econometrics? 
Economics is a social science which attempts to explain how individuals, firms, and 
governments go about allocating scarce resources to meet unlimited wants. 
Econometrics is a branch of economics which applies mathematical and statistical 
techniques to economic phenomena arising from this basic economic principle.  
As with any social science there are uncertainties and assumptions in any economic 
theory. This is because economic theories are applied to uncontrolled µUHDO¶ ZRUOG
settings and it is therefore impossible to control for all the influences that can impact 
on human behaviour. As a result people do not behave in the same predictable 
manner, nor indeed always act rationally; making modelling problematic. 
Econometrics applies statistical methods to economic problems to attempt to design 
causal regressions which explain observed economic relationships and events, using 
data from uncontrolled settings. It differs to statistics which is more generally 
applied to natural sciences, controlled settings, and seeks to predict behaviour or 
relationships, rather than precisely explaining them; looking for patterns, rather than 
causes. Different methodologies have consequently developed to fit these contexts. 
The approach taken by econometricians is to develop a model based on economic 
theory, which then guides data collection. Then based on limitations in the data 
available within real world settings such as; vaguely defined, missing or 
uncollectable data; to develop approaches to get as much information as possible 
from that data to explain the outcome of interest. This differs from medical statistics 
for instance where data is collected, generally in controlled settings, and then fitted 
into models based on their ability to predict the outcome of interest. One of the 
respects in which econometrics is in regards to model specification and the treatment 
of the error term. This is demonstrated in the simple linear equation (1) below: ܻ ൌ ߙ ൅ ߚଵܺ ൅ ߝ (1) 
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7KLV HUURU WHUP RU GLVWXUEDQFH WHUP İ LV D UDQGRP YDULDEOH ZKLFK FDSWXUHV WKH
variation in the outcome variable,ܻ, not captured by the included explanatory 
variables. Since econometrics operates in a world where variables are not observed 
or cannot be collected, the error term plays an important role, and methods such as 
fixed effects are more frequently used. The inclusion of this error term has 
implications in panel data which will be discussed subsequently.  
7.2.2 More on panel data 
A panel in economics refers to a group of economic agents be they individuals or 
higher level aggregates such as households, firms or countries. Panel data combines 
two dimensions, usually a cross sectional and a time series or longitudinal 
dimension. It does this by repeatedly analysing a cross section of individuals over a 
given period of time. If the same individuals are present throughout the study it is 
termed a balanced panel. If individuals enter, and/or, exit at different time periods, it 
is described as an unbalanced panel. A panel data regression model is written in 
functional form below:  ௜ܻ௧ ൌ ߙ ൅ ߚଵ ଵܺ௜௧ ൅ ڮ ൅  ߚ௞ܺ௞௜௧ ൅ ߝ௜௧ (2) 
7KH PRGHO SDUDPHWHUV VHHQ DUH WKH FRQVWDQW WHUP Į DQG WKH FRHIILFLHQWVߚଵ,...,ߚ௞, 
indicating the influence that the explanatory variables have on Y. 
Subscript i refers to individual i = 1,....,N, where there are a total of N individuals 
included in the panel, and time t = 1,...,T refers to the time period of which there are 
a total of T in the panel (in this study N=81,201 and T=11). The modelled variable Y 
is commonly referred to as the dependent variable,ܺଵ to ܺ௞ as the explanatory 
YDULDEOHV DQG İ GHQRWHV WKH XQREVHUYHG HUURU WHUP 7KHUH DUH D QXPEHU RI
assumptions made concerning the unobserved error term. These are: ܧሺߝȁ ௜ܺሻ ൌ  ?     Zero conditional mean: The expected value of the error term is zero 
for any given value of the explanatory variables               (3) ܸܽݎሺߝȁܺ௜ሻ ൌ  ߪఌଶ׊݅  Constant variance: The variance of the error term is the same 
for all values taken by the explanatory variables               (4) ܥ݋ݒሺߝ௧ǡ ߝ௦ሻ ൌ  ?׊ݐ ് ݏ  Correlation of error observations is zero: The error terms 
are independent and not related to each other, meaning there is no correlation over 
time, with t and s denoting different time periods.                       (5) 
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7.2.2.1 Advantages of panel data 
Panel data offers significant advantages over data measured in cross section alone or 
in time series alone. These are124 125: 
1. By combining time series and cross sectional observations panel data creates a 
larger number of data points (N*T) enabling a more information rich analysis. 
This has a number of potential benefits including reduced variability and 
collinearity, and larger degrees of freedom. This produces more efficient 
estimators, and allows for stronger inference. 
2. By studying repeated cross sections, panel data is particularly well suited to 
study the dynamics of change. This could be individual level choices such as the 
decision to quit smoking or the effects of periods of unemployment. 
Alternatively the dynamics of interest could be the effect of higher, national for 
instance, level changes, such as national minimum wage rates, on individual 
level units. 
3. Panel data allows greater flexibility in modelling differences in behaviours 
among individuals even when the model is not fully specified and there is 
unobserved heterogeneity. In particular panel data allows us to deal with omitted 
variables (unobserved or non-measurable) which are correlated with the included 
explanatory variables and can result in biased estimators in other forms of 
econometric analysis. Assuming that the omitted variable does not change over 
time (time invariant values) and has same effect over time (time invariant effects) 
fixed effects panel data analysis provides a means of dealing with their omission. 
Examples of variables fitting this description are gender, race, education level 
and innate ability.  
4. By observing the same unit across time, panel data enables the researcher to 
examine temporal effects, namely the effects of variables in previous periods on 
outcomes in the present period.  
7.2.2.2 Fixed and random effects  
For panel data regression analysis the choice of modelling option depends on model 
specification and assumptions. Most frequent are assumptions concerning fixed and 
random effects.   
The different modelling assumptions change the functional form in (2) depending on 
the presentation of the error term,ߝ. To explain these the error term presented needs 
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to be examined further along with assumptions regarding its relationship with the 
explanatory variables.  ߝ௜௧ ൌ ݒ௜ ൅ ݑ௜௧   (6)  
This is done in (6) above, which breaks the error term into two component parts. The 
first is an unobserved heterogeneity or fixed effects component, ݒ௜, which varies 
with the individual but is fixed over time. The second what is called an idiosyncratic 
or time varying error, ݑ௜௧, represents unobserved factors that change over time and 
affect the individuals outcome variable. This is a completely random component that 
is not associated with any of the cross sectional units, namely across individual 
entities. These can equally be described as between variation, namely between 
individual units within the panel and within variation, which considers the variation 
within the same unit over time.  
The idiosyncratic component of the error term,ݑ௜௧ , does not create problems as it is 
assumed to vary randomly over time and is therefore not correlated with any of the 
included explanatory variables. Hence it is treated the same in both fixed and random 
effects, retained within and captured by the error term. Where they differ is with 
respect to their treatment of the unobserved fixed effects component, ݒ௜.  
Random effects analysis assumes that the fixed effects component is not correlated 
with any of the explanatory variables, ܥ݋ݒሺ ௜ܺ௧ǡ ݒ௜ሻ ൌ  ?Ǥ This assumption does not 
mean that the individual effects are identical for every observation rather that their 
values are random with no association with the observed values of the explanatory 
variables. If this assumption does not hold random effects estimation produces 
biased estimates. 
Fixed effects analysis however relaxes this assumption and allows the fixed effects 
component to be correlated with the included explanatory variables. In this sense 
fixed effects views, ݒ௜, as an omitted variable that is correlated with the included 
explanatory variables. Fixed effects deals with this by including ݒ௜, in the constant 
WHUPĮVRWKDWWKHLQWHUFHSWYDULHVDFURVVHDFKXQLWRIREVHUYDWLRQDQGRUWLPH  ௜ܻ௧ ൌ ሺߙ ൅ ݒ௜ሻ ൅ ߚଵ ଵܺ௜௧ ൅ ڮ ൅ ߚ௞ܺ௞௜௧ ൅ ݑ௜௧      (7) 
This fixed effects error component captured in the intercept can then be dealt with in 
a number of different ways. The dummy variable approach introduces a dummy 
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variable for each unit of observation so that each has an individual specific intercept. 
This can however be extremely burdensome when there are a large number of 
individual units (large N) in the panel. An alternative is the first difference 
transformation, which involves subtracting the lag value for each variable from its 
present value. This differences away the ݒ௜ from (7) as it is fixed with respect to 
time t. A final method is referred to as the fixed effects estimator, which is the most 
common method used in applied econometric analysis. Most statistical packages, 
Stata included, have specific commands which carry out this operation, making 
appropriate adjustments to the degrees of freedom to calculate accurate standard 
errors. This involves time de-meaning the data by subtracting the mean value for all 
observed values for each individual unit of analysis from each of its observed values. 
It is explained in functional form in (8) and (9) below: ሺ ௜ܻ௧ െ തܻ௜ሻ ൌ ߚ଴ሺݒ௜ െ ݒҧ௜ሻ ൅ ߚଵሺ ௜ܺ௧ െ തܺ௜ሻ ൅ ሺݑ௜௧ െ ݑത௜ሻ    (8) ෨ܻ௜௧ ൌ  ߚଵ ෨ܺ௜௧ ൅ ݑ෤௜௧       (9) 
Time demeaning deals with any unobserved factors by removing from the regression 
the components that are fixed over time. By assumption that will be the entire 
amount of the unobserved fixed effects, ݒ௜.  
7.2.2.3 When to use fixed or random effects? 
Fixed effects are usually the preferred method in econometrics, compared to random 
effects in medical statistics, since it cannot often be assumed that models are fully 
specified and hence there may be omitted variables potentially correlated with 
included variables. These omitted variables will be captured in the error term. Fixed 
effects, assuming those omitted variables have time invariant effects, namely are 
fixed over the study period, is a way of dealing with them. While fixed effects 
removes the time invariant component of the error term it comes at a cost. Not only 
does it remove the fixed effect errors but any variable that is fixed over time. 
Consequently variables such as gender are removed completely. Hence the decision 
on which method to use comes down to a number of considerations: 
1. Whether or not time invariant explanatory variables are important in the model 
2. How well the model is specified and hence likely there are missing variables 
which are potentially correlated with included explanatory variables 
3. The level of within subject variation in time variant explanatory variables 
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4. Whether it can be assumed that the missing variables have time invariant values 
and effects 
If the model is well specified, such that, missing variables and correlation of the 
explanatory variables with the error term is unlikely, random effects is the preferred 
option. It includes more data, uses fewer degrees of freedom and produces more 
efficient estimators. Likewise if it is suspected that there may be omitted variable 
bias, but time constant variables are important in the model, fixed effects would not 
be suitable. In this instance potentially biased estimators would be a necessary trade 
off and attempts would need to be made to adjust standard errors for correlation 
within group. Outside of these instances fixed effects are preferable as it more likely 
than not that there are unobserved variables potentially correlated with the error 
term. Fixed effects analysis however is not a panacea as it can be ineffective in 
dealing with omitted variable bias. Referring back to (6), fixed effects analysis 
assumes that the unobserved fixed effects component of the error term is constant 
over time, in other words that it has time invariant effects. In random effects ݒ௜ seen 
in (6) is in effect replaced by ݒ௜௧, and the latter is assumed to vary randomly.  
7.2.2.4 Designing an econometric model 
When building an econometric model, the model should be underpinned by 
economic theory. This should guide the choice of variables and model specification.  
In this study, HFRQRPLF WKHRU\ZRXOGDUJXH WKDWXWLOLW\PD[LPLVLQJ*3¶VZLOOKDYH
responded to QOF financial incentives and provided better care in those areas which 
are incentivised. Those improvements in care in response to incentives will be 
detected by QOF target variables, which have a causal relationship with the study 
outcome measure. Hence the QOF targets will be included in any analysis as they are 
its focus, as will key confounding variables such as age and gender. Outside of these, 
variables will be included if they are expected to have a causal relationship with the 
study outcome, are well specified and add to the model. 
7.3 Model specification 
In this section the model is briefly specified in a simplified functional form and 
issues arising out of the use of a count outcome variable in a panel data setting, as 
well as potential solutions, are discussed. The model is specified as follows: ܻ ൌ ݂ሺܺଵ ǥ Ǥ ܺ௠ǡ ܷǡ ߚଵ ǥ Ǥ Ǥ ߚ௞ሻ 
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Where Y refers to either a hospital admission where MI formed the primary 
diagnosis, or an emergency hospital admission where selected IHD codes formed the 
primary diagnosis. Namely the alladmis or alladmisx variables  
The X variables are the explanatory variables. These are broken down into three 
groups which describe where these fit in the explanation of the dependent variable. 
The text in italics refers to the shortened variable name, where one was necessary, 
used in the datasets and referred to at various point in the text. 
(Quality of patient care variables) = QOF targets {Blood pressure control
150/90mmHg (BP),  &KROHVWHURO FRQWUROOHG PPROO Chol), The prescription of 
Aspirin, anti-platelets or coagulations (Anti), The prescription of beta blocker (BB), 
The prescription of ACE or A2 to MI patients (Acea2q), Smoking cessation advice 
to current smokers (Smcess)}, QOF related target (ACE) 
(Patient risk factors) =age; gender; Co-morbidities {Heart Failure (HF), Diabetes 
(Diab), Atrial Fibrillation (AF), Stroke and Transient Ischaemic Attack (STIA), 
Hypertension (Hyper), Rheumatoid Arthritis (RA), Chronic Kidney Disease (CKD)}; 
SHA Region (Region), Angina outcome pre-admission (Angpre), MI pre-admission 
(MIpre); Outcome pre-admission (Hospre); Index of Multiple Deprivation 2007 
(IMD); Current smoker (Smoker) 
(Practice level factors) = Practice size measured in quintiles (sizeq); Practice GP 
workload measured in quintiles (workldq); Practice level CHD QOF attainment 
(pracatt) 
U is the error or disturbance term which is created when the explanatory variables 
included in the model do not fully explain the value of the dependent variable 
7KHȕ¶VDUHWKHSDUDPHWHUVIRUWKHH[SODQDWRU\YDULDEOHV. 
7.3.1 Dependent variable 
Both the alladmis and alladmisx variables will be used in the same model 
specifications to see if results differ between the two. It is expected that results will 
not differ significantly between the two as the numbers of outcomes recorded in both 
are similar. In final reporting and model specification the alladmis variable will be 
used unless the results from using alladmisx are more significant and in keeping with 
a priori expectations 
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7.3.2 Specification of the outcome variable 
The HES outcome measures are all count variables. There are a number of issues 
concerning the use of count models and panel data that are discussed below along 
with possible solutions which will be followed in any analysis. Full details regarding 
the different regression models are detailed in Appendix 9 
7.3.2.1 Over dispersion  
The Poisson model assumes that the conditional mean and the conditional variance 
of the outcome variable are equal. Hence where the data deviates substantially from 
that assumption results can be unreliable. In those instances the negative binomial 
will be used which allows the variance to adjust independently of the mean.  
7.3.2.2 Excess zeros 
An excess of zeros leads to significant over dispersion immediately discounting the 
Poisson Model. The negative binomial is a possible alternative in these 
circumstances but it too may give misleading results when there are a large number 
of zeros in count models. To overcome this, all, or an excess of zeros, need to be 
accounted for separately within the data. Two approaches have been developed to do 
this, zero inflation models and hurdle models. Which of these is chosen depends on 
the nature of the data being modelled and any underlying theoretical assumptions. 
Zero inflated models assume there are two kinds of zeros, referred to as excess zeros, 
and true zeros. Excess zeros are due to specific structures in the data, which mean 
that certain observations will always generate a zero. For example in a study looking 
at the number of fish caught individuals who did not fish will always generate a zero. 
True zeros on the other hand represent true sample zeros, namely those individuals 
who were fishing but caught no fish.   A hurdle model splits the sample down into 
two groups, those who did and did and did not have the outcome. A binary model is 
used to model whether an outcome takes place, and a truncated count model is used 
IRU WKRVH ZKR µFOHDU¶ WKH KXUGOH DQG KDYH D SRVLWLYH FRXQW ,Q HVVHQFH WKH KXUGOH
model treats all zeros as true zeros but assumes those who do have an outcome are 
different to those who do not and hence models them separately.  
In the case of this study the vast majority, if not all zeros are expected to be true 
zeros as their CHD has been clinically verified, it is looking at clinically significant 
outcomes, and the data is quality assured. Hence a zero inflated approach would not 
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be appropriate. It is very reasonable on the other hand to assume that patients who 
have an event differ intrinsically from those who have not and can therefore be 
modelled separately. This will be explored within the data and where appropriate and 
feasible a hurdle specification will be developed. 
7.3.2.3 The Hurdle Model 
As mentioned the hurdle model consists of a binary model which predicts the 
outcome of interest taking place and passage into a truncated count model. Once an 
outcome has occurred those events are measured in a count model, truncated from 
below to remove the excess of zeros and deal with over dispersion. Consequently the 
count model component of the count model starts at 1 removing all the excess zeros. 
These then provide the reset starting point for the count model. Hurdle models have 
been used in a variety of areas including health care for cross sectional data126. 
However their implementation in panel data has been undertaken and explored to a 
much lesser extent, and no facilities to date have been developed in Stata to apply 
them. Hence any application will be explorative, utilise existing commands and be 
adaptive to the specific requirements of the analysis.  
7.3.2.4 Alternative to the hurdle model 
An alternative approach to dealing with excess zeros in a count model, besides a 
pragmatic approach of using the negative binomial and accepting there maybe bias in 
the estimators, is to dichotomise the data, i.e. replace counts greater than one with 
one. In instances where counts greater than one are a rarity this does not alter the 
outcome variable significantly and therefore this approach is justifiable and results 
will be similarly interpretable. It also represents a much simpler methodological 
approach to over dispersion thereby adding less complication and assumption.  
7.4 Data description 
This section descriptively analyses the outcome and key explanatory variables, as 
well as the surrogate measures that mapped to those variables. The reason for doing 
this is to get an understanding of what the individuals who make up the study 
population are like in terms of their demographics, socio-economic status, health 
status, and QOF attainment. It will also provide an insight into what was happening 
to those variables and this study population over the period of analysis. This will flag 
up any concerns with regard to how representative the study population is, and any 
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issues concerning variable construct. These details are ignored in any regression 
results, and considered in isolation can lead to their misinterpretation. This section 
providers some context for those results and to their generalisability. 
This section is split into 4 parts, which are: population dynamics; demographic and 
socio-economic measures; QOF targets and mapped measures; outcome measures; 
and panel data measures: 
7.4.1 Study population dynamics 
Table 7-2 Study population dynamics 
 
Table 7-2 provides details on the dynamics of the study population in terms of 
number of patients entering and exiting with each year. All figures, outside of the 
first year which ran from 1st January 2000 to 31st March 2001, relate to an annual 
QOF reporting period, 1st April to 31th March of the following year. Starting in the 
first column the figures show the total population at the year-end for each respective 
year. The new cases column refers to patients with a first recorded CHD code that 
year, and who therefore joined the study population during that year. Numbers 
exiting was calculated by subtracting the previous year population from the present 
year and then subtracting that figure from the number for new cases. Consequently 
the figure for the first year is zero despite the fact that patients died and transferred 
out that year. This is due to the way the study population was calculated. Any patient 
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present at the beginning of a QOF year qualified, and hence was counted, for the 
whole of that year regardless of whether or not they died or transferred out part way 
through it. 
Strictly speaking therefore the exiting column shows the number of patients who left 
the study population in the year prior, and who were consequently absent in the year 
shown. Total population represents the numbers of patients present at the beginning 
of the QOF year plus any newly diagnosed cases that year, as a patient joined the 
study population and became QOF qualifying immediately upon diagnosis. For the 
first year, 2000/01, the two figures tally, and represent patients who entered the study 
immediately due to a CHD coding prior to the study start and those who had a code 
during that year.  
7.4.2 Key patient socio-demographic measures 
7.4.2.1 Age and gender 
Table 7-3 Age gender statistics for the study population 
 
 
Table 7-3 shows the mean age and its standard deviation (SD) for the study 
population over the study period, as well as the number and percentage of that 
population who were male, over that period. The figures show that the study 
population aged over the course of the study, by on average nearly 3 years. At the 
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same time the percentage of the study population that was male increased, with 
males making up 3% more of the study population by the end of the study period 
compared to its start. These figures are generally reflective of national statistics. 
While statistics on the mean age of CHD diagnosis were not found, incidence rates 
for Angina, the first symptoms of CHD were. These show that at the English 
national level, the population from which the study is drawn, the incidence of 
Angina is very rare in those under 45 (3.2 per 100,000 patient years in 2011)20. The 
incidence rate starts to rise significantly thereafter to 44.7 in those aged 45-54, 109.3 
in those aged 55-64, peaking at 151.5 in the 65-74 age group before dropping to 98.3 
in those aged 75 plus; all figure per 100,000 patient years, 201120. These results are 
generally supportive of the age profile of the study population, as the mean age 
FRLQFLGHV ZLWK $QJLQD¶V KLJKHVW LQFLGHQFH :KLOH WKH ILJXUHV PD\ FRXQW PXOWLSOH
incidences, these are generally first symptoms. The ageing of the population is to be 
expected in a panel where the same patients are followed for multiple periods, and in 
the context of improvements in treatment and increasing longevity.  
Since males are more likely to suffer from CHD than females127; develop CHD 7-10 
years earlier than females128; and have a higher incidence rate of Angina20: The 
higher percentage of males in the study population is expected. Their increasing 
presence could be indicative of improved care over the study period; as such a 
situation would arise if patients were living longer with CHD and being diagnosed 
earlier. Under such a scenario as males make up a higher proportion of the 
population they would benefit in greater numbers from any falls in the mortality rate 
over the study period. These patients would be supplemented by proportionately 
higher numbers of males if diagnosis improved over the study period causing the 
effect seen. Indeed it would be evident but less so if new cases came in at a steady 
UDWHDVH[LVWLQJRQH¶VGied at a slower rate. 
7.4.2.2 Morbidity 
Details on the numbers and prevalence of selected co-morbidities in the CHD study 
population are explored in this subsection. The selected co-morbidities, Stroke and 
TIA (STIA); Diabetes (Diab); Atrial Fibrillation (AF); Chronic Kidney Disease 
(CKD); Hypertension (Hyper); Heart Failure (HF); and Rheumatoid Arthritis (RA) 
are all atherosclerotic diseases, or risk factors for cardiovascular disease, with a 
possible or probable impact on the study outcome. The effects of co-morbidities are 
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explored further in Appendix 9, which looks at how the co-morbidity free 
component of the study population differs from the total study population. This 
provides some insight into how an experimental controlled trial population would 
appear in comparison to the study population on a number of study variables.  
Table 7-4: Selected co-morbidities, numbers by study year 
 
In Table 7-4 all the co-morbidities increase at a faster rate than the CHD population. 
This could be caused by a number of factors. Firstly the initial population started off 
with no co-morbidities as the pre-study period was not searched to find codes prior 
to the study start, so there will have been a period of catch up. Secondly as patients 
spent longer in the study, they aged, had lived with CHD longer and were therefore 
more likely to develop co-morbidities129. Finally the QOF incentive scheme may 
have played a part as besides payments for establishing condition registers, patients 
with the co-morbidities shown, RA aside, could attract greater rewards for equal 
effort, as a number of targets were shared across multiple conditions. The effect of 
the introduction of the QOF on the recording and coding of a condition is most 
starkly demonstrated for CKD. This is a condition which was barely recorded prior 
WR WKH 42)¶V LQWURGXFWLRQ VWDUWHG WR LQFUHDVH QRWLFeably thereafter; and increased 
around 15 fold in its first year of introduction into the QOF alone. By the end of the 
study period it was the most common co-morbidity in the study population. It is 
difficult to trust the figures in light of its extraordinary rise. There is however some 
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support for the pattern evident in these figures. Studies have shown a high 
prevalence of the condition, particularly in the elderly, which would account for its 
high prevalence following its introduction in the QOF130. At the same time there is 
an acknowledgement of difficulties in diagnosing CKD, and differences in opinion 
as to how to do so, and hence wide variations in diagnosis rates which could partly 
account for the pattern pre QOF entry130 131. Nonetheless it makes it difficult if not 
impossible to include it in the context of this study. 
The figures in the Table 7-4 are also presented in Figure 7-1, though in this instance 
in terms of their prevalence in the CHD population. Prevalence is calculated as the 
number of people with a coding for the condition divided by the total number of 
patients in the study population that year. CKD is omitted due to the issues raised 
previously which make comparisons over the study period difficult. Vertical lines 
show when the QOF was introduced and when conditions of interest not present at 
the start of the QOF were added. 
Figure 7-1 Prevalence of co-morbidities in the CHD study population 
 
Every co-morbidity increases in prevalence over the course of the study period. This 
is not surprising for the reasons given previously. All the conditions are assumed to 
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be chronic, meaning that once diagnosed the patient had the disease throughout the 
study period. This is logical though for Atrial Fibrillation it is possible, albeit 
unusual, for it to be resolved, making this assumption false132. 
Lastly, co-morbidities in terms of numbers co-existing are shown in Table 7-5, with 
RA and CKD omitted from the figures. This shows that throughout the study most 
patients had none of the selected co-morbidities. However as the study progressed 
patients became increasingly co-morbid and moved into multi-morbidity states.  
Table 7-5: No, co, and multi morbidity numbers 
 
7.4.2.3 SHA Region 
Figure 7-2 shows two things. Firstly as denoted by the Rel CHD prev bars, how 
much greater or less prevalent CHD is in that region in percentage terms, relative to 
the English national average in 2010/1120. Secondly as denoted by the Rel CPRD 
size bars the amount under or over represented the region is in the study population, 
in percentage terms, in relation to its population size based on 2011 census 
figures133. From this graph it is evident that the North East, North West and 
Yorkshire and the Humber SHAs have a much higher prevalence of CHD in relation 
to the national average. Conversely London has a much lower prevalence. In terms 
of the study population the North West and South East Coast are significantly over 
represented while the East Midlands and Yorkshire and the Humber are significantly 
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under represented. Even allowing for the higher prevalence of CHD in the North 
West this region remains significantly over represented in the study. Furthermore on 
this basis the under-representation of the North East, East Midlands and Yorkshire 
and the Humber would be considered worse still. While the South East Coast SHA 
would become increasingly over represented and the South Central SHA could be 
considered significantly over represented.     
Figure 7-2: English regional SHA: CHD prevalence and CPRD population 
 
7.4.2.4 Deprivation-Index of Multiple Deprivation 
IMD was generated using the 2007 deprivation algorithms based on the most up to 
date information on the patient population at the time of request, March 2012. These 
are once only generated measures but were assumed to apply to the whole of the 
SDWLHQW¶VSDrticipation in the panel.  
If there were equal representation across the deprivation quintiles there would be 
approximately 16,204 (20%) in each column. While this is not the case the 
deprivation quintiles are fairly evenly represented. However there is noticeable 
under-representation of people from the lowest quintile, who account for just over 
16% of the total population. In their place there is an over representation of those in 
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the less than average 60-80% quintile, accounting for nearly 22.5% of the 
population. A relatively small proportion of the population, 1.25%, had no IMD 
2007 data and would need to be factored into those figures. 
As these patients have been included into the study on the basis of existing CHD 
however they are not representative of the population as a whole. Since the main risk 
factors for CHD; an unhealthy diet, lack of exercise, obesity and smoking are more 
common in individuals in lower socio-economic groups; they would be expected to 
have a greater representation than those from less deprived quintiles. Previous 
research has also shown a higher prevalence of CHD in more deprived grouping 
using, individual and neighbourhood level data in Sweden134 135. A link between 
higher deprivation and greater incidence of CHD has further been found at a local 
authority, practice, and electoral ward level in the UK118 136 137.  This would be evident 
in Figure 7-3 by bars increasing in height from left to right, as deprivation quintile 
increases. Hence the study population on this measure is unlikely to be 
representative of the UK CHD population as a whole.  
 Figure 7-3: IMD 2007 deprivation numbers by quintile in the study population 
 
164 
 
7.4.3 QOF target variables and mapped variables 
The following subsection looks at attainment on evidence based targets in the QOF 
over the study period and the underlying measures that mapped to those variables.  
7.4.3.1 Diastolic and systolic blood pressure 
Mean diastolic and systolic blood pressure level fell in most years, a finding 
supported by previous research discussed in Chapter 5119 120. These show that based 
on mean levels over a 15 month period, on average patients were meeting the QOF 
BP150/90mmHg target throughout the study period, comfortably so. Whilst in 
order to meet the BP QOF target the last reading over the 15 month period would 
have to be at or below that level, it nonetheless puts these figures in a context. 
Encouragingly the mean figures also met the more demanding levels suggested by 
the clinical guidelines of 140mmHg or below systolic and 85-90mmHg or below 
diastolic, for most of the study period68 72.  
Table 7-6 Mean systolic and diastolic blood pressure over the study period 
 
7.4.3.2 Total cholesterol 
Figures represent the mean of all reading taken over a 15 month period, for all 
patients in the study population in the respective years, as well as their standard 
deviations. Mean cholesterol levels have been falling for the majority of the study 
period, though they appear to have reached a plateau. This conforms to the trend 
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found in previous research discussed in Chapter 5119 120. While these figures do not 
take into account QOF business rules, they do indicate trends, based on which the 
mean patient reading, averaged over the QOF accounting period, met the QOF 
standard from 2002/03 onwards. They also show that based on yearly means, the 
average patient did not meet the more demanding target evidenced in the clinical 
guidelines, of 4 mmol/l or less, at any point over the study period86 87. This suggests 
this may have been an unrealistic target, had it been implemented.  
Table 7-7 Mean cholesterol levels over the study period 
 
7.4.3.3 Smoking status 
Table 7-8 shows the rates of the different smoking states in terms of their 
percentages relative to the total patient population in each year. The different 
smoking states map to the categories set out in the QOF business rule, and follow the 
codes set out in that guidance. While the recording of smoking status was a QOF 
target, as with the other recording targets such as blood pressure and cholesterol, the 
clinical benefits of interest to this study related to subsequent targets which used 
these records, in this instance smoking cessation advice. For most of the pre QOF 
study period, the majority of patients had no record of smoking status. The imminent 
and actual introduction of QOF incentives to record smoking status appears to have 
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had an impact on this ILJXUH6LQFHWKH42)¶VLQWURGXFWLRQWKHQRUHFRUGILJXUHWKH
missing column, has held reasonably constant in a range of 24% to 29%.  The 
proportion of current smokers has been stable around the 10.8% to 12% mark.  
Table 7-8 Smoking status, recorded and carried forward 
 
The figures relate to the QOF target, so smoking status had to be entered every year 
to qualify for payments. The same terms were applied within CPRD when modelling 
the QOF. The last two columns CurrentR and MissingR show what happens to those 
figures when missing values are replaced by records from previous periods, where 
one existed. In terms of current smokers the effect is more noticeable prior to the 
QOF, but in the QOF period would add around 1% to 2% to the population who are 
current smokers. The more noticeable impact is with respect to the two Missing 
columns. The difference between them represents the impact of carrying forward any 
of the smoking states. This approach would reduce the population with no record 
significantly, more noticeably as the study progressed. Clearly most of these would 
have a non-smoking status, and would therefore not be included in the QOF target 
were this approach adopted. The figures for current smoker used in the study are 
supported, certainly in the QOF period, by ONS survey data which shows a smoking 
rate in males and females aged 60 and over, of between 12 to 17% during the study 
period138. In a CHD population this figure would be expected to be lower. 
7.4.3.3 QOF target measures 
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Table 7-9: Performance on study CHD QOF targets 
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Figure 7-4: Study Smoking cessation and surrogate outcome QOF targets attainment 
 
Figure 7-5: Study QOF CHD Prescription targets attainment 
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Table 7-9; Figures 7-4 and 7-5 show attainment on the QOF CHD targets that were 
included in this thesis. 
The QOF variables reported are all binary variables, with zero representing a patient 
who missed the target or had no record, and 1, a patient who met the target. Numbers 
and  percentages of patients meeting the targets are reported in the table, while 
proportions of the study population meeting the target are shown in the graphs. 
These measures are equivalent.  
Table 7-9 and Figures 7-4 and 7-5 show improvements over the study period in 
patients meeting the targets. However a large amount of that improvement occurred 
prior to the QOF and the QOF built on an existing upward trend. That trend was 
maintained for all targets in the early years of the QOF though by 2006 a number of 
targets had reached a plateau. Only in the case of the aspirin, anti-platelet or 
coagulant target did attainment increase throughout the study period. In the final year 
of the study this target and that for blood pressure and cholesterol had a noticeable 
jump in attainment. Without further data it is impossible to determine if this is a blip 
before the resumption of the static or downward trend or represents the beginning of 
a new upward one. Taken as a whole these figures are indicative of national trends 
for the whole CHD target group shown in Figure 1-1.  
When placed in the context of their starting point, those targets which had lower 
attainment at the study start saw the biggest improvements over the study periods. 
While the BP target saw a much more modest increase in relation to some of the 
other targets, it nonetheless started and ended the study as the target which had the 
highest level of attainment. The prescription of beta blockers had the lowest level of 
achievement by the study end due to it experiencing the smallest rise over the study 
period. 
While informative the results will not be the same as those reported by the HSCIC 
on QOF attainment139. Firstly they are reported at a patient rather than a practice 
level, hence upper and lower thresholds have not been applied. Secondly exception 
reporting has not been taken into consideration as again this has an impact at the 
practice and not the patient level. 
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7.4.4 Secondary care outcome measures 
As the outcome is a count variable Figure 7-6 shows the number of events as a 
percentage of the patients in the study population, by each study year (01 April to 31 
March the following year). Hence the actual percentage of patients having an event 
will be lower still, albeit marginally. This highlights the fact that any admission, 
more so an MI hospitalisation, was rare within the study population and fell 
throughout the study period. Indeed even at its peak in the first year of the study, less 
than 10% of the population had any admission. This could present issues in any 
subsequent analysis, as an excessive number of zeros in a count model, no 
admissions in this model, can bias any results.  
Figure 7-6 Secondary care all and MI admissions as a % of study population 
 
Table 7-10 looks at the figures for patients over their whole study period. These 
show that 75% of the study population had no secondary care outcomes of interest 
over the whole of their study period. Fewer than 20% had one admission, meaning 
that just over 5% of the population had more than 1 admission during their time in 
the panel. 
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Table 7-10: Hospital admissions over the study period 
Admissions during the study period Total % 
No admissions during the study 60,822 75% 
1 admission during the study 15,847 19.6% 
More than 1 admission during the study 4,353 5.4% 
7.4.4.1 Outcomes prior to study participation 
Patients did not enter the study population unless they had CHD diagnosed using a 
Read code recognised by the QOF, and met certain requirements to ensure any data 
recorded on them was up to a research standard. Prior to this however a number of 
patients had one or more of the study outcomes of interest, which were not included 
in the outcome variable as they did not occur after the patient qualified for the QOF 
in this study period. In the vast majority of cases these events led to an immediate 
CHD diagnosis, suggesting that a study outcome was the first time CHD was evident 
in these patients. A small number had an event following a first QOF recognised 
CHD diagnosis, however as this fell outside the study period, and since those 
patients did not join until the study start; these have been counted as pre study 
events, as they constituted a risk factor for outcomes in the study period. These will 
all have entered in year 1 of the study and hence the higher figure for that year needs 
to be set in that context. Small percentages of the study population also had multiple 
events, and were diagnosed some time later. Whether a patient had a study outcome 
prior to their participation in it is shown by the three variables in Figure 7-7 which 
relate to the outcome classifications discussed in the previous chapter. While these 
variables are by right count variables, they have been dichotomised in this study.  
Figure 7-7 shows the percentage of patients in the study population that year, who 
had an outcome event (MI, emergency angina or either) prior to entry into it. Hence 
patients were included for each year they spent in the study in this figure, so long as 
they had one of the outcome events prior. The lines shows that the percentage of 
patients who had any of these outcomes measures declined over the study period, 
reaching a plateau around 2007.  
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Figure 7-7 Percentage of patients present in study who had an outcome prior to entry 
 
 
7.4.5 Panel data analysis 
As previously mentioned the data is a repeated sample on the same individuals over 
time, referred to as panel data. The panel is unbalanced because the population is not 
static with patients exiting and joining the study at different points in the study 
period. 
7.4.5.1 Panel participation breakdown 
Table 7-11 gives a breakdown of the most frequent patterns observed of the 81,022 
patients who participated in the study. It shows for which of the eleven years of the 
study period they were present in the panel, with a 1 denoting presence, going from 
2000/01 on the far left of the pattern column to 2010/11 on the right. 
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Table 7-11: Individual level panel participation, frequency and patterns 
 
This shows that the most frequently observed pattern is for a patient to spend all 
eleven years of the study period in the panel, though this accounts for just less than 
15.5% of the study population. Around 32% of the study population spent 8 or more 
consecutive years on the panel as evident by the cumulative figure four rows down. 
7KH ODUJHVW FDWHJRU\ LV µRWKHU SDWWHUQV¶ ZKLFK DUH DOO WKH SHUPXWDWLRQV RWKHU WKDQ
those displayed.  The ones of greatest interest within these are those with only 1 year 
of data as these will be lost entirely if a single lag is used. Individuals with 2 years of 
data in those circumstances would be lost in fixed effects analyses, as with only 1 
year of data, they would have no means of measuring within variance. For the 
permutations shown these groups accounts for 8.65% of the study population, but 
other patterns not shown will certainly add to that figure. 
7.4.5.2 Within, between and overall study variation 
One of the benefits of using panel data is the introduction of time effects through the 
repeated sampling of the same individuals, enabling examination of the effects of a 
state change in that individual on a specified outcome. This makes any results 
potentially more powerful than say a cross sectional study design which uses one 
sample of individuals or compares different samples in the case of a repeated cross 
section. However for this benefit to be realised individuals have to change state. In 
  81022    100.00            XXXXXXXXXXX
                                        
  38268     47.23  100.00   (other patterns)
   3195      3.94   52.77    .......1111
   3230      3.99   48.83    ........111
   3366      4.15   44.84    .........11
   3373      4.16   40.68    ....1111111
   3650      4.50   36.52    ..........1
   3991      4.93   32.02    ...11111111
   4635      5.72   27.09    .1111111111
   4765      5.88   21.37    ..111111111
  12549     15.49   15.49    11111111111
                                        
   Freq.  Percent    Cum.    Pattern
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table 7-12 this is explored for the main explanatory variables that were not fixed over 
the study period. 
Table 7-12: Study QOF variables variance: overall, between and within percentages 
 
Figures are presented for the overall population, between panels in the study and 
within the same individuals. The No and Yes refer to whether the individual missed 
or met the target, respectively; or in the case of the Smokstat variable whether they 
had a record of the specified smoking state or not. The overall column shows the 
percentages that did and did not meet the target for all the observations, person years, 
in the panel data. These can be viewed as pooled figures since they are a global 
figure for all patients. As these are expressed as percentages the figures sum to 100. 
Taking the BP figure for instance this shows that for 26.2% of all observations on 
this variable, patients failed to meet the target, and in 73.8% they did. The between 
column shows the percentage of patients who spent some time in that state. Using 
the figures for BP these show that 73.75% of patients failed to meet the target at 
some point during their time in the panel, while 92% of patients met the target for at 
least one of the periods they spent in the panel. Finally the within figures show, 
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conditional on the individual having a Yes or a No; the percentage of their 
observations that were a Yes or a No. Hence among those individuals who ever met 
the BP target, over 75% of their observations met the target. While those individuals 
who failed to meet the target did so for 41% of all their observations. 
Overall the figures show variability among the patients and most importantly for 
fixed effects panel analysis, within patients over time. They also highlight a high 
level of state persistence, particularly for the prescription targets. In the case of the 
prescription of ACE or A2 post MI over 85% of patients who received an ACE did 
so for all their observations in the panel. This is to be expected as these were 
relatively easy to meet and it is important for chronically ill patients to be given 
medication in order to manage their condition, even more so if they have had an MI. 
However patients who did not meet the ACE inhibitor target, did not meet it for over 
73% of all their observations. This is a smaller number but still a large figure, 
suggesting that a section of qualifying patients did not receive the recommend care 
for a large proportion of their time in the study. It is possible that these individuals 
were exempted from the QOF for some or all of those periods. For all the QOF 
targets patients were more likely to change from not meeting the target to meeting it, 
than to go from meeting it to not meeting it, as evidenced by the higher percentages 
of Yes in the within column relative to No.  
For smoking status the figures show a high percentage of patients who did not have a 
record for all observations. Over 87% of patients had no record at some point in their 
study period and of those who had no record; over half of their observations showed 
no record. The most important figures are for current smokers which potentially 
offer some clues into the effectiveness of smoking cessation. Interpreting these and 
the figures for other states are however made more difficult by the high level on non-
recording. They show that current smokers accounted for fewer than 10% of all 
observations; just under 17% of the study population had a current smoker status at 
any point in the study period; and those who smoked had a current smoking record 
for over 55% of their observations.  This suggests patients may have been quitting 
but there was relatively high persistence among smokers during the study period.  
This is explored further in Table 7-13 which shows transitions between the different 
smoking states. These show some movement from current smoker and ex-smoker to 
never smoked, which is impossible and therefore points to inaccuracies in data 
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recording. Thankfully the percentages are small, for smokers certainly, at 0.6%. The 
figures show that over 72% of smokers continued to smoke in the next period, with a 
similarly high figure for ex-smokers. Around 10% of patients who smoked were ex-
smokers LQWKHQH[WSHULRGSRLQWLQJWRVRPHSDWLHQW¶VFKRRVLQJWRFHDVHVPRNLQJEXW
still a persistently high percentage that did not. The small percentage of ex-smokers 
moving into the current smoking state, around 2.5%, and high percentage of ex-
smokers who were ex-smokers in the next period, 75.7%, both point to patients 
successfully quitting and not taking up smoking again.  
Table 7-13: Transitions between smoking states, percentage rates 
 
Finally the variation within and between patients on the outcome measure is 
explored in Table 7-14 for the all hospital admissions, alladmis, variable. The row of 
particular significance and the one which dominates the table is for those with no 
admission. These accounted for over 94% of all patient data years, and over 98% of 
patients had no admissions for at least one of their years in the study. Of those who 
ever had no admission, nearly 94.5% of their years in the study had no admission. 
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Table 7-14: All admissions, overall, between and within study variation 
 
7.4.6 Key descriptive findings 
 The key descriptive findings from this section which inform this thesis are: 
1. The population aged and the co-morbidities measured figured more prominently 
in the study population over the course of the study, as it became increasingly co-
morbid and multi-morbid. These are atherosclerotic risk factors, expected to 
aggravate CHD and therefore will be importance variables in panel data models.  
2. While the number of patients in the study population with a CKD coding 
increased nearly nine fold in the period prior to the QOF, it was still rarely 
recorded. The first two years of the QOF saw big increases, over 200 fold, in 
&.'UHFRUGVEXWLWZDVQRWXQWLO&.'¶VLQWURGXFWLRQLQWRWKH42)LQ
that it became a highly prevalent; indeed the most prevalent by the study end, co-
morbidity in the study population. This makes it difficult to include in the 
context of this study. 
3. Mean systolic and diastolic BP, and cholesterol levels fell during most years in 
the study, in line with trends evidenced in previous research on QOF qualifying 
CHD patients. 
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4. The study population has an over-representation relative to its size nationally  of 
LQGLYLGXDOV IURPWKH1RUWK:HVWDQG6RXWK&HQWUDO6+$¶V LQSDUWLFXODUDQG LV
under-represented most significantly in the East Midlands and London SHA. 
Taking into consideration regional differences in CHD prevalence did not correct 
for this and in some instances made it worse.  
5. Smoking status was poorly recorded particularly in the early years of the study 
when around 85% of individuals had no record. This situation improved 
significantly with, and immediately prior to, the introduction of the QOF. In the 
context of this study the percentage of current smokers, fell within a range of 10-
12%, around 2-5% lower than that nationally in those aged 60 and over. 
6. The percentage of individuals meeting the QOF targets increased over the study 
period, and for most years in the study, conforming to national trends. 
7. The number of secondary care outcomes relative to the study population fell 
throughout the study period, conforming to national trends. 
8. Over 75% of individuals had none of the study outcomes during their 
participation in the panel, and nearly 95% of those who did not have an outcome 
in one of their years in the study did not have an outcome for all of their years in 
the study. This means there will be a large amount of zeros in the outcome count 
variable with implications for analysis. 
9. All of the QOF targets, specifically the prescription targets, had high percentage 
values for within variance meaning that there was little variation in whether the 
individual met or missed the target. This will have implications for fixed effects 
analysis. 
7.5 Econometric analysis 
7.5.1 Objective 
This section conducts econometric panel data analyses to examine the impact of 
QOF CHD targets, and other relevant variables, on CHD clinical outcomes at an 
individual patient level. 
7.5.2 Methods 
The following structure will be used in the construct of economic panel data models: 
1. There are a number of key explanatory variables that will be included in all 
regressions. These are all the QOF targets that apply to the whole CHD group as 
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they are the focus of the study, practice attainment, age and co-morbidities with 
the exception of CKD (see point 4). The non QOF ACE variable will be included 
in all regressions outside of those for the MI subgroup. ACE inhibitors have a 
number of cardiac benefits that may be realised in a wider CHD population and 
not just those with recently diagnosed MI.   
2. The subgroup QOF targets, smoking cessation (Smcess) and ACE inhibitors, 
which apply only to individuals who smoke or with newly diagnosed MI 
respectively, will be included in separate subgroup analyses. 
3. Time invariant variables, whose values do not change during the study: gender, 
IMD, region, Angpre, MIpre, Hospre will be included where  model specification 
allows 
4. Where there are alternative specifications of the same measure (covariates and 
dependent variables), e.g. whether someone is a current smoker, the specification 
used in the model will be chosen on the basis of: That which either is most 
significant, behaves according to prior expectations (suggesting a better 
specification), or where differences are negligible; that which there is most 
confidence in.   
5. Due to concerns over the surge in use of CKD QOF FRGHV IROORZ WKH 42)¶s 
LQWURGXFWLRQ DQG PRUH VR IROORZLQJ &.'¶V LQWURGXFWLRQ LQWR WKH 42) WKH
decision on whether or not to include it will be based on preliminary model 
analysis 
6. The remaining practice variables outside of practice attainment, namely size and 
workload will be included if there is evidence of significance in preliminary 
analysis 
7. Random and fixed effects models will both be utilised. Random effects are 
important as a number of key variables such as gender and IMD are fixed over 
time. There is also a high level of individual time invariance in a number of the 
QOF targets variables. Fixed effects are important as models are rarely fully 
specified and therefore there are likely to be variables omitted from the model 
which are potentially correlated with included explanatory variables. Both 
specifications will have their results reported to enable comparison, and 
appropriate tests will be conducted to determine which specification best fits the 
model.   
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8. Population averaging will also be conducted, averaged at the individual level, 
using robust standard errors. These correct for heterogeneity in the variance of 
the error term.    
Data analysis will follow a four stage process. These will start from initially 
specifying the model before moving into panel data regressions which will explore 
the impact of alternative specifications of the outcome variable. They are set out 
below: 
Stage 1 Model specification 
Stage 2 Analysis using panel count data models 
Stage 3 Analysis of count data using a panel hurdle model 
Stage 4 Logit panel data analysis using a binary transformed outcome measure 
7.5.3 Stage 1 Model specification 
7.5.3.1 Objective 
1. To confirm the existence of time effects within the data to justify the use of panel 
data analysis 
2. In the presence of the year variable and the key study variables to determine 
which outcome measure should be used and explanatory variables included 
7.5.3.2 Background 
Given the scale of the data under investigation cross sectional analysis provides a 
quick overview of the relationship between the explanatory and dependent variables. 
In the presence of time dummies these relationships are expected in large part to be 
borne out in more computationally complex models. It therefore provides an 
opportunity not only to flag up initial talking points and concerns but also 
importantly to guide model specification for subsequent stages 
7.5.3.3 Methodology 
A model was built around the QOF targets selected in chapter 3. All additional 
covariates were selected on the basis that they were expected to have an important 
explanatory relationship with the outcome (dependent) variable which contains the 
clinical outcomes identified in chapter 3. Further details about all these explanatory 
variables and their expected relationship with the dependent variable are given in 
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Appendix 8. In defining the model the process was constrained by the availability of 
data within the CPRD and HES datasets, and the quality of data collection in those 
databases. This meant that a covariate that ideally would be in the model, ethnicity, 
could not be due to a large amount of missing data. Other variables were constrained 
by the unit and frequency of measurement. Hence while data shows that death rates 
from CHD, and MI more specifically, do vary by strategic health authority in 
England, and that there is a general north-sRXWK GLYLGH ZLWK WKH QRUWKHUQ 6+$¶V
having higher rates; this unit of measure hides significant pockets of variation in 
deaths from CHD20. As such while this variable could have an important explanatory 
role for differences in outcomes between individuals, this was dependent on those 
individuals being generally representative of those regions, of which we had no 
indication or control over. The results for the IMD variable, presented in figure 7-3, 
suggest that if this result is due to regional variations in deprivation, that the study 
population may not be representative.  
Other variables such as workload and size were constructed by this study. In addition 
alternative specifications were attempted on a number of variables and the outcome 
measure. This section therefore undertook preliminary regressions to determine if 
these variables had an independent relationship with the study outcome, in the 
presence of key study variables, which would warrant their inclusion in the model. 
Or in the case of variables with alternative specifications, determine which, in 
instances if any, should be included. 
The key variables included in all the analyses are specified below. The additional 
variables were added separately in the presence of those key variables, with the 
exception of Smoker2 which was entered in the place of Smoker. The results 
presented in the tables show the regression coefficients for the individual variables in 
the presence of the key variables only. Negative binomial regressions were run as the 
outcome variables were over dispersed, meaning their variance was greater than their 
mean.  The choice of the negative binomial over the Poisson was also verified by 
H[DPLQLQJWKHYDOXHRIWKHGLVSHUVLRQSDUDPHWHUĮDQGWKHOLNHOLKRRGWHVWRQLWERWK
of which confirmed over dispersion and the choice of the negative binomial. 
Dependent (outcome) variable: alladmis (All ICD10, I21 and I23 codes and selected 
I20, 24 and 25 codes; for full breakdown of codes used see Appendix 7, page 279 
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and 280) ; alladmisx (including additional MI Read codes, see page 143 and 144 for 
details)  
Key covariates (explanatory variables) included: age; gender; QOF variables {Blood 
pressure controlOHG PP+J (BP), &KROHVWHURO FRQWUROOHG PPROO Chol), 
The prescription of Aspirin, anti-platelets or coagulations (Anti), The prescription of 
beta blocker (BB), The prescription of ACE or A2 to MI patients (Acea2q), Smoking 
cessation advice to current smokers (Smcess)}, QOF related target (ACE), Index of 
Multiple Deprivation 2007 (IMD); Years; Co-morbidities {Heart Failure (HF), 
Diabetes (Diab), Atrial Fibrillation (AF), Stroke and Transient Ischaemic Attack 
(STIA), Hypertension (Hyper), Rheumatoid Arthritis (RA)}; current smoker 
(Smoker); Practice level CHD QOF attainment (pracatt) 
Additional covariates tested: Smoker2, SHA Region (Region), Angina outcome pre-
admission (Angpre), MI pre-admission (MIpre), Outcome pre-admission (Hospre), 
Chronic Kidney Disease (CKD), Practice size measured in quintiles (sizeq), Practice 
GP workload measured in quintiles (workldq) 
7.5.3.4 Discussion and results 
7.5.3.4.1 Years 
7KHILUVWVWDJHDQDO\VHVLJQRUHGWKHGDWD¶VSDQHOVWUXFWXUHDQGH[DPLQHGLWDVDVLQJOH
cross section. This was in order to study the impact of the year variable in the 
presence of the key variables and other possible explanatory variables to explore 
potential model specifications. Since panel data analysis considers time and 
individual unit effects, as denoted in equation (2), these effects play an important 
part in any panel analysis. A lack of time variance would favour a simple pooled 
regression, as the analysis would simplify down to an individual cross section if time 
played no part in outcomes. This preliminary analysis also provided an opportunity 
to see if there were any differences in results between the alladmis and alladmisx 
outcome measures. 
The results are presented in a series of tables on the following pages, starting with 
the effect of time (years) on the outcome variables and key explanatory variables. 
The coefficients show log values, however since these are logs of counts, their 
interpretation is more difficult. Nonetheless they still provide an indication of effect, 
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with a negative value showing the variable reduces the outcomes, a positive the 
opposite, and the larger the value the bigger the effect. 
Table 7-15 Effect of time period on study outcome measures 
 
Table 7-15 clearly shows that time, measured in years (01 April to 31 March the 
following year), had a statistically significant negative effect on the outcome 
variables, i.e. reduced their numbers, relative to the base year 2000/01, holding the 
key variables constant. In other words, adjusting for all the key variables, the 
outcome variable was declining over the study period. CHD statistics reported in 
Chapter 1 show supporting evidence for a declining trend in deaths and admissions 
for the study outcomes over the period of analysis20. This demonstrates the 
importance of considering time effects as cross sectional analyses could wrongly 
attribute the relationship shown to other included variables.  The results suggest that 
there were large declines in relation to the base year in 2001/02, but that 
improvement stalled in the early years of the QOF, before figures improved again.  
Overall they point to the importance of time on the study outcome measures, an 
effect included in panel data analysis. This is done by setting the data by time, and 
also in this study with respect to the individual, which allows for the effect of time to 
be examined in different contexts within this study. Firstly through introducing lags 
on variables it is possible to examine temporal effects and determine the impact of 
previous period variable values on present period outcomes. More generally looking 
at the individual unit level, in this case the patient, since the data is set by time, 
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depending on the method of analysis it is possible to see what happens within the 
individual or between individuals. Hence allowing for temporal effects the data tells 
us what the impact is when an explanatory variables changes value on the outcome at 
the individual level using within effects analysis, and what is the difference in 
outcomes between individuals when an explanatory variable changes value, in 
between effects analysis. In this setting what is happening to the outcome variable 
over the study period does not affect the validity of the results, since we are 
concerned with what is happening to outcomes within patients over time, or the 
effect of changes in covariate values between individuals, allowing for time effects.   
7.5.3.4.2 Deprivation 
The results for deprivation, one of the key explanatory variables, are shown in Table 
7-16. Once again the results are very similar for both specifications of the outcome 
variable. Compared to the least deprived these results show that moving up the 
deprivation quintiles increases the expected number of admissions, increasingly so, 
with each increase in deprivation quintile. Hence being in the most deprived quintile 
increases the expected number of admissions relative to the next quintile, those with 
greater than average deprivation, and so on and so forth. All results are statistically 
significant, p<0.001. This results suggests that the more deprived the individual is, 
based on IMD 2007 metrics, the higher their rates of the study outcomes. 
Table 7-16 Effect of deprivation quintile on study outcome measures 
 
7.5.3.4.3 Region 
For the region variable which is based on the 10 SHAs there is no natural order to its 
categorisation. The order used was that in which it was placed by CPRD, with the 
North East used as the baseline comparator. Using other regions as the baseline 
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either due to their expected affluence or deprivation, did not give improved results. 
Furthermore it can be argued that the North East performs the role well given its 
expected relative deprivation in relation to the other regions. The coefficients for this 
variable, holding the key variables constant, are shown in Table 7-17. 
Table 7-17 Effect of region on study outcome measures 
 
Surprisingly therefore the coefficients show that other regions are associated with an 
expected increase in admissions relative to the North East. This effect is highly 
significant in the Southern regions producing a reverse of the usual north south 
divide. When interpreting region in this way it is assumed that it is a measure of 
regional deprivation but as the figures are for SHA, they can hide significant 
variation and are possibly a blunt tool in this respect. At the same time it may be 
replicating the work done by the IMD variable and therefore there may be correlation 
between the two giving misleading results. This was not apparent in the IMD 
variable which remained highly significant with regions included, though the 
coefficients were smaller and the staged increases through the quintiles not as 
marked. Therefore the regression was run with IMD absent. In this instance the sign 
of the coefficients did not change but their size reduced while their standard errors 
increased. As a result the coefficients for the East of England and South Central were 
no longer significant and the significance level for the South West reduced to 5%.  
This did not suggest high correlation, which was confirmed by further analysis 
which showed a correlation coefficient between the two variables of, -0.2224. What 
this perhaps highlights is that due to the broad geographical categories there is 
186 
 
potentially a relationship between region and deprivation for certain patients 
accounting for its effects on that variable. However since the categories contain 
pockets of affluence and deprivation it does not form a good measure of relative 
deprivation across the regions of England. It may be capturing regional differences 
in access to and quality of health and wider social services. Or the fact that relative 
to living costs incentives in these regions will have been less generous than the 
North East. While its interpretation is presently unclear, the significant differences 
between some regions are worth exploring further to see if consistencies occur and 
patterns emerge, which could aid interpretation. 
7.5.3.4.4 Sizeq and workldq 
These were included as quintiles as the coefficients were near zero and insignificant 
when they were included as non-categorised variables. Both are attempts to capture 
the impact of practice level factors on individual patient outcomes.  
Table 7-18 Effect of size quintile and workload quintile variables on alladmis outcome 
variable 
 
The results are largely non-significant in both instances with the exception of those 
practices with the highest workload and practices in the mid range for size. The 
coefficients are however the correct size and increase in magnitude as we go through 
the quintiles as expected, for workload certainly. Results are presented with respect 
to the alladmis outcome variable only, though the coefficients for the alladmisx 
variable were similar, and their statistical significance identical. These results 
suggest that while it may not be evident in each quintile, relative practice size and 
workload does have an effect on the study outcome, which merits exploration. 
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7.5.3.4.5 Remaining variables 
The results from the remainder of the variables are shown in the Table 7-19.  
Table 7-19 Remaining variables, effect on outcome measures 
 
Firstly with regard to the different versions of the explanatory variables (alladmis 
and alladmisx), results in terms of coefficients and significance are very similar; as 
has been evident in the other tables produced. Looking further into the results the 
coefficients for all the co-morbidities are postive and significant as expected with the 
exception of CKD, perhaps unsurprisingly due to issues raised previously. The QOF 
outcome measures BP and Cholesterol are the expected sign, namely meeting the 
target reduced the number of admissions and significant but all the prescription 
targets are positive suggesting that receiving these increased admissions. This 
relationship will have to be explored further within panel data analysis to look at 
188 
 
potential reasons. Having an outcome event prior to the patients participation in the 
QOF was a postive and significant predictor for future outcomes. This could support 
some form of hurdle structure. This was the case whether the variables were 
specified separately by MI or Angina or merged to create the Hospre variable, 
placing it on the same basis as the outcome variable. Different specifications of the 
smoking variable were included, one using codes recorded in CPRD, Smoker, and 
the second, Smoker2, by carrying a smoking record forward into subsequent periods, 
if details were missing. Both of these variables had the expected sign and were 
significant. 
7.5.3.4.6 Structure of the count variable 
The final analysis in this stage looked at various model specifications incorporating 
the key explanatory variables and the alladmis outcome measure using the countfit 
command in Stata. This commands examines whether a Poisson or negative 
binomial is the best fit for the model and whether zero inflated models should be 
used. This command does not look at hurdle models but the results can be used more 
generally to see if the model has an excess of zero outcomes which some form of 
excess zero correction could improve upon.  The results are also not applied to a 
panel structure though years were included in the model specification. The summary 
results of the output are shown in Table 7-20 and Figure 7-8.  
The results in Table 7-20 show a strong preference for the negative binomial 
(countNBRM) over the Poisson (countPRM) confirming the results from other 
checks, and for a zero inflation correction. The effectiveness of the different model 
specifications in fitting the data are shown in Figure 7-8 below that table. This shows 
that the negative binomial is better at predicting the value of the count variable 
alladmis than the Poisson for values between 0 and 2, with the Poisson under-
predicting zeros and overpredicting ones. Overall both the non zero inflated negative 
binomial and the zero inflated models for both specifications appear to be a good fit 
for the data when interpreting the graph only. However the results from Table 7-20 
argue strongly for a zero inflated approach and the use of a zero inflated negative 
binomial (ZINB) in preference to a zero inflated Poisson (ZIP). 
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Table 7-20 Preferred model specification 
 
Figure 7-8 Predictive accuracy of different model specifications 
 
-------------------------------------------------------------------------
               LRX2=  856.786  prob=    0.000  ZINB    ZIP   p=0.000    
               AIC=     0.473  dif=     0.002  ZINB    ZIP
  vs countZINB BIC=-6.180e+06  dif=   843.685  ZINB    ZIP   Very strong
-------------------------------------------------------------------------
countZIP       BIC=-6.179e+06  AIC=     0.474  Prefer  Over  Evidence
-------------------------------------------------------------------------
               Vuong=   2.955  prob=    0.002  ZINB    NBRM  p=0.002    
               AIC=     0.473  dif=     0.009  ZINB    NBRM
  vs countZINB BIC=-6.180e+06  dif=  4051.979  ZINB    NBRM  Very strong
-------------------------------------------------------------------------
               AIC=     0.474  dif=     0.007  ZIP     NBRM
  vs countZIP  BIC=-6.179e+06  dif=  3208.294  ZIP     NBRM  Very strong
-------------------------------------------------------------------------
countNBRM      BIC=-6.176e+06  AIC=     0.481  Prefer  Over  Evidence
-------------------------------------------------------------------------
               AIC=     0.473  dif=     0.041  ZINB    PRM
  vs countZINB BIC=-6.180e+06  dif= 19723.409  ZINB    PRM   Very strong
-------------------------------------------------------------------------
               Vuong=  36.433  prob=    0.000  ZIP     PRM   p=0.000    
               AIC=     0.474  dif=     0.039  ZIP     PRM
  vs countZIP  BIC=-6.179e+06  dif= 18879.724  ZIP     PRM   Very strong
-------------------------------------------------------------------------
               LRX2=15684.531  prob=    0.000  NBRM    PRM   p=0.000    
               AIC=     0.481  dif=     0.032  NBRM    PRM
  vs countNBRM BIC=-6.176e+06  dif= 15671.430  NBRM    PRM   Very strong
-------------------------------------------------------------------------
countPRM       BIC=-6.160e+06  AIC=     0.513  Prefer  Over  Evidence
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7.5.3.5 Summary and conclusion 
There is no evidence with respect to any of the variables examined to use the 
alladmisx outcome variable in preference to alladmis. Due to this it was decided to 
focus on the original alladmis variable for subsequent analysis as this contains 
known hospital admissions for the codings of interest, and there is no additional 
benefits from including further possible but uncertain events. Likewise nor does 
Smoker2 improve upon Smoker in terms of its fit with other variables and 
relationship with the outcome variable. For this reason Smoker is retained for 
subsequent analysis as this uses only actual recorded entries. CKD is not included, 
not simply on the lack of significance in this analysis but also due to wider concerns 
with the consistency of its coding over the study period. Hospre,  which incorporates 
both the emergency angina and MI pre-study outcome measures variables will be 
used rather than splitting it down into its component variables. The analysis 
confirmed that both are significant in increasing the count of  the outcome variable in 
the study period, an effect that was captured in this one variable. Region, sizeq and 
workldq are also included. These were found to be significant for certain regions and 
quintiles, in relation to the base measure, and therefore may play some role in 
explaining study outcome. For brevity and clarity of presentation only those 
cateJRULHV WKDW GLIIHU VLJQLILFDQWO\ S IURP WKH EDVHOLQH FRPSDUDWRU ZLOO EH
reported in output tables. 
Therefore the model to be used in all subsequent analysis is as follows.  
For whole population analyses: 
Dependent variable: Original outcome measure (alladmis) in count models, or the 
binary derivation of the same outcome measure, in binary models (Admis) 
Explanatory variables (covariates): QOF variables {Blood pressure control
150/90mmHg (BP), &KROHVWHUROFRQWUROPPROOThe prescription of Aspirin, anti-
platelets or coagulations (Anti), The prescription of beta blocker (BB)}; QOF related 
variable, the prescription of ACE inhibitors or A2 antagonists (ACE); Practice size 
measured in quintiles (sizeq); Practice GP workload measured in quintiles (workldq); 
Index of Multiple Deprivation 2007 (IMD); Current smoker (Smoker); SHA region 
(Region); Co-morbidities {Heart Failure (HF), Diabetes (Diab), Atrial Fibrillation 
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(AF), Stroke and Transient Ischaemic Attack (STIA), Hypertension (Hyper), 
Rheumatoid Arthritis (RA)} 
In those analyses looking at the MI subgroup: 
The additional QOF variable will be included, the prescription of ACE or A2 
antagonists (Acea2q), which is applied in the QOF to that subgroup. The ACE 
variable which applies that target to the whole of the CHD population (ACE) will be 
removed in these analyses. 
In those analyses looking at the smoking subgroup: 
The QOF target of offering smoking cessation advice to smoker will be included 
(Smcess), and the current smoker variable (Smoker) removed, as there will be 
collinearity with the added variable.  
7.5.4 Stage 2: Analysis using count panel regression analysis 
7.5.4.1 Introduction 
A benefit of regression methods that consider time is the ability to look at temporal 
effects through the imposition of time lags. The downside of such an approach is that  
data is inevitably lost as patients with only one year of data are removed from the 
analysis when lags are introduced. Introducing lags of QOF explanatory variables 
makes intuitive sense in the context of this study. Patients could join the study at any 
point in a QOF year following a first recorded CHD QOF code. Likewise they were 
assumed to be QOF qualifying for a full year so long as they were present at the 
beginning of that QOF year. In both cases lags become important, though for 
different reasons. When joining not only may there not be enough time to measure 
an impact depending on the timing of their first coding but naturally there is a period 
of treatment initiation and then compliance before the intervention has an impact on 
the condition and reaps clinical benefits. Likewise as the outcome can occur at any 
point in the QOF year, and hence prior to the administration of the evidence based 
QOF targets, depending upon its timing, treatment in the previous year may be more 
pertinent to the outcome in that year. 
Regression without time lags were run, these produced very similar results to those 
reported in Stage 1 as expected. The more interesting results are for those in which 
lags were introduced that are presented below. Random effects, fixed effects and 
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population average with robust standard errors were performed on the same model 
specification, dropping time invariant variables for the fixed effects analysis. Any 
variable with a suffix -1, refers to its one year lagged value. Results for deprivation 
and practice size are shown in relation to the lowest quintile, the least deprived and 
smallest practices respectively. SHA region and practice GP workload were also 
included but values are only shown for those regions and quintiles where the results 
were signifcant. N represents the number of patients who were included in that 
regression and T, the number of time periods. In all tables the evidence based QOF 
variables, identified in chapter 3, are shown at the top of the output table followed by 
age and gender, and then the remaining study explanatory variables. 
7.5.4.2 Whole population targets 
The results for whole population targets are shown in Table 7-21. The coefficients 
show incident rate ratios (IRR), which are easier to interpret than the previous results 
which showed the difference between the logs of expected counts. For those 
coefficients a positive figure indicated that the variable increased the number of 
counts, a negative that it decreased the number of counts, though the magnitude of 
WKRVHHIIHFWVLVGLIILFXOWWRLQWHUSUHWZKHQH[SUHVVHGLQORJV)RU,55¶VVKRZQLQWhe 
Table 7-21, a figure greater than one means that a unit increase in the variable 
increases the rate of counts, those less than one that it reduced them. Hence looking 
at the coefficient for gender for random effects this shows that holding other 
variables constant being male compared to female is expected to increase the rate of 
alladmis counts by a factor of 1.086. IRRs are presented for all analyses where the 
outcome variable is specified as a count variable. 
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Table 7-21 Whole population QOF targets, Negative Binomial 
 
The results in terms of their size and significance are similar across the different 
model specifications. Clearly introducing a lag makes a difference and all QOF 
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targets, and the additional ACE prescription target applied to the whole population, 
reduce rates of admissions, significantly so, p<0.0001, when lagged by one year. 
This effect is most noticeable for aspirin, anti-platelets and coagulants, where 
meeting the target in the previous period is seen to reduce the rates of the outcome 
by nearly 40% (IRR=0.611 to 0.623). With the exception of the cholesterol target the 
results suggest that meeting the QOF target increases the rate of admissions in the 
present year. This relationship is harder to interpret. It could be that immediately 
following an admission the patient is more intensively managed and hence meets the 
targets and this effect is being captured in the same year panel. Meeting the target in 
the previous year, in this instance, has a more causal relationship with events 
subsequently, which is being accurately captured by the lag. 
All co-morbidities are significant with the exception of rheumatoid arthritis, and 
increase rates of admission with the exception of hypertension, which only does so 
in fixed effects analysis. Increasing practice GP workload, size, as well as SHA 
region were insignificant in these analyses, and hence are not produced in the table. 
Having an admission for the outcomes of interest prior to entry into the study 
increased the rates of admissions by a factor of around 2.5 in non-fixed effects 
analyses (IRR=2.480 to 2.532, p<0.001). Current smoking also increased rates of 
outcomes as expected by near 20% in random effects (IRR=1.199, p<0.001) and 
population averaging (IRR=1.184, p<0.001), and 5% within patient using fixed 
effects analysis (IRR=1.058), a result that was non-significant. There was a 
significant and linear stepped increase in rates of outcomes as the patients moved 
into more deprived quintiles, with the most deprived quintile having around a 45% 
increase in rates of outcomes (IRR=1.447 random effects; 1.455 population average, 
p<0.001). This variable was not included in fixed effects analysis as it was fixed 
over the study period for the individual patient, and therefore time and would be 
removed by fixed effects adjustments.  Practice CHD QOF attainment significantly 
reduces rates of admissions (p<0.001), by 0.4% for each 1% increase in attainment 
in fixed effects analysis (IRR=0.996), and around 1.4% for each 1% increase in 
attainment in random effects (IRR=0.986) and population averaged analyses 
(IRR=0.987).  
A Hausman test was conducted which looks at the differences in the variance of the 
fixed and random effect estimators to indicate which specification is most efficient. 
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This test came out in favour of fixed effects estimation whose results are reported, 
time constant variables aside. The fixed effects coefficients need to be interpreted 
differently as they consider only within individual variation and not that between 
individuals which is also included in the random and population average coefficients. 
Hence gender which does not differ within an individual is lost in fixed effects 
analysis, while in the random and population averaged analysis the coefficient refers 
simply to the differences between male and female patients in the study. 
Alternatively for a variable such as Heart Failure (HF) which does change within 
patients during the study, the fixed effects regression coefficient shows that having 
an HF diagnosis significantly increases the individual rate of admissions by just over 
2 fold (IRR=2.020, p<0.001). The random effects coefficient on the other hand 
shows that an individual diagnosis of HF, and an individual with HF compared to 
one without, significantly increases the rate of outcomes by a factor of nearly 2.1 
(IRR=2.098, p<0.001). Encouragingly in fixed effects the results are similar and the 
QOF targets remain significant with a lag, as does prescriptions of ACE or A2. The 
results for co-morbidities are also similar although RA is now a significant risk factor 
(IRR=1.439, p<0.05) and hypertension is associated with an increase in rates 
(IRR=1.072), though is insignificant. Age also becomes insignificant in fixed effects 
(IRR=1.001), while patients in larger practices (largest two quintiles) have around a 
20% lower rate of admissions compared to the smallest practice size quintile, 
p<0.01.  A 1% increase in practice attainment reduces rates of admissions by 0.4% 
for the individual. These results are however based on a much smaller dataset 
involving 12,709 patients, with large numbers of observations and patients lost, in 
addition to those through lags, to individual time invariance in included time variant 
variables, predominantly the QOF targets. 
7.5.4.3 Sub group CHD targets: MI 
The coefficients for the MI subgroup targets largely mirror those for the whole 
population, see Table 7-22. The ACE inhibitor or A2 prescription QOF target 
applied to its designated QOF population is significant in all models when lagged, 
reducing rates of admission by around 27% (IRR=0.726, p<0.001) in fixed effects 
analysis, and around 15% in non-fixed effects analyses (IRR=0.854, p<0.001 
random effects; 0.881, P<0.05 population averaged) in the subsequent period, when 
met in the present period. The reduction in incident rate ratios is lower than that seen 
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when the target was applied to the whole population. Rates do not increase 
incrementally with each increase in deprivation as witnessed in the whole study 
population, with there now being no significant difference in rates of outcomes 
between the least deprived 20% and those in the least deprived 20-40%. However 
more generally increased deprivation is seen to increase rates of admissions, by 
around 33% for the most deprived individuals compared to the least deprived 
(IRR=1.324-1.329, p<0.001). This variable is fixed over the study period and 
therefore could not be run in fixed effects analyses, and the impact of changes in an 
LQGLYLGXDO¶V GHSULYDWLRQ VWDWXV RQ WKH study outcome could not be examined.  In 
fixed effects besides Heart Failure (IRR, 2.131) and Hypertension (IRR, 1.391) none 
of the co-morbidities increase rates of outcomes significantly. Hypertension is no 
longer significant outside of fixed effects analysis (IRR=1.39,p<0.05), the reverse of 
the findings found in the whole population, suggesting that in this population having 
hypertension does not increase admissions between individuals, but it does within a 
patient who goes from being non-hypertensive to hypertensive. While none of the 
size quintiles are significant in any of the analyses, individuals in practices where GP 
workload was in the lowest 20-40% quintile had significantly higher rates of 
outcomes than those in the lowest workload quintile in all analyses, of between 12% 
and 20% (IRR=1.119-1.120, p<0.05). The only remaining difference between this 
group and the whole study population is that there is no evidence for male patients 
being at higher risk of having an outcome than female patients in the MI subgroup.    
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Table 7-22 MI subgroup, Negative Binomial 
 
7.5.4.4 Smoking subgroup, Smoking cessation target 
The results for the smoking subgroup are shown in Table 7-23. Of specific relevance 
to this group, smoking cessation is seen to reduce rates of each admission by around 
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25%, a result that is significant in all models (IRR=0.728-0.745, p<0.01). However 
in this instance in the present period and not when lagged. With the exception of the 
blood pressure target, all the remaining QOF targets are seen to significantly reduce 
rates of outcomes after a lag, as does the ACE inhibitor target when applied to this 
population. Higher practice attainment significantly reduces the rates of patient 
admissions in random effects and population averaged models (IRR=0.983-0.984, 
p<0.001), though this effect is not significant in fixed effects analysis (IRR=0.992). 
Having an outcome prior to admission remains a significant factor in increasing rates 
of admission, more than doubling those rates (IRR=2.350-2.514, p<0.001). Being 
registered in a mid-sized GP practice significantly reduces rates of outcomes by 
nearly 30% compared to the smallest 20% of practices in non-fixed effects analyses 
(IRR=0.707-0.715, p<0.05). Males have significantly higher rates of outcomes 
relative to females, by around 30% in non-fixed effects analyses (IRR=1.277-1.317, 
p<0.05) 
The only co-morbidity that consistently significantly increases rates of outcomes 
across all models is Heart Failure, by around 2 fold in non-fixed effects analyses 
(IRR=2.068-2.118, p<0.01) and over 3 fold in fixed effects analyses (IRR=3.088, 
p<0.001). Diabetes (IRR=1.2, p<0.05) and Atrial Fibrillation (IRR=1.429, p<0.01) 
are additionally significant in random effects and Hypertension in fixed effects 
(IRR=2.496, p<0.01). Rheumatoid Arthritis is seen to reduce rates in non-fixed 
effects analysis but increase them four fold in fixed showing great variability in 
effect for this variable, though none of the coefficients are significant.  
Deprivation has an insignificant effect on outcomes except in the most deprived 
where it increases rates by around 40% (IRR=1.147-1.149, p<0.05). Age 
significantly reduces rates of admissions by around 1% outside of fixed effects, 
where they increased with age, but insignificantly so. Again when the Hausman test 
was performed it showed a preference for fixed effects analysis.  
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Table 7-23 Smoking subgroup, Negative binomial 
 
200 
 
7.5.5 Stage 3 Hurdle model 
In this part of the analysis only the whole study population targets were analysed as 
patient numbers in sub group analysis were insufficient to allow fixed effects 
analysis to converge on a result and small sample sizes gave volatile and potentially 
misleading results in all models. As discussed this approach splits the study 
SRSXODWLRQ LQWR WZRFRPSRQHQWV)LUVWO\ DELQDU\ µDW ULVN¶PRGHOZKLFK WKHZKROH
population particiSDWHV LQ ,Q WKLV µDW ULVN¶ PRGHO WKH FRHIILFLHQWV VKRZ WKH
relationship between the variable and the individual having an outcome. For those 
who have an event the hurdle is crossed and they participate in a count model, where 
the coefficients represent the effect of the variable on the number of events. The 
hurdle approach deals with potential over-dispersion issues arising from excess 
zeros.  
7.5.5.1 Binary component 
In a panel data setting for a binary outcome variable, the choice was between using 
logit or probit regression. The logit was used in preference to the probit as this has a 
fixed effects option in Stata, and enables the production of odds ratios which are 
easy to interpret. Besides these factors the two distributions are near identical with 
the logit having slightly longer tails, which may be more accommodating to the large 
number of zeros in the dataset. Nonetheless the two models generally give very 
VLPLODUUHVXOWV7KHUHVXOWVIRUWKHµDWULVN¶ORJLWPRGHODUHVKRZQLQWKH7DEOH-24. 
In this instance the results for fixed effects are not included as the regression did not 
converge. As the outcome variable has a binary specification the coefficients show 
odds ratios (OR). These are interpreted similar to IRRs, in that a figure above one 
shows that the variable increases the outcome measure, while those below one, that it 
decreases them. However since the outcome variable is simply showing whether an 
outcome occurs or not, the coefficients represent the impact that the variables have 
on the odds of an outcome occurring. As opposed to IRRs, which show the impact of 
the outcome variable on the rates of outcomes. 
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Table 7-24 Whole population QOF targets, Hurdle model, binary component 
 
The results are in keeping with those found in count model specifications. Meeting 
the QOF targets reduces the odds of having an admission when the targets are 
lagged. These results are statistically significant, most at a 99.9% significance level. 
Co-morbidities significantly increase odds of having an outcome with the exception 
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of hypertension which reduces odds between patients, namely an individual with 
hypertension has lower odds of having an outcome compared to one without 
(OR=0.890-0.902, p<0.001), and Rheumatoid Arthritis where the increase is 
insignificant. Smoking increases odds by over 20% (OR=1.219-1.236, p<0.001), 
while having an admission for one of the chosen outcomes prior to CHD diagnoses 
is associated with around a doubling of odds of a study admission in both models 
(OR=1.996-2.307, p<0.001). For each percentage increase in WKH LQGLYLGXDO¶V 
practice attainment on the selected CHD QOF targets, the odds of an outcome fall by 
around 1.5% (OR=0.983-0.985, p<0.001). Both size and workload were insignificant 
risk factors for having an admission and are not reported in the table. So too was 
region in the random effects model, though in the population averaged model, 
Yorkshire and the Humber (OR=0.877, p<0.05), and the East of England 
(OR=0.883, p<0.05), had around 12% lower odds of an admission compared to the 
North East. 
7.5.5.2 Count component 
The results for those who had an admission for an outcome of interest; the count 
element of the hurdle model, are shown in Table 7-25. In these results there is some 
commonality with the binary model, certainly in the direction of effects for the 
majority of variables.  Meeting QOF targets is still important in how many 
admissions an individual has when lagged, namely if they met the target in the 
previous period they have lower rates of outcomes in the present period in all 
models. Meeting the cholesterol target in the present period also reduces rates by 
around 8% (IRR=0.912-0.923, p<0.001), suggesting more immediacy with this 
target, though this figure is not as great as its lagged value (IRR=0.786-0.843, 
p<0.001).  Being male in this instance reduces rates, though only by around 1%, and 
only in the random effects model (IRR=0.987, p<0.05).  Four regions (West 
Midlands, South West, London, and South East Coast) are associated with 
significantly lower rates of admissions in the random effects model. For the West 
Midlands, London and South East Coast rates of admission are additionally 
significantly lower in the population averaged model relative to the North East. The 
effects size range from a 15% reduction in rates of admissions (London, random 
effects, IRR=0.853, p<0.01) to a 10% reduction (South East Coast, population 
averaged, IRR=0.901, p<0.05). As these are in the population who had an event this 
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may be indicative of better access to, and response by, not only primary health care 
services but also secondary care and wider social services. There is mixed results 
with regard to co-morbidities. Rheumatoid Arthritis and Hypertension are 
insignificant in all models, Stroke is significant only in random effects (IR=1.077, 
p<0.05), and Diabetes (IRR=1.203, p<0.01) and Atrial Fibrillation (IRR=1.384, 
p<0.001) in fixed effects. Only Heart Failure is significant in increasing the odds of 
admission in all models. Higher practice CHD QOF attainment continues to 
significantly reduce rates of admissions, by around 2% for each 1% increase in non-
fixed effects analyses, and by 0.3% with each 1% increase in fixed effects analysis. 
Smoking increases them in all models, by between 11.4% (population averaged, 
p<0.001) and 25% (fixed effects, p<0.001). 
Increases in age are shown to reduce rates of outcomes in fixed effects analysis 
(IRR=0.71, p<0.001), an effect also seen in fixed effects in the MI subgroup, and 
non-fixed effects analyses in the smoking subgroup. It would appear that for 
individuals that could be considered to be in poorer health groups, namely those with 
recently diagnosed MI; or who had a study outcome during the study period, 
increasing age has a within patient protective effect. A possible explanation is that 
WKLVLVGXHWRDµVXUYLYRUHIIHFW¶LQWKHVHLQVWDQFHV,QWKHFDVHRIWKRVHZKRKDGDQ
outcome or with recently diagnosed MI, the risk of having an event are often highest 
immediately following an event. Hence if the individual survives beyond that 
immediate period their chance of having an outcome decreases; resulting in the 
finding that age reduces rates.  
For smoking the comparison is in non-fixed effects, primarily between patients. In 
this instance the more chronically ill smokers may be quitting and exiting the 
smoking population, meaning that the smoking population is relatively healthier in 
comparison. In that scenario increasing age would be seen to reduce rates of 
outcomes between patients, in a smoking subgroup. Smokers were certainly younger 
on average than non-smokers, by nearly 8 years, mean 63.9 years compared to 71.8, 
which could point to this part of the study population being in better health.   
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Table 7-25 Whole population QOF targets, Hurdle model, count component 
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7.5.6 Stage 4 Logit panel data analysis using a binary 
transformed outcome measure 
7.5.6.1 Whole population 
It was shown in the data description section that there is a large dominance of zero 
outcomes within the data, amounting to 94.55% of all outcomes. Individuals having 
one event account for 4.43% of all outcomes, meaning that counts of greater than 
one account for just over 1%. Applying count models with such a high proportion of 
zeros may produce biased estimators. One of the solutions is to apply a form of 
hurdle to the data which was done previously. However this led to issues of 
convergence, meaning that subgroup targets had to be excluded entirely and fixed 
effects did not converge in the whole study binary component.  An alternative was to 
dichotomise the outcome measure. This approach alters a small portion of outcomes, 
removes issues concerning zero inflation pertinent to count models and enables 
regressions to be completed on a greater proportion of the study data. To this effect a 
new variable, Admis, was created which replaced all counts greater than 1 with 1. As 
in the hurdle model the logit was used in preference to the probit, for the reasons 
discussed previously. Hausman tests were performed where possible throughout this 
stage and showed a preference for fixed effects. The results from this analysis are 
presented in Table 7-26.  
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Table 7-26 Whole population QOF targets, Logit 
 
They show a general consistency in results among the different forms of analyses. 
All the QOF targets significantly reduce odds (p<0.001) when that variable is 
lagged, as does the ACE inhibitor/A2 prescription target when applied to the whole 
CHD population.  Cholesterol was also found to reduce odds of an admission in the 
present period (OR=0.91-0.915, p<0.001) outside of fixed effects analysis. Each one 
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year increase in age increases the odds of having an outcome; by 1.5% in fixed 
effects and population averaged models, and 1.8% in random effects. Being male 
increases the odds of an admission by near 1% in models where the variable is 
present (OR=1.086-1.099, p<0.001). The odds of having an outcome increase as the 
deprivation quintiles increase, in a clear stepped manner, relative to the least 
deprived. With the exception of Rheumatoid Arthritis in all models and Diabetes in 
fixed effects (OR=1.092), the effect of co-morbidities are significant. The odds in all 
cases are increased by the presence of the included co-morbidities with the exception 
of hypertension in the random effects and population average specifications where it 
is seen to reduce odds between and within patients by 9-10% (p<0.001). Each 1% 
increase in practice attainment reduces the odds of having an outcome, by around 
1.5% (p<0.001) in between effects analyses and 0.6% in within, fixed effects 
analysis (p<0.001). Smoking increases odds, by a range of 5% in fixed effects (not 
significant) to 22% in random effects (p<0.001). Having one of the study outcomes 
of interest prior to entry into the study increased odds of having an outcome during 
the study by around 2.5 times, in non-fixed effects analyses (OR=2.423-2.762, 
p<0.001) where the variable could be included. GP workload, SHA region and 
practice size were included in all analyses but were not significant in any of their 
categories relative to their baseline comparator.  
7.5.6.2 MI subgroup 
Regression results for the MI subgroup are shown in Table 7-27, and are similar to 
those reported in Table 7-26 for the whole study population. In comparison to those 
figures QOF targets continue to be significant when lagged, including the 
prescription of ACE or A2 to recently diagnosed MI patients. Hypertension is 
however no longer significant except in fixed effects where it continues to increase 
odds, though by a much bigger magnitude of over 86% within patients (OR=1.864, 
p<0.01). Atrial Fibrillation is no longer significant in population averaged analysis 
(OR=1.126). Region continues to be an insignificant predictor of events, as are the 
size quintiles in this subgroup, while workload increases odds in the 20-40% quintile 
(OR, 1.112 to 1.271, p<0.05). Diabetes is no longer significant in fixed effects 
analysis (OR=1.195) and neither is smoking (OR=1.125). Males have lower odds of 
an outcome in non-fixed effects analysis, but the effect is insignificant. In terms of 
deprivation there is no longer a clear increase in odds of an outcome as we move into  
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Table 7-27 MI subgroup, Logit model 
 
 
more deprived quintiles. Being in the least deprived 20-40% quintile no longer 
increases odds of an outcome in random effects and population average models, nor 
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does being in the most deprived 20-40% in random effects relative to the least 
deprived quintile. Having an outcome prior to entry into the study is still a large and 
significant predictor of an admission during the study, more than doubling odds 
(OR=2.335-2.704, p<0.001). Increases in practice attainment continue to 
significantly reduce odds of an outcome (OR=0.986 to 0.991, p<0.001). In fixed 
effects analysis age is again shown to significantly reduce odds of an admission in 
those with recently diagnosed MI (OR=0.902, p<0.001). 
7.5.6.3 Current smokers-smoking cessation 
In the non-fixed effects analyses just less than 11% of the total patient population are 
involved, in fixed effects that figure is down to just over 1%, making results from 
fixed effects less generalisable. Results are shown in Table 7-28. 
The results are very similar to those presented for the negative binomial count model 
presented in stage 2 for this population. Coefficients for age again show this variable 
to significantly reduce, in this instance the odds of an outcome, in random effects 
models by near 1% (OR=0.991, p<0.001). 
The BP QOF target is only significant in fixed effect analysis increasing odds in the 
immediate period (OR=1.326, p<0.05), though not when lags were introduced. 
Meeting the cholesterol target reduces odds of an outcome in both the immediate 
period and the subsequent period, though the lagged effect was not significant in 
fixed effects analysis. The remaining QOF targets are seen to significantly reduce the 
odds of an outcome, but only when lagged. 
The results concerning co-morbidities are mixed. Heart Failure increases odds of an 
outcome by near double in population averaged (OR=1.917) analysis to over treble 
in fixed effects analysis (OR=3.225), p<0.001. Atrial Fibrillation increases odds by 
around 1.5 times (OR=1.5 random effects, p<0.01; 1.397 population averaged, 
p<0.05) but this is not significant in the fixed effects model. Rheumatoid Arthritis is 
insignificant in all models and Hypertension only in fixed effects analysis where it 
increases odds within patients by over 2.5 times (OR=2.763, p<0.05). Stroke is 
insignificant in all analyses and diabetes only in random effects where it increases 
odds within and between patients by 23% (OR=1.232, p<0.05). 
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Table 7-28 Smoking subgroup, Logit model 
 
Receiving an ACE inhibitor or A2 antagonist reduces odds of having an outcome in 
the smoking population when the variable is lagged in all analyses, by between 40 
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and 45% (OR=0.54 to 0.610, p<0.001). Deprivation is no longer a significant 
predictor of an outcome with the exception of the most deprived quintile where odds 
are increased by over 40% (OR= 1.426, p<0.05) in the population averaged and 50% 
in random effects analyses (OR=1.52, p<0.05), relative to the least deprived. 
Percentage increases in practice attainment continue to decrease odds of an outcome, 
by around 2% in random effects (OR=0.981, p<0.001) and population averaged 
analyses (OR=0.984, p<0.001); though the variable is no longer significant in fixed 
effects. Having an outcome prior to entry into the study remains a significant cause 
of admissions during the study increasing odds by around 2.5 times (OR=2.376 to 
2.783, p<0.001). Smoking cessation is seen to have an immediate effect, reducing 
odds in all analyses by nearly 30% (OR=0.702 to 0.744 non-fixed effects, p<0.001; 
0.732 fixed effects, p<0.05). However the variable is not significant when lagged. 
This may point to the long run ineffectiveness of this target, as it suggests that while 
it may have resulted in immediate benefits, possibly brought about by individuals 
quitting smoking, in the subsequent period it had no significant impact. This may be 
due to patients resuming smoking once the intervention was withdrawn or because, 
in this chronically ill population, many of whom had co-morbidities, there were no 
longer term benefits in terms of reduced adverse outcomes from quitting smoking. It 
should also be noted that there may be wider issues when interpreting figures for this 
subgroup due to the way the data is set up. This is because individuals only feature in 
this population if they are current smokers, so those who were recorded as non or ex-
smokers would not feature. Hence when interpreting lags we are only looking at 
patients who continued to smoke and naturally the target would be ineffective in 
respect of that population. What is not known is how representative this patient 
population is of the wider population who received smoking cessation advice.  
Finally being in a mid-sized practice is seen to reduce the odds of an admission 
relative to the smallest practice size quintile, by up to 28% in non-fixed effects 
analysis (OR=0.717 to 0.731, p<0.05). 
7.5.7 Summary 
Table 7-29 shows a summary of the main results for the regression coefficients on 
analyses undertaken on the whole study population. The exception to this being the 
QOF target variables for the prescription of ACE or A2 to MI patients (Acea2q) and 
smoking cessation advice to current smokes (Smcess), which applied to their relevant 
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subgroups only, detailed in the table. The coefficients on the remaining variables are 
not shown for these subgroups though they have been detailed previously. Also 
omitted are the coefficients for SHA region, practice size and GP workload variables 
as these were largely insignificant. Only the lags of the QOF target variables are 
reported as only these were significant, with the exception of the cholesterol target, 
which also had an immediate impact. 
Table 7-30 shows the regression coefficients from the hurdle model analyses. Again 
SHA region, practice size and GP workload were excluded for the same reasons 
given above.  Subgroup target variables are not shown as they were not analysed in 
the hurdle model. The results in the binary hurdle represent the odds of a patient 
having an outcome and the count hurdle the rates of outcomes in those who had an 
outcome. They are not intended for comparison as they show different risk groups, 
with those in the count model assumed to be higher risk patients as they have had an 
outcome in the study. 
These tables shown a general consistency in the size and significance of the key 
variables, certainly the QOF variables, and subgroup specific targets where included 
across all analyses. For the binary and count model specifications for the whole 
study population, the results are very similar for all variables. In these two analyses 
co-morbidities, Rheumatoid Arthritis and Hypertension aside, significantly increase 
the odds of the study outcome.  These results are largely but not wholly replicated in 
the hurdle model. Further discussion follows after Table 7-31. 
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Table 7-29 Whole study binary and count models results summary 
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Table 7-30 Hurdle model results summary 
 
 
The results for all the regressions are summarised in the Table 7-31 for the key and 
consistently included variables. A number of variables from this list are excluded: 
Rheumatoid Arthritis is absent as this was significant in the negative binomial fixed 
effects model only. Practice size, practice GP workload and the SHA region 
variables are also excluded as they showed no consistency in effect and it was 
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therefore not practical to include them.  Subgroup specific targets, ACE inhibitors in 
recently diagnosed MI patients and the smoking cessation target are not included as 
they applied only to their specific context, though did significantly reduce rates or 
odds in all instances when included. The results are broken down into the whole and 
subgroup populations as well as to the different models analysed in Stage 2-4; 
negative binomial, hurdle and logit models. Results are only reported if the 
FRHIILFLHQW ZDV VLJQLILFDQW DW D  RU JUHDWHU OHYHO S 7KH - reflects the 
direction of the effect of the explanatory variable on the outcome measure, as the 
explanatory variable increased or went from zero to one. The absence of results for 
fixed effects analysis in the binary component of the hurdle model reflects the fact 
that the regression in this instance could not converge on a result.  
Table 7-31 incorporates all the pertinent information on all analyses and is therefore 
information heavy. In interpreting it therefore there are a number of general pointers. 
As the table shows instances (regressions) where the variable was significant 
S WKH PRUH HQWULHV WKHUH DUH DJDLQVW D YDULDEOH WKH PRUH FRQVLVWHQWO\
significant it was. Changes in sign show inconsistency in the direction of effect, 
hence regular changes, particularly in the same regression type or outcome variable 
specification, show that the variable had an inconsistent effect and was unstable in 
this respect. This may be indicative of a badly specified variable, and certainly 
makes it difficult to interpret its impact. To avoid confusion where the absence of 
detail could be interpreted as the absence of any effect, those variables that could not 
be included in fixed effects analyses are denoted by a not applicable, N/A, entry. 
Hence when looking for variables which play a significant role in predicting an 
outcome or outcomes, a greater number of entries and consistency on the sign 
recorded, indicate this. A quick examination of the table reveals importantly that the 
lagged QOF variables were all important explanatory variables.   
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Table 7-31 Summary of results for all models 
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7.5.7.1 Key findings 
A number of significant and consistent findings interest are evident in these results. 
These are: 
1. Regardless of the functional form specification of the outcome variable, whether 
fixed or random effects, or population averaged models were used; the QOF 
CHD target variables used in the model significantly reduced outcomes with a 
lag. This applied to the subgroup targets also, the only exceptions to this result 
being: 
i. For BP, all forms of the negative binomial and logit regression in the 
smoking subgroup 
ii. For Cholesterol, the fixed effects logit in the smoking subgroup 
2. Meeting the cholesterol target was found to have an immediate and significant 
reductive impact on outcomes in all analyses aside from the fixed effects logit 
model. 
3. The ACE inhibitor/A2 antagonist QOF target was additionally found to reduce 
outcomes in all analyses when applied to the whole study population. 
4. Of all the co-morbidities only HF was a significant contributor to the number of 
outcomes in all analyses. 
5. Where other co-morbidities were significant they led to increases in outcomes. 
The only exception to this being hypertension which increased outcomes in fixed 
effects analyses but reduced them in and non-fixed effects analyses. This result 
suggests that within patients, i.e. being diagnosed with hypertension increases 
outcomes, however comparing between patients, having a hypertension diagnosis 
reduced outcomes. The possibility that the result could be caused by covariance 
with the BP target was considered and explored but no evidence was found, 
correlation=0.0122. 
6. Having a study outcome prior to entry significantly increased outcomes in all 
analyses. 
7. Increased practice attainment on QOF CHD targets significantly reduced 
outcomes in all analyses, with each 1% increase in practice attainment generally 
increasing outcomes by a greater than equivalent amount in non-fixed effects 
analyses and by a lower than equivalent amount in fixed effects analyses. 
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8. More deprived quintiles, with the exception of the least deprived 20-40%, were 
associated with a significantly greater number of outcomes relative to the least 
deprived in all analyses outside of the smoking subgroup. 
9. Increasing age predominantly increased outcomes in random effects analyses, 
with the exception of the smoking subgroup where increasing age decreased 
outcomes. In fixed effects analysis the variable was largely insignificant, but 
tended to reduce outcomes where it was in whole population models. In what 
could be considered more chronically ill subgroups, namely those who had a 
recent MI diagnosis or an outcome during their participation in the study; 
increasing age reduced outcomes within individuals. This could be indicative of a 
µVXUYLYRUHIIHFW¶ 
10. Males had a higher number of outcomes relative to females in all models except 
in MI subgroup analysis, and random effects in the hurdle count model. 
11. Both Diabetes and Stroke TIA increase outcomes in all random effects analyses 
outside out of the count component of the hurdle model. 
12. Smoking increases outcomes in all instances in non-fixed effects models but is 
only significant in fixed effects analysis in the hurdle count model. This suggests 
that at the individual level smoking does not increase outcomes but it does 
between non-smoking and smoking individuals. This could be the result of more 
chronically ill patients giving up smoking, hence in this context, the smoking 
subgroup would represent a healthier cohort of the study population.  
13. Practice size and GP workload had no significant impact on the study outcomes 
in whole population analyses. In the MI subgroup practices in the lowest 20-40% 
quintile for GP workload had a significantly higher rates (between 12% and 
20%) or odds (between 11% and 27%) of outcomes relative to those in the lowest 
GP workload quintile. In the smoking subgroup mid-sized practices had a 
significantly lower rate (approx 29%, p<0.01) and odds (approx 28%, p<0.05) of 
outcomes relative to the smallest practices   
7.5.8 Discussion 
Previous research on CHD patients in the QOF found improvement on QOF target 
measures and in the case of BP and Cholesterol the surrogate outcomes that mapped 
to those targets119-122. This research has confirmed those findings and taken a number 
of steps forward. Firstly in terms of the period covered, in comparison to previous 
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research which tended to examine incentives for short periods or limited time points, 
here individuals have been followed over an 11 year period. In comparison to the 
QOF, which does not have a control group, by using individual level panel data, 
patients have been able to act as form of comparator in this research. Finally 
attainment to QOF target standards has been linked at an individual level to linked 
clinical outcomes. No research to date has done this. This research suggests that 
when evidence based QOF CHD targets are met the odds ratios, or incidence rates of 
hospital admissions for CHD complications are reduced, within a one year lag. This 
is important as it suggests, in an uncontrolled real world environment outside of 
experimental conditions, there is significant patient benefits from meeting these 
targets. Furthermore, more generally, that other targets supported by high level 
evidence, may have benefits in the population.  These benefits in the case of the 
targets examined, serious hospital admissions for complications arising from CHD 
avoided, could have service implications, although these went unexamined in this 
thesis. The targets examined represent a small subset of the total number of QOF 
targets, those which were strongly evidence based and had extractable outcomes in 
large datasets, and the findings cannot be therefore applied to the QOF more 
generally. It remains to be seen therefore, and is a challenge still remaining, to see if, 
or ensure that, this applies to the wider QOF P4P scheme. 
This research, as with most economic analyses, has been undertaken in an 
uncontrolled setting and has consequently relied on observational data. As such, as 
with all work conducted outside of experimental conditions, it can only with 
certainty show causation and not causality. However it is often not possible to prove 
causation and correlation is sufficient (e.g. higher insurance for male drivers due to 
higher risk of accident); and a number of approaches have been used which suggest 
causation. Firstly through the use of multivariate analyses, the study has controlled 
for a number of potential confounders. Furthermore in fixed effects analyses, even if 
potential confounders have been omitted from the model, so long as these are fixed 
over time, these have been controlled for.  
Correlation refers to variables moving together, in causality there is a cause and 
effect, with the change in the dependent variable preceding the change in the 
outcome. Fixed effects analyses allow us to analyse changes within patients, observe 
µVKRFNV¶ZKLFKDUHRIWHQXVHGLQHFRQRPHWULFVZKLFKUHOLes on observational data to 
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infer causation. Shocks refer to sudden unexpected changes, so for example if there 
is DVXGGHQIDOOLQDFRPSDQ\¶VVKDre prices following the unexpected resignation of 
its owner, causality is assumed. In the context of this thesiV ZKLOH QRW µVKRFNV¶
changes within a patients have been examined, which act in a similar manner. Hence 
it has been demonstrated that a patient who goes from failing a QOF target, to 
meeting it, significantly reduces their odds or rates of having an outcome. In much 
the same manner, the use of lags, enables the examination of a causal effect. Here we 
see the impact of a variable in a previous period on an outcome in the present period, 
holding other variables constant. In this thesis the effects of QOF targets were all 
shown to be significant with a lag, suggesting causation rather than correlation. 
Finally all of the QOF targets and linked outcomes were selected on the basis of high 
level evidence using experimental study designs, suggesting a causal relationship. 
Regression to the mean is also a possibility in any regression analysis. This refers to 
the phenomenon that a variable will regress towards the mean over time, so if a 
variable is extreme on one measure it will tend closer to the average on its next 
measure. In the context of this thesis this would manifest itself in an individual not 
having an outcome in the next period if they had one in this, due to regression to the 
mean rather than any treatment effects. While regression to the mean cannot be 
discounted there are a number of factors which mitigate against it. Firstly in panel 
data time is captured within the panel, and rather than looking at time trends where 
regression to the mean can be an issue; individual level panel data examines the 
effects of changes in state within an individual or differences in state between 
individuals. Hence the results show us that both within and between patients that 
meeting the QOF targets examined significantly reduced the odds or rates of an 
outcome. Finally the hospre variable, which recorded whether or not the individual 
had a study outcome prior to entry into the study, had a consistently large and highly 
statistically significant impact in all analyses. This suggests that for the outcomes 
examined in this study, rather than reverting to the mean, if the individual had an 
outcome, WKH\KDGDKLJKHUµULVN¶RIDIXUWKHURXWFRPHGXULQJ the study period. 
This research has demonstrated the benefit of panel data in terms of the ability to 
examine temporal effects and introduce lags into the data. The results, as discussed, 
show that evidence based CHD targets in the QOF are effective in reducing evidence 
linked CHD hospital admissions within a year. They also suggest that in the current 
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period, when those same targets are met, with the exception of cholesterol control 
and smoking cessation, those hospital admissions increase. This reversal of effect 
could be argued is evidence for regression to the mean, as present period values 
suggest the targets are ineffective and indeed do harm. This thesis does not believe 
this to be the case for the reasons discussed previously. Rather it argues that the 
present period values are more illustrative of correlation and the lags demonstrate 
causation. This is due to a number of reasons. Firstly most treatments once initialised 
require a period of repeated compliance before the treatments effects are evident. 
Secondly due to the way the panel data was organised, in the present period, 
treatment did not necessarily precede the outcome. Lags on the other hand ensured 
that treatment preceded any recorded outcome. The fact that the cholesterol control 
target was also shown to be largely effective without a lag, may have been due to the 
study population receiving statins prior to entry. These were recommended for use in 
patients with a 20% or greater 10 year risk of CVD, so it is possible that cholesterol 
was being monitored and controlled prior to entry. The thesis did not explore this 
and it should be noted that the recommendation pre-dates much of the study period. 
For smoking cessation, the target is effective in the present period but not when 
lagged. This target was examined in the current smokers only, hence if they quit, 
they would not feature in the subsequent period. In this population the lagged values 
could give a distorted picture for a persistent and hard to treat smoking population. 
The results show that rates or odds of outcomes did not differ significantly between 
SHA regions in the main analyses outside of the hurdle model. However the hurdle 
PRGHOVSURGXFHGVRPHLQWHUHVWLQJUHVXOWV7KHµDWULVN¶PRGHOVXJJHVWVWKDWUHODWLYH
to the North East, individuals in the Yorkshire and the Humber and the East of 
England, who had CHD, had lower odds of having a study outcome. In those 
individuals who had a study outcome, the count component, relative to the North 
East, individuals from the West Midlands, South West, London and South East 
Coast, all had significantly lower rates of outcomes. In the USA much work has been 
undertaken by the Dartmouth Institute looking at disparities in Medicare spending 
across the USA and the impact of location on the delivery of, and access to, services, 
and health outcomes140. This shows big discrepancies in per capita Medicaid 
expenditure across the states, not explained by poverty. Furthermore that greater 
spending does not explain better health outcomes, and that there is enormous scope 
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for improving efficiency and quality in US health care, by rewarding providers for 
providing evidence based care and reducing unnecessary care. The results in this 
thesis would suggest that the NHS performs better in this respect, and on the whole 
people with similar study characteristics can expect to have similar outcomes, for 
CHD at least, regardless of SHA in England. This is perhaps not surprising for a 
condition such as CHD where care protocols are standardised, and in a universally 
provided, free at the point of use, healthcare system. At the same time incentive 
schemes like the QOF and other initiatives like National Service Frameworks may 
have played a role. The differences in the hurdle model suggest two things: Firstly 
that some SHAs are more successful at preventing first admissions for complications 
arising from CHD following first diagnosis. Secondly that other SHAs are better at 
preventing subsequent admissions once a first admission has occurred. No SHAs 
feature in both of these results. Strong support could not be found for this result from 
national hospital statistics which showed that with the exception of the South East 
Coast and the South West all these SHAs had above national average rates for 
emergency hospitalisations for CHD, and MI, and for deaths from CHD141. This 
suggests that the individuals from the SHAs outside of the exceptions mentioned, 
used in this study are not representative of the population in those areas as a whole. 
The deprivation profile of the population would support this. Or, that the individuals 
in those SHAs receive care which is not representative of the region as a whole. This 
would be in keeping with the work by the Dartmouth Institute, but requires further 
research.    
7.5.9 Limitations 
This research has assumed that the explanatory variables are strictly exogenous, 
namely that they are uncorrelated with the error term, see (3). Some attempts have 
been made to adjust for potential endogeneity of the explanatory variables, such as 
by using fixed effects, but others such as the use of instrumental variables has not.  
No commands existed within Stata to analyse panel count models. The study 
therefore used existing Stata commands to create an approximate hurdle model. A 
possible alternative however was to use facilities within Stata to write commands 
specifically for this purpose, which may have produced a better specified model and 
more efficient estimators.  
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This study did not explore the effect of interactions between treatments and/or 
conditions. QOF treatment is condition specific hence this is in keeping with an 
analysis of QOF targets. Nonetheless this may have highlighted different responses 
to treatments in subgroups with different co-morbidities, which could have informed 
policy. 
The statistical significance of the Hospre variable in all models is suggestive of 
dynamics in the outcome measure, namely whether or not the individual had an 
outcome in the previous period or periods, plays a significant role in whether they 
have one in the present period. Lagged dependent variables create problems with 
respect to the error term and exogeneity assumption, and require complex 
econometric solutions, which were beyond the scope of the study 
This study looked at specific outcome measures using IHD ICD 10 codes in the 
primary diagnosis by hospitalisation file. Other outcomes were considered or 
examined briefly before rejection such as hospital length of stay. Other important 
outcomes were not, such as number of relevant surgical procedures, time to an 
outcome and death within a specified duration of diagnosis.  
7.6 Implications for practice 
This work has shown that meeting the selected evidence based CHD targets used in 
the QOF significantly reduces evidence linked hospital admissions. This is the case 
whether the outcome is specified as a count or binary measure; fixed or random 
effects are used; when adjustments are made for excess zeros, and whether whole 
population or subgroup targets are considered; in the vast majority of cases. As such 
the effectiveness of the chosen QOF targets has been conclusively analysed and 
demonstrated. However the improvement is lagged meaning that compliance with 
targets reduces outcomes in the subsequent period. The cholesterol target is alone in 
having an immediate reductive impact on outcomes in addition to a lagged one.  
ACE inhibitors were shown to be effective in all patients. This would support 
extending the existing QOF target to all patients with CHD, not just those with MI. 
Deprivation was generally a strong predictor of outcomes. This shows that more 
deprived CHD patients had worse clinical outcomes, and future design changes in 
the QOF may wish to focus care more intensively on those patients. Descriptive 
analysis showed that the study population became increasingly comorbid over the 
study period. Panel data models that most comorbidities played a significant role in 
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increasing outcomes. There are very few multi-morbidity targets in the QOF, despite 
this situation becoming increasingly common and having significant health 
implications, particularly with respect to polypharmacy142. There are a number of 
targets that could be merged across conditions in the QOF to avoid the potential 
harm and costs brought about by the proliferation of drugs in those patients. 
7.7 Implications for future research 
The study has highlighted the possibility for research utilising individual level linked 
data and panel data techniques and hence demonstrated the opportunity for future 
research in this area. This could explore alternative hurdle and zero inflated model 
specification to correct for excess zeros. An excess of zeros is a problem common to 
many measures in health care, whether they be hospital outcomes or visits to a GP, 
which require zero inflated model solutions. Hence there is scope for much greater 
research and refinement in this area, with large administrative datasets offering the 
opportunity to undertake it on a range of outcome measures and to conduct it 
relatively quickly. There is also opportunity to study dynamics in the outcome 
measure and interactions between included variables. Finally this research looked at 
hospitalisations where selected IHD ICD 10 codes were the primary diagnosis for 
that hospitalisation. Future research may wish to consider alternative outcomes such 
as hospital length of stay and surgical procedures.  
7.8 Conclusion 
This chapter has explored the key explanatory and outcome variables in the study 
dataset and examined the impact of co-morbidities. The results from the descriptive 
analysis show that the data extracted is largely representative of the wider English 
disease population, and that trends in QOF target attainment and their mapped 
surrogate measures found in the study population, are largely mirrored in the primary 
literature and QOF statistics produced by the HSCIC. 
Those variables were then included in a number of econometric models. The results 
showed that meeting the selected evidence based targets in the QOF consistently 
reduced evidence linked hospital admissions at an individual patient level. In 
addition to this co-morbidities, higher deprivation and having an outcome prior to 
entry, in the main resulted in a greater number of outcomes. Improvements in QOF 
CHD practice attainment consistently reduced outcomes.  
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Chapter 8 Discussion and synthesis 
8.1 Objective 
To summarise and synthesise the information gathered in this thesis, discuss its 
relevance to the research aim, identify policy implications, and areas for future 
research.  
8.2 Background 
The thesis set out to explore the effectiveness of physician incentives on individual 
level clinical outcomes. This was undertaken from an NHS perspective, where 
service reorganisation on the back of significant new investments in primary care, 
saw the introduction of the QOF in 2004, recognised as one of the biggest 
investments in P4P in the world1 3. To examine the effectiveness of evidence based 
targets in the QOF this thesis used individual level data extracted from large 
administrative medical databases. Rather than examining the whole QOF clinical 
domain, CHD target were chosen because they had good evidence of clinical 
effectiveness and extractable data from administrative datasets. The effectiveness of 
evidence based targets in the QOF were analysed using panel data econometric 
models. 
This chapter details how the separate chapters informed this thesis, and together 
addressed the research aim. It further identifies the specific strengths and limitations 
of each chapter and any overall implications for practice and future research. 
8.3 Executive summary 
The literature reviews identified a number of weaknesses in research to date. There 
was little high level study design evidence and incentives were examined over short 
durations. The outcome measures used were mostly process and surrogate outcomes, 
no study on P4P looked at clinical outcomes, and none outside of P4P considered 
condition specific clinical outcomes. The research on the QOF and CHD usually 
involved only two time points, had no control, and was largely reliant on data from 
one PCT. This work has sought to correct the problems identified in the present 
literature. It has used administrative datasets to extract data on a large sample of 
CHD patients from across England and tracked them, at an individual level, in 
primary and secondary care. QOF targets and clinical outcome measures were 
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selected on the basis of high level clinical evidence. The impact of evidence based 
standards in the QOF has been examined over an 11 year period four of which were 
prior to the QOF. By utilising panel data model techniques, individual patients have 
been able to act as their own comparator. Adjustments were made to model 
specifications for over dispersion, excess zeros, heterogeneity in, and covariance 
with, the error term. In all whole population and most subgroup models evidence 
based CHD targets in the QOF were found to significantly reduce evidence linked 
hospital admissions after a one year delay. This shows that evidence based targets 
can have a significant and positive impact on patient health in real world 
uncontrolled settings outside of clinical trials. 
8.4 The effectiveness of physician incentives and 
evidence for QOF clinical targets 
8.4.1 Context and relevance to the thesis 
The QOF was introduced in April 2004 and near universally adopted; hence there is 
no control group by which to judge its effectiveness. Furthermore there is no 
published research conducted prior to the QOFs introduction to justify the choice of 
targets, the design of the QOF, or the specific choice of P4P as the means of 
incentivising GPs. This thesis attempted to establish a clear methodological approach 
to assess the impact of QOF targets in this context. It did so over the course of three 
literature reviews and a review of the clinical guideline evidence for QOF clinical 
targets. 
Chapter 2 undertook a review of systematic reviews of incentives in primary care, 
limited to high level study designs. This sought to determine the evidence for the 
effectiveness of physician incentives in primary care to provide a context for the 
QOF and P4P. This revealed that: 
1. There is a paucity of high level research evidence on the effect of physician 
incentives. 
2. A lack of high level research, and heterogeneity of outcome measures, prevented 
meta-analyses of findings. 
3. There was no evidence found that would justify the use of P4P as the chosen 
payment method for the QOF. 
4. There is an urgent need for research which meets the following requirements: 
i. Examines the effectiveness of incentives over a longer duration 
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ii. Considers the effectiveness of physician incentives on clinical outcomes 
The first literature review in Chapter 2 clearly showed that there is great uncertainty 
over the effectiveness of financial incentives and a number of methodological 
weaknesses in the high level research evidence, common among which were 
selection bias, a lack of blinding for both physicians and patients, and poor external 
validity. 
To remove bias in the selection of targets and outcomes, it was important to base 
those decisions on high level clinical evidence11 18. Chapter 3 therefore selected from 
the QOF, exemplar targets, with demonstrable, and relevant, clinical outcomes, 
supported by high level clinical evidence. The process surrounding the introduction 
and retirement of new targets has undoubtedly become more robust and formalised 
with the introduction of the QOF committee in 2009. Nonetheless there is a lack of 
critical appraisal of the clinical effectiveness of QOF targets. Specifically there are 
no studies which incorporate the evidence base in their analysis of the QOF or 
incentives generally. This chapter identified that many of the QOF targets, 2009/10, 
were not supported by high level clinical evidence. Hence studies which do not 
consider the clinical evidence, ignore clinical outcomes, and simply report process 
measures in their work, often wrongly assume that improvements in recording and 
activity are, or have, a clinical benefit. 
Following the selection of CHD as the exemplar condition Chapter 4 undertook a 
literature review to look at the effects of physician incentives on CHD clinical 
outcomes. This was in order to determine if research similar to that about to be 
attempted by this thesis had been undertaken, and how previous research could 
inform this study. Chapter 2 included only high level design and primary care 
incentives; it was felt based on the evidence of that review that replicating that 
approach would draw few if any studies. It was therefore decided to include any 
study design with a within or between group comparator, so long as some attempt 
was made to match patients on key socio-demographic variables at baseline or the 
results stage. Key findings from the review that informed this thesis were: 
1. There was a paucity of research on the impact of physician incentives on clinical 
outcomes 
2. No studies were found linking primary care physician incentives to clinical 
outcomes 
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3. No strong evidence was found for the effectiveness of P4P.  
Lastly a review of the research literature on CHD and the QOF was undertaken. 
Since the previous reviews had required some form of comparator arm, QOF studies 
had not been returned in those reviews. As the QOF formed the policy and financial 
intervention in this thesis, this was an important omission. This review therefore was 
a broad literature review on the CHD QOF literature with few limitations on study 
design or outcome measures. Key findings from the review that informed this thesis 
were: 
1. There was a very limited research evidence base on the effects of the QOF on 
individuals with CHD 
2. The research evidence was predominantly focused on one administrative 
database in Wandsworth PCT, an inner London borough, and was therefore 
unlikely to be reflective of the UK as a whole. 
3. There was no assessment of the clinical effectiveness of QOF targets beyond the 
surrogate and process measures which formed those targets.  
4. The CHD QOF literature generally used uncontrolled before and after cross 
sectional study designs. Only one study followed or observed patients over a 
significant period and considered pre-existing trends when looking at the impact 
of the QOF119. This study found that the QOF did not lead to a significant 
improvement on existing trends119. 
The literature reviews highlighted the difficulty of conducting research in this area, 
hence a limited role for what are considered high level study designs, and a number 
of limitations in existing research. Nonetheless a number of important findings were 
revealed with respect to incentivisation. The evidence suggests that physicians do 
respond according to the incentives on offer and these can be used to direct physician 
behaviour. Hence in FFS physicians tended to provide more of the services that drew 
incentives. Another way of interpreting this is that while incentives may influence 
physician behaviour, physicians remain the principal and not the agent. In this regard 
physicians ensure that regardless of the incentives on offer they provide a certain 
amount and type of activity in order to maximise their income or utility, in line with 
the target income hypothesis examined in the paper by Krasnik52. Perhaps 
unsurprisingly therefore was little evidence for one form of incentivisation being 
µVXSHULRU¶DQGOLPLWDWLRQVLQDOOIRUPV of physician incentives were uncovered. With 
respect to P4P no significant body of evidence was found to justify its use in the 
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QOF. Overall, and of specific interest to this thesis there was little examination of 
the effects of incentives on evidence based outcomes. 
8.4.2 Strengths 
There have been a number of reviews on the effect of incentivisation in health care, 
P4P specifically. Hence there are recent examples by Eijkenaar et al who undertook 
a review of systematic reviews on P4P and Van Herck et al who undertook a broad 
based systematic review of primary studies on P4P43 143. Likewise for the QOF P4P 
incentive scheme specifically, Steel et al have undertaken a review of the existing 
primary literature144. Within the Cochrane collaboration there have been a number of 
systematic reviews looking at the impact of P4P and physician incentives more 
generally36 40 45. 
The literature reviews in this thesis do not attempt to replicate any of those studies. 
Rather in conjunction with the clinical guidelines they have sought to triangulate the 
evidence around physician incentives, and their impact on clinical outcomes, 
focusing on the exemplar condition, CHD. None of the previous reviews have 
analysed incentives from this perspective, linking into the clinical evidence, to see if 
research has focused on clinically significant and relevant outcomes. The approach 
adopted by this thesis provided a formal process for the analysis of evidence based 
QOF targets in this research and could do so in further work. This is important for 
research on the QOF due to the lack of a control and questions over its design and 
implementation discussed previously.  
8.4.3 Limitations of the reviews 
There are a number of weaknesses in the reviews with regard to their inclusion 
criteria specifically and generally with regard to the studies found beyond those 
previously mentioned. These are: 
1.  Due to heterogeneity in the conditions examined, study designs used, and 
outcomes measured, there was no opportunity to undertake a meta-analysis of 
their outcomes 
2. As with any literature review there is the potential for publication bias. A number 
of other sources of bias were mentioned within the systematic reviews. Common 
among the P4P literature was a lack of blinding in the intervention, bias in the 
selection of physicians and patients; and poor external validity of the outcome 
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measures45. These limitations equally applied to the literature reviewed in 
Chapters 4 and 5. 
3. The review of the evidence for QOF targets focused on NICE and SIGN 
guidelines evidence to recommendations and publications by large disease 
representative bodies. The primary literature was consulted only if the evidence 
from those sources was unclear. 
4. Two of the reviews focused on CHD care only, which has been the focus of this 
thesis. Extending these reviews to other conditions may have found more 
substantive evidence on the effectiveness of incentives. 
5. The reviews only considered English language publications and for the most part 
search engines available through the OvidSP search platform. Consequently the 
literature was predominantly from the USA and UK. English language journals 
not available through OvidSP and PubMed were missed from the reviews; as was 
literature from the majority of non-English speaking countries and their 
respective health services. 
8.5 Analysis of the QOF using large administrative 
datasets 
Following the literature and guidelines reviews the thesis moved onto data analysis. 
This was conducted and described in Chapters 6 and 7. These two chapters are 
described below. 
8.5.1 Using CPRD and HES data 
8.5.1.1 Context and relevance to the thesis 
Chapter 6 explained how the CPRD and HES administrative datasets were used to 
extract patient linked data and construct variables for inclusion in panel data models. 
This was primarily a descriptive chapter outlining the file structures present within 
the data sources and describing in detail the construction of key variables. Any 
concerns with respect to data quality, and the protocols used to overcome them were 
discussed. Strengths and limitations of the data outside of clear anomalies, or 
missing data, were examined during data descriptive analysis in Chapter 7. 
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8.5.2 Data description and analysis 
8.5.2.1 Context and relevance to the thesis 
In this chapter the study variables were descriptively analysed to find out how 
representative the study population was of the wider English national population, 
and whether variables followed trends or agreed with levels published in national 
level statistics and previous research. Econometrics, panel data models specifically, 
were described before formal analyses was undertaken using those techniques. Panel 
data models were then used to determine if there was a statistically significant 
relationship between evidence based CHD targets in the QOF and evidence linked 
hospital admissions, at an individual patient level.  
8.5.2.2 Principal finding 
From the review of the evidence on the QOF in this thesis, the literature identified 
simply showed a link between the introduction of the QOF and attainment on QOF 
targets, or their mapped surrogate measures. This was usually done for two time 
periods and for an inner London borough. The data analysis in this research has 
advanced that research significantly. It has shown at an individual level, that there is 
a statistically significant relationship between meeting an evidence based standard in 
the QOF and the rates or odds of evidence linked hospital admissions. This 
relationship has been verified in a number of model specifications, where the 
variable coefficients have been largely consistent in magnitude and significance, 
showing that this is a robust finding. The effectiveness of QOF targets has been 
examined over an 11 year period and from a large sample population drawn from 
across England, suggesting the results are generalisable and have high validity. 
,PSRUWDQWO\WKHUHVXOWVKDYHEHHQGHPRQVWUDWHGLQDµUHDOZRUOG¶XQFRQWUROOHGVHWWLQJ.   
8.5.3 Critical appraisal 
8.5.3.1 Strengths 
There are a number of strengths of the approaches taken in this chapter. These are: 
1. Descriptive analysis found the study population to be representative of trends 
evidenced in previous research and national statistics in terms of the direction of 
QOF target attainment and levels on mapped surrogate outcomes over the study 
period. The same was true of the study outcome measure as well as the age and 
gender mix of the study population. 
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2.  Individuals were followed for up to eleven years, seven following the 
introduction of the QOF. This enabled the study to look at the impact of repeated 
compliance with evidence based standards in the QOF, and state changes.  
3. Panel data analyses were used to model individual level outcomes. The benefits 
of this approach were: 
i. Given the absence of a control or comparator group in the QOF, individual 
level panel data enables patients to act as their own comparator. In this 
context, within patients, the previous period in the panel provides the 
comparator/control for the present period. In much the same way as they do 
in a controlled before and after study. 
ii. Variables could be lagged to assess temporal effects. This is important for the 
QOF as treatment can be initiated at any point in the financial year, including 
post a study outcome. Also with prescriptive targets in particular full clinical 
benefits are often realised some time after treatment initiation. 
4. Analyses allowed for fixed and random effects, included robust standard errors 
and adjusted for over dispersion and excess zeros in the outcome variable.  
8.5.3.2 Limitations 
There were a number of limitations to the approaches taken in the chapter that may 
limit its findings. These were: 
1. This research used hurdle models to account for excess zeros in the count 
outcome variable. As there were no existing commands to do this in Stata, it 
relied on adapting pre-existing commands to create a hurdle model. 
2. This research did not include dynamics in the outcome variable due to the 
complications to econometric modelling these create, which were beyond the 
scope of this research. However the significance of the Hospre variable in all 
models is highly suggestive of dynamics in the outcome variable 
3. The effect of workload in relation to *3¶VRQO\ZDV examined. This ignored other 
staff grades that play an important role in the delivery of the QOF such as nurses, 
and hence may not have been a representative figure. Nor was the effect of staff 
case mix on outcomes examined. 
4. The focus in this research has been on the effects of QOF targets on clinical 
outcomes at the individual level. Effects have not been examined at the practice 
level and due to this nor has the impact of exception reporting. 
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5. The outcome measures used have all been primary diagnoses by hospitalisation 
pertinent to CHD Secondary prevention. Other potential outcomes not considered 
are surgical procedures; death within a set time frame of diagnosis or 
hospitalisation; and other measures of resource usage such as time spent in 
intensive care or hospital. 
6. To act as their own comparator in a panel model, individuals are required to 
transition between states, in this study specifically, move from meeting to not 
meeting a QOF target and vice versa. A significant number of individuals 
remained in the same state throughout their time in the study, meaning that they 
could not perform that role; the variables became time invariant and were lost in 
fixed effects analysis.  
8.6 Implications for practice 
This research suggests strongly that the selected evidence based targets in the QOF 
targets work, namely that meeting the QOF standard leads to significant 
improvements in evidence linked hospital admissions, at the individual patient level. 
However there are aspects of the QOF that could be improved. This research shows 
that there are significant clinical benefits to be gained from extending ACE inhibitors 
to the entire CHD population, and not limiting it to those with recently diagnosed 
MI.  
The CHD study population aged, and became increasingly co-morbid and multi-
morbid over the course of the study. Despite this situation becoming increasingly 
common and having health and cost implications, particularly in the area of 
polypharmacy, the QOF still largely focuses on single conditions142. There remains 
scope within the QOF to merge conditions such as the cardiovascular diseases, and 
targets such as blood pressure which may not only have clinical benefits but could 
free up QOF points for use in other areas.  
This research demonstrated the importance of linking targets to evidence, and was 
surprised at how little of the QOF was evidence based and how few targets had 
process measures or surrogate outcomes that mapped to clinical outcomes. There 
have been significant improvements made since the end of the study period in this 
area. These have been brought about by innovations such as the NICE QOF 
committee which has led to more robust use of evidence to guide the introduction of 
234 
 
new targets and retirement of existing ones. The most recent QOF guidance, 
2013/14, is now much slimmed down and most of the targets based on simple record 
keeping have been stripped out. Nonetheless there are still a number of incumbent 
targets which lack a high level evidence base and have clinical benefits that are 
difficult to measure and extract from administrative datasets.  
This work found in most models, that there still remains a significant inequality gap, 
which was statistically significant throughout in the most deprived quintile. The 
most deprived quintile were found to have higher odds or rates for the outcome 
measures of around 30%-50%, compared to the least deprived quintile. Given the 
significant sums of money spent on the QOF, this may have been a missed 
opportunity to make more progress in eliminating these inequalities. Future changes 
therefore may want to address this by for instance increasing incentives to those who 
treat more deprived patients or incorporating socio-economic measures into QOF 
targets. 
There was also evidence found to support the target income hypothesis which argues 
that individuals have a target income and so will work a requisite amount to get to 
that income. Hence incentives can lead to an initial spurt in activity until the 
physician determines how much activity is required to meet their target income, at 
which point it settles. While this was not applied in a QOF context, it is possible to 
see supporting evidence for it in the QOF, where greater incentives and contractual 
changes saw significant numbers of GPs decide to opt out of out of hours surgery, 
and a fall in the hours worked by GPs as incomes rose145. This finding would support 
a reduction in QOF payments or more demanding payment thresholds, the latter of 
which has been shown to increase attainment, most significantly among poorer 
performing practices146. 
8.7 Comparison to previous research 
The extension of ACE inhibitors to those with stable CHD has been shown to be 
both clinically and cost effective147. This was based on data from the EUROPA trial 
which involved over 12,000 randomised patients from 24 countries with a mean 
follow up of over 4 years147.  The findings do however relate only to one specific 
ACE inhibitor, perindopril. The American Heart Association recommends that  long 
term ACE therapy should be considered in all  patients with coronary or other 
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vascular diseases unless contraindicated148. It has also been recognised by the Joint 
British Societies, which notes that ACE inhibitors have wider benefits outside of 
those who have just had an MI, in particular in individuals with elevated BP 87. 
These findings however have yet to be incorporated in guideline to evidence 
recommendations in the UK, by bodies such as NICE and SIGN81.  
The investigation of lagged effects is common in economics, particularly in 
macroeconomic models when studying the implications of changes in interest rates 
for example. Within the medical literature and health economics they are examined 
far less frequently. Hence it is difficult to find evidence which looks at lagged patient 
level effects in clinical treatment, and none was found which looked at them in the 
context of the QOF targets used in this study. This highlights the fact that this 
research is novel. Nonetheless there is general evidence to support a lag in clinical 
benefits, for the QOF targets examined, and indeed for immediate benefits from the 
use of statins. However these benefits have been mostly demonstrated using general 
mortality measures and not for the outcomes measured in this study.  
The clinical benefits of statins, specifically atorvostatin, have been shown to be in 
evident within 30 days of treatment initiation in the treatment of artherosclerotic 
vascular disease, in terms of significant reductions in all-cause mortality149. This 
would support the immediate benefits evidenced in the majority of models in the 
study from meeting the cholesterol QOF target, which related to statin use. Studies 
show clinical benefits of ACE inhibitors within patients post MI, occurring within 6 
weeks, when measured in terms of mortality. However these are often not 
significant, and build with long term initiation, which would support a lagged effect 
certainly in the MI subgroup, the group covered by the QOF target150 151. The 
benefits of beta blockers have been demonstrated in terms of reduced mortality over 
a one year to four year follow up period. This does provide some evidence for a 
delay in treatment effect, however no studies could be found that measured its effects 
over a shorter period to fully validate this, and the results referred specifically to post 
MI patients152. Anti-platelets have been shown to significantly reduce risks of 
serious vascular event in those with stable angina and in post MI patients at 2 
years153. This outcome measure links closely to the study outcome measure. 
The finding that the co-morbidities were largely significant was expected as they are 
all atherosclerotic conditions or risk factors. However while risk models have been 
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developed for the primary prevention of CHD which look at co-morbidities, no 
similar research could be found for secondary prevention154. This would have 
provided some assistance in interpreting the results in this study. Heart Failure was 
the only condition that significantly increased outcomes in all models. It is known 
that an MI is a significant risk factor for heart failure, and it is unsurprising therefore 
that those who had damage to the heart and may have suffered a previous MI were a 
high risk group155. What is not clear however is why this condition should figure 
more prominently than Stroke, AF, and Diabetes. Rheumatoid Arthritis is a known 
risk factor in the primary prevention of CHD, and was included in the study for that 
reason154.  Research from a Danish wide cohort has shown that rheumatoid arthritis 
significantly increases the risk of having an MI (IRR =1.7, 95% CI 1.5-1.9)156. This 
was of a similar magnitude to the increased risk of MI witnessed in patients with 
diabetes in the same study. Given the significance of diabetes in this study, albeit not 
consistently so, this makes the results found for RA in this study potentially 
questionable. However it should be noted that the results were for the general 
population of Denmark, and not those with CHD, hence results do not translate 
across into this study. Since RA is an autoimmune disease and not atherosclerotic, 
the causal pathway in relation to the outcome measures is not as clear as it is for the 
other co-morbidities. As the least common of the co-morbidities it is also possible 
that there were insufficient number of patients with the condition to pick up a 
significant effect, assuming one exists. 
The evidence on the impact of the QOF on inequalities, shows that the QOF had a 
very limited impact on inequalities, which largely persisted157 158. This is supportive 
of the finding in this thesis. However whereas previous research has measured 
inequalities largely in relation to QOF attainment and at a practice level, this work 
has done so for clinical outcomes at the individual patient level. 
8.8 Implications for future research 
This research has opened up a wide range of future research opportunities, 
particularly in relation to individual level analysis using linked primary and 
secondary care data, which may improve upon or expand this work. This study used 
specific ICD 10 codes extracted from the primary diagnoses over a hospitalisation 
file to create its outcome measure. Future research may wish to look at alternative 
outcomes available in linked HES. Examples include clinical procedures, ICU or 
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hospital length stay of stay. There are a number of additional individual linked data 
sources available to users of CPRD among them Office for National Statistics (ONS) 
mortality data and MINAP, that could also be used to create alternative outcome 
measures, or in the case of the latter alternative population specifications. Examples 
include time from diagnosis to death, RU0,¶VFRQILUPHGXVLQJ0,1$3. 
This research looked at the impact of dynamics in the study explanatory variables 
but not in the outcome measures, which could be analysed in future econometric 
models. Existing Stata commands were used to generate the hurdle model in this 
thesis. Future work could look at alternative specifications of the hurdle model and 
explore the possibility of using Stata commands to generate a panel hurdle model. 
In terms of the literature this research has only looked at the English language 
evidence on the effectiveness of incentives. Future research could look at non 
English peer reviewed and grey literature to see if this can provide more evidence on 
the effects of incentivisation. 
8.9 Summary and conclusion 
To ensure there was a strong evidence link and the outcome was extractable using 
large administrative datasets this research used clinical guideline evidence to direct 
the choice of targets. This ensured the process was transparent, methodical, and 
importantly evidence driven. The literature reviews identified a clear need for 
research which linked primary care incentives to clinical outcomes which this thesis 
then addressed.  
This thesis has shown that meeting evidence based CHD targets in the QOF 
significantly reduces evidence based hospital admissions after a one year lag. It has 
done so using individual linked data from large administrative datasets over an 11 
year period. The data extracted has been analysed using panel data econometric 
models. These models adjusted for over dispersion and excess zeros in the outcome 
term, used random and fixed effects to deal with potential correlation with included 
explanatory variables, and reported robust standard errors to account for 
heterogeneity in the error term. The analyses undertaken in this thesis are innovative 
in a QOF context. 
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Chapter 9 Appendices 
9.1 Appendix 1 Incentives in primary care search terms 
9.1.1 Medline 
1. Physician Incentive Plans/ [ML] 
2. ((physician? or practitioner? or doctor?) adj4 (bonus$ or incentive? or financial or 
monetar$ or payment? or profit shar$ or reward? or salar$)).ti,ab. 
3. exp Physicians/ and (incentiv$ adj (economic or financial or monetar$ or 
payment? or reimburs$)).ti,ab,hw. 
4. or/1-3 
5. Fees, Medical/ [ML] 
6. exp Income/ [ML] 
7. insurance, health, reimbursement/ or reimbursement mechanisms/ or fee-for-
service plans/ or physician payment review commission/ or medicare payment 
advisory commission/ or reimbursement, disproportionate share/ or reimbursement, 
incentive/ or relative value scales/ [ML] 
8. ((fees.mp. and charges/) or capitation fee/ or fee-for-service plans/ or fees, 
medical/ or fees, pharmaceutical/ or prescription fees/ or rate setting.mp.) and 
review/ [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
9. (capitation or capitated or capitating or fundhold$ or fund-hold$).ti,ab. 
10. (rate setting or rate review).ti,ab. 
11. (gainshar$ or payer-provider? or payer-patient?).ti,ab. 
12. ((incentiv$ or bonus$ or reward?) adj (economic or employee? or financ$ or 
insurer? or insurance or market$ or monetar$ or payment? or physician? or 
practitioner? or program$ or provider? or reimburs$ or salary or staff or team$ or 
value-based)).ti,ab. 
13. (reimburs$ adj (disproportion$ or health$ or insur$ or mechanism? or plan$ or 
physician? or practitioner? or program$ or proportion$ or provider? or relative or 
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scale? or share? or sharing or value-based or performance-base? or QI or quality or 
scheme?)).ti,ab. 
14. (pay for compliance or pay for participation or pay for performance or 
performance pay$ or P4P or pay for quality improvement? or P4QI or fee-for 
service?).ti,ab. 
15. (payment? adj (blend$ or blue cross or bonus$ or capped or episode of care or 
fixed or government$ or insurance or insurer? or level? or linear or medicaid or 
medicare or non-linear or per-patient or per-episode or per-visit or performance or 
prospectiv$ or retroactiv$ or retrospectiv$ or reward$ or schedule? or system? or 
target$ or third-part$ or threshold? or uncap$ or shared or variable or per-
visit?)).ti,ab. 
16. ((compensation or compensatory) adj (doctor? or physician? or plan? or 
practitioner? or system?)).ti,ab. 
17. (copay$ or co-pay$ or cost-shar$ or prepaid or pre-paid or prepay$ or pre-
pay$).ti,ab. 
18. or/5-17 
19. exp Primary Health Care/ [ML] 
20. (primary adj2 care).ti,ab. 
21. Physicians, Family/ [ML] 
22. exp physicians/ [ML] 
23. Family Practice/ [ML] 
24. exp Group practice/ [ML] 
25. ((community or family or general or group) adj2 (doctor? or physician? or 
practice? or practitioner?)).ti,ab. 
26. Partnership practice/ or Private practice/ [ML] 
27. ((partner$ or private) adj (practice? or practitioner?)).ti,ab. 
28. or/19-27 
29. 4 or 18 
30. 28 and 29 
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31. limit 30 to (yr="1990 - 2013" and systematic reviews) 
9.1.2 Embase 
1. (Physician? adj2 Incentiv$ adj (plan? or program or policy)).ti,ab. 
2. ((physician? or practitioner? or doctor?) adj4 (bonus$ or incentive? or financial or 
monetar$ or payment? or profit shar$ or reward? or salar$)).ti,ab. 
3. exp Physicians/ and (incentiv$ adj (economic or financial or monetar$ or 
payment? or reimburs$)).ti,ab,hw. 
4. or/1-3 
5. *Medical fee/ [EM] 
6. *Income/ or *Salary/ or Physician Income/ [EM] 
7. Reimbursement/ or reimburs$.ti. [EM] 
8. *Income/ or *Salary/ or Physician Income/ [EM] 
9. (pay for performance or pay for compliance or pay for participation or 
performance pay$ or P4P or pay for qualityimprovement? or P4QI or fee-for 
service?).ti,ab. 
10. ((doctor? or physician? or general practitioner? or pa?ediatrician?) adj2 (fee? or 
income or salary or salaries)).ti,ab. 
11. ((incentiv$ or bonus$ or reward?) adj (economic or employee? or financ$ or 
insurer? or insurance or managed care or HMO or market$ or monetar$ or payment? 
or performance based or physician? or practitioner? or program$ or provider? or 
reimburs$ or salary or staff or team$ or value-based)).ti,ab. 
12. (reimburs$ adj (disproportion$ or health$ or insurer? or mechanism? or plan$ or 
physician? or practitioner? or program$ or proportion$ or provider? or relative or 
scale? or share? or sharing or value-based or performance-base? or QI or quality or 
scheme?)).ab. 
13. ((compensation or compensatory) adj2 (doctor? or physician? or plan? or 
practitioner? or system?)).ti,ab. 
14. (capitation or capitated or capitating or fundhold$ or fund-hold$).ti,ab. 
15. (rate setting or rate review).ti,ab. 
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16. (gainshar$ or payer-provider? or payer-patient?).ti,ab. 
17. (pay for compliance or pay for participation or pay for performance or 
performance pay$ or P4P or pay for quality improvement? or P4QI or fee-for 
service?).ti,ab. 
18. (payment? adj (blend$ or blue cross or bonus$ or capped or episode of care or 
fixed or government$ or insurance or insurer? or level? or linear or medicaid or 
medicare or non-linear or per-patient or per-episode or per-visit or performance or 
prospectiv$ orretroactiv$ or retrospectiv$ or reward$ or schedule? or system? or 
target$ or third-part$ or threshold? or uncap$ or shared or variableor per-
visit?)).ti,ab. 
19. ((copay$ or co-pay$ or cost-shar$ or prepaid or pre-paid or prepay$ or pre-pay$) 
adj4 (physician? or practitioner? or performance)).ti,ab. 
20. or/5-19 [Incentives] 
21. physician/ or female physician/ or general practitioner/ or pediatrician/ [EM] 
22. (physician? or doctor?).ti. 
23. primary health care/ or primary medical care/ [EM] 
24. (primary adj2 care).ti,ab. 
25. General Practitioner/ [EM] 
26. General Practice/ [EM] 
27. Group practice/ [EM] 
28. ((community or family or general or group) adj2 (doctor? or physician? or 
practice? or practitioner?)).ti,ab. 
29. Private practice/ [EM] 
30. ((partner$ or private) adj (practice? or practitioner?)).ti,ab. 
31. or/21-30 [Practitioners or Primary Care] 
32. 20 and 31 
33. 4 or 32 
34. limit 33 to ("systematic review" and yr="1990 - 2013" and journal) 
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9.1.3 PubMed 
systematic[sb] AND ((financial incentives) AND primary care) 
systematic[sb] AND ((payment mechanisms) AND primary care) 
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9.2 Appendix 2 PRISMA checklist 
Table 9-1 PRISMA checklist details 
Section/Topic Number Checklist item 
TITLE 
Title  1 Identify the report as a systematic review, meta-analysis, or both.  
ABSTRACT 
Structured 
summary  
2 (1) Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
INTRODUCTION 
Rationale  3 (2) Describe the rationale for the review in the context of what is already known.  
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
244 
 
METHODS 
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
Eligibility 
criteria  
6 (3) Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
Information 
sources  
7 (4) Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
Search  8 (5) Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Study selection  9 (6) State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
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simplifications made.  
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).  
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
Risk of bias 
across studies  
15 (7) Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
RESULTS 
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
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Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  
DISCUSSION 
Summary of 24 (8) Summarize the main findings including the strength of evidence for each main outcome; consider their relevance 
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evidence  to key groups (e.g., healthcare providers, users, and policy makers).  
Limitations  25 (9) Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval 
of identified research, reporting bias).  
Conclusions  26 (10) Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
FUNDING 
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
Source:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed100009747 
Checklist items shown in italics represent those selected for the review of reviews in Chapter 2. 
( Question number used in Chapter 2 shown in bold and parentheses) 
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9.3 Appendix 3 Population calculations 
The population percentage figures represent the prevalence of the condition in 
2009/10 based on England population level data published on the HSCIC QOF 
website139 159. If the target applied to a subset of, rather than the whole condition 
population, that percentage figure has been calculated by finding the target 
denominator for that target and dividing it by the denominator of a target that applied 
to the whole condition population. In each instance the blood pressure record target 
has been used for the latter as this is present in all the conditions examined and is 
routinely collected. As before the information to populate these figures was retrieved 
from the HSCIC QOF website139. SHA level data has been used to make these 
calculations as the national level data is not broken down by targets, only by 
condition. This calculation produced the percentage of the condition population 
treated by the QOF targets. The figures in the tables represent the percentage of the 
UK population treated by the QOF target. To produce this figure the result from the 
calculation described above was multiplied by the condition prevalence. This will 
very closely match the actual disease population but not exactly as a small number of 
exception reported patients will have been removed from it. For example the 
population figure for target CHD11 has been calculated as follows: ܵݑ݉݋݂ܥܪܦ ? ?݀݁݉݋݉݅݊ܽݐ݋ݎݏܵݑ݉݋݂ܥܪܦ ?݀݁݊݋݉݅݊ܽݐ݋ݎݏ ൈ ܥ݋݊݀݅ݐ݅݋݊݌ݎ݁ݒ݈ܽ݁݊ܿ݁ 
Where the numerator represents all patients who qualified for the CHD11 target, 
namely all patients with recently diagnosed MI minus those exception reported. 
While the denominator is all those who qualified for the BP record target, which is a 
very close approximation of the condition population, the difference being the 
number of patients exception reported.   
As an illustrative example to show how the figures shown in the table would relate to 
events of interest in HES based on a conservative figure for the HES linked 
population of two million. Assuming an outcome event rate of 5% a year, and that 
the study wanted to be assured of finding at least 3,000 events a year; would require 
a population percentage figure of 3% or more.  
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9.4 Appendix 4 CHD Physician Incentives Search Terms 
9.4.1 Medline  
1. Physician Incentive Plans/ [ML]   
2. ((physician? or practitioner? or doctor?) adj4 (bonus$ or incentive? or financial or 
monetar$ or payment? or profit shar$ or reward? or salar$)).ti,ab.   
3. exp Physicians/ and (incentiv$ adj (economic or financial or monetar$ or 
payment? or reimburs$)).ti,ab,hw. 
4. or/1-3   
5. Fees, Medical/ [ML]  
6. exp Income/ [ML]   
7. insurance, health, reimbursement/ or reimbursement mechanisms/ or fee-for-
service plans/ or physician payment review commission/ or medicare payment 
advisory commission/ or reimbursement, disproportionate share/ or reimbursement, 
incentive/ or relative value scales/ [ML]   
8. ((fees.mp. and charges/) or capitation fee/ or fee-for-service plans/ or fees, 
medical/ or fees, pharmaceutical/ or prescription fees/ or rate setting.mp.) and 
review/ [mp=title, abstract, original title, name of substance word, subject heading 
word, protocol supplementary concept, rare disease supplementary concept, unique 
identifier]   
9. (capitation or capitated or capitating or fundhold$ or fund-hold$).ti,ab.   
10. (rate setting or rate review).ti,ab.   
11. (gainshar$ or payer-provider? or payer-patient?).ti,ab.   
12. ((incentiv$ or bonus$ or reward?) adj (economic or employee? or financ$ or 
insurer? or insurance or market$ or monetar$ or payment? or physician? or 
practitioner? or program$ or provider? or reimburs$ or salary or staff or team$ or 
value-based)).ti,ab.   
13. (reimburs$ adj (disproportion$ or health$ or insur$ or mechanism? or plan$ or 
physician? or practitioner? or program$ or proportion$ or provider? or relative or 
scale? or share? or sharing or value-based or performance-base? or QI or quality or 
scheme?)).ti,ab.   
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14. (pay for compliance or pay for participation or pay for performance or 
performance pay$ or P4P or pay for quality improvement? or P4QI or fee-for 
service?).ti,ab.   
15. (payment? adj (blend$ or blue cross or bonus$ or capped or episode of care or 
fixed or government$ or insurance or insurer? or level? or linear or medicaid or 
medicare or non-linear or per-patient or per-episode or per-visit or performance or 
prospectiv$ or retroactiv$ or retrospectiv$ or reward$ or schedule? or system? or 
target$ or third-part$ or threshold? or uncap$ or shared or variable or per-
visit?)).ti,ab.   
16. ((compensation or compensatory) adj (doctor? or physician? or plan? or 
practitioner? or system?)).ti,ab.  
17. (copay$ or co-pay$ or cost-shar$ or prepaid or pre-paid or prepay$ or pre-
pay$).ti,ab.  
18. or/5-17   
19. myocardial ischemia/ or angina pectoris/ or coronary disease/ or myocardial 
infarction/   
20. 4 or 18   
21. 19 and 20   
22. limit 20 to yr="1990 -Current"  
9.4.2 Embase 
1. *Medical fee/ [EM]   
2. *Income/ or *Salary/ or Physician Income/ [EM]   
3. Reimbursement/ or reimburs$.ti. [EM]  
4. *Income/ or *Salary/ or Physician Income/ [EM]   
5. (pay for performance or pay for compliance or pay for participation or 
performance pay$ or P4P or pay for quality improvement? or P4QI or fee-for 
service?).ti,ab.  
6. ((doctor? or physician? or general practitioner? or pa?ediatrician?) adj2 (fee? or 
income or salary or salaries)).ti,ab.  
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7. ((incentiv$ or bonus$ or reward?) adj (economic or employee? or financ$ or 
insurer? or insurance or managed care or HMO or market$ or monetar$ or payment? 
or performance based or physician? or practitioner? or program$ or provider? or 
reimburs$ or salary or staff or team$ or value-based)).ti,ab.  
8. (reimburs$ adj (disproportion$ or health$ or insurer? or mechanism? or plan$ or 
physician? or practitioner? or program$ or proportion$ or provider? or relative or 
scale? or share? or sharing or value-based or performance-base? or QI or quality or 
scheme?)).ab.  
9. ((compensation or compensatory) adj2 (doctor? or physician? or plan? or 
practitioner? or system?)).ti,ab.  
10. (capitation or capitated or capitating or fundhold$ or fund-hold$).ti,ab.  
11. (rate setting or rate review).ti,ab.  
12. (gainshar$ or payer-provider? or payer-patient?).ti,ab.  
13. (pay for compliance or pay for participation or pay for performance or 
performance pay$ or P4P or pay for quality improvement? or P4QI or fee-for 
service?).ti,ab.  
14. (payment? adj (blend$ or blue cross or bonus$ or capped or episode of care or 
fixed or government$ or insurance or insurer? or level? or linear or medicaid or 
medicare or non-linear or per-patient or per-episode or per-visit or performance or 
prospectiv$ orretroactiv$ or retrospectiv$ or reward$ or schedule? or system? or 
target$ or third-part$ or threshold? or uncap$ or shared or variableor per-
visit?)).ti,ab.  
15. ((copay$ or co-pay$ or cost-shar$ or prepaid or pre-paid or prepay$ or pre-pay$) 
adj4 (physician? or practitioner? or performance)).ti,ab.  
16. or/1-16 [Incentives]  
17. ischemic heart disease/  
18. heart infarction/  
19. 17 or 18 
20. 16 and 19  
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38. limit 20 to yr="1990 -Current"   
9.4.3 PyscINFO   
1. monetary incentives/ or monetary rewards/  
2. incentives/  
3. salaries/ or bonuses/ or income/ or economic/ or income level/ or professional 
fees/  
4. ((incentiv$ or bonus$ or reward?) adj (economic or employee? or financ$ or 
insurer? or insurance or market$ or monetar$ or payment? or physician? or 
practitioner? or program$ or provider? or reimburs$ or salary or staff or team$ or 
value-based)).ti,ab.  
5. (reimburs$ adj (disproportion$ or health$ or insur$ or mechanism? or plan$ or 
physician? or practitioner? or program$ or proportion$ or provider? or relative or 
scale? or share? or sharing or value-based or performance-base? orQI or quality or 
scheme?)).ti,ab.  
6. (pay for compliance or pay for participation or pay for performance or 
performance pay$ or P4P or pay for quality improvement? or P4QI or fee-for 
service?).ti,ab.  
7. (payment? adj (blend$ or blue cross or bonus$ or capped or episode of care or 
fixed or government$ or insurance or insurer? or level? or linear or medicaid or 
medicare or non-linear or per-patient or per-episode or per-visit or performance or 
prospectiv$ or retroactiv$ or retrospectiv$ or reward$ or schedule? or system? or 
target$ or third-part$ or threshold? or uncap$ or shared or variable or per-
visit?)).ti,ab.   
8. ((compensation or compensatory) adj (doctor? or physician? or plan? or 
practitioner? or system?)).ti,ab.  
9. (copay$ or co-pay$ or cost-shar$ or prepaid or pre-paid or prepay$ or pre-
pay$).ti,ab.  
10. (gainshar$ or payer-provider? or payer-patient?).ti,ab.  
11. (rate setting or rate review).ti,ab.  
12. (capitation or capitated or capitating or fundhold$ or fund-hold$).ti,ab.  
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13. fee for service/  
14. reimburs$.ti.  
15. medical fee?.ti,ab. 
16. or/1-15 [Financial Incentives]  
17. exp Heart Disorders/  
18. 16 and 17  
9.4.5 Health Management Information Consortium (HMIC) 
1. exp Coronary diseases/  
2. limit 1 to (abstracts and yr="1990 -Current")    
3. exp Performance indicators/ or exp Performance related pay/ 
4. limit 3 to (abstracts and yr="1990 -Current")   
5. exp payment by results/ 
6. limit 5 to yr="1990 -Current"  
7. 4 or 6 
8. 2 and 7 
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9.5 Appendix 5 Down and Black ranking scale checklist 
Reporting 
1. Is the hypothesis/aim/objective of the study clearly described? 
Yes 1 
No 0 
2. Are the main outcomes to be measured clearly described in the Introduction or 
Methods section? (1) 
If the main outcomes are first mentioned in the Results section, the question should 
be answered no. 
Yes 1 
No 0 
3. Are the characteristics of the patients included in the study clearly described? 
In cohort studies and trials, inclusion and/or exclusion criteria should be given. In 
case-control studies, a case-definition and the source for controls should be given. 
(2) 
Yes 1 
No 0 
4. Are the interventions of interest clearly described? 
Treatments and placebo (where relevant) that are to be compared should be clearly 
described. 
Yes 1 
No 0 
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5. Are the distributions of principal confounders in each group of subjects to be 
compared clearly described? 
A list of principal confounders is provided. 
Yes 2 
Partially 1 
No 0 
6. Are the main findings of the study clearly described? 
Simple outcome data (including denominators and numerators) should be reported 
for all major findings so that the reader can check the major analyses and 
conclusions. (This question does not cover statistical tests which are considered 
below). (3) 
Yes 1 
No 0 
7. Does the study provide estimates of the random variability in the data for the main 
outcomes? 
In non normally distributed data the inter-quartile range of results should be 
reported. In normally distributed data the standard error, standard deviation or 
confidence intervals should be reported. If the distribution of the data is not 
described, it must be assumed that the estimates used were appropriate and the 
question should be answered yes. 
Yes 1 
No 0 
8. Have all important adverse events that may be a consequence of the intervention 
been reported? 
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This should be answered yes if the study demonstrates that there was a 
comprehensive attempt to measure adverse events. (A list of possible adverse events 
is provided). 
Yes 1 
No 0 
9. Have the characteristics of patients lost to follow-up been described? 
This should be answered yes where there were no losses to follow-up or where losses 
to follow-up were so small that findings would be unaffected by their inclusion. This 
should be answered no where a study does not report the number of patients lost to 
follow-up. 
Yes 1 
No 0 
10. Have actual probability values been reported( e.g. 0.035 rather than <0.05) for 
the main outcomes except where the probability value is less than 0.001? (4) 
Yes 1 
No 0 
 
External validity 
All the following criteria attempt to address the representativeness of the findings of 
the study and whether they may be generalised to the population from which the 
study subjects were derived. 
11. Were the subjects asked to participate in the study representative of the entire 
population from which they were recruited? 
The study must identify the source population for patients and describe how the 
patients were selected. Patients would be representative if they comprised the entire 
source population, an unselected sample of consecutive patients, or a random 
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sample. Random sampling is only feasible where a list of all members of the relevant 
population exists. Where a study does not report the proportion of the source 
population from which the patients are derived, the question should be answered as 
unable to determine. 
Yes 1 
No 0 
Unable to determine 0 
12. Were those subjects who were prepared to participate representative of the entire 
population from which they were recruited? 
The proportion of those asked who agreed should be stated. Validation that the 
sample was representative would include demonstrating that the distribution of the 
main confounding factors was the same in the study sample and the source 
population. 
Yes 1 
No 0 
Unable to determine 0 
13. Were the staff, places, and facilities where the patients were treated, 
representative of the treatment the majority of patients receive? 
For the question to be answered yes the study should demonstrate that the 
intervention was representative of that in use in the source population. The question 
should be answered no if, for example, the intervention was undertaken in a 
specialist centre unrepresentative of the hospitals most of the source population 
would attend. 
Yes 1 
No 0 
Unable to determine 0 
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Internal Validity-bias 
14. Was an attempt made to blind study subjects to the intervention they have 
received? 
For studies where the patients would have no way of knowing which intervention 
they received, this should be answered yes. 
Yes 1 
No 0 
Unable to determine 0 
 
15. Was an attempt made to blind those measuring the main outcomes of the 
intervention? 
Yes 1 
No 0 
Unable to determine 0 
 
16. ,IDQ\RIWKHUHVXOWVRIWKHVWXG\ZHUHEDVHGRQ³GDWDGUHGJLQJ´ZDVWKLVPDGH
clear? 
Any analyses that had not been planned at the outset of the study should be clearly 
indicated. If no retrospective unplanned subgroup analyses were reported, then 
answer yes. 
Yes 1 
No 0 
Unable to determine 0 
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17. In trials and cohort studies, do the analyses adjust for different lengths of follow-
up of patients, or in case-control studies, is the time period between the intervention 
and outcome the same for cases and controls ?  
Where follow-up was the same for all study patients the answer should yes. If 
different lengths of follow-up were adjusted for by, for example, survival analysis the 
answer should be yes. Studies where differences in follow-up are ignored should be 
answered no. (5) 
Yes 1 
No 0 
Unable to answer 0 
18. Were the statistical tests used to assess the main outcomes appropriate? 
The statistical techniques used must be appropriate to the data. For example 
nonparametric methods should be used for small sample sizes. Where little statistical 
analysis has been undertaken but where there is no evidence of bias, the question 
should be answered yes. If the distribution of the data (normal or not) is not 
described it must be assumed that the estimates used were appropriate and the 
question should be answered yes. (6) 
Yes 1 
No 0 
Unable to answer 0 
19. Was compliance with the intervention/s reliable? 
Where there was non compliance with the allocated treatment or where there was 
contamination of one group, the question should be answered no. For studies where 
the effect of any misclassification was likely to bias any association to the null, the 
question should be answered yes. 
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Yes 1 
No 0 
Unable to answer 0 
20. Were the main outcome measures used accurate (valid and reliable)? 
For studies where the outcome measures are clearly described, the question should 
be answered yes. For studies which refer to other work or that demonstrates the 
outcome measures are accurate, the question should be answered as yes. (7) 
Yes 1 
No 0 
Unable to answer 0 
 
Internal validity - confounding (selection bias) 
21. Were the patients in different intervention groups (trials and cohort studies) or 
were the cases and controls (case-control studies) recruited from the same 
population? (8) 
For example, patients for all comparison groups should be selected from the same 
hospital. The question should be answered unable to determine for cohort and case 
control studies where there is no information concerning the source of patients 
included in the study. 
Yes 1 
No 0 
Unable to answer 0 
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22. Were study subjects in different intervention groups (trials and cohort studies) or 
were the cases and controls (case-control studies) recruited over the same period of 
time? (9) 
For a study which does not specify the time period over which patients were 
recruited, the question should be answered as unable to determine. 
Yes 1 
No 0 
Unable to answer 0 
23. Were study subjects randomised to intervention groups? 
Studies which state that subjects were randomised should be answered yes except 
where method of randomisation would not ensure random allocation. For example 
alternate allocation would score no because it is predictable. 
Yes 1 
No 0 
Unable to answer 0 
24. Was the randomised intervention assignment concealed from both patients and 
health care staff until recruitment was complete and irrevocable? 
All non-randomised studies should be answered no. If assignment was concealed 
from patients but not from staff, it should be answered no. 
Yes 1 
No 0 
Unable to answer 0 
25. Was there adequate adjustment for confounding in the analyses from which the 
main findings were drawn? 
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This question should be answered no for trials if: the main conclusions of the study 
were based on analyses of treatment rather than intention to treat; the distribution of 
known confounders in the different treatment groups was not described; or the 
distribution of known confounders differed between the treatment groups but was not 
taken into account in the analyses. In nonrandomised studies if the effect of the main 
confounders was not investigated or confounding was demonstrated but no 
adjustment was made in the final analyses the question should be answered as no. 
(10) 
Yes 1 
No 0 
Unable to answer 0 
26. Were losses of patients to follow-up taken into account? 
If the numbers of patients lost to follow-up are not reported, the question should be 
answered as unable to determine. If the proportion lost to follow-up was too small 
to affect the main findings, the question should be answered yes. 
Yes 1 
No 0 
Unable to answer 0 
 
Power 
27. Did the study have sufficient power to detect a clinically important effect where 
the probability value for a difference being due to chance is less than 5%? 
Sample sizes have been calculated to detect a difference of x% and y%. 
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 Size of smallest intervention group  
A ൏ ݊ଵ 0 
B ݊ଵ െ ݊ଶ 1 
C ݊ଷ െ ݊ସ 2 
D ݊ହ െ ݊଺ 3 
E ݊଻ െ ଼݊ 4 
F ଼݊ ൅ 5 
Source110 
Questions selected for ranking scale used in Chapter 4 are shown in italics 
(Question number used in Chapter 4 shown in bold and parentheses) 
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9.6 Appendix 6 CHD QOF Search Terms 
9.6.1 PsycInfo 
1. exp Heart Disorders/ 
2. Quality Outcome* Framework.mp. 
3. QOF.mp. 
4. P4P.mp. 
5. Pay for performance.mp. 
6. 2 or 3 or 4 or 5 
7. 1 and 6 
9.6.2 Medline  
1. Coronary Disease/ 
2. Quality Outcome* Framework.mp. 
3. QOF.mp. 
4. P4P.mp. 
5. Pay for performance.mp. 
7. 2 or 3 or 4 or 5 
8. 1 and 7 
9. limit 8 to yr="2004 -Current" 
9.6.3 HMIC  
1. exp Coronary diseases/ 
2. Quality Outcome* Framework.mp. 
3. QOF.mp. 
4. P4P.mp. 
5. Pay for performance.mp. 
6. 2 or 3 or 4 or 5 
7. 1 and 6 
8. limit 7 to yr="2004 -Current" 
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9.6.4 Embase   
1. ischemic heart disease/ 
2. Quality Outcome* Framework.mp. 
3. Pay for performance.mp. 
4. P4P.mp. 
5. QOF.mp. 
6. 2 or 3 or 4 or 5 
7. 1 and 6 
8. limit 7 to yr="2004 -Current" 
9.6.5 ISI Web of Knowledge 
Topic=(Quality ADJ outcome* ADJ framework) AND Topic=(Coronary Heart 
Diseases) 
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9.7 Appendix 7 Codes used in the study 
9.7.1 Codes used to define the CHD population  
Table 9-2 lists all the qualifying Read and medical codes for the CHD study 
population a description of what each Read terms relate to.  
Table 9-2 CPRD CHD Read and Medcodes 
Medcode Readcode Readterm 
241 G30..00 Acute myocardial infarction 
1204 G30..14 Heart attack 
1430 G33..00 Angina pectoris 
1431 G311.13 Unstable angina 
1677 G30..15 MI - acute myocardial infarction 
1678 G308.00 Inferior myocardial infarction NOS 
2491 G30..12 Coronary thrombosis 
3704 G307.00 Acute subendocardial infarction 
4656 G311.11 Crescendo angina 
5387 G301.00 Other specified anterior myocardial infarction 
7320 G343.00 Ischaemic cardiomyopathy 
8935 G302.00 Acute inferolateral infarction 
9507 G307000 Acute non-Q wave infarction 
10562 G307100 Acute non-ST segment elevation myocardial infarction 
12139 G300.00 Acute anterolateral infarction 
13566 G30..11 Attack - heart 
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13571 G30..16 Thrombosis - coronary 
14658 G30z.00 Acute myocardial infarction NOS 
14897 G301z00 Anterior myocardial infarction NOS 
14898 G305.00 Lateral myocardial infarction NOS 
17689 G30..17 Silent myocardial infarction 
17872 G301100 Acute anteroseptal infarction 
18842 G35..00 Subsequent myocardial infarction 
23892 G304.00 Posterior myocardial infarction NOS 
24126 G360.00 Haemopericardium/current comp folow acut myocard 
infarct 
25842 G33z.00 Angina pectoris NOS 
28736 G30y000 Acute atrial infarction 
29421 G344.00 Silent myocardial ischaemia 
29553 G366.00 Thrombosis atrium,auric append&vent/curr comp foll 
acute MI 
29643 G303.00 Acute inferoposterior infarction 
29758 G30X.00 Acute transmural myocardial infarction of unspecif 
site 
29902 G330z00 Angina decubitus NOS 
30330 G309.00 Acute Q-wave infarct 
30421 G30..13 Cardiac rupture following myocardial infarction (MI) 
32272 G38..00 Postoperative myocardial infarction 
268 
 
32854 G30B.00 Acute posterolateral myocardial infarction 
34803 G30y.00 Other acute myocardial infarction 
36523 G311.00 Preinfarction syndrome 
36609 G342.00 Atherosclerotic cardiovascular disease 
38609 G351.00 Subsequent myocardial infarction of inferior wall 
39546 Gyu3000 [X]Other forms of angina pectoris 
40429 G301000 Acute anteroapical infarction 
41221 G30y200 Acute septal infarction 
41835 G384.00 Postoperative subendocardial myocardial infarction 
45809 G350.00 Subsequent myocardial infarction of anterior wall 
46017 G30yz00 Other acute myocardial infarction NOS 
46112 G380.00 Postoperative transmural myocardial infarction 
anterior wall 
46166 G35X.00 Subsequent myocardial infarction of unspecified site 
46276 G381.00 Postoperative transmural myocardial infarction inferior 
wall 
52517 Gyu3.00 [X]Ischaemic heart diseases 
62626 G30y100 Acute papillary muscle infarction 
63467 G306.00 True posterior myocardial infarction 
68748 G38z.00 Postoperative myocardial infarction, unspecified 
72562 G353.00 Subsequent myocardial infarction of other sites 
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9.7.2 Codes for MI, co-morbidities and smoking cessation 
A number of other searches were done in CPRD on co-morbidities of interest, to 
determine if and when the CHD population was coded for that condition. The details 
of these codes are given in Table 9-3. 
Table 9-3 CPRD Read and Medcodes for MI, co-morbidities and smoking cessation 
Condition Read codes v2 Medcodes 
Diabetes C10E.% 
C10F.% 
(excluding 
C10F8) 
758,1549,1407,18390,10692,26054,22884,12640,
18496,25627,47954,51261,32627,30323,10418, 
18387,30294,34450,35288,12455,40837,25591, 
18777,53392,18425,34268,35385,44982,55239, 
49074,64668,39070,47315,60796,47321,63690, 
62674,22871,46917,18683,54008,69676,95636, 
12736,43921,47582,49655,40682,47650,37806, 
5267,51756,42831,59253,62209,46301,47649, 
49554,45276,18642,43227,69993,96235,97849, 
49949,54600,57278,68105,85991,91646,93875, 
93878,95343,95351,102112,50527,62613,72702, 
91942,93468,95539,99719,100964,66145,91943, 
93727,97894,98071,98616,98704,98723,99311, 
99716,100770,101311,101735,102163,102201, 
102620 
Atrial 
Fibrillation 
3272.  
8H41.  
8H44.  
8HR1.  
8H4R.  
1664, 2212, 1268, 23437, 96076, 96277, 35127 
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8HVJ. 
Hypertension G2...  
G20..%  
G24.. - G2z.. 
(Excluding 
G24z1) 
799,204,351,10818,3712,7057,1894,8732, 
4372,16292,15377,7329,4668,8857,18765, 
29310,16059,16173,17434,83473,15106, 
34744,31387,42229,39649,31464,32423, 
25371,57288,31755,28684,61166,51635, 
43935,62718,21837,63466,52427,50157, 
52127,59383,61660,57987,68659,73293, 
63000,67232,95334,72668 
Stroke G61..% 
(excluding 
G617.)  
G63y0 - 
G63y1  
G64..%  
G66..%  
G6760  
G6W..  
G6X..  
G65..- G654.  
G656.- G65zz  
F4236 
1469,504,1433,1298,5363,3149,8837,6116,1195, 
5051,6960,2417,5268,15788,3132,5602,569,7780,
12833,16517,6253,6155,10794,3535,18604,15019
,9985,10504,17322,13564,23942,33543,8443, 
23671,25615,36717,26424,23465,15252,18689, 
5185,33499,24446,19260,7912,19280,53745, 
40758,39344,19354,40338,28314,27975,19201, 
51767,31595,46316,34758,31060,44765,91627, 
47642,57315,30045,53810,92036,94482,62342, 
90572,50594,96630 
Heart Failure G58..%  
G1yz1  
662f. ± 662i. 
398,884,2062,2906,4024,1223,5942,13189, 
18853,5255,19066,32671,10079,9524,17278, 
10154,27964,23481,23707,27884,51214,11424, 
22262,43618,12590,94870,101138,101137 
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Rheumatoid 
Arthritis 
N040.00 
N04..00 
N040S00 
N040N00 
N040Q00 
844,27603,31054,30548,18155 
 
Smoking 
cessation 
6791.  
67A3.  
67H6.  
8B2B.  
8CAL.  
8HkQ.  
8HTK.  
13p..%  
9OO..%  
9N4M.  
9N2k.  
8H7i.  
67H1.  
8B3Y.  
8B3f.  
745H.%  
8IAj.  
2111,7130,7622,9833,10184,10211,10742,10898,
11356,11527,12953,18573,18926,19485,21637, 
28834,28886,32083,32572,34126,34127,34374, 
38112,40417,40418,41405,42722,53101,58597, 
60720,63901,66387,74907,81440,85247,85975, 
89464,90522,91708,94958,98137,98154,100099, 
101764 
CHD 
Myocardial 
Infarction 
G30..% 
(Excluding 
G30A.) 
241,14658,1677,1678,1204,2491,3704, 
14897,5387,12139,8935,17872,9507,23892, 
14898,1357,29643,17689,46017,18842, 
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codes  
 
G35..% 
G38..% 
Gyu34 
13566,32272,34803,30421,41221,29758, 
30330,40429,28736,38609,45809,63467, 
32854,41835,46276,68748,46166,46112, 
72562,62626,96838,10562 
9.7.3 Codes for QOF prescription targets 
In table 9-4 are the BNF codes used for each of the prescribing targets along with the 
product codes which qualified under the BNF code. 
 Table 9-4 CPRD BNF and Product codes: Prescriptions 
BNF Header BNF 
code 
Product codes 
Beta-blockers 18 5;24;26;197;220;297;472;581;594;599;707;739;751;753; 
769;786;817;822;940;1006;1048;1050;1124;1288;1290; 
1295;1333;1334;1448;1572;1597;1684;1788;2361;2414; 
2432;2499;2587;2590;2629;2775;2780;3005;3087;3167; 
3344;3474;3516;3526;3588;3691;3748;3827;4004;4025; 
4265;4410;4429;4542;4588;4605;4725;4771;4796;4983; 
5284;5330;5478;5713;5721;5858;5968;6066;6751;7049; 
7066;7091;7429;7474;7528;7543;7553;7620;7852;7853; 
7974;8023;8061;8068;8071;8113;8147;8172;8189;8262; 
8290;8331;8369;8555;8623;8642;8673;8707;8807;8935; 
8978;8987;9016;9143;9178;9185;9273;9292;9783;10191; 
10294;10429;10627;10716;10777;10892;11338;11380; 
11711;11793;12037;12054;12141;12296;12456;12495; 
12517;12519;12651;13051;13394;13415;13487;13499; 
13526;13871;14030;14057;14058;14117;14126;14146; 
14438;14502;14552;14673;14808;15042;15117;15176; 
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15488;15619;15730;16645;16776;16786;17082;17149; 
17322;17462;17615;17679;17783;18185;18287;18414; 
18743;18950;19055;19068;19142;19172;19178;19182; 
19191;19200;19202;19437;19853;19858;19998;20012; 
20082;20093;20169;20468;20502;20728;21025;21133; 
21182;21838;21839;21866;21873;21885;21905;21966; 
22208;22793;22912;23131;23134;23326;23587;24083; 
24094;24191;24195;24218;24280;24461;24635;24832; 
25359;25363;25367;25462;25644;25730;26211;26228; 
26229;26248;26255;26529;26741;26895;26922;27357; 
27486;27700;27719;27727;27946;27964;28048;28128; 
28177;28700;28788;28996;29180;29230;29368;29398; 
29427;29610;29762;29763;29827;29998;30400;30519; 
30541;30636;30770;31214;31470;31536;31708;31776; 
31833;31934;32094;32114;32135;32162;32552;32630; 
32787;32836;33079;33085;33092;33184;33374;33376; 
33569;33578;33602;33644;33650;33657;33659;33836; 
33839;33850;33909;34012;34034;34092;34094;34125; 
34171;34177;34185;34188;34208;34214;34265;34365; 
34371;34378;34407;34430;34443;34449;34492;34501; 
34509;34520;34575;34584;34585;34600;34640;34690; 
34695;34740;34741;34754;34783;34804;34821;34825; 
34854;34867;34868;34882;34884;34890;34899;34925; 
34945;34949;34963;34976;35054;35062;35695;35710; 
35778;35938;35940;36261;36576;36603;37118;37725; 
37837;38370;38433;38498;38991;39233;39423;39646; 
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39819;39846;40167;40240;40241;40761;41555;41572; 
41591;41740;41827;42152;42795;43251;43525;43549; 
43564;44000;44083;44808;44858;45250;45289;45297; 
45309;45343;45494;45765. 
Aspirin; Anti-
platelets; Anti- 
coagulants; 
Dipyridamole; 
Clopidogrel 
15 
196 
912 
918 
919 
3;16;34;45;61;254;377;393;434;489;572;657;689;714;771;
833;836;1049;1137;1781;1814;1902;2105;2106;2607;2628
;3832;4446;4679;5305;5882;6006;6007;6262;6666;6696; 
7516;8185;8186;8466;8467;8645;9144;9301;9939;10031; 
10305;11977;13348;13501;13502;13503;13504;13505; 
13644;13882;15006;15376;16597;17130;17449;17704; 
17920;17965;18030;18217;18329;19189;21019;21380; 
21382;21921;21989;22138;22232;22618;23078;23488; 
23593;23878;23932;24025;24960;25232;25284;25335; 
25718;28810;29759;29848;30202;30203;30554;30920; 
30975;30976;31192;31210;31211;31511;31858;31870; 
31937;31938;31953;31954;31956;32036;32210;32992; 
33293;33320;33656;33662;33668;33676;33711;33877; 
34019;34086;34087;34088;34095;34299;34309;34385; 
34386;34416;34417;34418;34434;34485;34517;34526; 
34576;34611;34666;34691;34709;34758;34762;34796; 
34797;34864;34918;34942;35108;35809;36099;36521; 
36543;37541;38041;38044;38349;38998;39119;39444; 
39503;39639;39738;39755;39866;39932;40114;40143; 
40144;40381;40591;40913;41229;41512;41569;41594; 
41766;42474;42750;43060;43407;43408;43409;43434; 
43530;43655;43679;43709;43806;44639;44866;45576; 
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45643. 
ACE 
inhibitors; 
Angiotensin II 
antagonist 
5 
142 
65;69;78;80;82;97;147;196;277;448;520;529;531;575;593;
624;633;654;709;756;761;764;828;1021;1121;1143;1144; 
1293;1299;1520;1780;1807;1904;2971;2982;3069;3203; 
3222;3310;3720;3839;3929;4103;4155;4226;4540;4571; 
4645;4685;4741;4818;5013;5047;5117;5159;5189;5275; 
5612;5723;5735;5800;5861;5988;6078;6200;6217;6243; 
6261;6285;6288;6314;6351;6359;6362;6364;6408;6437; 
6468;6518;6765;6786;6794;6806;6807;6877;6939;7043; 
7314;7338;7419;8025;8026;8105;8106;8268;8800;8830; 
9196;9646;9693;9731;9745;9764;9915;9948;10316;10323;
10882;10902;11133;11197;11251;11252;11348;11351; 
11448;11469;11526;11561;11567;11641;11864;11937; 
11965;11983;11987;12313;12411;12412;12574;12815; 
12836;12858;12874;13026;13123;13589;13755;13821; 
14228;14283;14387;14477;14478;14738;14870;14943; 
14960;14965;14983;15031;15085;15096;15108;15121; 
15135;15605;15958;16060;16161;16196;16197;16212; 
16285;16371;16701;16708;16710;16924;17006;17120; 
17474;17545;17624;17633;17655;17686;17689;18200; 
18202;18219;18223;18263;18269;18325;18903;18910; 
19198;19204;19208;19223;19690;20117;20188;20579; 
20849;20975;21053;21162;21231;21423;21943;22439; 
22708;23252;23456;23478;23642;24041;24268;24359; 
24482;24484;24632;25382;25998;26995;27520;27871; 
28127;28438;28486;28586;28724;28725;28820;28902; 
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29130;29530;29627;29634;30039;30921;31072;31307; 
31587;31716;31810;32048;32166;32241;32514;32560; 
32597;32857;32934;33057;33078;33095;33336;33353; 
33646;33811;33894;33977;34357;34382;34390;34400; 
34412;34429;34431;34432;34453;34471;34490;34505; 
34528;34539;34540;34544;34562;34567;34583;34589; 
34651;34652;34657;34696;34698;34710;34712;34719; 
34732;34768;34798;34799;34877;34893;34936;34937; 
34943;34952;34953;35007;35096;35173;35174;35189; 
35196;35302;35304;35317;35329;35343;35380;35481; 
35697;35731;35794;36742;36753;36939;37080;37087; 
37573;37650;37655;37710;37747;37778;37908;37930; 
37964;37965;37971;37978;38026;38034;38285;38308; 
38367;38395;38459;38510;38854;38889;38899;38995; 
39021;39137;39147;39199;39227;39242;39355;39421; 
39512;39786;39944;39984;40316;40355;40384;40571; 
40639;40668;40711;41203;41205;41232;41417;41522; 
41532;41538;41573;41617;41633;41694;41743;41746; 
42081;42285;42723;42894;42901;42902;42908;43012; 
43322;43411;43412;43413;43416;43418;43432;43507; 
43563;43566;43649;43813;43915;44527;44657;44778; 
45217;45228;45264;45300;45319;45324;45337;45340; 
45554;45600. 
 
277 
 
9.7.4 ICD 10 codes used in HES 
9.7.4.1 Codes for outcome variable name miadmis  
I21.0 Acute transmural myocardial infarction of anterior wall  
I21.1 Acute transmural myocardial infarction of inferior wall  
I21.2 Acute transmural myocardial infarction of other sites  
I21.3 Acute transmural myocardial infarction of unspecified site  
I21.4 Acute subendocardial myocardial infarction  
I21.9 Acute myocardial infarction, unspecified  
I22.0 Subsequent myocardial infarction of anterior wall  
I22.1 Subsequent myocardial infarction of inferior wall  
I22.8 Subsequent myocardial infarction of other sites  
I22.9 Subsequent myocardial infarction of unspecified site  
I23.0 Haemopericardium as current complication following acute myocardial 
infarction  
I23.1 Atrial septal defect as current complication following acute myocardial 
infarction  
I23.2 Ventricular septal defect as current complication following acute myocardial 
infarction  
I23.3 Rupture of cardiac wall without haemopericardium as current complication 
following acute myocardial infarction  
I23.4 Rupture of chordae tendineae as current complication following acute 
myocardial infarction  
I23.5 Rupture of papillary muscle as current complication following acute 
myocardial infarction  
I23.6 Thrombosis of atrium, auricular appendage, and ventricle as current 
complications following acute myocardial infarction  
I23.8 Other current complications following acute myocardial infarction 
278 
 
9.7.4.2 Codes for outcome variable emang  
I20.0 Unstable angina  
I20.1 Angina pectoris with documented spasm  
I20.8 Other forms of angina pectoris  
I20.9 Angina pectoris, unspecified  
I24.0 Coronary thrombosis not resulting in myocardial infarction  
I24.1 Dressler's syndrome  
I24.8 Other forms of acute ischaemic heart disease 
I24.9 Acute ischaemic heart disease, unspecified 
I25.0 Atherosclerotic cardiovascular disease, so described  
I25.1 Atherosclerotic heart disease  
I25.6 Silent myocardial ischaemia  
I25.8 Other forms of chronic ischaemic heart disease  
Variable name, alladmis, combines these two variables, forms the main outcome 
measure and is a count of all poor outcomes. 
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9.8 Appendix 8 Study variables ruleset 
Details on how QOF target and outcomes variables were created are provided in 
Chapter 6. Details on how the databases were used to create the remaining variables 
are detailed in the Table 9-5. These follow the same protocols set out in Chapter 6 
namely: 
x The absence of a record of an event is interpreted as meaning the event did not 
take place 
x The targets applied to the whole study population except where specified 
x Outcomes measured in HES had to take SODFH SULRU WR WKH SDWLHQW¶V GHDWK RU
transfer out date and when their practice was up to standard. 
Table 9-5 Remaining study variables ruleset 
Variable  CPRD/HES Ruleset 
age Created using Birth year, yob, variable in CPRD. This figure was 
subtracted from 1999 to create an age prior to the study start. To this 
figure the study year (1 to 11) was added for each year the patient was 
present on the database to give their age at that point 
gender This is recorded in the patient file and mapped to the SEX lookup file 
Years With the exception of Year 1 which spanned 15 months, 01/01/2000 
to 31/03/2001, it refers to a 12 month 01 April to 31 March the 
following year period. The year figure relates to the date the event 
measured took place or the period the patient had CHD. 
Denominator All patients in the study population 
Exclusions An event recorded prior to the patient having a Read code for CHD 
7KHSDWLHQWV¶practice was not up to standard 
It did not occur in the patients current registration period 
The event occurred after the patients recorded transfer out or death 
date 
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Missing data Where the date of the event was missing the system date was used in 
its SODFHSURYLGLQJLWZDVLQWKHSDWLHQW¶VFXUUHQWUHJLVWUDWLRQDQGWKH
practice up to standard period. 
ACE At least one prescription for an ACE inhibitor or Angiotension II 
antagonist (bnfcodes 5 or 142) recorded in the therapy file in the last 
six months of a QOF year.  
HF, AF, 
RA, DM, 
Hyper, 
CKD, STIA 
These are separate variables which show whether or not the CHD 
population had Heart Failure (HF), Atrial Fibrillation (AF), 
Rheumatoid Arthritis (RA), Diabetes (DM), Hypertension (Hyper), 
Chronic Kidney Disease (CKD), and Stroke and Transient Ischaemic 
Attack (STIA). They were generated by a search on the define tool for 
disease specific medcodes which related to QOF Read codes for the 
conditions. In the case of RA, which is not in the QOF, the Read 
codes were determined by searching for Rheumatoid in the Read term 
in the Medical browser 
Exclusions None matched study years, namely, periods prior to first CHD coding 
newMI This relates to a newly diagnosed MI. In the pre-QOF  period this 
relates to a diagnosis after 01/04/1999 in the post QOF period to a 
diagnosis after 01/04/2003 
Denominator All patients in the study population 
Exclusions Any subsequent MI code after the first code 
First code prior to 01/04/1999 in the pre QOF period 
First code prior to 01/04/2003 in the QOF period 
Missing data Assumed no diagnosis had been made 
Region This shows which of the ten strategic health authorities (SHA) in 
England, created by the reorganisation of 6+$¶V LQ -XO\  WKH
SDWLHQW¶V SUDFWLFH UHVLGHV LQ ,W LV UHFRUGHG LQ WKH SUDFWLFH ILOH DQG
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mapped to the PRG lookup file 
pracatt 7KLVLVDPHDQSHUFHQWDJHILJXUHIRUWKHSUDFWLFH¶V42)SHUIRUPDQFH
It has been created by adding the percentage of their patients who met 
the seven QOF targets that are examined, and dividing it by the total 
number of targets, 7. This variable was also separated into quintiles 
based on all practice years figures, variable name pracattq, to see if 
effects were more evident between categories  
Denominator All patients present on the database that belong to that practice 
size This is the total number of patients within the practice for each study 
year. It has also been broken down into quintiles to create the 
variable, sizeq. 
Denominator All patients registered to that practice in CPRD based on Feb 2012 
upload 
workld This is a measure of GP workload in a practice. It was calculated by 
dividing the number of patients present in the practice for each year 
(size variable) by the number of staff given a GP grade. These are 
staff given the following codes: 1, Senior Partner; 2, Partner; 8, GP 
registrar; 10, Sole Practitioner; and 47, Salaried Partner, in the role 
field of the staff file. Staffs with these codes were then matched 
across the clinical, test, therapy and referral files to determine the 
QXPEHU RI *3¶V DFWLYH RYHU each of the study years. The workload 
variable generated was also split into quintiles based on aggregate 
workload data for all practice years to produce the variable workldq 
Denominator All staff present in the database for the specific year given the GP 
codes identified above  
IMD This is a measure of deprivation using the IMD 2007 algorithm using 
the most up to date data on all my study population at the point of 
request, March 2012  
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Missing data Given a missing value code 
Smoker A current smoker QOF Read code recorded in the clinical file 
MIpre This records whether or not an MI primary diagnosis by 
KRVSLWDOLVDWLRQ RFFXUUHG RQ RU EHIRUH WKH VDPH GD\ DV WKH SDWLHQW¶V
first CHD Read code. These were created following the same rules as 
those for the miadmis outcome variable. As these occurred prior to or 
RQ WKH ILUVW 42) 5HDG FRGH GDWH EHIRUH WKH SDWLHQW¶V VWXG\ SHULRG
they were not recorded in the miadmis variable. 
Angpre This records whether or not a non MI primary diagnosis for an 
emergency hospitalisation, occurred on or before the same day as the 
SDWLHQW¶V ILUVW &+' 5HDG FRGH These were created following the 
same rules as those for the emang outcome variable. As these 
occurred prior to or on the first QOF Read code date, before the 
SDWLHQW¶VVWXG\SHULRGWKH\ZHUHQRWUHFRUGHGLQWKHemang variable. 
Hospre This is formed from the variables MIpre and Angpre and shows 
whether or not the patient had one of these events prior to their entry 
into the study 
Table 9-6 details how the study variables are recorded in the study dataset.  
Table 9-6 Variable labels and formats 
Name Label Format 
DEPENDENT VARIABLE 
alladmis All hospital admissions Count (0-13) 
This consists of the sum of the following two measures 
miadmis MI admission post QOF CHD coding Count (0-8) 
emang Emergency angina admission post 
QOF CHD coding 
Count (0-13) 
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EXPLANATORY VARIABLES 
gender Gender Binary (Female/Male) 
age Age in Years Continuous 
BP Met QOF BP target Binary (No/Yes) 
Chol Met QOF Cholesterol target Binary (No/Yes) 
BB Met QOF BB prescription target Binary (No/Yes) 
Anti Met QOF Aspirin, anticoagulant or 
anti-platelet prescription target 
Binary (No/Yes) 
Acea2q Met QOF ACEI/A2 prescription 
target 
Binary (No/Yes) 
Smcess Met QOF smoking cessation target Binary (No/Yes) 
Smoker Current Smoker Binary (No/Yes) 
Smokstat Smoking status Nominal categorical (1 Never 
smoked, 2 Ex, 3 Current) 
Years Year in study Ordered categorical (1, 
2000/01 to 11, 2010/11) 
ACE Received ACEI or A2 in the previous 
6 months 
Binary (No/Yes) 
MI QOF Read code for MI Binary (No/Yes) 
HF QOF Read code for HF Binary (No/Yes) 
AF QOF Read code for AF Binary (No/Yes) 
Diab QOF Read code for Diabetes Binary (No/Yes) 
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Hyper QOF Read code for Hypertension Binary (No/Yes) 
CKD QOF Read code for CKD Binary (No/Yes) 
RA Read code for Rheumatoid Arthritis Binary (No/Yes) 
size Practice size (Patient numbers) Continuous 
sizeq Practice size in quintiles Ordered categorical (1-5) 
workld Practice GP workload Continuous 
workldq Practice GP workload in quintiles Ordered categorical (1-5) 
pracatt Practice QOF attainment Continuous (%) 
pracattq Practice QOF attainment in quintiles Ordered categorical (1-5) 
IMD Index of Multiple Deprivation 2007 Ordered categorical (0-4) 
Region SHA Region Nominal categorical (1-10) 
MIpre Had an MI hospital admission prior 
to CHD coding 
Binary (No/Yes) 
Angpre Had an emergency angina hospital 
admission prior to CHD coding 
Binary (No/Yes) 
Hospre Had one of the outcomes of interest 
(MIpre or Angpre) prior to CHD 
QOF coding 
Binary (No/Yes) 
All of the explanatory variables are expected to explain some of the variance in the 
outcome variable, hence their inclusion in the study dataset. The expected direction 
of that relationship and the reason behind it is explained in Table 9-7.  The +/- 
column shows prior expectations of the variables regression coefficient, namely its 
expected relationship with the dependent variable. A positive means that the 
dependent variable should increase as the variable increases or moves from zero to 
one. A negative signifies the reverse. In the case of Region both are shown as while 
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it is expected that certain regions will be associated with higher counts it is 
impossible to be certain for all regions, and will depend on which region is used as 
the baseline.  
Table 9-7 Explanatory variables-expected relationship with dependent variables with 
rationale 
Name +/- Explanation 
gender   + Prior to menopause CHD is two to five times less common in 
females than males160. Although the risk of CHD increases 
markedly in post menopausal women, the risk of CHD 
increases with age in males also so there remains a noticeable 
difference in risk of CHD between the genders160 161.  Once 
diagnosed with CHD men have a high risk of mortality from 
CHD relative to females with CHD162 
age + As the body ages, fatty deposits accumulate on the lining of the 
coronary arteries increasing the risk of CHD and its 
progression160. Therefore the risk of adverse CHD events 
should increase with age. 
BP - As all the targets have been selected on the basis of high level 
clinical evidence, it is expected that patients who meet these 
targets will have fewer of the study outcomes. 
 
Chol - 
BB - 
Anti - 
Acea2q - 
Smcess - 
Smoker + Smoking is a risk factor for cardiovascular disease, but one that 
mitigates when someone ceases to smoke, even in those who 
have done so for long periods88. Hence smokers are expected to 
be at higher risk of adverse outcomes relative to ex smokers 
Smokstat + 
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whom have a higher risk relative to non smokers. 
Years - It is expected, particularly following the QOF, that as better 
care has become incentivised and embedded, that the number of 
outcomes has fallen. 
ACE - ACE inhibitors/A2 antagonists have wider benefits in 
preventing disease progression in CHD patients, outside of 
those who have had an MI: In particular in those with elevated 
blood pressure. Therefore there is expected to be a reduction in 
adverse outcomes in patients receiving these products73 87 163.  
HF + The presence of these co-morbidities means the patient is likely 
to be in poorer health increasing odds of disease specific 
complications, CHD among them. Furthermore they are all 
cardiovascular diseases, or in the case of rheumatoid arthritis 
and diabetes risk factors for cardiovascular disease154; and 
hence are themselves stand alone risk factors for the study 
outcomes. 
AF + 
Diab + 
Hyper + 
CKD + 
Arth + 
size - The balance of evidence tends to show that larger practices 
have the ability to provide a greater package of care and 
therefore have better patient outcomes164 sizeq - 
MIpre + Having an MI prior to the study is expected to increase the odds 
of poor outcomes because the patient will have suffered 
irreparable damage to heart muscle tissue, thereby increasing 
the likelihood of subsequent coronary events89. 
Angpre + Although this is a less serious event than an MI, it is still a 
reflection of disease progression and will therefore increase the 
chances of another event or progression onto MI89.   
Hospre + See Angpre and MIpre above for reasons 
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workld + While not totally reflective of care as nurses are commonly 
used in the delivery of the QOF, it expected that there will be 
some trade off between the quality of a consultation and the 
workload of a GP. In the sense that a GP with a higher 
workload will have less time to devote to a consultation, and 
getting to know their patient needs,  and is therefore more likely 
to offer worse care and have poorer outcomes, than a GP who 
has a lower workload. 
workldq + 
pracatt - A higher overall score on the QOF targets is taken to be an 
indication that the practice provides good care and therefore it 
is expected that patients in these practices will have better 
outcomes as a result 
pracattq - 
IMD + Patients in more deprived quintiles will have poorer outcomes 
as unemployment, morbidity, poor housing, crime, income and 
WKHOLYLQJHQYLURQPHQWDOO LPSDFWRQDQLQGLYLGXDO¶VTXDOLW\RI
life, and their health165 166. There is evidence that the QOF has 
reduced inequalities in outcomes but that having a lower socio-
economic status is still associated with poorer health 
outcomes13 157 167 
Region +/- This variable uses the 10 English Strategic Health Authorities 
6+$¶VFUHDWHGLQ-XO\ZKLFKUHSODFHGWKH previous 28. 
As these cover large areas with a heterogeneous population it is 
difficult to be specific on expected effects. Nonetheless it is 
expected to show differences across the regions, with areas like 
the North West and North East having comparatively poor 
outcomes compared to the generally more affluent South East 
and South West. 
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9.9 Appendix 9 Regression model specifications 
9.9.1 Negative binomial 
The negative binomial is used to model count data, and is employed in preference to 
the Poisson when the equal dispersion restriction imposed by that model needs to be 
relaxed. It is specified below168 ܧሾݕ௜ȁݔ௜ ǡ ߝ௜ሿ ൌ ሺߙ ൅  ݔ௜ǡ ߚ ൅ ߝ௜ሻ ൌ ݄௜ߣ௜ 
Where ݄௜= exp(ߝ௜ሻ is assumed to be a one parameter gamma distribution, 
īșș with mean 1 and variance ș ț 
It has a conditional mean ܧሾݕ௜ȁݔ௜ሿ ൌ ߣ௜  and 
Variance, ܸܽݎሾݕ௜ȁݔ௜ሿ ൌ ߣ௜ሾ ? ൅ ߢߣ௜ሿ 
Where ț 9DU>݄௜], is referred to as the index parameter, which is the inverse of 
the dispersion parameter, ș. The inclusion of this enables the negative binomial to fit 
FRXQWGDWDZKHUHWKHPHDQYDULDQFH,Iț  the negative binomial is the 
equivalent of the Poisson distribution.  
9.9.2 Logit 
The logit is the inverse of the logistic function and is used where the observed 
outcome is binary. The logit of an outcome, p, which takes a value between 0 and 1 
is given by the formula: 
 
The linear predictor for the logit as a function of several regressors is given is 
represented as169: 
 ߨ௜ ൌ ଵଵା௘షೣ೔ᇲഁ     
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Where ɴ represents the coefficient parameters for the included explanatory variables 
(ߚଵ ǥ ǡ ߚ௞ሻ and ݔ the included explanatory variables (ݔଵ ǥ ǡ ݔ௞ሻ 
9.9.3 Hurdle model specification 
The hurdle model removes excess zeros from a count outcome variable by breaking 
it down into two separate components which are then modelled separately. An initial 
binary model includes the whole study population. The coefficients in this model are 
interpreted as the effect of that variable on the individual having an event. Those 
who do have an outcome cross the hurdle and move into a truncated at zero count 
model; which shows the relationship between the explanatory variable and the 
number of outcomes an individual has. 
This approach removes the excess zeros problem from the count model by removing 
them entirely in the case of cross sectional data. However this becomes somewhat 
more complicated in a count panel data model. In such circumstances the hurdle 
could reset and apply separately to each period in the panel. This is a logical 
approach if it can be assumed that all patients are the same at the beginning of each 
period regardless of whether or not they crossed the hurdle (had an event) in a 
previous period. There are examples where this may be the case but for this study the 
outcomes were serious CHD complications, and hence this was unlikely to be the 
case. Consequently it was decided that those who breached the hurdle should be 
treated as a distinct group, with different risks of having an event to those who did 
not, for the remainder of their time in the study period. In this study the hurdle model 
was implemented as follows: 
The whole study population participated in the binary component of the hurdle 
model until the point of their first outcome event. This was modelled using the logit 
described above. If the patient had an outcome they crossed over into the count 
component of the hurdle model, where they remained for the remainder of their time 
in the study. As it was possible for those patients to have no events in subsequent 
time periods in the panel, namely a zero count, that count model was not truncated at 
zero. The negative binomial was used to model these patients, which is described 
above.  
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The specific setup of the hurdle in this thesis is best described in the fictional 
example presented in Table 9-8 for patient 2260. Patid represents the unique patient 
identifier, alladmis, the study outcome count measure, which for purposes of the 
hurdle is split into a binary model (risk), and a count model (event). Patient 2260 
remained in the binary component until 2006/07 when they had two admissions. 
Prior to that period they did not participate in the count component, where they were 
represented by the missing value (.).  When the patient first had an outcome this was 
recorded in the binary model as a 1 value, and the number of events was counted in 
the count component. This fits the standard application of the hurdle model in single 
observation data, as at this point the count model is truncated at zero. Had the hurdle 
reset for the following period, 2007/08 the count component would have remained 
truncated at zero. However in this study patients remained in the count model (event) 
following an outcome, and were missing from the binary model: Shown by counts in 
the event column and missing values, (.), in the risk column. This approach fitted the 
circumstances of the study population and also meant patients had continuous 
observations for their periods in either model, rather than potentially intermittent 
periods in both. This was important because analysis of the effect of the QOF 
variables on the outcome measures included lags of those explanatory variables  
Table 9-8 Application of the hurdle model: An example 
patid years alladmis risk event 
2260 2004/05 0 0 . 
2260 2005/06 0 0 . 
2260 2006/07 2 1 2 
2260 2007/08 0 . 0 
2260 2008/09 2 . 2 
2260 2009/10 0 . 0 
2260 2010/11 1 . 1 
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9.10 Appendix 9 The effect of co-morbidities on key 
study variables 
9.10.1 Introduction and specification  
To explore the effects of co-morbidities in relation to the study population, a sub 
group of the study population, those without selected co-morbidities of interest, are 
presented. In this subgroup study population, patients who had a QOF coding for any 
of the following: Diabetes, Hypertension, Atrial Fibrillation, Heart Failure and 
Stroke were excluded, from the point where their first co-morbidity was recorded 
onwards. Chronic Kidney Disease (CKD) was not excluded due to uncertainty over 
the conditions prevalence prior to entry into the QOF.  Rheumatoid Arthritis as the 
only condition not in the QOF, and not derived using QOF Read codes, was also not 
excluded. This study population has been termed a CHD only population as 
important co-morbidities have been removed though it is possible that the patient 
had other serious clinical conditions not considered as well as CKD and RA. 
Figure 9-1 Total and CHD only study population, 2000-2011 
 
The impact of removing co-morbidities from the study population is shown in Figure 
9-1, as compared against the total study population. Population numbers show the 
number of patients who were present for an\SHULRGRI WKDW\HDU<HDU¶V UXQ LQ
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April to 31st March the following year cycles, with the exception of the first year 
which ran from 1st January 2000 to 31st March 2001, and the figures given are for the 
year end totals.  
Removing patients with chosen co-morbidities (CHD only) reduces the total patient 
population considerably. Both populations increase initially as more patients join the 
study. However the differential between the two increases over time as more of those 
patients acquire the selected co-morbidities. The CHD only portion of the total 
population falls from the beginning of the QOF onwards, which may be the result of 
better recording of co-morbidities, and greater efforts to diagnose, in response to 
incentives. This proposition concurs with the continued increase in the total 
population until 2007 which is consistent with the continued increase in the 
diagnosis and recording of CHD. A static total population from 2008, and its 
subsequent fall, could be the result of better primary prevention resulting in fewer 
cases of CHD. This could explain the relationship seen as improved primary 
prevention could lead to the number of new cases falling below the number exiting 
the study to die or transfer out.  
9.10.2 Comparisons between the study and CHD only 
population on key explanatory variables 
 
Comparisons are made between the study population and the CHD only component 
of that population on a number of key explanatory variables in a series of tables 
below.  
Starting with differences in age; table 9-9, looks at the mean age of the study 
population specifications and their standard deviations over the course of the study. 
As the study progresses, patients acquired co-morbidities and the two populations 
separated. Unsurprisingly given that health deteriorates and chronic conditions are 
acquired as people grow older the whole population, which includes individuals with 
co-morbidities, is older than the part of it which has none of the selected co-
morbidities, CHD only. 
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Table 9-9 Age by population specification, 2000-2011 
 
Table 9-10 looks at the gender split in the two populations, in terms of their 
percentage numbers who are male. The percentage share of the population that are 
male, increases year on year, in both specifications. Throughout the study period 
males have a greater representation than female in both population specifications as 
expected, however that percentage is lower in the CHD only part of the total 
population. A possible explanation is that individuals are more likely to develop co-
morbidities as they age and health deteriorates. Females live longer than males and 
there is also evidence to show they live longer in poorer health states which would 
account for the figures seen170 171. 
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Table 9-10 Percentage of population male, by population specification, 2000-2011 
 
Tables 9-11 and 9-12 show mean diastolic and systolic blood pressure respectively 
over a QOF accounting period, for the total population and its CHD only component. 
Table 9-11 Mean diastolic blood pressure by population specification, 2000-2011 
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Table 9-12 Mean systolic blood pressure by study population specification, 2000-2011 
 
Mean diastolic and systolic blood pressure are very similar between the two 
population specifications, and fall in most years. The CHD only component of the 
total population has a slightly higher mean and standard deviation throughout for 
systolic blood pressure, and in most years for diastolic blood pressure.  
Table 9-13 Mean cholesterol by study population specification, 2000-2011 
 
Figures for total cholesterol are presented in Table 9-13 and represent the mean of all 
reading taken over a 15 month period, for all patients in the study population in the 
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respective years, as well as their standard deviations. Again the results are similar for 
the two population specifications. However there appears to have been bigger 
improvements in the co-morbid population following the QOF, leading to that group 
having noticeably lower level in the latter years of the study. For both groups mean 
cholesterol levels have been falling, throughout the majority of the study period, 
though we seem to have reached a plateau for both.  
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9.11 Appendix 10 Training, Presentation and 
Publications 
9.11.1 Graduate School Courses 
26/10/2010, Essential skills for new researchers in the social sciences, 1 credit 
12/11/2010, Using posters to communicate research, 1 credit 
15/11/2010, Creating and managing long documents in Microsoft word, 2 credit 
18/11/2010, Referencing and citing using Endnote, 1 credit 
18/11/2010, Nature of the doctorate and supervision process, 1 credit 
25/11/2010, Planning your research, 1 credit 
01/12/2010, Systematic review, 1 credit 
14/12/2010, An introduction to Health Economics, 2 credits 
19/04/2011, Presentation skills for researchers (Arts and Social Sciences), 2 credits 
08/01/2013, Finishing your thesis, 1 credit 
9.11.2 University of Nottingham Postgraduate MPH Courses 
All undertaken in the Academic Year 2010/2011 
CHS-A34591 Research Methods in Epidemiology with Basic Statistics, 15 credits 
CHS-A34582 Advanced Statistical Methods, 10 credits 
CHS-A34583 Advanced Epidemiology, 10 credits 
CHS-A34585 Practical Uses of Routine Data for Epidemiological Research, 10 
credits 
CHS-A34589 Health Economics, 10 credits 
9.11.3 Other training courses 
14th & 15th   June 2011, Centre for Health Economics, University of York, Analysing 
Patient Data using Hospital Episode Statistics 
14th-16th December 2011, Applied Methods of Cost-effectiveness Analysis, 
University of Oxford 
Jan/Feb 2012, Stata NetCourse 101: Introduction to Stata 
March/April 2012, Stata NetCourse 151: Introduction to Stata programming, 
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2nd & 3rd April 2012, Writing a Dissertation, Englishwise, Chesterfield 
3rd-6th July 2012, Nottingham Systematic Review Course, Cochrane Collaboration, 
University of Nottingham 
24th-26th September 2012, Microeconometrics using Stata, Cambridge University, 
Timberlake 
10th-12th October 2012, Introductory Econometrics, Cemmap, University College 
London 
1st & 2nd November 2012, Panel / longitudinal data analysis, Cemmap, University 
College London 
3rd-7th December 2012, Economic Evaluation in Health Care, University of 
Birmingham 
16th-18th January 2013, Discrete Choice Modelling, Cemmap, University College 
London 
24th & 25th January 2013, Microsimulation, Cemmap, University College London 
30th January ± 1st February 2013, Statistics for Health Economics, University of 
Birmingham 
4th -8th March 2013, Modelling for Health Economics, University of Birmingham 
14th & 15th March 2013, Utility Data for Health Technology Assessment, University 
of Sheffield 
25th & 26th March 2013, Survival Analysis, Cemmap, University College London 
8th- 10th April 2013, Applied Econometrics with Stata, CASS Business School, 
Timberlake 
22nd April 2013, Stata Graphics, Cemmap, University College London 
23rd- 26th April 2013, Policy Evaluation Methods, Pepa, University College London 
9th & 10th May 2013, Data Management, Regression, Panel Data Analysis & 
Research Output using Stata, CASS Business School, Timberlake 
20th & 21st June 2013, Panel Data Analysis using Stata, CASS Business School, 
Timberlake 
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10th ± 12th July 2013, Systematic Reviews in Health Care: Meta-Analysis in Context, 
University of Bristol 
13th & 14th July 2013, Advanced Meta Analysis, University of Bristol 
9.11.4 Presentations 
14th September 2011, National School of Primary Care Research (NSPCR) Trainee 
Conference, Evaluation of the evidence for QOF clinical targets, Oxford University, 
Poster presentation 
20th September 2012, NSPCR Trainee Conference, The effect of primary care 
interventions on secondary care outcomes: The Quality Outcomes Framework and 
Secondary prevention of CHD, Oxford University, Poster presentation 
19 October 2012, NSPCR Research Showcase, An analysis of the effect of CHD 
QOF targets on secondary care outcomes using large patient databases, Royal 
College of Physicians, London, Oral Presentation 
5 July 2013, Society of Academic Primary Care conference, An econometric analysis 
of the effect of CHD QOF targets on adverse cardiac complications, University of 
Nottingham, Oral Presentation (Nominated for travel prize) 
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